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ABSTRACT 
Chronic kidney disease and chronic periodontitis are common diseases that are 
found disproportionately comorbid with each other and have been reported to have 
a detrimental effect on the progression of each respective disease. They have an 
overlap in risk factors and both are underpinned by systemic inflammation along with 
a wide selection of immunological and non-specific effects that can affect the body 
over the lifespan of the conditions. The oral microorganisms involved in chronic 
periodontitis have demonstrated the ability to translocate and elicit distal effects in 
a variety of systemic diseases but currently there has been little research into the 
associations with chronic kidney disease. Previous studies have investigated the 
directionality of the relationship between these two diseases; however, there is a 
lack of evidence on how these diseases may be interacting at the local sites such as 
the oral cavity and systemic level, especially looking at periodontitis associated 
microbial products that could damage the kidneys. 
The aim of this study was to investigate the microbial products produced by 
periodontitis associated microorganisms using a novel metabolomics approach and 
identify if any of these products are capable of eliciting in vitro a cytotoxic (cell 
viability testing), migratory (wound healing assay) and fibrotic response (qPCR) in 
renal cells. 
A selection of microorganisms associated with periodontitis were cultivated in a 
novel media representative of the diseased environment, and the microbial products 
secreted in bacterial supernatants over their lifecycle were collected. These 
supernatants were prepared for testing by centrifugation and filtering at 0.2 µM in 
order to remove microbial cells; the prepared samples were stored at -80oC. A novel 
metabolomics approach utilising liquid chromatography mass spectroscopy was 
developed and trialled as a fast screening method for identifying potentially toxic 
metabolites but it was not suitable for this study.  
Testing of the collected microbial supernatants against human kidney cells identified 
that only Porphyromonas gingivalis supernatants were capable of inducing a 
cytotoxic and mild anti-migratory effect. Tests to identify the causative agent behind 
 XV 
 
these effects suggest this effect could be protein derived, as the addition of a 
protease inhibitor attenuated the cytotoxic effects of the supernatants, suggesting 
the role of microbe specific proteases known as Gingipains. Investigations in the 
fibrotic potential of the collected supernatants showed that only Porphyromonas 
gingivalis supernatants were capable of significantly inducing the production of a 
three pro-fibrotic markers: Collagen, type I, alpha 1, transforming growth factor β 
and tissue inhibitor of metalloproteinases 1. 
In conclusion, this study showed that one periodontitis associated microorganism, 
Porphyromonas gingivalis is capable of eliciting cytotoxic and mild anti-migratory 
effects in renal cells, along with inducing the production of three pro-fibrotic 
markers. This study sheds light on how this key microorganism may pay a role in the 
mediation of chronic kidney disease. 
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OVERVIEW OF THE THESIS STRUCTURE 
The focus of this study was to investigate the putative link between two systemic 
diseases, chronic periodontitis and chronic kidney disease, and how they may 
interact with each other. This was investigated by identifying microorganisms 
implicated in chronic periodontitis and specifically observing at how the microbial 
products they produce may interact with chronic kidney disease. The first chapter 
(Chapter 1) provides an overview of this research topic and of how these two 
diseases may interact. 
The first research chapter (Chapter 2) covers the selection of periodontitis associated 
microorganisms that have been implicated in systemic disease and/or related to 
chronic periodontitis and chronic kidney disease. These microorganisms were then 
cultivated in a novel developed growth medium that was designed to mimic the 
gingival crevicular fluid and the microbial supernatants were sampled over their life 
cycle in order to purify their microbial products for testing. 
The second research chapter (Chapter 3) focuses on the design, development and 
proof of concept of a novel metabolomics approach from scratch to investigate 
microbial metabolites produced by periodontal pathogens. Liquid Chromatography - 
Mass Spectroscopy was utilised along with a specifically designed analysis pathway 
in order to identify compounds that disproportionately account for the difference 
between bacterial samples and the controls. While the development of a pipeline 
was successful, issues surrounding identification of compounds prevented this 
technique from being useful for screening purposes. 
The third research chapter (Chapter 4) focuses on testing all microbial supernatants 
against human kidney cells and assaying a variety of parameters such as cytotoxicity, 
migration and fibrosis induction. The final research chapter (Chapter 5) focuses on 
the identification of the causative agent behind the kidney cell damage observed 
using a variety of different approaches. The second focus of chapter 5 was further 
investigating fibrosis induction using quantitative polymerase chain reaction. 
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1.1 INTRODUCTION 
Chronic kidney disease (CKD) is one of the most common chronic diseases with the 
worldwide prevalence estimated to be approximately 13.4% and projected to 
continue to rise annually, especially in developing countries where renal healthcare 
is limited (Couser et al., 2011, Hamer and El Nahas, 2006, Coresh, 2017). Chronic 
Periodontitis (CP) is a chronic infection of the supporting structures of teeth that is 
predominately found in adults and the elderly. CP is ubiquitous, with worldwide 
prevalence estimated to be approximately 10% (Kassebaum et al., 2014, Frencken et 
al., 2017). As chronic diseases persist for long periods, there is a significant amount 
of comorbidity in patients, especially with other chronic diseases (Jones, 2010, 
Schellevis et al., 1993). Indeed, these comorbidities have been reported as a source 
of adverse outcomes (Tonelli et al., 2015) and highlight that complex interactions 
between chronic diseases could lead to effects that are detrimental for the health of 
the patient. 
There have been reports highlighting a link between CKD and CP, which both have an 
overlap in terms of risk factors. While some studies have reported significant 
associations between both diseases, there is increasing evidence suggesting a 
directional link between CKD and CP that can affect their progression and cause 
adverse outcomes (Zhao et al., 2018). Both CKD and CP have well documented 
systemic effects on the body such as chronic inflammation and dysfunction of 
immune cells (Oberg et al., 2004, Vaziri et al., 2012, Akar et al., 2011, Loos, 2005); 
however, how their individual systemic effects may interact with each other is 
relatively unstudied. Furthermore, the combined effect of both chronic diseases on 
the localised site of periodontal disease (the oral cavity and periodontium) has not 
been fully elucidated and may explain why both diseases have been reported to have 
a detrimental effect on each other. 
1.1.1 The Oral Microenvironment  
The mouth is one of the most biologically complex regions in the mammalian body. 
It provides an entrance and transit point for both the digestive and respiratory 
systems, plays a role in rudimentary pre-processing of food, and is pivotal for oral 
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communication and sensory functions (Marsh et al., 2009). Within the oral cavity 
there are the hard tissues of the teeth and soft mucosal structures such as the 
tongue, soft and hard palate, cheeks, periodontium and the gingiva sulcus which 
provide an array of microhabitats for the large numbers of diverse microorganisms 
present (Figure 1.1) (German and Palmer, 2006, Marsh, 2000, Verran, 1991). In this 
environment the two key biofluids, saliva and gingival crevicular fluid (GCF), play an 
important physiological role. The saliva is the predominant oral fluid. It acts as a 
lubricant, assists in preliminary digestion through the action of enzymes such as 
lipase and amylase, and plays a role in the forming of a food bolus and taste (Edgar 
et al., 2004). In contrast, the GCF is normally present in small amounts bathing the 
gingiva. However, in pathological conditions (e.g. local inflammation), the secretion 
of GCF increases significantly as a defensive mechanism in the immune response 
(Taylor and Preshaw, 2016). 
 
Figure 1.1 The selection of structures present in the oral cavity that can provide a differential habitat 
for oral microorganisms (adapted from (Goldenberg and Koch, 2009)) 
 
The microorganisms in the oral cavity change in response to a wide variety of stimuli 
such as dietary energy sources, age, host and bacterial metabolite production, poor 
oral hygiene and systemic diseases (Rasiah et al., 2005). Over 700 microbial species 
have been characterised in the human oral cavity alone, highlighting the high levels 
of diversity (Dewhirst et al., 2010). This resident microbiota does not have a singularly 
passive relationship with the host since it contributes to the host defences, can 
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synthesise vitamins which are beneficial to the host and plays a vital role in 
preventing colonisation of potential pathogens (Marsh, 2000, Kumar et al., 2013). 
However, as the oral cavity is a key barrier and entry point between the external 
environment and the body, it is open to opportunist pathogens that can infiltrate the 
blood, the lower respiratory tract and the digestive system (Tada and Hanada, 2010). 
Despite much of the microbiota living in symbiosis with the host, the oral cavity can 
further act as a reservoir for infection with many commensal microorganisms being 
the cause of opportunist infections in immunocompromised individuals (Gendron et 
al., 2000, Akpan and Morgan, 2002). 
1.1.2 Chronic Periodontitis 
Periodontitis is the inflammation and infection of the periodontium, which is due to 
the accumulation of sub-gingival dental plaque and is mediated by a wide spectrum 
of oral microorganisms (Hajishengallis, 2015). It presents as repetitive inflammation, 
recession of the gingiva, gingival bleeding and the formation of deep periodontal 
pockets between teeth which over time can leave to bone loss and loss of attachment 
(Figure 1.2) (Darveau, 2010, Schatzle et al., 2004). The disease can be classified into 
three different stages depending on the clinical connective tissue attachment loss: 
slight 1-2 mm of loss, moderate 3-4 mm of loss and severe >5 mm loss (Wiebe and 
Putnins, 2000).  
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Figure 1.2 The presentation of chronic periodontitis (Right) in comparison to healthy individuals (Left). 
In healthy tissue, the teeth are supported by connective tissue, the gingival epithelium and alveolar 
bone. In chronic periodontitis, the accumulation of the pathogenic dental plaque biofilm leads to 
inflammation, formation of periodontal pockets and the destruction of the gingival epithelium along 
with alveolar bone loss (Adapted from (Darveau, 2010)).  
 
There are seven identified subtypes of periodontitis with CP being by far the most 
common and severe of all forms in the adult population. CP is categorised by the 
formation of periodontal pockets of which increase in depth with the severity of the 
disease and provide a space for the aetiological microorganisms. It has been reported 
that 45% of adults in England have at least one periodontal pocket, with 8% of the 
population having severe periodontal pocketing (Heidari et al., 2015). The worldwide 
prevalence of severe CP was estimated to be 10%, making it the sixth most prevalent 
disease worldwide (Kassebaum et al., 2014, Frencken et al., 2017). CP is of particular 
interest as it is a global chronic disease and can be detrimental to the health of the 
patient and a risk factor for myriad other diseases such as Alzheimer’s (Dominy et al., 
2019), cardiovascular disease (Dietrich et al., 2008), diabetes mellitus (Engebretson 
et al., 2013), chronic obstructive pulmonary disease (Usher and Stockley, 2013) and 
pre-term birth (Marsh et al., 2009, Han et al., 2004). 
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The main aetiological agents driving the inflammatory processes in CP are the plaque 
associated oral bacteria which form biofilms and dysregulate the normal oral 
microbiota (Wahid et al., 2013). CP is caused by the inflammatory response to dental 
plaque accumulation and formation of calculus (hardened plaque) around the 
gingiva, which may result in an increased flow of GCF, and further favours the growth 
of anaerobic microorganisms (Marsh et al., 2009, Winning et al., 2015). These Gram-
negative anaerobes include Porphyromonas gingivalis, Tannerella forsythia and 
Treponema denticola, which have been isolated from the majority of CP cases and 
are referred to as the ‘red complex’ (Wade, 2013). Indeed, the levels of P. gingivalis 
and T. denticola in subgingival plaque can predict the progression of CP, highlighting 
the key role of these organisms in the pathogenesis of CP (Byrne et al., 2009). 
Previously it was thought that these ‘red complex’ organisms affected the signalling 
pathways of the human host, which led to a dysbiosis of the oral microbiota  thereby 
resulting in disease (Darveau, 2010). However, it has since become apparent that CP 
is more complex than a singular group of organisms, with a current predominating 
theory being the Polymicrobial Synergy and Dysbiosis (PSD) model (Hajishengallis and 
Lamont, 2012).  
In the PSD model of CP, keystone pathogens such as those of the ‘red complex’ 
colonise the gingiva, interact with accessory organisms and increase the virulence of 
the community causing dysbiosis and disruption of homeostasis, which leads to 
destruction of tissue (Hajishengallis and Lamont, 2012, Payne et al., 2019). In this 
model, there are a wide range of microorganisms involved, with keystone pathogens 
such as the aforementioned ‘red complex’ and periodontitis accessory organisms 
(Table 1). These accessory organisms are predominately commensals commonly 
found in the healthy microbiota, which can interact with the keystone pathogens to 
assist in the pathogenesis of CP. However, due to the complicated nature of these 
interactions such as specific adhesion, metabolic symbiosis, complex biofilm 
formation and virulence modulation, many of the mechanisms are yet to be 
elucidated (Shaikh et al., 2018). 
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Table 1.1 List of key pathogens and accessory organisms with the reported roles in periodontitis 
Keystone Pathogens 
Name Reported Roles Reference 
Porphyromonas 
gingivalis 
A key pathogen in CP because of complex host-pathogen and community 
interactions, which can cause dysbiosis and promote a pro-inflammatory 
phenotype. In addition, a multitude of virulence factors are produced which 
can cause damage and destruction of the periodontium. 
(Hajishengallis, 
2009) 
Tannerella 
forsythia 
A key pathogen associated with the clinical attachment loss seen in CP and has 
been shown to cause alveolar bone loss. It has a few identified virulence factors 
and many synergistic associations with accessory organisms. 
(Kesavalu et al., 
2007) 
Treponema 
denticola 
A key pathogen of CP of which the severity of the disease can be predicted by 
levels of P. gingivalis and T. denticola. Also has a multitude of virulence factors, 
which assist with adherence, instigating dysbiosis in the subgingival microbiota 
and damaging the gingival tissues. 
(Byrne et al., 
2009, Dashper 
et al., 2011) 
Accessory Organisms 
Name Reported Roles Reference 
Actinomyces 
israelii 
Present in patients with CP more frequently than healthy patients, along with 
those with high scores on the plaque index. It may play a role in the maturation 
of sub and supra gingival plaque. It is commonly isolated alongside A. 
actinomycetemcomitans suggesting synergy in periodontal infection. 
(Vielkind et al., 
2015, Könönen 
and Wade, 
2015) 
Aggregatibacte
r 
actinomycetem
comitans 
A facultative anaerobic organism, which is commonly found in CP and is 
considered a key pathogen. It has numerous reported virulence factors 
promoting periodontal disease with stimulation of inflammatory cytokines and 
the production of a leukotoxin, which is reported to be pro-apoptotic towards 
gingival epithelial cells. 
(Henderson et 
al., 2010) 
Campylobacter  
(C. rectus, C. 
showae) 
Campylobacter organisms are not common commensals but present as 
transient members of the healthy microbiota. C. rectus is predominately found 
in initial periodontal lesions and shallower pockets, which leads to suggestions 
it may play a role in the initiation of periodontitis. C. showae is predominately 
found in deeper pockets and later stages of CP with its role in the pathogenesis 
relatively under studied. 
(Macuch and 
Tanner, 2000) 
Eubacterium 
nodatum 
Commonly mistaken for A. israelii due to similar morphology. It is reported to 
be a key accessory organism in periodontitis along with having synergy with T. 
denticola in the induction of periodontitis. However, due to misidentification 
there is a lack of studies looking at the interplay of this organism in CP. 
(Haffajee et al., 
2006, Arora et 
al., 2014) 
Fusobacterium 
nucleatum 
Reported to play a role as a ‘bridge’ for early and late colonisers to co-
aggregate. It has also been reported to have synergy with T. forsythia in 
inducing an immune response and causing alveolar bone loss. 
(Settem et al., 
2012) 
Parvimonas 
micra 
A commensal organism commonly found in the subgingival plaque is found in 
the top layer of periodontal plaque. It is not thought to form biofilm structures, 
but has a significant association with periodontal destruction. However, it is 
relatively understudied in CP so many the biochemical interactions are 
unknown. 
(Zijnge et al., 
2010, Al-hebshi 
et al., 2014) 
Prevotella  
(P. intermedia, 
P. 
melaninogenica
, P. nigrescens) 
These are anaerobic commensal organisms within supragingival plaque, which 
increase over the course of periodontal disease. Biofilms produced by 
Prevotella spp can be used to subvert the innate immune system causing the 
periodontal plaques to chronically colonise the periodontal pockets. 
Furthermore, it has also been reported that P. intermedia can release pro-
inflammatory cytokines and matrix metalloproteinases, which can stimulate 
periodontal destruction. 
(Stingu et al., 
2013, Tanaka et 
al., 2008, Fukui 
et al., 1999, 
Yamanaka et al., 
2009, Guan et 
al., 2008) 
Streptococcus 
anginosus 
group (S. 
anginosus, S. 
constellatus, S. 
intermedia) 
This group are commensals that inhabit the subgingival periodontal pockets in 
those with periodontitis and are usually present even after treatment. It has 
been suggested that they provide an attachment substratum, which can allow 
for recolonization of periodontal pathogens after treatment as they have 
strong anti-phagocytic resistance to leukocytes.  
(Rams et al., 
2014) 
Streptococcus 
mitis group 
(S. gordonii, S. 
sanguinis, S. 
oralis) 
This group are thought to assist the key pathogens in adherence by providing 
an attachment substratum and facilitate signal transduction. Furthermore, 
synergy between S. gordonii, P. gingivalis and A. actinomycetemcomitans has 
been demonstrated causing increased pathogenicity when in co-culture. 
(Whitmore and 
Lamont, 2011, 
Hendrickson et 
al., 2017) 
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Infection of the periodontium can provide a method of systemic entry into the body 
for microorganisms along with microbial products and potential antigens. These may 
induce inflammatory responses in distant tissues by dissemination using the 
circulatory system (Bastos et al., 2011), with evidence of this seen in infective 
endocarditis (Baddour et al., 2015) and infective glomerulonephritis (Brodsky and 
Nadasdy, 2017). In addition, CP associated microorganisms and products are 
released into the digestive system by the swallowing of the inflammatory exudate, 
periodontal bacteria and bacterial products (Olsen and Yamazaki, 2019). 
1.1.3 Chronic Kidney Disease  
The kidneys play a vital role in the body by filtering blood and metabolic waste, while 
also modify the content and composition of fluids in the body. They facilitate waste 
excretion, nutrient reabsorption, secrete hormones, regulate osmolarity, regulate 
blood pressure and maintain systemic acid base homeostasis (Jameson and Loscalzo, 
2016). The anatomy of the kidney reflects its unique role in the body with the 
functional unit of the kidney being the nephrons, which filter the blood to form urine. 
Damage to the nephrons can lead to acute or chronic kidney diseases, which may 
predispose to end-stage renal failure which requires dialysis or transplantation (Hoy 
et al., 2005).  
It is estimated that in England 2.6 million people aged 16 years and older have CKD 
stage 3-5 which equates to 6.1% of the general population (Aitken, 2014). CKD is 
defined as reduced kidney function that is present for over three months, and has 
implications for the health of the patient such as kidney failure and cardiovascular 
death (Inker et al.). The reduced kidney function is measured using the estimated 
glomerular filtration rate (eGFR), with the severity of CKD staged from 1-5 based on 
the decrease in eGFR (Hemmelgarn et al., 2010). CKD often goes undiagnosed and 
can present idiopathically along with co-morbidities such as diabetes, cardiovascular 
disease and chronic periodontitis (Levey et al., 2003, Dyck et al., 2012, Borawski et 
al., 2006). The progression of CKD is characterised by the loss of renal cells and the 
replacement of these with extracellular matrix, which leads to the reduction of renal 
function and related symptoms such as uremia, proteinuria and oedema (Nogueira 
et al., 2017).  
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The function of the kidney in acting as a filtering agent of waste products for the 
blood increases their risk of their damage by toxins (Finn, 1977). The blood flow to 
the kidney is greater per gram of tissue compared to any other organ (Finn, 1977) 
meaning that the total amount of waste/toxins delivered will be disproportionately 
high. Furthermore, as the kidneys are able to concentrate substances through 
filtration, reabsorption and secretion, this can cause various metabolites and toxins 
to build up to levels which can be damaging to the nephrons (Finn, 1977). 
Many factors increase the risk of CKD such as age, gender, ethnicity, concurrent 
diseases such as hypertension and diabetes and socio-economic status (Kazancioglu, 
2013). Indeed, a key strategy for management of CKD is identification of modifiable 
risk factors, which would allow for earlier detection of the disease. The identification 
of predisposing risk factors for CKD can also allow intervention-based strategies to 
facilitate early treatment of the disease. Current research has focused on 
investigating risk factors that may have a directional link with CKD independent of 
other risk factors such as Alzheimer’s Disease (Shi et al., 2018b), obstructive sleep 
apnoea (Mirrakhimov, 2012) and CP (Wahid et al., 2013). Identification of these 
directional risk factors is of particular importance, as many of these can have a 
significant impact on progression of both diseases and if controlled could be a useful 
treatment to deal with both diseases. 
1.2 ORAL BACTERIA AND DISTAL PATHOGENIC EFFECTS 
Although the effect of pathogenic oral bacteria on the health and disease of the oral 
cavity has been acknowledged for many years, the interplay between these 
organisms and other systemic diseases has only recently re-emerged. The first 
proposal of distal pathogenic effects by microorganisms was in 1891 with W. Miller 
suggesting that oral microorganisms could access distal body parts, known as the 
focal infection theory (Miller, 1891). This was built upon and suggested to be the 
cause of a number of systemic diseases such as endocarditis, diabetes and nephritis 
(Billings, 1916). At the time these suggestions were not taken seriously, however the 
proposal re-emerged in the 1990’s with the American Academy of Periodontology 
and the world workshop in periodontitis suggesting that oral infection is frequently 
Chapter 1: Introduction 
10 
 
related to local and general disease (Scannapieco, 1998). This has led to 
modernisation of the focal infection theory to the periodontal medicine concept 
which highlights the relationship between chronic periodontitis and systemic 
disease, with oral status connected to systemic health  (Pizzo et al., 2010). 
Many of these putative links have been identified through epidemiological 
associations adjusted for known risk factors. However, the mechanisms behind many 
of these interactions still need to be elucidated (Seymour et al., 2007). There are a 
few known case studies of distal pathogen effects from oral microorganisms namely: 
bacterial endocarditis, acute post-streptococcal glomerulonephritis and infective 
endocarditis glomerulonephritis (Carapetis et al., 2005, Lusco et al., 2016, Majumdar 
et al., 2000). 
1.2.1 Translocation of Oral Pathogens 
In a healthy mouth, the mucous membrane along with host-produced antimicrobial 
molecules such as defensins provide a barrier to external pathogens, preventing the 
commensal and opportunist microbes from damaging the host. This barrier can be 
disrupted in multiple ways including physical disruption via trauma such as micro 
abrasions caused by tooth brushing (Addy and Hunter, 2003), by periodontal 
pathogens invading the gingival margin (Bosshardt, 2017) or if a host is 
immunocompromised through medication or disease where they are more at risk of 
infection. 
There are three possible mechanisms of how oral microbes can facilitate further 
diseases: (1) infection due to metastatic transient bacteraemia; (2) metastatic 
immunological injury and; (3) metastatic toxic injury (Thoden van Velzen et al., 1984, 
Pizzo et al., 2010). Metastatic transient bacteraemia refers to the damage caused by 
translocation of microorganisms throughout the body. Metastatic immunological 
injury refers to the damage caused by the stimulation of an immune response such 
as the process of inflammatory mediation seen in chronic periodontitis by the 
microorganisms involved. Metastatic toxic injury is the damage caused by the release 
of toxic compounds which can be produced by microorganisms or by components of 
the cell ultrastructure such as Lipopolysaccharide (LPS) which can stimulate an 
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immune response through host toll like receptors (TLRs) (Gendron et al., 2000, 
Aderem and Ulevitch, 2000). 
1.2.2 Bacteraemia 
Bacteraemia is defined as the presence of viable bacteria in the bloodstream, with 
primary bacteraemia occurring through direct access from the outer environment 
such as through injection or venepuncture, and secondary bacteraemia being related 
to the disruption of a local barrier such as the mucosal membranes or wounds 
(Jawetz, 2007). Bacteraemia can be categorised based on the longevity of the 
microorganisms in the bloodstream: transient, intermittent or persistent (Poveda-
Roda et al., 2008). Transient bacteraemia originating from the oral cavity is a 
relatively common event which can be caused by dental procedures including daily 
oral hygiene routines, such as tooth brushing and flossing, and while being 
asymptomatic it usually only lasts for up to fifteen minutes (Everett and Hirschmann, 
1977, Roberts et al., 2006). In contrast, intermittent and persistent bacteraemia are 
not as common and are associated with increased severity of periodontal disease and 
accumulation of plaque within the gingival crevice and periodontal pocket. 
Bacteraemia is particularly common in CP, with the bacteria and their products being 
able to enter the bloodstream through the inflamed gingiva and elicit a response in 
distal tissues (Fisher et al., 2010). For example the key CP pathogen P. gingivalis has 
been isolated from atherosclerotic plaques (Serra e Silva Filho et al., 2014), the 
placenta (Katz et al., 2009), the liver (Ishikawa et al., 2013) and is capable of invading 
arterial cells (Deshpande et al., 1998) and causing endothelial dysfunction (Tonetti et 
al., 2007). The accessory organism A. actinomycetemcomitans has also been isolated 
from periodontal pockets and atherosclerotic plaques (Padilla et al., 2006). While the 
microbiota of periodontal and atheromatous plaques has been reported to be highly 
similar, indicating translocation rather than sporadic infection (Serra e Silva Filho et 
al., 2014), there is currently no study to demonstrate the clonal nature between 
periodontal plaques and atherosclerotic plaques. 
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1.2.3 Bacterial Endocarditis 
Bacterial endocarditis (BE) is an infection of the inner lining of the heart, most 
commonly the heart valves but it can also affect artificial implants such as 
pacemakers and artificial valves (Carmona et al., 2002). This infection is caused by a 
subset of circulating microorganisms that can bind to the endocardium, or an 
abrasion/micro-clot already present, forming a biofilm. This can lead to the activation 
of complement and formation of a clot with a notable absence of white blood cell 
recruitment (Cabell et al., 2003). It is a relatively uncommon disease with an 
incidence of 2.3 cases per 100,000 people in the UK, with a poor prognosis in lower 
income countries (Ambrosioni et al., 2017). 
Oral microorganisms such as Streptococcus mutans and Streptococcus sanguinis 
were previously the most common microorganisms isolated as causative agents of 
bacterial endocarditis, most likely due to their strong thrombogenic potential which 
allows adherence to the surfaces of the heart (Coykendall, 1989). Bacterial 
adherence is related to intrinsic dextran production, which allows attachment to the 
heart valves along with fibrin and platelets leading to the formation of plaques 
(Scheld et al., 1978).  
Renal glomerular lesions have been reported in cases of BE (Majumdar et al., 2000). 
The pathogenesis of endocarditis related glomerulonephritis is similar to acute post-
streptococcal glomerulonephritis, as both are a form of infective glomerulonephritis. 
Infective Endocarditis Glomerulonephritis (IEGN) is be mainly caused by 
Staphylococcus aureus endocarditis with Streptococcal endocarditis being the second 
most common pathogen, they both can lead to tubular damage as identified by renal 
biopsies (Boils et al., 2015). Previous work investigating pathogenesis of the IEGN had 
identified the activation and deposition of C3 of the complement cascade and the 
involvement of IgG antibodies (Boils et al., 2015). However many of these studies 
used cadaver kidneys and more recent renal biopsy studies demonstrated that  the 
activation of C3 is the primary cause of damage, with IgG and other antibodies being 
present in a much smaller amount (Bayer and Theofilopoulos, 1990). These studies 
demonstrate that IEGN is more complex than previously thought and the activation 
of the complement cascade may be stimulated by various virulence factors such as 
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Staphylococcal superantigens which may cause direct tissue damage (Salgado-Pabon 
et al., 2013) and various immunological complexes produced by Streptococci as 
further discussed in the related acute post-streptococcal glomerulonephritis 
condition. 
1.2.4 Evidence for Kidney Damage Induced by Oral Microorganisms 
Although several reports link oral microorganisms and kidney damage there are 
inconsistencies regarding the causative species, type of damage and putative 
mechanisms of damage (Nasr et al., 2008, Trivedi et al., 2017, Ramanathan et al., 
2017, Nasr et al., 2011). Acute post-streptococcal glomerulonephritis (APGN) is a 
well-studied example of pathogenic oral microorganisms eliciting a distal response 
and damage to kidneys. 
APGN represents an inflammation of the glomeruli in the kidneys and is widely 
attributed to group A streptococci (Ahn and Ingulli, 2008). AGPN is one of the most 
common nephric conditions, with over 490,000 cases estimated globally per year. 
The majority of the AGPN cases occur in developing countries and are easily treated 
with antibiotics (Carapetis et al., 2005). As group A streptococci can be present in the 
oral and skin microbiota, the source of infection mainly depends on the climate, with 
the colder climates associated with upper respiratory tract infections and warmer 
climates with skin infections (Earle, 1985). In one such case, swabs were taken from 
four neighbouring rural families who contracted acute glomerulonephritis (Almroth 
et al., 2005). Kidney biopsies of the patients showed acute diffuse proliferate 
glomerulonephritis, which could be a consequence of streptococcal nephritis, with 
Streptococcus constellatus and Streptococcus pyogenes being isolated from these 
biopsies. While the direct mechanism for this kidney damage is unknown, it has been 
suggested that the post-streptococcal glomerulonephritis could be caused by 
deposition of nephrogenic streptococcal proteins in the glomerulus and the 
production of an antibody-mediated response (Cronin et al., 1989) or deposition of 
bacterial toxins in the kidneys. A recent review on this topic suggests that this 
pathogenesis was probably immunological rather than toxin-related, as the level of 
observed kidney damage is not proportional to the infection as is the case in other 
toxin mediated diseases (Brodsky and Nadasdy, 2017). A number of streptococcal 
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proteins have been identified (e.g. nephritis strain-associated protein (Ohkuni et al., 
1983), Endostreptosin (Yoshizawa et al., 1997) and streptococcal M protein (Vosti et 
al., 1971)) which induce detectable antibody titres in a large proportion of patients. 
However, the lack of specificity to acute post-streptococcal glomerulonephritis of 
these proteins is a major drawback in the identification of causative agent(s). This 
has led to other mechanisms such as autoimmunity (Zabriskie et al., 1970) and 
coagulation (Alkjaersig et al., 1976) to be proposed as playing a role in the disease. 
1.3. THE SYSTEMIC EFFECTS OF CHRONIC DISEASE 
Systemic disease refers to a disease affecting the whole body rather than a single 
body part such as the oral cavity (Li et al., 2000). With chronic diseases, the long-term 
exposure to various by-products of the disease and complications related to 
disruptions in homeostasis can lead to distal effects in a variety of body functions and 
sites. These distal effects could conceivably lead to predisposition to other chronic 
diseases, especially as many have overlapping risk factors, and could be a key reason 
as to why many chronic diseases are comorbid within chronic disease populations 
(Jones, 2010). 
1.3.1 The Systemic Effects of CP  
Although it has been suggested that the oral cavity might provide an entry point to 
multiple diseases, how this is accomplished and what systemic consequences it can 
produce has only been partly explained. Recent research has demonstrated that CP 
is linked with diseases outside of the oral cavity, such as atherosclerosis, diabetes, 
stroke and coronary heart disease, with the pathogenesis mechanisms being under 
investigation (Gualtero et al., 2018, Sen et al., 2018, Beck et al., 2018, Preshaw et al., 
2012). Many of the systemic effects associated with CP are resultant of the dysbiosis 
of oral microbiota, and the dissemination of the microorganisms or their products to 
distal parts of the body. With this in mind, it may be hypothesized that a similar 
systemic oral link may be influencing the incidence of CKD (Figure 1.3). 
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Figure 1.3 The systemic diseases linked with periodontal disease and putative mechanisms behind 
their relationship. 
 
CP has an effect on the oral cavity over the course of the disease in numerous ways. 
It can modify the site of the infection, the periodontium, and the wider oral cavity. 
This is evidenced by disruption of the microvasculature (Zoellner et al., 2002), loss of 
attachment of teeth and bone damage (Flemmig, 1999), gingival bleeding (Albandar 
and Kingman, 1999) and the formation of periodontal pockets up to 1500-2000 mm2 
(Loos, 2006) with bacteria potentially in excess of 1 x 108 colony forming units in each 
pocket (Pihlstrom et al., 2005). The local production of inflammatory cytokines 
interleukin-6 and tumour necrosis factor-α in CP can increase the systemic levels of 
C-reactive protein and thus induce systemic inflammatory effects (Moutsopoulos and 
Madianos, 2006, Dye et al., 2005, Slade et al., 2003). 
The localised damage to the oral cavity and periodontium along with the systemic 
inflammation can have a detrimental effect on the consumption of food and 
medication in CKD patients, affecting their quality of life and potentially leading to 
malnutrition and predisposition to other diseases (Anand et al., 2013, Akar et al., 
2011, Chen et al., 2006). Indeed, the systemic inflammatory effects of CP could be 
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predicted to exacerbate the inflammation already present in CKD with potential 
interactions possibly acting as a further stressor on the already damaged kidneys. 
1.3.2 The Systemic Effects of CKD 
CKD causes a multitude of systemic effects on the human body, which are due to the 
kidneys progressively failing to remove waste products from the blood. Over time, 
this can lead to long-term exposures of the body to a variety of uremic toxins (e.g. 
amino acid metabolic products such as urea and creatinine) (Vanholder et al., 2003). 
This can lead to the development of uremic syndrome (uremia), which results in the 
accumulation of organic waste products which would normally be cleared by the 
kidneys (Inker and Levey, 2014, Meyer and Hostetter, 2007). Alongside this, in CKD 
changes are observed in processes linked to the normal function of the kidney such 
as the regulation of blood pressure and the homeostasis of electrolytes and acid-base 
balance (Dhondup and Qian, 2017), which lead to hypertension (Judd and Calhoun, 
2015), hyperphosphatemia (Hruska et al., 2008), and hypocalcaemia (Kalantar-Zadeh 
et al., 2010). There are a multitude of other non-specific effects of CKD, such as a 
general inflammation, infection and protein wasting (Akar et al., 2011). 
The oral cavity is a site where the systemic effects of CKD have been reported and is 
of particular interest as it encompasses gingival tissue, the site for CP pathogenesis. 
The effects are multifaceted and dependent on factors such as: the drugs used for 
the treatment of CKD, the stage of CKD, dialysis status, oral healthcare regime and 
confounding diseases such as diabetes. Increased plaque, gingival inflammation and 
calculus have been extensively reported (Craig, 2008). Although the cause is not 
clear, as other factors such as immune dysfunction, confounding diseases and poor 
oral hygiene may play a role. It has also been reported that oral lesions are much 
more common in CKD patients who display increased serum urea concentrations and 
elevated pH in the oral cavity (Honarmand et al., 2017, Oyetola et al., 2015). There 
are a large selection of other changes to the oral cavity reported to take place in CKD 
such as changes to teeth, periodontium, oral mucosa, bone and tongue (Akar et al., 
2011, Craig, 2008). With multiple reports highlighting the increased incidence of 
periodontal disease in those with CKD it is possible that changes in the oral cavity 
may predispose CKD patients to developing CP (Ariyamuthu et al., 2013).  
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With the onset of CKD, increasing levels of urea in the oral cavity can lead to a range 
of changes that contribute to the development of CP. The hydrolysis of urea can 
increase salivary pH through the formation of alkaline ammonia compounds, which 
cause ‘uremic fetor’ (a fish like odour on the breath on patients with renal failure) 
(Simenhoff et al., 1977, Epstein et al., 1980). An alkaline oral environment favours 
periodontal pathogens and their colonisation, and promotes calculus deposition 
(Ismail et al., 2015, Bots et al., 2006). Xerostomia, a dryness of the mouth and 
mucosal surfaces, is also a side effect in CKD patients, which is thought to be caused 
by a spectrum of factors such the changes in oral mucosa, reduced salivary flow and 
drugs used for CKD management (de la Rosa Garcia et al., 2006). The reduced flow of 
saliva in xerostomia has been shown to predispose patients to infections, gingival 
inflammation and the development of chronic periodontitis (de la Rosa Garcia et al., 
2006, Kho et al., 1999, Porter et al., 2004). Intriguingly, CKD patients have a 
decreased incidence of caries, which is due  to the alkaline oral environment not 
being amenable for cariogenic organisms (Peterson et al., 1985).  
The persistent long-term increase of urea and uremic toxins (uremic toxaemia) has 
an effect on the immune system and can lead to immune dysregulation and chronic 
inflammation (Cohen and Hörl, 2012). Uremic toxins can cause a dysfunction of 
polymorphonuclear leukocytes (PLs) such as basophils, monocytes and neutrophils 
and dysregulate the innate immune response (Haag-Weber and Horl, 1996, Vaziri et 
al., 2012). Interestingly, previous studies have also shown that the ammonia 
produced by the degradation of the increased urea concentrations can inhibit 
neutrophil function which could result in an additive effect to the already 
dysregulated innate immune system (Niederman et al., 1990). Such dysregulation in 
the innate immune system may lead to an increased risk of infection in the oral cavity, 
which can predispose CKD patients to CP. 
The drugs utilised for immunosuppressive therapy after kidney transplantation 
(Calcinurin inhibitors) and calcium channel blockers, which are used to regulate the 
increased cytosolic calcium along with hypertension in those with renal disease, have 
also been reported to cause gingival hyperplasia (the overgrowth of the gingival 
tissue) (Somacarrera et al., 1994, Bharti and Bansal, 2013, Brown and Arany, 2015). 
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Interestingly, this gingival overgrowth can be enhanced by poor oral hygiene which 
is reported to be particularly endemic in CKD patients and it has been suggested that 
such gingival overgrowth can lead to gingival inflammation and subsequent increased 
risk of CP (Reali et al., 2009, Pihlstrom et al., 2005). 
Evidence suggests a multifactorial effect of the systemic consequences of CKD on the 
oral cavity, the result of which is the predisposition to CP (Figure 1.4). However, it 
should be noted that these mechanisms and their interactions need further 
investigation and there may be more complex interactions not yet elucidated. 
Indeed, there may be redundant pathways that still predispose to CP. For example, 
while increased cytosolic calcium has been shown to cause dysfunction in immune 
cells, this can usually be treated by drugs such as calcium channel blockers. However, 
calcium channel blocker can induce gingival hyperplasia and inflammation, which can 
predispose to CP. 
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Figure 1.4 The systemic effects of chronic kidney disease in the oral cavity that can interact with 
chronic periodontitis. ↑=Increased; ↓=Decreased. 
 
1.3.3 Interactions Between the Systemic Effects of CKD and CP 
The systemic and localised effects of CKD and CP and their impact on each other is 
difficult to elucidate, partly due to the complexity of the diseases but also because 
this is an under studied area. However, with careful consideration of the known 
systemic and localised effects of each disease, it is possible to suggest ways in which 
they may interact with each other. The potential interaction of the effects of CP 
(Section 1.3.1) and CKD (Section 1.3.2) is summarised in Figure 1.5 to hypothesize 
how these two diseases may lead to a potential bidirectional relationship. 
The pathogenesis of CKD induces systemic inflammation and a more amenable 
environment in the oral cavity for the growth of periodontal pathogens. 
Furthermore, a dysfunction of the polymorphonuclear leukocytes would make the 
environment more amenable for the colonisation and persistence of periodontal 
pathogens (Rijkschroeff et al., 2016). Considered alone, these changes would 
predispose CKD patients to an increased risk of CP, even without factoring in other 
known confounders such as age, smoking status and diseases such as diabetes. In 
addition, the establishment of CP has the potential to affect CKD due to the systemic 
inflammation produced along with the increased exposure to microorganisms and 
their products into the blood through persistent bacteraemia. With the kidneys 
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playing a vital role through the filtration of the blood, it may cause bacterial products 
to affect renal cells, potentially leading to glomerular and/or tubular damage and 
fibrosis. 
In CKD, the damage to the oral cavity (e.g. loss of teeth and gingival tissue) may also 
cause difficulties in the intake of food and medicine, and may be one of the 
contributing factors to the significant association of CKD and CP. The loss of teeth 
and gingiva may be accelerated in CKD by poor oral hygiene, as it has been shown 
that CKD patients access dental care less frequently (Grubbs et al., 2012). 
Furthermore, uremic patients are reported to be more prone to bacterial infections 
due to malnutrition (Mitch and Maroni, 1999), which impedes the production of 
antibodies and immune cells (De Rossi and Glick, 1996).  
At this current moment in time, much of the evidence for a directional relationship 
(onset of exposure takes places before the outcome) between CKD and CP, points in 
favour of CKD causing CP as there is less to support CP as a cause of CKD. However, 
current consensus suggest that it is more likely that there is a non-directional link 
(onset of the exposure can happen before, during or after the outcome) due to the 
lack of evidence currently available for directional associations. Furthermore, while 
the evidence for the association between CKD and CP is plausible due to interaction 
of systemic effects alone, it would be prudent to investigate the effects of the 
organisms involved in periodontal disease and how they may directly affect CKD and 
the kidneys. This is especially important as periodontal organisms and their products 
have been shown to be directly involved in other systemic diseases, and there is 
evidence for oral microorganisms damaging the kidneys already in other microbial 
diseases. 
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Figure 1.5 Possible interactions between the systemic effects of CKD and CP. 
 
1.4. THE PROPOSED LINK BETWEEN CKD AND CP 
CKD and CP are both common diseases in the general populace and have common 
risk factors such as malnutrition and inflammation, along with their presence being 
more pronounced in developing countries (Van Dyke and Dave, 2005, Luyckx et al., 
2017). As both diseases are highly prevalent independently of each other, it is to be 
expected that there would be some co-morbidity within patients. Indeed, it has been 
described that those patients who have CKD have an increased prevalence of 
periodontitis compared to a geographically matched non-diseased population (Jha et 
al., 2013), with a systematic review of the relationship confirming this in multiple 
populations with an odds ratio of 1.65 (Chambrone et al., 2013). Furthermore, until 
recently the effect of CP on mortality rates was relatively unstudied with only small 
sized cohort studies over short durations. This has made accurate determination of 
mortality effects difficult, as both diseases are multifactorial. Consequently, the 
evidence is contradictory with some studies reporting a detrimental effect (Linden et 
al., 2012, Chen et al., 2011) while other research suggests a more marginal effect 
(Avlund et al., 2009). However, a recent 10 year survival analysis of a large cohort of 
CKD patients found that the mortality rate increased from 32% to 41% when 
periodontitis existed (Sharma et al., 2016). This has also been confirmed by a meta-
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analysis of cohort studies which showed that periodontal disease was associated 
with an increased risk of death in CKD (Zhang et al., 2017). It is therefore plausible to 
suggest that CP increases the severity of CKD and as both CKD and CP are 
inflammatory mediated, this provides an avenue of enquiry to investigate. 
As discussed in Section 3.3, CKD can affect the oral microenvironment with pH 
changes and gingival hyperplasia, making the environment more amenable for 
certain periodontal pathogens that thrive in a more alkaline environment (Listgarten, 
1986). CP also effects CKD by increasing the systemic inflammation, which is evident 
by increased C-reactive protein (Paraskevas et al., 2008). It is plausible that this could 
exacerbate systemic inflammation which is already present in CKD (Pihlstrom et al., 
2005). Indeed, it is becoming more evident that the systemic inflammation induced 
by CP is a potential cause and/or non-traditional risk factor in the progression of CKD 
(Wahid et al., 2013). There have also been suggestions that there is a bidirectional 
relationship between CKD and CP, with gingival tissue being a source of chronic 
inflammation and treatment of CP having a positive effect of glomerular filtration 
rate (Bastos et al., 2011, Fisher et al., 2011).  
While there is increasing evidence in support of a link between the two diseases, the 
mechanisms behind this relationship remain relatively unstudied. Much of the 
evidence reported for the mechanisms is purely observational through cohort studies 
and correlation, not resultant of a direct investigation. Furthermore, as the focal 
infection theory has been modernised to the periodontal medicine concept (Section 
1.2.1), it is important to consider the potential ways in which these periodontal 
microorganisms might cause disease. It may not be as simple as a single causative 
mechanism; it is likely to be a summation of multiple mechanisms. 
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1.5 AIM AND OBJECTIVES 
1.5.1 Aim 
Despite the growing collection of evidence to support an association between CKD 
and CP, the relationship between how the diseases interact with each other is 
unclear. While there has been some large cohort studies investigating CKD and CP, it 
is particularly difficult to find a patient population without various other systemic 
diseases and mitigating factors that can be adjusted for confounding and derive a 
decisive conclusion of the putative interaction. Therefore, laboratory based 
investigations would be useful in order to investigate the effects of  periodontal 
organisms at the biochemical level and determine whether the microorganisms 
implicated in CP have the ability to directly interact with CKD. As there is substantial 
evidence showing that oral microorganisms have multiple mechanisms to elicit a 
distal response in a multitude of diseases, it would be of interest to investigate 
whether these microorganisms and their products can have an effect on in vitro 
kidney based models.  
Thus, the aim of this study was to investigate the microbial products produced by 
periodontitis associated microorganisms using a novel metabolomics approach and 
to identify if any of these products are capable of eliciting a cytotoxic and fibrotic 
response in kidney cell based models. 
 
1.5.2 Objectives 
 Identify and culture a selection of periodontitis keystone pathogens, 
accessory organisms and non-associated microorganisms in a growth 
medium representative of the diseased environment.   
 
 Explore the use of metabolomics as a screening tool to investigate microbial 
products produced by selected microorganisms.  
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 Determine whether the microbial products produced by these 
microorganisms can induce cytotoxic and migratory effects in human kidney 
cells. 
 
 Determine whether the microbial products produced by the selected 
microorganisms can induce fibrotic effects in human kidney cells. 
 
 Identify which, if any, constituent/s of the microbial products have cytotoxic, 
migratory or fibrotic effects on human kidney cells. 
  
Chapter 2: Selection and Growth of Selected Periodontal Pathogens 
25 
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2.1 INTRODUCTION 
The oral bacteria associated with biofilm formation are the main aetiological agents 
behind the inflammatory processes seen in CP with dysregulation of the normal oral 
microbiota being observed (Wahid et al., 2013). CP is caused by the inflammatory 
response to the accumulation of dental plaque around the gingiva that results in an 
increased flow of GCF an inflammatory exudate which bathes the gingival crevice, 
and favours the growth of anaerobic microorganisms (Marsh et al., 2009, Winning et 
al., 2015). 
Many of these periodontitis associated pathogens are difficult to culture in vitro 
which is partly compounded by the lack of available broad host range growth media. 
Indeed, many oral pathogens are also particularly fastidious anaerobes and in some 
notable examples, such as Tannerella forsythia, rely on nutrients secreted by other 
bacteria during synergism (Sharma, 2010). With the growth requirements of many of 
these organisms being specifically evolved to the unique environment of the gingival 
crevice, one of the best ways of cultivating a large collection of these microorganisms 
would be to use a growth medium, which can mimic the biofluid present at this 
environmental interface, which in this case is GCF. However, currently no such 
medium for the universal culture of periodontitis associated organisms is available. 
As this project aims to investigate a selection of microorganisms involved in CP along 
with microbial products produced, it is of particular importance to culture all of these 
organisms in the same growth medium that is more representative of the diseased 
environment. Since the choice of the media that the bacteria are grown in influences 
the biochemical and metabolic state (Dalwai et al., 2006), the development of a 
single medium would allow for better comparisons between the bacteria and 
facilitate further in vitro investigations into the effects of microbial products. 
2.1.1. Background behind Growth Medium Development 
GCF is an inflammatory exudate, which is produced by the epithelial cells that line 
the gingival crevice in the oral cavity and bath the gingiva. The flow of GCF is relatively 
slow in healthy patients. However, in periodontal disease it can increase by up to 30 
fold as part of the inflammatory response to the plaque accumulation (Marsh et al., 
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2009). It is a useful biofluid that can be collected non-invasively and be used to 
monitor periodontal disease and is reported to have a multiple applications in health 
and disease (Mikkonen et al., 2016). The composition has been well characterised 
(Table 2.1) with the inorganic and organic ion content similar to that seen in plasma, 
which is because GCF is derived from this source (Ferguson, 2006). Small organic 
molecule content includes lactic acid, urea, hydroxyproline and Prostaglandin E2 
(PGE2) (Ferguson, 2006). Lactic acid and PGE2 concentrations usually increase with 
severity of inflammation present while urea, which is present at concentrations 
several times higher than in plasma or saliva, appears to decrease with the severity 
of gingivitis, most likely because it is metabolised by periodontal organisms to 
ammonia (Ferguson, 2006). GCF also has a wide range of enzymes derived from 
bacterial leucocytes, and squamous cells with some inter-individual variability 
depending on the bacterial species present.  
Table 2.1 Composition of human gingival crevicular fluid compared to saliva and plasma adapted from 
(Ferguson, 2006) 
Component GCF Saliva Plasma 
Sodium (mmol/L) 91.6 ± 31.1 6-24 152 
Potassium (mmol/L) 17.4 ± 11.7 13-40 4 
Calcium (mmol/L) 5 ± 1.8 0.5-2.8 2.5 
Magnesium (mmol/L) 0.4 ± 0.2 0.3-0.6 1.6 
Phosphate (mmol/L) 1.3 ± 1 0.4-5 2.1 
Protein (g/L) 70 1.2-1.7 70 
Albumin (g/L) 35 0.025 35 
Gamma globulins (g/L) 7.4 0.050 6-12 
 
2.1.2 The Effect of CKD on the Oral Cavity 
It has been well reported that CKD has a multitude of systemic effects on the human 
body, along with localised effects that can alter the balance of different 
environments such as the oral cavity in CP (Chapter 1.3.2). There are some 
suggestions that the increased incidence of periodontal disease in those with CKD is 
due to changes in the oral cavity such as increased urea concentration that may 
predispose CKD patients to increased plaque deposition and predisposition to 
developing CP (Ariyamuthu et al., 2013). 
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To investigate this, the presence of a urease gene was evaluated in microorganisms 
to indicate if the increased urea concentration and subsequent pH changes may act 
as a selection pressure. Using the National Centre for Biotechnology Information 
(NCBI) web platform, all urease like genes were searched for which were present in 
all bacterial species. This highlighted 38 bacteria of 17 different species which had 
this gene or homologous gene present. Of these 17 species identified, four were 
found to be related to periodontal disease and three of these species were from the 
same Fusobacterium genus (Table 2.2) 
Table 2.2 List of microorganisms identified to have a urease gene and implicated in periodontal 
disease.   
Species Identifier Identified Gene 
Fusobacterium nucleatum 
subsp. animalis 
N/A Hypothetical protein FSDG_RS11485 and 
hypothetical protein FSDG_RS04160 
Fusobacterium nucleatum 
subsp. nucleatum  
ATCC 25586 Urease accessory protein UreG, hypothetical 
protein BKN39_RS06810 and hypothetical 
protein FN0683 
Fusobacterium periodonticum  Hypothetical protein FSAG_RS08490 and 
hypothetical protein FSAG_RS07755 
Fusobacterium necrophorum 
subsp. funduliforme 
ATCC 51357 Hypothetical protein HMPREF1049_RS04085 
Treponema denticola  ATCC 35405 hydrogenase nickel incorporation protein 
HypA and hypothetical protein  TDE2660 
 
The Fusobacterium genus is heavily linked to periodontal disease and is known to 
play an important role as an accessory organism due to its ability to co-aggregate 
with other organisms, in particular the keystone pathogens (Signat et al., 2011). 
Furthermore, due to its co-aggregation abilities it can act as an important bridge for 
early and late colonisers of the periodontal pocket and can form synergistic reactions 
with a variety of Gram negative and positive microorganisms, which can facilitate the 
development of CP (Bolstad et al., 1996). Indeed, T. denticola is one of the keystone 
pathogens highly associated with CP and can interact with Fusobacterium species to 
instigate the development of CP (Hajishengallis and Lamont, 2012). 
The high prevalence of Fusobacterium species and T. denticola microorganisms with 
urease genes indicate that the CKD oral cavity may be a more suitable environment 
for these organisms. In particular, with Fusobacterium species playing a pivotal role 
in linking polymicrobial periodontal biofilms and early and late colonisers, the 
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establishment of these species in the CKD oral cavity could be potential factor behind 
the increased levels of periodontal diseases in those with CKD.  
2.1.3 Changes in Oral Microbiota Related to CP and CKD 
There has only been a few studies that have investigated changes in the microbiota 
associated with CKD and CP (Castillo et al., 2007, Torres et al., 2010, Takeuchi et al., 
2007). There is also some confusion over whether there is a significant change in the 
microbiota between CKD patients with CP versus patients only with CP, which is 
compounded by differences between CKD patients on haemodialysis and those who 
are not. One such study observed haemodialysis patients compared with patients not 
receiving haemodialysis; this highlighted that the presence of periodontitis 
microorganisms were more prevalent in those without haemodialysis but there was 
no specific microbial signature and did not present as more severe (Castillo et al., 
2007). A further study assessed the periodontal status and presence of red complex 
periodontal organisms in those with CP alone compared to haemodialysis and CP. 
This found haemodialysis patients had more red complex organisms even when 
shallower periodontal pockets were present compared to those without CKD (Torres 
et al., 2010). Indeed, the differences reported for periodontal status between 
haemodialysis CKD patients and those CKD patients not undergoing haemodialysis 
conceivably could be due to better control of the systemic disease by the 
haemodialysis treatment. This argument is supported by another study which 
showed that while CKD patients with and without haemodialysis have more 
detectable periodontal organisms than healthy controls, those undergoing 
haemodialysis having lower detection rates of these same organisms with the CKD 
subgroup (Takeuchi et al., 2007). 
A pilot study which looked at the effect of end stage renal disease on the subgingival 
microbiome found little difference in the proportional makeup, except for a slight 
decrease in microorganism diversity in those undergoing long term dialysis (Araújo 
et al., 2015). However, a cross sectional study that determined the association of nine 
periodontal pathogens with CKD did not find a specific periodontal profile in CKD but 
did find that T. denticola, T. forsythia and P. micros were significantly associated with 
periodontitis within CKD patients (Ismail et al., 2015). Once a multivariate model had 
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been applied to the data, only age and T. forsythia was independently associated 
with periodontitis in CKD patients. The periodontal pathogens present in CP patients 
with and without CKD was also studied and a strong association was identified 
between more severe CP and an increased frequency of C. albicans, P. gingivalis, T. 
forsythia, and T. denticola in patients with CKD who were on renal replacement 
therapy and pre-dialysis (Bastos et al., 2011).  
From the published works, it may be hypothesized that CP appears to be more severe 
in those with CKD. This could possibly be explained by the presence of two systemic 
diseases having detrimental and/or synergistic interactions with each other. As those 
on haemodialysis had higher detection of periodontal organisms compared to 
controls but less than CKD patients pre-dialysis, this evidence further supports this 
theory given those on haemodialysis would arguably have better control of their CKD. 
The association with a specific profile of periodontal organisms for CKD patients is 
yet to be proved as the small-scale studies that have identified periodontal 
pathogens associated with CKD do not all agree on specific organisms. Furthermore, 
those microorganisms identified as having increased frequency such as P. gingivalis, 
T. forsythia and T. denticola are the keystone pathogens of CP, so might be attributed 
to the development of CP as a whole rather than a specific signature for CKD patients 
alone. 
2.1.4 Chosen Microorganisms 
As there are a large number of periodontitis associated organisms, a selection of 
eight microorganisms were chosen for this study. Six were associated with 
periodontitis, some of which had associations with other systemic diseases. Two 
were not associated with periodontitis with one of these a common member of the 
oral microbiota and the other normally not associated with the oral cavity. The 
chosen microorganisms were divided into three groups: keystone pathogen, 
accessory organisms and non-associated organisms (Table 2.3).  
Whilst there are three identified keystone pathogens in periodontal disease, P. 
gingivalis and T. denticola and T. forsythia (Hajishengallis and Lamont, 2012), only P. 
gingivalis was investigated due to the known difficulties in cultivation of the other 
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keystone pathogens.  P. gingivalis is the easiest of the three keystone pathogens to 
cultivate and is consistently isolated in CP along with the bacterial products produced 
being implicated in various other systemic diseases such as Alzheimer’s (Dominy et 
al., 2019). 
For the accessory organism group five different organisms were chosen to reflect a 
selection of accessory organisms implicated as interacting within CP and also    
implicated in systemic diseases (Table 2.3).  
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Table 2.3 The microorganisms chosen to study for this study and the reasoning behind the choice. 
Microorganism Group Reasoning Reference 
Porphyromonas 
gingivalis 
Keystone 
Pathogen 
A key pathogen in CP because of complex host-
pathogen and community interactions, which can 
cause dysbiosis and promote a pro-inflammatory 
phenotype. In addition, a multitude of virulence 
factors are produced which can cause damage 
and destruction of the periodontium. 
(Hajishengallis, 
2009) 
Actinomyces 
israelii 
Accessory 
organism 
Present in patients with CP more frequently than 
healthy patients, along with those with high 
scores on the plaque index. It may play a role in 
the maturation of sub and supra gingival plaque. 
It is commonly isolated alongside A. 
actinomycetemcomitans suggesting synergy in 
periodontal infection. 
(Vielkind et al., 
2015, Könönen 
and Wade, 
2015) 
Fusobacterium 
nucleatum 
Accessory 
organism 
Reported to play a role as a ‘bridge’ for early and 
late colonisers to co-aggregate. It has also been 
reported to have synergy with T. forsythia in 
inducing an immune response and causing 
alveolar bone loss. Has a putative urease gene. 
(Settem et al., 
2012) 
Parvimonas 
micra 
Accessory 
organism 
A commensal organism commonly found in the 
subgingival plaque and in periodontal plaque 
forms in the top layer. It is not thought to form 
biofilm structures, but has a significant 
association with periodontal destruction. It has 
been associated with CP within the CKD 
subgroup. 
(Zijnge et al., 
2010, Al-
hebshi et al., 
2014) 
Streptococcus 
constellatus 
Accessory 
organism 
A member of the ‘Streptococcus anginosis’ group 
which are common commensals in the oral cavity 
and associated in periodontitis. Implicated in 
periodontitis as providing an attachment 
substratum allowing attachment and 
recolonization of other periodontitis associated 
organisms. Implicated in systemic disease with 
isolates identified from brain abscesses being 
linked to a periodontal pocket source.  
(Colombo et 
al., 1998, Rams 
et al., 2014, da 
Silva et al., 
2004) 
Streptococcus 
sanguinis 
Accessory 
organism 
 A member of the ‘Streptococcus mitis’ group 
which are common commensals in the oral cavity 
and associated in periodontitis. S. sanguinis is 
suggested to play a role in binding of other 
periodontitis associated organisms. The group is 
also linked to systemic disease and are the most 
common cause of infectious endocarditis. 
(Whitmore 
and Lamont, 
2011, 
Hendrickson et 
al., 2017, 
Baker et al., 
2019, Zhu et 
al., 2018) 
Enterococcus 
faecalis 
Non 
associated 
organism 
A normal commensal microorganism commonly 
found in the gastro-intestinal tract and a 
opportunist pathogen in nosocomial infections. It 
is not part of the normal oral microbiota and is 
merely transient. While not linked with 
periodontitis it has been commonly found as a 
cause of root canal infections post treatment. 
(Vidana et al., 
2011, Zehnder 
and 
Guggenheim, 
2009) 
Streptococcus 
mutans 
Non 
associated 
organism 
A normal commensal microorganism found in the 
oral cavity. Not involved in periodontal disease 
but the most common cause of tooth decay 
(dental caries). 
(Loesche, 
1986, Nicolas 
and Lavoie, 
2011) 
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2.2 AIM AND OBJECTIVES 
2.2.1 Aim 
To investigate a selection of periodontitis associated organisms, culture the 
organisms in a suitable medium and collect microbial supernatants over the 
microorganisms lifecycle.  
2.2.2 Objectives 
 Identify a selection of periodontitis associated microorganisms to investigate. 
 Develop a new growth medium that is more representative of the gingival 
crevicular environment and can cultivate all chosen microorganisms. 
 Cultivate the chosen microorganisms in this newly developed growth medium. 
 Collect microbial supernatants from cultivated organisms and control media for 
further investigations.  
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2.3 METHODS 
2.3.1 Development of Artificial Gingival Crevicular Fluid Periodontal (AGCF-P) 
The development and reasoning behind the development of the AGCF-P growth 
medium is fully described in Hickey et al. (2019). 
2.3.1.1 Composition of Base Medium 
The base medium used to modify for the development of AGCF-P was basal medium 
mucin (BMM)(Table 2.4). 
Table 2.4 Ingredients of Basal Medium Mucin 
 
2.3.1.2 Composition of Artificial Gingival Crevicular Growth Medium 
The new growth medium, AGCF-P was composed of (BMM) (Wong and Sissions, 
2001) with multiple modifications as described (Section 2.4.1). The full composition 
of AGCF-P is shown in (Table 2.5). All reagents were procured from Sigma Aldrich, UK 
with the exception of trypticase peptone (Scientific Laboratory Supplies, UK) and 
horse blood (TCS Biosciences, UK). 
  
Ingredient Amount Supplier 
Partially purified pig gastric mucin 2.5 g/L Sigma Aldrich, UK 
Protease peptone 10  g/L Oxoid, UK 
Trypticase peptone 5  g/L Scientific Lab Supplies, UK 
Yeast extract 5  g/L Sigma Aldrich, UK 
Potassium Chloride 2.5  g/L Sigma Aldrich, UK 
Urea 1 mmol/L Sigma Aldrich, UK 
Arginine 1 mmol/L Sigma Aldrich, UK 
Haemin 1 mg/L Sigma Aldrich, UK 
Menadione 1 mg/L Sigma Aldrich, UK 
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Table 2.5 Constituents of Artificial Gingival Crevicular Fluid – Periodontal (AGCF-P) 
 
2.3.2 Cell Culture 
2.3.2.1 Human Gingival Fibroblast Cells 
Human Gingival Fibroblast (HGF-1) primary cells (LGC standards, UK) were cultured 
in Dulbecco Modified Eagle Medium (DMEM) with Glutamine and Glucose (Lonza, 
UK), supplemented with 10% foetal calf serum (Lonza, UK), 50 μg/mL streptomycin 
(Lonza, UK) and 50 μg/mL penicillin (Lonza, UK). Cells were growth-arrested in serum 
free cell culture media, in the absence of foetal calf serum. 
2.3.2.2 Human Kidney Proximal Tubule Cells 
Immortalised Human Kidney Proximal Tubule cells (HK-2) (ATCC, UK) were cultured 
in 50:50 glucose free DMEM (Invitrogen, UK) and Hams F-12 medium (Lonza, UK) 
supplemented with 10% foetal calf serum (Lonza, UK), 50 µg/mL streptomycin 
(Lonza, UK), 50 µg/mL penicillin (Lonza, UK) and 2.5 mMol glutamine (Lonza, UK). 
Cells were growth-arrested in serum free cell culture media, in the absence of foetal 
calf serum.  
2.3.2.3 Maintenance of Cells 
All cells were maintained in a 37°C incubator with 5% CO2, the respective cell culture 
media were changed every other day dependent on the confluency of the cells. When 
cell reached confluency trypsin-EDTA solution (Lonza, UK) was used to disassociate 
cells from the cell culture flasks allowing re-seeding of the cells and continued 
culturing. In order to seed cells, sterile filtered 0.4% trypan blue (Sigma Aldrich, UK) 
was used to check cell viability using a 1:1 ratio with cell suspension. Cell viability was 
Ingredient  Amount (g/L) 
Protease peptone 10 
Trypticase peptone 5 
Yeast extract 5 
KCL 2.5 
Pig Mucin 2.5 
L-cysteine 0.5 
L-arginine 0.17 
Urea 0.18 
Agar no 3 (If solid media required) 12 
Potassium Phosphate monobasic anhydrous 1.68 
Sodium Phosphate dibasic heptahydrate 41.31 
Blood added 5% horse blood serum 
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measured using either a haemocytometer or a TC10 automated cell counter (Bio-
Rad, USA), the number of viable cells was used to work out number of cells seeded 
per well.  
2.3.3 Cell Viability Testing 
To assess the effect of AGCF-P bacterial growth medium on mammalian cell viability, 
the AGCF-P medium was incubated for 5 days in anaerobic conditions without 
bacterial inoculation. At 0 D, 1 D, 2 D, 3 D, 4 D and 5 D aliquots of the AGCF-P medium 
were plated out to check for bacterial contamination. The remaining media was 
centrifuged at 600 x g for 10 min, then filtered using a 0.2 µM Acrodisk filters 
(Scientific Lab Supplies, UK) and stored at -80°C until used.  
The cell viability of HGF-1 and HK-2 cells were tested using the cell counting kit-8 
(Tebu-bio, UK) (Tominaga et al., 1999) which is a more sensitive detector of viable 
cells in comparison to other tetrazolium salts. Cells were seeded into a 96 well plate 
at 5 x 103 cells per well and incubated at 37°C in 5% CO2; a cell culture plate was 
seeded separately for 24 h and 48 h cell viability experiments to allow double dosing 
of the 48 h experiment. The cells were washed with phosphate buffered saline (PBS) 
(Lonza, UK) once 80% confluency was reached and the medium was changed to 
serum free medium. After 24 h in serum free medium, the medium was refreshed 
and bacterial supernatants were added at a 1:20 dilution.  
For 24 h cell viability experiments the plates were observed and photographed 
before and after the experiment, at 24 h 10 µL of the CCK-8 dye was added to each 
well and absorbance readings were taken at 1 h, 2 h and 3 h at 450nm and 600nm using 
a microplate reader (Thermo-Scientific Multiskan 60, UK). For the 48 h incubations 
with supernatants, the serum free media with dilutions was refreshed after 24 h and 
re-incubated at 37°C in 5% CO2. Then, at 48 h the CCK-8 dye was added and 
absorbance readings were taken at 1 h, 2 h and 3 h. 
2.3.3.1 Cell Viability Data Analysis 
All absorbance data was exported to excel and the absorbance at 600nm was taken 
away from the absorbance at 450nm, then the dilutions and dye without cells 
absorbance was taken away in order to produce accurate absorbance values.  
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𝐶𝑒𝑙𝑙 𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =
((450 𝐴𝐵𝑆 –  600 𝐴𝐵𝑆) –  𝐵𝑙𝑎𝑛𝑘 𝑀𝑒𝑑𝑖𝑎 𝑤𝑖𝑡ℎ 𝐷𝑦𝑒)
𝐶𝑒𝑙𝑙 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑜𝑓 𝑐𝑒𝑙𝑙 𝑐𝑢𝑙𝑡𝑢𝑟𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 
× 100 
Individual percentage standard error was calculated and graphs were plotted on 
Prism GraphPad 8.1.1 
% 𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑒𝑟𝑟𝑜𝑟 =
(𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑒𝑟𝑟𝑜𝑟 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒𝑠) 
𝐶𝑒𝑙𝑙 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑜𝑓 𝑐𝑒𝑙𝑙 𝑐𝑢𝑙𝑡𝑢𝑟𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
× 100 
2.3.4 Bacterial Strains and Culture Technique 
2.3.4.1 Microorganisms for testing AGCF-P media 
The microorganisms used to test AGCF-P media were Actinomyces israelii NCTC 
12972, Candida albicans ATCC 2091, Capnocytophaga ochracea NCTC 12371, 
Prevotella intermedia NCTC 13070, Rothia dentocariosa NCTC 10917, Streptococcus 
oralis NCTC 11427, Streptococcus mitis NCTC 12261 and Streptococcus salivarius 
NCTC 8618. 
C. albicans, R. dentocariosa, S. oralis, S. mitis and S. salivarius were grown on AGCF-
P agar or broth at 37oC for 48 h before pictures were taken. A. israelii, was grown on 
AGCF-P agar or broth at 37oC in anaerobic conditions (80% N2 - 10% H2 - 10% CO2) in 
a Baker-Ruskin Concept Plus anaerobic incubator (Ruskin, UK) for 48 h before 
pictures were taken. 
2.3.4.2 Chosen Microorganisms to study 
The microorganisms used in this study were Actinomyces israelii NCTC 12972, 
Enterococcus faecalis NCTC 775, Fusobacterium nucleatum sub fusiforme NCTC 
11326, Parvimonas micra NCTC 11808, Porphyromonas gingivalis NCTC 11834, 
Streptococcus constellatus NCTC 11325, Streptococcus mutans NCTC 10449 and 
Streptococcus sanguinis NCTC 7863. 
A. israelii, F. nucleatum, P. micra and P. gingivalis were grown on AGCF-P agar or 
broth at 37 oC in anaerobic conditions. E. faecalis, S. constellatus, S. mutans and S. 
sanguinis were grown on AGCF-P agar or broth at 37oC in carbon rich conditions (5% 
CO2) in a CO2 incubator (LEEC, UK). 
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2.3.5 Preparation of Overnight Cultures 
Overnight cultures were prepared by inoculating a single colony of a chosen organism 
into 5 mL of AGCF-P liquid media and incubated for 24 h in anaerobic conditions or 
in 5% CO2 for E. faecalis, S. constellatus, S. mutans and S. sanguinis. Due to the slow 
growth of P. gingivalis overnight cultures, they were cultured for 48 h to allow 
sufficient growth. Once grown, the cultures were centrifuged at 600 x g for 10 min 
taking care to use Suba Seals (Sigma, UK) for strict anaerobic cultures when 
centrifuging outside the anaerobic environment. Once centrifuged, the supernatants 
were removed and the cells were re-suspended in PBS (Sigma Aldrich, UK). The 
bacteria were adjusted to an optical density (OD) of 1.0 ± 0.05 using a 
spectrophotometer (Jenway 6305, UK) which was calibrated with PBS.  
2.3.6 Growth Curves 
Three overnight cultures were grown of the chosen microorganism and once an OD 
of 1.0 ± 0.05 was obtained, 1 mL per 100 mL of overall culture was inoculated into 
three sterile culture flasks with liquid AGCF-P growth media (n=3). In order to account 
for the degradation of growth media over time, three non-inoculated culture flasks 
with liquid AGCF-P growth media were also sampled alongside the chosen 
microorganisms and for the same time points. Alternatively, large vented cell culture 
flasks (Fisher Scientific, UK) were used for long-term cultures in the anaerobic cabinet 
to reduce contamination. 
For the chosen keystone pathogen, P. gingivalis, six time points were chosen (0 D, 1 
D, 2 D, 3 D, 4 D, 5 D) to reflect the different stages of bacterial growth. For all these 
time points, CFU/mL of culture (Section 2.2.5) were recorded to quantify the 
numbers of viable microorganisms over time and bacterial supernatants (Section 
2.2.6) were sampled at (0 D, 1 D, 2 D, 3 D, 4 D, 5 D) for further analysis. 
For all chosen accessory organisms and non-associated organisms, six time points 
were chosen (0 h, 2 h, 4 h, 6 h, 24 h and 48 h) to reflect the different stages of 
bacterial growth taking into account the manufacturer’s recommendations. CFU/mL 
of culture were recorded at all time points to quantify the numbers of viable 
microorganisms over time. Bacterial supernatants were also sampled at four time 
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points (0 h, 6 h, 24 h, 48 h), due to the first four time points being close and limitations 
regarding long-term storage space for the supernatants.  
2.3.7 Colony Forming Unit per mL Quantification  
At each time point CFU/mL were quantified using the Miles-Misra droplet method 
(Miles et al., 1938). Serial dilutions were completed from 10-1 to 10-8 of the triplicate 
bacterial cultures and three technical replicate droplets of 20 µL for each serial 
dilution was plated out on AGCF-P agar plates divided into thirds. These agar plates 
were incubated for a 24-48 h period in the chosen growth conditions dependent on 
the microorganism. Once grown the plates were stored at 4°C in a refrigerator until 
ready to be counted. For each time point the droplets with the lowest dilution and a 
countable number of colonies (between 3 and 30) was chosen. The average number 
of colonies for the three technical replicates was recorded for each biological and 
exported into an Excel spreadsheet. The CFU/mL was calculated using this formula: 
𝐶𝑜𝑙𝑜𝑛𝑦 𝐹𝑜𝑟𝑚𝑖𝑛𝑔 𝑈𝑛𝑖𝑡𝑠 𝑝𝑒𝑟 𝑚𝐿 (𝐶𝐹𝑈/𝑚𝐿)  
=  
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠 ×  𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟
 𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑐𝑢𝑙𝑡𝑢𝑟𝑒 𝑝𝑙𝑎𝑡𝑒
 
Standard error was calculated of the biological replicates using this formula: 
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝐸𝑟𝑟𝑜𝑟 (𝑆𝐸)  =  
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑏𝑖𝑜𝑙𝑜𝑔𝑖𝑐𝑎𝑙 𝑟𝑒𝑝𝑙𝑖𝑐𝑎𝑡𝑒𝑠
 √ number of replicates
  
2.3.8 Preparation of Bacterial Supernatants  
Bacterial supernatants were prepared for further analysis by sampling the control 
and inoculated AGCF-P broth. At each chosen time point, 5 mL of inoculated broth 
and respective controls were sampled into separate 10 mL plastic universals and 
centrifuged at 3018 x g for 10 min. Ensuring the pellet was not disturbed; the 
supernatants were filtered into two sterile glass bijoux per sample using 5 mL 
disposable syringes and 0.2 µM Acrodisk filters (Scientific Lab Supplies, UK). These 
samples were labelled and stored at -80oC until ready for use. 
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2.3.9 Statistical Analysis 
A two-way ANOVA with multiple comparisons was used to determine significant 
differences between the cell viability control and different time points of AGCF-P. All 
statistical analysis was conducted using Prism GraphPad 8.1.1 software. 
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2.4 RESULTS 
2.4.1 Development of a Suitable Growth Medium for this Study 
After a literature search for a suitable media to use as the base to develop a new 
medium, it was determined that the best candidate was an artificial saliva based 
media called Basal Medium Mucin (BMM) (Table 2.4) (Wong and Sissions, 2001).  
2.4.1.1 Modifications to Create the New Growth Medium AGCF-P 
While BMM was an excellent base to design a medium that represents the GCF, it 
needed to be modified to be more representative of the GCF, as BMM was designed 
to mimic saliva along with having supplements for the growth of Treponema spp and 
haemin and menadione supplemented in the absence of blood. From the base BMM 
medium, haemin and menadione were removed. 
As the inorganic and organic constituents of GCF are most similar to serum (Table 
2.1) the addition of 5% horse blood was added to the medium after autoclaving. In 
order to more accurately mimic the GCF in periodontal disease the pH was modified 
to physiological level.  
The full composition of AGCF-P is shown in (Table 2.5). 
2.4.1.2 Testing Suitability for Liquid and Solid Culture 
A selection of microorganisms present in the laboratory and related to chronic 
periodontitis or oral health (Section 2.3.4.1) were tested for their ability to grow in 
both liquid and solid AGCF-P medium. The microorganisms were cultured in liquid 
culture (Images not shown as the media is viscous) and streaked onto solid AGCF-P 
agar plates, with (Figure 2.1) showing a selection of these organisms grown on agar.
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Figure 2.1 A selection of images of oral associated microorganisms grown on AGCF-P agar. A) A. israelii B) C. albicans C) C. ochracea D) F. nucleatum E) P. intermedia F) R. 
dentocariosa G) P. gingivalis H) S. salivarius  
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2.4.1.3 Testing Suitability for Cell Culture Applications 
The effect of the AGCF-P medium on the cell viability of HGF-1 (Figure 2.2), and HK-2 
(Figure 2.3) cells was assessed by exposure to 1:20 dilutions of AGCF-P supernatants 
incubated over a 5-day period in anaerobic conditions.  Although the cell viability of 
HGF-1 was slightly increased (Figure 2.3), there was no significant effect of AGCF-P 
supernatants on the viability of these cells or HK-2 cells after 24 h (Figure 2.2A and 
2.3A) or 48 h (Figure 2.2B and 2.3B) of incubation, as compared to control cells 
exposed to serum-free cell culture medium only. 
 
Figure 2.2 Cell viability of HGF-1 cells after 24 h (A) or 48 h (B) of incubation with 1:20 dilutions of AGCF-P 
supernatants collected over 5 days. Viability is presented as percentage change from the control (C: cells exposed 
to serum-free cell culture medium) and error bars represent SEM (n=3). 
 
Figure 2.3 Cell viability of HK-2 cells after 24 h (A) or 48 h (B) of incubation with 1:20 dilutions of AGCF-P 
supernatants collected over 5 days. Viability is presented as percentage change from the control (C: cells exposed 
to serum-free cell culture medium) and the error bars represent SEM (n=3). 
2.4.2 Cultivation of Keystone Pathogens 
2.4.2.1 Porphyromonas gingivalis 
Growth curves of P. gingivalis were conducted in AGCF-P broth over 5 days in 
triplicate. CFU/mL were recorded of all biologicals and standard error was calculated 
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and plotted on a graph (Figure 2.4). P. gingivalis reached a good level of growth after 
1 D, averaging at 108 CFU/mL indicating that the developed AGCF-P media was 
sufficiently nutritious to support the growth. The exponential phase of bacterial 
growth approximately takes place from 0-1 D, stationary phase from 1-4 D and death 
phase from 4-5 D (Figure 2.4). 
 
Figure 2.4 Colony forming units per mL of Porphyromonas gingivalis cultured in AGCF-P and anaerobic 
conditions for 5 D (n=3). 
2.4.3 Cultivation of Accessory Organisms 
2.4.3.1 Actinomyces israelii 
Growth curves of A. israelii were conducted in AGCF-P broth over 48 h in triplicate, 
with CFU/mL recorded (Figure 2.5). A. israelii reached a good level of growth after 1 
D, averaging at 107 CFU/mL indicating that the developed AGCF-P media was 
sufficiently nutritious to support the growth. The exponential phase of bacterial 
growth approximately takes place from 0-8 h, stationary phase from 8-48 h with 
death phase beginning upon 48 h (Figure 2.5). 
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Figure 2.5 Colony forming units per mL of Actinomyces israelii cultured in AGCF-P and anaerobic 
conditions for 48 h (n=3). 
2.4.3.2 Fusobacterium nucleatum 
Growth curves of F. nucleatum were conducted in AGCF-P broth over 48 h in 
triplicate, with CFU/mL recorded (Figure 2.6). A. israelii reached a good level of 
growth after 1 D, averaging at 107 CFU/mL indicating that the developed AGCF-P 
media was sufficiently nutritious to support the growth. The exponential phase of 
bacterial growth approximately takes place from 0-8 h, stationary phase from 8-48 h 
with death phase beginning upon 48 h (Figure 2.6).  
 
Figure 2.6 Colony forming units per mL of Fusobacterium nucleatum cultured in AGCF-P and anaerobic 
conditions for 48 h (n=3). 
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2.4.3.3 Parvimonas micra 
Growth curves of P. micra were conducted in AGCF-P broth over 48 h in triplicate, 
with CFU/mL recorded (Figure 2.7). P. micra reached a good level of growth after 1 
D, averaging at 108 CFU/mL indicating that the developed AGCF-P media was 
sufficiently nutritious to support the growth. The exponential phase of bacterial 
growth approximately takes place from 0-20 hours, stationary phase from 20-40 h 
with death phase beginning upon 40 h (Figure 2.7). 
 
Figure 2.7 Colony forming units per mL of Parvimonas micra cultured in AGCF-P and anaerobic 
conditions for 48 h (n=3). 
2.4.3.4 Streptococcus constellatus 
Growth curves of S. constellatus were conducted in AGCF-P broth over 48 h in 
triplicate, with CFU/mL recorded (Figure 2.8). S. constellatus reached a good level of 
growth after 1 D, averaging at 107 CFU/mL indicating that the developed AGCF-P 
media was sufficiently nutritious to support the growth. The exponential phase of 
bacterial growth approximately takes place from 0-20 h, stationary phase from 20-
40 h with death phase beginning upon 40 h (Figure 2.8). 
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Figure 2.8 Colony forming units per mL of Streptococcus constellatus cultured in AGCF-P and carbon 
rich conditions (5% CO2) for 48 h (n=3). 
2.4.3.5 Streptococcus sanguinis 
Growth curves of S. sanguinis were conducted in AGCF-P broth over 48 h in triplicate, 
with CFU/mL recorded (Figure 2.9). S. sanguinis reached a good level of growth after 
1 D, averaging at 108 CFU/mL indicating that the developed AGCF-P media was 
sufficiently nutritious to support the growth. The exponential phase of bacterial 
growth approximately takes place from 0-25 h, stationary phase from 25-48 h with 
death phase beginning upon 48 h (Figure 2.9). 
 
Figure 2.9 Colony forming units per mL of Streptococcus sanguinis cultured in AGCF-P and carbon rich 
conditions (5% CO2) for 48 h (n=3). 
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2.4.4 Other Organisms Related to Oral Disease 
2.4.4.1 Enterococcus faecalis 
Growth curves of E. faecalis were conducted in AGCF-P broth over 48 h in triplicate, 
with CFU/mL recorded (Figure 2.10). E. faecalis reached a good level of growth after 
1 D, averaging at 108 CFU/mL indicating that the developed AGCF-P media was 
sufficiently nutritious to support the growth. The exponential phase of bacterial 
growth approximately takes place from 0-8 h, stationary phase from 8-48 h with 
death phase beginning upon 48 hours (Figure 2.10). 
 
Figure 2.10 Colony forming units per mL of E. faecalis cultured in AGCF-P carbon rich conditions (5% 
CO2) for 48 h (n=3). 
2.4.4.2 Streptococcus mutans 
Growth curves of S. mutans were conducted in AGCF-P broth over 48 h in triplicate 
with CFU/mL recorded (Figure 2.11). S. mutans reached a good level of growth after 
1 D, averaging at 107 CFU/mL indicating that the developed AGCF-P media was 
sufficiently nutritious to support the growth. The exponential phase of bacterial 
growth approximately takes place from 0-20 h, stationary phase from 20-30 h with 
death phase beginning upon 48 h (Figure 2.11). 
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Figure 2.11 Colony forming units per mL of Streptococcus mutans cultured in AGCF-P and carbon rich 
conditions (5% CO2) for 48 h (n=3). 
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2.5 DISCUSSION 
2.5.1 The Development of a Representative Growth Medium 
BMM was chosen as base medium for modification as it has been successfully used 
to emulate saliva and grow dental plaque bacteria in an ‘artificial mouth’ system. 
Furthermore, it is useful as it has been reported GCF has a similar composition to 
saliva while having similar organic and inorganic components to those found in blood 
plasma (Table 2.1) (Ferguson, 2006). 
2.5.1.1 Reasoning Behind Modifications 
The pH of the growth medium was modified as the pH of GCF is often stated to be 
between 7.5 and up to 8.0, it is also has been shown that the pH of GCF increases 
with severity of GCF. One thing to consider is many readings of pH take place in 
absence of physiological CO2 (pCO2). However, when the PCO2 of 4.7 kPa (35 mmHg) 
and physiological temperature (37oC) was taken into account, the measured pH was 
7.96 ± 0.10 (Wong and Sissions, 2001). Furthermore, at pCO2 the total buffering 
power becomes high above pH 8.0 because of the high bicarbonate concentration, 
therefore the pH of GCF cannot surpass 8.0 regardless of the severity of 
inflammation. In order to attain the desired pH of 7.9 ± 0.1 for AGCF-P the phosphate 
buffer system was utilised which uses potassium phosphate monobasic anhydrous 
(KH2PO4) and sodium phosphate dibasic heptahydrate (Na2HPO4 · 7H2O). In order to 
achieve the desired pH of 7.9 ± 0.1, even after the addition of blood it was calculated 
that the addition 1.68 g/L potassium phosphate monobasic anhydrous and 49.89 g/L 
sodium phosphate dibasic heptahydrate was required. 
Urea composition was modified as it is several times higher in GCF compared to saliva 
(Table 2.4). The actual urea concentration is reported to be similar to the amount in 
serum at between 1-10 mM and it is also reported that urea levels decrease with 
severe gingivitis (Golub et al., 1971). This may be related to the pH as it has been 
suggested that the rise in pH seen in periodontitis is related to urea being hydrolysed 
by periodontal pathogens to ammonia potentially explaining the inverse relationship 
between urea concentrations and pH of the GCF in severe periodontitis. Urea 
concentration in the saliva or controls was reported at around 18 mg/dL ± 2 (Peterson 
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et al., 1985) while that is the saliva concentration we can relate this to GCF as urea 
levels are similar between the two biofluids. The chosen urea concentration to reflect 
the amount found CP GCF was 3 mmol/L (0.18 g/L). Cysteine was also added as a 
reducing agent to further mimic the reducing capacity and support the growth of 
anaerobic organisms. Indeed, the addition of horse blood rather than horse serum 
takes into account the red blood cell infiltration that is reported in GCF (Barros et al., 
2016). 
2.5.1.2 Summary 
Currently, the development of media optimally designed for the growth of 
periodontal organisms has predominately focused on selective growth media for 
specific organisms such as for Aggregatibacter actinomycetemcomitans and their 
clinical isolation (Rurenga et al., 2012, Tsuzukibashi et al., 2008). Mimicking the 
chemical components of the physiological environment is a strategy that has been 
used to cultivate particularly fastidious or uncultivatable organisms and can influence 
the bacterial products present (Kaeberlein et al., 2002, Vartoukian et al., 2010). 
Emulating some of the elements of GCF should allow for more representative growth 
of disease-related organisms. As alternative nutrient sources available may stimulate 
regulatory changes in gene expression profiles leading to the production of 
environment specific bacterial products, such as metabolites and secreted proteins 
(Shimizu, 2014, Balleza et al., 2009). 
One of the objectives of this chapter was to develop a general-purpose growth 
medium that was representative of the gingival crevicular environment and could 
cultivate a large selection of periodontitis associated organisms. The developed 
AGCF-P medium was successful at cultivating a selection of periodontitis associated 
pathogens and should further facilitate research into their role in the pathogenesis 
of CP as it produces more biologically relevant conditions. Furthermore, cell viability 
testing of incubated AGCF-P media against human cells also indicated that the 
developed media had no adverse effects on either cell type after 24 h or 48 h of 
exposure. Indeed, the mild positive effect of AGCF-P on the viability of primary 
gingival fibroblasts can be attributed to an increased cell proliferation due to 
nutrients provided by AGCF-P. The lack of negative effects of AGCF-P medium on 
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human cell viability can further facilitate the development of in vitro and ex vivo 
models of CP. 
2.5.2 The Growth of the Chosen Microorganisms 
The microorganisms selected to investigate were representative of the two groups 
of microorganisms reported to be involved in CP, the keystone pathogens and 
accessory organisms, along with two non-associated organisms as controls. All of 
these microorganisms grew successfully in the developed growth medium AGCF-P, 
indicating its usefulness as a growth media for investigating CP. 
The starting CFU/mL of all microorganisms was not necessarily consistent; this is 
because the AGCF-P medium could not be used to adjust absorbance to the desired 
OD due to opacity so PBS had to be used. This may also be the reason behind a wider 
difference in starting CFU/mL between all microorganisms especially in the different 
growth conditions of anaerobic and carbon rich. All the microorganisms reached 
exponential and stationary stages of growth with the majority reaching death phase. 
This is of particular importance as microbial products can change dependent on stage 
of growth and these microbial products are the subject of this study. From each 
microorganism, bacterial supernatants were successfully collected and stored for 
further experiments (Chapters 3, 4 and 5). 
  
Chapter 2: Selection and Growth of Selected Periodontal Pathogens 
53 
 
2.6 CONCLUSIONS 
The developed AGCF-P was a robust medium for cultivating a selection of 
periodontitis associated pathogens that will further facilitate research into their role 
in the pathogenesis of CP by producing more biologically relevant conditions. This 
singular medium can allow for more comprehensive and robust comparisons 
between organisms in order to further identify key microbial products produced and 
effects on the human host. The lack of negative effects of AGCF-P medium on human 
cell viability can further facilitate the development of in vitro and ex vivo models of 
CP infection.  
The cultivation of a selection of microorganisms implicated in CP along with control 
organisms and the collection of bacterial supernatants can facilitate further 
investigations into the microbial products produced. The collected supernatants can 
be investigated for microbial products that may play a role in pathogenesis of CP and 
play a role in interacting with other systemic diseases such as CKD. Initially, it would 
be of interest to utilise a method such as untargeted metabolomics to mass-screen 
these supernatants for any microbial products of interest; this forms the content of 
the next chapter (Chapter 3). 
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CHAPTER 3: METABOLOMICS 
BASED INVESTIGATIONS 
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3.1 Introduction 
3.1.1 Metabolomics 
The study of metabolites, metabolomics, is an emerging ‘omics’ field which focuses 
on the study of the chemical pathways and products which are present within an 
organism. Unlike genes and proteins which are subject to various post translational 
or epigenetic changes, metabolites are the direct biochemical signature of the 
reactions and biochemical pathways being undertaken and are a therefore a more 
realistic comparison to the phenotype (Patti et al., 2012). Metabolomics is 
increasingly being used to study plant (Allwood et al., 2008), microbial (Bradley et al., 
2009) and mammalian (Kenny et al., 2010) systems in order to elucidate which 
metabolites are of biological importance in relation to genes, environmental 
interactions or diseased states. With advances in mass spectroscopy it is now 
possible to use untargeted metabolomics to rapidly measure thousands of 
metabolites from small samples and interpret them, while overlaying genetic and 
proteomic data to provide a greater overview of interactions (Pirhaji et al., 2016).  
Bacterial metabolites can be considered the language of the microbiota as they 
change directly based on host-organism interactions, organism-organism 
interactions, diet and disease state. Microorganisms can also be directly responsible 
for changes seen in the diseased microenvironment; with the metabolism of urea to 
ammonium ions thought to be responsible for the rise in pH seen in the gingival 
crevice in CP (Ferguson, 2006). Microorganisms are known to generate primary and 
secondary metabolites and some of these have been shown to interact with the 
human body through immune regulation (Brestoff and Artis, 2013), protection 
against pathogens (Clarke et al., 2010) and metabolism of synthetic substances (Kuhn 
et al., 2014). With CP providing a point of entry to systemic circulation through its 
blood supply and bacteraemia, it is plausible that oral microorganisms and their 
metabolites can freely circulate around the body, with the potential of deleterious 
effects on the mammalian host especially in those organs such as the liver and 
kidneys that are responsible for filtration and detoxification. 
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3.1.2 Evidence for the Role of Metabolites in CKD  
While the field of metabolomics is a relatively new phenomenon, identification of 
individual metabolites that are dysregulated within diseases has been an area of 
interest for a long period of time in CKD, particularly for clinical diagnoses. The most 
well-known example of this is urea which is a nitrogenous degradation product of 
protein in mammals and was identified as dysregulated in CKD in the 1850s and 
useful for clinical diagnosis of the disease (Thudichum, 1857). In addition, other 
endogenous filtration factors representative of glomerular filtration rate such as 
Creatinine and Cytostatin C have thereafter been identified and successfully 
employed for the clinical diagnosis of CKD in gold standard blood tests for kidney 
function (Sandilands et al., 2013). While these metabolites have been identified as 
useful for the diagnosis of kidney disease, it is predominately due to the increased 
presence of these metabolites being indicative of the kidney not functioning properly 
rather than being involved in the pathogenesis of the disease. However, more recent 
investigations into identification of ‘dietary metabolites’ which are indicative of CKD 
and the progression of the disease has highlighted advanced glycated end products 
and indoxyl sulphate as being closely linked to progression as well as being uremic 
toxins that can directly affect the disease (Hasegawa et al., 2017). 
Advances in technology have allowed a host of other metabolites to be identified 
from various methods such as Genome Wide Association Studies (GWAS) and Liquid 
Chromatography Mass Spectroscopy (LCMS) analysis of urine and serum metabolites 
and their association with kidney decline. A GWAS investigating the excretion of 
serum and urine metabolites in relation to CKD highlighted genetic influences on 
metabolite concentrations that can effect CKD. Some of the main genetic influences 
detected were in polyamines such as putrescine, medium-chain acylcarnitines and 
various amino acid ratios such as lysine/glutamine ratio that may be associated with 
CKD (Li et al., 2018). The role of polyamines such as putrescine, spermidine and 
spermine along with  acrolein which is the by-product of polyamine degradation, has 
previously been highlighted in CKD patients with acrolein levels found to be fivefold 
higher compared to controls in serum and may act as a uremic toxin (Igarashi et al., 
2006). Indeed, LCMS based investigations further highlighted the polyamine 
spermidine along with two other metabolite ratios, the phosphatidylcholine diacyl 
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C42:5-to-phosphatidylcholine acyl-alkyl C36:0 ratio and the kynurenine-to-
tryptophan ratio to higher incidences of CKD (Goek et al., 2013). 
3.1.3 Evidence for the Role of Metabolites in CP 
In CP, investigations into the role various metabolites may play in progression or for 
the clinical diagnosis of the disease is much less studied. This is possibly due to the 
success of oral periodontal pocket examination for accurate staging of the 
progression of disease. However, the diversity of the microbiota and the different 
organisms existent in disease states such as CP, present a unique opportunity for 
metabolic profiling to take place. Preliminary metabolomic analysis of saliva samples 
has shown that healthy patients can be separated from those who have various forms 
of periodontitis by analysing the metabolites present, with CP having a distinct 
metabolic signature (Aimetti et al., 2012). Indeed, metabolomic analysis of saliva 
samples before and after removal of supragingival plaque has highlighted two 
metabolites, cadavarine and hydrocinnamate, which are associated with periodontal 
inflammation (Sakanaka et al., 2017). Other pathways such as polyamine 
metabolism, arginine and proline metabolism, butyric acid metabolism, and lysine 
degradation have also been associated with periodontal inflammation (Sakanaka et 
al., 2017, Shah and Swiatlo, 2008). Some progress has been made into the 
development of prediction models for CP based on metabolite concentrations, with 
the combination of cadavarine, 5-oxoproline, and histidine biomarkers being shown 
to be the most accurate predictor of periodontitis out of the metabolites identified 
so far (Kuboniwa et al., 2016). 
3.1.4 Metabolites Reported to be Dysregulated between Both Groups 
Despite various metabolites having been reported to be dysregulated in both CP and 
CKD, the only common metabolites/metabolite class identified is polyamines and 
their degradation by-products. Polyamines (PA) such as Spermine, Putrescine and 
Cadavarine are a fundamental class of small polycations that are relatively genetically 
conserved within nature and are reported to have a wide range of roles in 
mammalian cells such as transcription, stress response, translation, growth and 
apoptosis (Pegg, 2009). Indeed, in microorganisms their role is not fully elucidated 
either with suggestions of being involved in stress response along with stabilisation 
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of DNA and RNA and gene deletion studies predominately highlighting cell 
proliferation and survival (Gevrekci, 2017). PAs are predominantly produced from the 
amino acids ornithine and methionine (Kuksa et al., 2000), which corresponds with 
the theme of amino acid metabolic by-products which have been identified as 
potentially dysregulated metabolites in CP and CKD. There has been some toxicity 
studies on PAs with high levels of spermine being reported to be potentially 
nephrotoxic and most likely capable of renal damage (Tabor and Rosenthal, 1956, 
Pegg, 2009). Indeed, dysregulation of PAs and associated metabolites has been 
reported to potentially lead to conditions such as cancer, diabetes, renal failure, 
stroke and inflammation (Pegg, 2013, Park and Igarashi, 2013) 
However, despite being essential across all kingdoms of life and tightly regulated 
there is no unifying biochemical role of PAs identified as of yet (Miller-Fleming et al., 
2015). With a large number of essential cellular processes being linked to PAs it is 
understandable that the wide number of associated diseases has led to PAs being 
heavily identified as dysregulated in many metabolomics studies (Miller-Fleming et 
al., 2015). The relative non-specificity of PAs and associated metabolites along with 
the ubiquitous nature of the molecules would be a large hindrance for associations 
with diseases, especially as multiple sources such as number of specific 
microorganisms, inflammation, other diseases and genetics may affect the 
concentration of PAs.  
3.1.5 Approach to Investigating Potential Metabolites Dysregulated in CP and CKD 
With little research having been carried out on this topic area and only one 
metabolite class of interest, it would not be beneficial in conducting a targeted 
metabolic investigation. Instead, by utilising an untargeted screening approach it 
should allow the identification of a wide selection of molecules/classes of molecules 
that change with the addition of microorganisms of interest. With an untargeted 
approach the only metabolite group linked as dysregulated in both diseases, PAs, can 
be looked for alongside a wide selection of other known molecules as the PA mass 
spectrum has already been well reported (Magnes et al., 2014). 
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We hypothesize that development of an LCMS based untargeted metabolomics 
pipeline can facilitate rapid screening of microorganisms associated with CP and 
potentially identify metabolites of interest that may elicit an effect on renal cells. 
In order to trial an untargeted metabolomics approach to identification of 
dysregulated metabolites one microorganism, Streptococcus constellatus, was 
chosen to be provisionally investigated due to its role as a normal member of the 
microbiota associated with periodontitis (Colombo et al., 1998) and systemic 
diseases such as bacteraemia and abscesses (Balleza et al., 2009, da Silva et al., 2004).  
S. constellatus was cultured over 48 hours in two separate growth media, brain heart 
infusion broth (BHIB) and tryptone soya broth (TSB) to investigate discernible 
microbial products following growth in different broths. The newly developed 
medium AGCF-P (Chapter 2) was not used for this provisional test as it was being 
developed concurrently to this metabolomics pipeline. The S. constellatus samples 
cultured in BHIB and TSB were analysed through an untargeted metabolomics 
workflow developed in house and the results analysed to evaluate the suitability of 
this workflow for this study. 
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3.2 AIM AND OBJECTIVES 
3.2.1 Aim 
To develop a microbial metabolomics workflow in house utilising LCMS, that is 
capable of analysing the supernatant of microbial samples for dysregulation of 
metabolites.  
3.2.2 Objectives 
 Develop a workflow for the metabolomic analysis of bacterial products. 
 Test the developed workflow with one oral microorganism. 
 Evaluate the developed workflow and its suitability for identification of 
dysregulated metabolites. 
 Evaluate the workflow for the potential to mass screen a selection of 
periodontitis associated microorganisms. 
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3.3 METHODS 
3.3.1 Bacterial Culture and Statistical Analysis 
The S. constellatus type strain NCTC 11325 was grown on Brain Heart Infusion Agar 
(Oxoid, UK) and Tryptone Soya Agar (Oxoid, UK) in a 5% CO2 incubator for 48 h. A 
single colony was used to inoculate 5 mL of BHIB (Oxoid, UK) and 5 mL of TSB (Oxoid, 
UK) for static overnight cultures. Three biological replicates of each organism were 
grown in 250 mL culture flasks for 48 h for each growth media with a starting bacterial 
absorbance of 1.0 ± 0.1 at an optical density (OD) of 540 nm and control broths were 
also prepared and sampled alongside. OD and CFU/mL monitored growth over a 48 
h period at 0 h, 2 h, 4 h, 6 h, 24 h and 48 h hours. A t-test with Welch’s correction 
was applied to the OD and CFU/mL results using Prism GraphPad 8.1.1 software to 
determine any significant difference between samples. Cell supernatants were taken 
at 0 h, 6 h, 24 h and 48 h to be prepared for LCMS analysis. 
3.3.2 Preparation of Microbial and Control Supernatants for LCMS Analysis 
Cold phase methanol extraction was used to prepare microbial and growth media 
supernatants for LCMS analysis. At chosen time points, 5 mL samples were taken in 
triplicate from bacterial cultures and untreated media and centrifuged at 3018 x g 
for 10 min. The resultant supernatant was transferred into a sterile universal and the 
pellet discarded. From each sample, 1000 µL was transferred into a 1.5 mL 
microcentrifuge tube and 300 µL of cold methanol with 0.1 M formic acid (Sigma 
Aldrich, UK) was added, followed by centrifugation at 13400 x g for 20 min. From 
each sample 400 µL was transferred into a sterile Bijoux and diluted with 800 µL of 
LCMS grade water, then 200 µL was taken and diluted with 800 µL of methanol 
(Sigma Aldrich, UK). The resultant solution was filtered using a 0.2 µM Acrodisk filter 
(Scientific Lab Supplies, UK) into 2 mL LCMS vials (Agilent, USA) and labelled. The 
calculated dilution factor was 0.256. 
3.3.3 Preparation of Wash Samples and Blanks 
Wash samples were created to clean out the column after quantification of analytical 
standards to enable better sensitivity; 1 mL of methanol with 0.1 M formic acid was 
filtered through a 0.2 µM Acrodisk filter into 2 mL LCMS vials. Blanks were created to 
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account for any residual contaminants in the LCMS column; 1 mL of HPLC grade water 
(Sigma Aldrich, UK) was filtered through 0.20 µM filter into 2 mL LCMS vials. All 
samples were frozen at -80oC until ready for analysis. 
3.3.4 Instrument Parameters 
LCMS analysis was performed using an Agilent 6540 UHD Q-TOF LCMS system 
(Agilent, USA) equipped with an ACE UltraCore 2.5 µm SuperC18™ 100 mm x 2.1 mm 
column (Advanced Chromatography Technologies, Scotland). The analysis was 
conducted in positive ion mode at 45°C with a MS range of 100-3000 and calibrated 
using four reference masses. The mobile phase used was LCMS grade acetonitrile 
with 0.1% formic acid (Sigma Aldrich, UK) and LCMS grade H2O with 0.1% formic acid 
(Sigma Aldrich, UK) was the polar solvent. A flow rate of 0.3 mL/min was used with 
each sample run for 30 min and 10 µL injections taken from each sample. 
3.3.5 Data Processing 
3.3.5.1 Conversion of Files 
All .D output files from the LCMS were converted to the open source .mzML format 
to facilitate further analysis using the open source converter ProteoWizard 
MSConvert (Chambers et al., 2012). The output format selected was .mzML and the 
peak-picking filter was chosen as this uses centroidisation, which facilitates the use 
of the centWave for feature detection. 
3.3.5.2 Deconvolution of Data 
Deconvolution of the data was completed through the open source LCMS data 
processor XCMS online (Gowda et al., 2014). A single job was conducted of all 
samples using a customised parameter created based on HPLC/UHD Q-TOF template, 
which is the closest to our LCMS analyser Agilent LCMS 6540 UHD Q-TOF and a 
feature detection limit of <50% and relative standard deviation of <20 was chosen. 
This customised parameter was saved as ‘MMU LCMS Parameter’ and used for 
analysis of both datasets. The results folder was then downloaded and the annotated 
excel results file was used for further analysis. 
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3.3.5.3 Quality Assurance  
In order to reduce the number of false positives and negatives, quality assurance of 
raw data files was undertaken prior to further analysis. In the excel spreadsheet the 
average intensity for each peak of all the samples was calculated along with the 
average intensity of the blanks. The percentage contribution of the blanks to the 
sample intensity of each peak was calculated using this formula: 
% 𝐵𝑙𝑎𝑛𝑘 𝐶𝑜𝑛𝑡𝑟𝑖𝑏𝑢𝑡𝑖𝑜𝑛 = (
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑏𝑙𝑎𝑛𝑘𝑠
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒𝑠
) × 100  
The results were then filtered with peaks removed with a percentage blank 
contribution of >5%. 
3.3.5.4 Analysis of Data  
Once the data had undergone quality assurance, the data matrix was changed to 
facilitate analysis using the open source LCMS analysis and interpretation software 
MetaboAnalyst (Xia and Wishart, 2016). When processing the MS peak list into 
MetaboAnalyst a mass tolerance of 0.025 (m/z) and a retention time tolerance of 
30.0 was employed.  
3.3.5.5 Missing Values 
Missing value correction using MetaboAnalyst was undertaken in order to improve 
the quality of the data. Features with >50% of missing values were removed and 
those with less that that were replaced using the K-nearest neighbour methodology. 
3.3.5.6 Normalisation and Scaling 
Data normalisation, transformation and scaling was undertaken using 
MetaboAnalyst. Samples were normalised by quantile normalisation and Pareto 
scaling was employed which is mean-centered and divided by the square root of 
standard deviation of each variable. 
3.3.5.7 Univariate and Multivariate Analysis 
Using MetaboAnalyst, a univariate volcano plot was plotted of all bacterial samples 
against the blank media samples with a fold change threshold of 2.0 and a p-value of 
0.05 used as significance cut-offs. The volcano plot image was saved and the data 
table was exported as a .csv file. A multivariate principle component analysis was 
plotted to ascertain whether the variance within the data could be used to sort the 
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data into the bacterial and control classes without referring to them, the 2D scores 
plot was saved as a .png file. Next, multivariate partial least squares - discriminant 
analysis was conducted to work out which variables have the class separating 
information. The 2D scores plot was saved as a .png file and the Variable Importance 
in Projection (VIP) score graph which shows the top 15 features showing a larger 
contribution to class discrimination, was plotted and saved as a .png file.  
3.3.5.8 Supervised Data Analysis 
Using MetaboAnalyst a supervised learning algorithm Random Forest (RF) was used 
to analyse the dataset, which uses random feature selection and classification trees 
to predict class based on majority vote. RF can identify features which are highly 
associated with a class and when removed decrease the classification accuracy of the 
model. The top 15 features which are associated with classification accuracy were 
plotted in graph and exported as a .png file. 
3.3.5.9 Metabolite Identification 
All significant features identified from univariate, multivariate and supervised data 
analysis were collated into a single excel spreadsheet and prepared for metabolite 
identification using MetaboSearch (Zhou et al., 2012). The five database plugins used 
for comparison were the Human Metabolome Database (Wishart et al., 2012), the 
Metlin mass spectral database (Smith et al., 2005), the Madison metabolomics 
consortium database (MMCD) (Cui et al., 2008), LIPID MAPS database (Fahy et al., 
2009) and MetaCyc database (Caspi et al., 2013). The metabolite search was run in 
positive ion mode with a molecular weight tolerance of five parts per million and 
exported to Excel when completed. The results were then manually curated, 
removing matches to synthetic drugs and filling in the putative role of the metabolite 
match, the results were then formulated into a table. 
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3.4 RESULTS 
3.4.1 Growth Curves 
Concurrent growth curves were undertaken of S. constellatus in both BHIB and TSB 
to see if there were any discernible difference in metabolic products and to test the 
suitability of the designed untargeted metabolomics pathway. The growth, measured 
as absorbance at 540 nm (Figure 3.1), of S. constellatus over 48h for both BHIB and 
TSB indicated log phase between 6 and 24 h and stationary phase between 24 and 
48 h, with slightly slower initiation of log phase in TSB. However, the difference 
between the absorbance at 540 nm over 48 hours of BHIB and TSB was found to be 
non-significant (p=0.8377). The growth, measured as CFU/mL (Figure 3.2), of S. 
constellatus over 48 h for both BHIB and TSB indicated log phase between 6 and 24 
h, stationary from 24h and the potential beginning of death phase at 48h for both 
media. TSB appeared to initiate log phase slower than BHIB. However, the difference 
between the CFU/mL over 48 hours of BHIB and TSB was found to be non-significant 
(p=0.6341). 
 
Figure 3.1 Absorbance at 540nm of Streptococcus constellatus cultivated in Brain Heart Infusion Broth 
(BHIB) and Tryptone Soya Broth (TSB) over 48 h and in carbon rich conditions (5% CO2). Error bars 
presented as standard error (n=3). 
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Figure 3.2 Colony forming units per mL of culture of Streptococcus constellatus cultivated in Brain 
Heart Infusion Broth (BHIB) and Tryptone Soya Broth (TSB) over 48 h and in carbon rich conditions 
(5% CO2). Error bars presented as standard error (n=3). 
 
3.4.2 LCMS Analysis of S. constellatus Cultured in BHIB 
From the growth curve of S. constellatus in BHIB described in Section 3.2.1, sampling 
in triplicate was undertaken at 0 h, 6 h, 24 h and 48 h and these samples were 
prepared for untargeted LCMS analysis. A media control of BHIB kept in the same 
conditions (5% CO2 and 37oC) was also sampled in triplicate at 0, 6, 24 and 48 h and 
prepared for untargeted LCMS analysis alongside the bacterial cultures in order to 
account for abiotic degradation. 
After LCMS analysis and deconvolution using XCMS online, quality assurance of the 
raw data files reduced the number of total features from all samples from 8003 to 
5428. Peak alignment, missing value imputation and data normalisation was then 
conducted through MetaboAnalyst with (Figure 3.3) showing the normalisation step 
which allows for better comparison of features.  
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Figure 3.3 Box plots and kernel density plots before and after normalization of LCMS data of S. 
constellatus cultured in BHIB (Indicated as B) and control BHIB samples (Indicated as T) at 0, 6, 24 
and 48h. The normalisation using quantile normalization and Pareto scaling. (n=3). 
 
3.4.2.1 Univariate Analysis 
Univariate analysis was conducted of all features to ascertain which features were 
significantly upregulated or downregulated (p=<0.05 and fold change of 2 ≥ or -2 ≤) 
from the BHIB control to S. constellatus cultured in BHIB. From the 5428 features 
initially identified 124 were identified to be significantly changed with 43 upregulated 
and 81 downregulated (Figure 3.4). 
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Figure 3.4 Important features from BHIB LCMS analysis selected by univariate volcano plot with fold 
change threshold (x) 2 and t-tests threshold (y) 0.05. The red circles represent features above the 
threshold and all values are log transformed. The further its position away from the (0, 0) the more 
significant the feature. 
 
3.4.2.2 Principle Component Analysis 
Principle component analysis (PCA) is an unsupervised method that attempts to find 
directions that can explain the variance in data irrespective of class. The scores plot 
of all BHIB bacterial and control samples (Figure 3.5) shows that the BHIB control is 
much more tightly clustered (Red) than BHIB inoculated with S. constellatus (Green). 
All 0 h and 6 h samples are tightly clustered together indicating that not much biotic 
degradation has taken place. The 24 h and 48 h bacterial samples with the exception 
of 24H-B1 are very different from a large selection of the samples highlighting a larger 
difference in the components present. Another notable outlier is a control 24H-1 
which is clustered with the bacterial samples rather than all the other controls. 
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Figure 3.5 A 2D scores plot of a PCA between all BHIB bacterial (SC) and control (BHIB) classes. The 
explained variances are shown in brackets. B after a class denotes Bacterial and T denotes controls 
with the number denoting a biological replicate.  
3.4.2.3 Partial Least Squares – Discriminant Analysis 
Partial least squares – discriminant analysis (PLS-DA) is a supervised method of 
multivariate regression which is similar to PCA, however it takes into account the 
classes of samples and attempt to work out which variables have the class separating 
information. The 2D scores plot of all BHIB bacterial and control samples (Figure 3.6) 
shows that the BHIB control is much more tightly clustered (Red) than BHIB 
inoculated with S. constellatus (Green), this correlates with the PCA (Figure 3.5). PLS-
DA usually has sharper separation between classes than PCA, which is shown with 
the difference between (Figure 3.5 and Figure 3.6). All 0H and 6H samples from each 
class are tightly clustered together indicating that not much biotic degradation has 
taken place, with the exception of 6H-B2. The 48 h bacterial samples have the largest 
variance between them, which is most likely due to the metabolic by-products. A 
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notable outlier is a 48-T1 that is distinctly variable from the rest of the BHIB control 
samples, however the reason for this is unknown. A Variable Importance in 
Projection (VIP) score graph was plotted (Figure 3.7) which calculates weighted sum 
of squares of the PLS loadings taking into account the amount of explained Y-
variation in each dimension for each component. A higher VIP indicates that the 
feature in question has a larger contribution to class discrimination in the PLS-DA 
model. The top 15 VIP features identified were selected for metabolite identification. 
 
Figure 3.6 A 2D scores plot of a PLS-DA between all BHIB bacterial (SC) and control (BHIB) classes. The 
explained variances are shown in brackets. B after a class denotes Bacterial and T denotes controls 
with the number denoting a biological replicate.  
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Figure 3.7 Important features identified by a PLS-DA of BHIB bacterial and control samples. The 
coloured boxes on the right indicate the relative concentrations of the corresponding metabolite in 
each group under study. The x axis denotes VIP scores and y axis the feature m/z and retention time 
separated by /. 
 
3.4.2.4 Significant feature selection using Random Forest algorithm 
RF is a supervised algorithm for data analysis which uses random feature selection 
and classification trees to predict class based on majority vote. It is useful for feature 
selection as it can identify important features by measuring the increase error in class 
identification when a feature is omitted. The BHIB control and bacterial samples were 
analysed using RF (Figure 3.8) in order to identify features that are important for class 
segregation. The top 15 significant features identified were selected for metabolite 
identification. 
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Figure 3.8 Significant features from BHIB (control) and SC inoculated of BHIB identified by Random 
Forest. The features are ranked by the mean decrease in classification accuracy when they are 
permuted. The x axis denotes mean decrease in accuracy and y axis the feature m/z and retention 
time separated by /. 
 
3.4.2.5 Metabolite identification 
All significantly upregulated and downregulated features identified by volcano plots, 
Variable Importance in Projection features identified by PLS-Da and important 
features in classification identified by RF were extracted into a Microsoft Excel 
spreadsheet for identification of metabolites. The program MetaboSearch was used 
to compare the m/z and retention times of the metabolites of interest with a 
selection of mass spectral databases for putative identification and the results 
extracted. For all significant features, there was a 7.1% success rate in identification. 
There are no clear metabolite identification trends associated with the control and 
the bacterial groups due to the low metabolite identification rate. The only exception 
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being amino acids and their various degradation products being associated with the 
BHIB control group most likely due to the enriched nature of the medium. 
Table 3.1 Putative metabolite identification of significantly up and downregulated metabolites 
identified by volcano plots of BHIB bacterial and control samples.  
 
m/z RT FC p value Name Formula Mass of Match ppm deviation Putative Role
2256.227 10.58 3.2003 0.002432 - - - - -
2255.226 10.56 3.1777 0.002067 - C104H183N5O47 2254.2084 4.332174693 Unknown LipidMaps match
2257.23 10.57 3.0488 0.003 - C104H185N5O47 2256.224 0.541038062 Unknown LipidMaps match
1128.62 10.58 2.7427 0.002408 - - - - -
1128.118 10.58 2.7131 0.002601 - - - - -
2279.211 10.58 2.6852 0.002157 - - - - -
2278.209 10.57 2.6592 0.002719 - - - - -
2277.206 10.56 2.6171 0.003046 - - - - -
1194.642 11.11 2.5857 0.003271 - - - - -
1129.622 10.58 2.4603 0.004522 - - - - -
1129.122 10.31 2.4456 0.003755 - - - - -
2157.169 10.23 2.4334 0.005785 - - - - -
1130.123 10.58 2.4331 0.003263 - - - - -
2280.214 10.58 2.4238 0.004028 - - - - -
1195.646 11.11 2.4156 0.00353 - - - - -
1078.588 10.23 2.3877 0.004693 - - - - -
1216.625 11.11 2.385 0.003773 - - - - -
1217.628 11.11 2.3528 0.003103 - - - - -
2156.167 10.22 2.2947 0.008951 - - - - -
752.7498 10.58 2.2739 0.003819 - - - - -
719.7299 10.23 2.2641 0.004179 - - - - -
1079.092 9.76 2.2622 0.003944 - - - - -
2179.152 10.22 2.2438 0.005953 - - - - -
753.084 10.58 2.2404 0.004108 - - - - -
598.8284 11.11 2.2238 0.00443 - - - - -
2178.148 10.23 2.2219 0.006794 - - - - -
1218.631 11.1 2.1905 0.002629 - - - - -
1149.618 8.07 2.1708 0.009203 - - - - -
720.0641 10.23 2.1597 0.004207 - - - - -
1150.621 8.07 2.1471 0.007951 - - - - -
752.4154 10.58 2.1347 0.004444 - - - - -
1196.649 11.11 2.1052 0.001943 - - - - -
1079.591 10.23 2.0962 0.006308 - - - - -
1139.108 10.58 2.0919 0.004198 - - - - -
1140.111 10.58 2.0815 0.00368 - - - - -
2294.184 10.58 2.077 0.010277 - - - - -
1139.61 10.58 2.0637 0.004416 - - - - -
597.8198 9.59 2.0634 0.002626 - - - - -
1689.93 10.12 2.0302 0.008977 - - - - -
1130.623 10.58 2.0205 0.003392 - - - - -
1155.079 10.58 2.0187 0.005722 - - - - -
1688.925 10.11 2.016 0.006074 - - - - -
Upregulation
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m/z RT FC p value Name Formula Mass of Match ppm deviation Putative Role
1136.527 7.36 0.49921 0.001961 - - - -
204.6169 3.83 0.49875 0.024434 - - - - -
448.2438 11.98 0.49873 0.003225 - - - - -
666.8456 6.92 0.49852 0.000699 - - - - -
622.3146 8.3 0.49721 0.003161 - - - - -
585.2516 1.7 0.49205 0.014277 - - - - -
738.8582 4.11 0.49182 0.03096 - - - - -
1026.307 2.8 0.48892 0.001528 - - - - -
1010.421 7.72 0.48569 0.003604 - - - - -
960.9337 7.99 0.4849 0.00254 - - - - -
1009.919 7.71 0.48425 0.00281 - - - - -
1122.955 6.84 0.48192 0.009388 - - - - -
287.1172 1.16 0.47889 0.029239 Methionyl-Histidine C11H18N4O3S 286.1099612 0.106663811 AA degradation product
263.6354 2.87 0.47707 0.012558 - - - - -
1027.306 2.78 0.47709 0.023711 - - - - -
1236.012 9.9 0.47209 0.030586 - - - - -
858.2423 2.64 0.46912 0.005648 - - - - -
691.2196 0.96 0.46639 0.034861 - - - - -
255.1321 2.87 0.4625 0.002188 - - - - -
599.307 6.95 0.46174 0.046807 - - - - -
623.3427 9.16 0.45758 0.024729 - - - - -
254.6301 2.87 0.45481 0.002925 - - - - -
911.4864 7.07 0.44715 0.038863 - - - - -
264.1368 2.87 0.44537 0.00389 - - - - -
2117.807 7.2 0.4437 0.005626 - - - - -
2019.83 7.52 0.4388 0.013175 - - - - -
2116.804 7.19 0.43785 0.005281 - - - - -
2018.828 7.52 0.41565 0.01141 - - - - -
1060.411 7.19 0.41546 0.008823 - - - - -
526.2414 5.16 0.41366 0.014891 - - - - -
1058.907 7.18 0.41237 0.006014 - - - - -
489.2571 5.56 0.40846 0.005003 - - - - -
865.7988 5.9 0.4081 0.034019 - - - - -
1059.91 7.18 0.40552 0.008451 - - - - -
1137.528 7.38 0.40496 0.002661 - - - - -
902.4643 7.32 0.40406 0.01542 - - - - -
1059.409 7.18 0.40405 0.005674 - - - - -
497.3256 5.06 0.4021 0.010901 PG(P-18:0/0:0) C24H49O8P 496.3165 3.627800239 Glycerophospholipid, no known role
1000.914 8.02 0.40099 0.003134 - - - - -
430.2006 9.46 0.40067 0.044284 - - - - -
1001.416 8.02 0.40042 0.00497 - - - - -
1050.903 7.77 0.38686 0.006815 - - - - -
2197.772 7.14 0.38609 0.00535 - - - - -
815.2732 5.25 0.37905 0.011886 - - - - -
1049.902 7.76 0.37633 0.004057 - - - - -
512.2882 7.43 0.37591 0.041827 - - - - -
550.3341 4.97 0.37513 0.01648 - - - - -
1060.912 7.19 0.3745 0.017569 - - - - -
445.1952 5.12 0.37258 0.009205 - - - - -
317.1358 5.63 0.37065 0.011438 - - - - -
418.1469 3.57 0.36895 0.007001
N6-ISOPENTENYL-ADENOSINE-5'-
MONOPHOSPHATE C15H24N5O7P 417.1413347 4.09689538 Unknown MMCD match
999.8795 7.19 0.3676 0.014563 - - - - -
372.2499 8.04 0.36704 0.047759 - - - - -
706.6092 7.18 0.35931 0.004251 - - - - -
575.285 5.43 0.35615 0.047476 - - - - -
1001.916 8.03 0.35476 0.034334 - - - - -
732.9282 7.1 0.35471 0.006386 - - - - -
999.3794 7.19 0.35293 0.011896 - - - - -
1100.394 7.1 0.34935 0.009142 - - - - -
1294.515 6.95 0.34861 0.029785 - - - - -
875.9217 8.53 0.34853 0.001028 - - - - -
938.3601 6.15 0.34813 0.049058 - - - - -
1100.895 7.1 0.34754 0.016444 - - - - -
2196.77 7.14 0.34318 0.003553 - - - - -
749.3458 7.54 0.33753 0.048659 - - - - -
2198.775 7.11 0.32591 0.009097 - - - - -
903.467 7.31 0.32483 0.012736 - - - - -
1039.362 7.1 0.32137 0.01123 - - - - -
1039.863 7.1 0.31609 0.00874 - - - - -
733.2653 7.11 0.30588 0.008742 - - - - -
937.3592 6.13 0.29974 0.034927 - - - - -
113.0219 1.23 0.29656 0.036827 - - - - -
1185.462 6.96 0.2921 0.034409 - - - - -
1040.365 7.08 0.29038 0.024667 - - - - -
1295.519 6.96 0.28804 0.042714 - - - - -
733.5986 7.1 0.2855 0.010161 - - - - -
982.2709 4.97 0.2514 0.031258 - - - - -
446.1993 5.12 0.24519 0.030043 - - - - -
1262.354 6.66 0.24461 0.043261 - - - - -
577.2204 8.43 0.2235 0.034154 - - - - -
427.2556 4.08 0.14218 0.039381 - - - - -
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Table 3.2 Putative metabolite identification of Variable Importance in Projection features identified 
by PLS-Da of BHIB bacterial and control samples. Grey = Control BHIB, Blue = BHIB inoculated with S. 
constellatus 
 
Table 3.3 Putative metabolite identification of important features in classification identified by RF 
analysis of BHIB bacterial and control samples. Grey = Control BHIB, Blue = BHIB inoculated with S. 
constellatus 
 
 
3.4.3 LCMS analysis of S. constellatus cultured in TSB 
From the growth curve of S. constellatus in TSB described in Section 3.2.1, sampling 
in triplicate was undertaken at 0 h, 6 h, 24 h and 48 h and these samples were 
prepared for untargeted LCMS analysis. A growth medium control of TSB kept in the 
same conditions (5% CO2 and 37oC) was also sampled in triplicate at 0 h, 6 h, 24 h and 
48 h and prepared for untargeted LCMS analysis alongside the bacterial cultures in 
order to account for abiotic degradation. 
After LCMS analysis and deconvolution using XCMS online, quality assurance of the 
raw data files in Microsoft Excel reduced the number of total features from all 
samples from 5568 to 5460. Peak alignment, missing value imputation and data 
normalisation was then conducted through MetaboAnalyst with Figure 3.9 showing 
the normalisation step that allows for better comparison of features. 
VIP Rank m/z RT Class Name Formula Mass of Match ppm deviation Putative Role
1 652.4043 6.09 C - - - - -
2 231.1707 3.73 C Valyl-Leucine C11H22N2O3 230.1630426 1.723684721 Incomplete AA degradation product
3 1100.581 7.8 C - - - - -
4 229.155 3.79 B Leucyl-Proline C11H20N2O3 228.1473925 1.538269332 Incomplete AA degradation product
5 427.2556 4.08 B - - - - -
6 751.3683 7.23 C OKOOA-PI C35H59O15P 750.3592 0.00177002 Oxidised glycerophospholipid
7 263.1417 4.77 B Leucyl-Methionine C11H22N2O3S 262.1351133 2.561224023
8 1101.584 7.8 C - - - - -
9 439.2927 6.63 B - - - - -
10 572.3445 7.84 B - - - - -
11 279.1346 3.1 B Tyrosyl-Proline C14H18N2O4 278.1266571 2.304234942 Incomplete AA degradation product
12 653.4079 5.82 C - - - - -
13 889.4847 8.44 C PIP(16:1(9Z)/18:0) C41H78O16P2 888.4765095 1.099142744
Phosphatidylinositol, cell wall component
14 562.824 8.67 C - - - - -
15 1025.57 8.1 B - - - - -
VIP Rank m/z RT Class Name Formula Mass of Match ppm deviation Putative Role
1 1244.328 10 B - - - - -
2 1038.567 7.6 B - - - - -
3 1015.478 3.6 B - - - - -
4 756.3998 6.49 B - - - - -
5 2196.77 7.1 B - - - - -
6 888.4218 5.06 B - - - - -
7 790.1095 10.6 C - - - - -
8 513.231 1.95 B - - - - -
9 429.2155 8.9 B - - - - -
10 1231.674 10 B - - - - -
11 1587.8 9.2 B - - - - -
12 741.0824 11.5 C - - - - -
13 709.357 6.66 B - - - - -
14 2397.803 9.6 B - - - - -
15 419.233 6.52 C - - - - -
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Figure 3.9 Box plots and kernel density plots before and after normalization of LCMS data of S. 
constellatus cultured in TSB (Indicated as B) and control TSB samples (Indicated as T) at 0,6,24 and 
48h. The normalisation using quantile normalization and Pareto scaling. (n=3). 
 
3.4.3.3 Univariate Analysis 
Univariate analysis was conducted of all features to ascertain which features were 
significantly upregulated or downregulated (p=<0.05 and fold change of 2≥ or -2≤) 
from the BHIB control to S. constellatus cultured in TSB. From the 5460 features 
initially identified, 13 were identified to be significantly changed with 1 upregulated 
and 12 downregulated (Figure 3.10). 
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Figure 3.10 Important features from TSB LCMS analysis selected by univariate volcano plot with fold 
change threshold (x) 2 and t-tests threshold (y) 0.05. The red circles represent features above the 
threshold and all values are log transformed. The further its position away from the (0, 0) the more 
significant the feature is. 
 
3.4.3.2 Principle Component Analysis 
The 2D scores plot of all TSB bacterial and control samples (Figure 3.11) showed that 
the TSB control is much more tightly clustered (Red) than BHIB inoculated with S. 
constellatus (Green). All 0 h and 6 h samples are tightly clustered together indicating 
that not much biotic degradation has taken place along with the control media being 
tightly clustered even after 48 h, indicating that little has changed chemically. The 24 
h and 48 h bacterial samples are different from a large selection of the samples 
highlighting a larger difference in the components present, most likely due to 
microbial metabolism.  
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Figure 3.11 A 2D scores plot of a PCA between all TSB bacterial (TSB) and control (Control) classes. The 
explained variances are shown in brackets. B after a class denotes Bacterial and T denotes controls 
with the number denoting a biological replicate.  
 
3.4.3.3 Partial Least Squares – Discriminant Analysis 
The 2D scores plot of all TSB bacterial and control samples (Figure 3.12) shows that 
the TSB control is much more tightly clustered (Red) than TSB inoculated with S. 
constellatus (Green), this correlates with the PCA (Figure 3.11). PLS-DA usually has 
sharper separation between classes than PCA, which is shown with the difference 
between (Figure 3.11 and Figure 3.12). All 0 h and 6 h samples from each class are 
tightly clustered together indicating that not much biotic degradation has taken 
place. A Variable Importance in Projection (VIP) score graph was plotted (Figure 3.13) 
which calculates weighted sum of squares of the PLS loadings taking into account the 
amount of explained Y-variation in each dimension for each component. A higher VIP 
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indicates that the feature in question has a larger contribution to class discrimination 
in the PLS-DA model. The top 15 VIP features identified were selected for metabolite 
identification. 
 
Figure 3.12 A 2D scores plot of a PLS-DA between all TSB bacterial (TSB) and control (Control) classes. 
The explained variances are shown in brackets. B after a class denotes Bacterial and T denotes controls 
with the number denoting a biological replicate.  
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Figure 3.13 Important features identified by a PLS-DA of TSB bacterial and control samples. The 
coloured boxes on the right indicate the relative concentrations of the corresponding metabolite in 
each group under study. The x axis denotes VIP scores and y axis the feature m/z and retention time 
separated by /. 
 
3.4.3.4 Significant feature selection using Random Forest algorithm 
The TSB control and bacterial samples were analysed using RF (Figure 3.14) in order 
to identify features that are important for class segregation. The top 15 significant 
features identified were selected for metabolite identification. 
Chapter 3: Metabolomics Based Investigations 
81 
 
 
Figure 3.14 Significant features from TSB (control) and SC inoculated of TSB identified by Random 
Forest. The features are ranked by the mean decrease in classification accuracy when they are 
permuted. The x axis denotes mean decrease in accuracy and y axis the feature m/z and retention 
time separated by /. 
 
3.4.3.5 Metabolite identification 
All significantly upregulated and downregulated feature identified by volcano plots, 
Variable Importance in Projection features identified by PLS-Da and important 
features in classification identified by RF were extracted into an excel spreadsheet 
for identification of metabolites. The program MetaboSearch was used to compare 
the m/z and retention times of the metabolites of interest with a selection of mass 
spectral databases for putative identification and the results extracted. For all 
significant features, there was a 30% success rate in identification. Of the metabolites 
identified with the TSB control, the majority were amino acids and their derivative 
products, which is expected due to the nature of TSB as an enriched growth medium. 
Subsequently, the majority of identified metabolites associated with S. constellatus 
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cultured in TSB are degradation products of amino acids indicating microbial 
metabolism of TSB. 
Table 3.4 Putative metabolite identification of significantly up and downregulated metabolites 
identified by volcano plots of TSB bacterial and control samples. 
 
Table 3.5 Putative metabolite identification of Variable Importance in Projection features identified 
by PLS-Da of TSB bacterial and control samples. Grey = Control TSB, Blue = TSB inoculated with S. 
constellatus. 
 
Table 3.6 Putative metabolite identification of important features in classification identified by RF 
analysis of TSB bacterial and control samples. Grey = Control TSB, Blue = TSB inoculated with S. 
constellatus. 
 
m/z RT FC p value Name Formula Mass of Match ppm deviation Putative Role
268.10245 1.49 2.579 0.011201 Neuraminic acid C9H17NO8 267.0954165 0.91405767 Common sialic acid, bacterial by-product
m/z RT FC p value Name Formula Mass of Match ppm deviation Putative Role
1102.59141 10.37 0.49762 0.033504 - - - - -
1081.61181 10.37 0.49418 0.045468 - - - - -
291.2165 11.29 0.49158 6.12E-05 - - - - -
1101.5889 10.37 0.48451 0.029317 - - - - -
290.18624 11.71 0.45793 1.65E-07 - - - - -
212.10094 1.54 0.45664 0.008294 - - - - -
540.80886 10.37 0.42304 0.049912 - - - - -
558.32232 4.44 0.36865 0.007062 - - - - -
474.58769 4.3 0.36135 0.038094 - - - - -
752.37342 7.2 0.35351 0.015483 - - - - -
751.3674 7.2 0.29249 0.012941 OKOOA-PI C35H59O15P 750.3592 1.220118783 Oxidised glycerophospholipid
132.06547 3.23 0.12041 0.002889 Glutaramic acid C5H9NO3 131.0582 0 Non-essential amino acid
Upregulation
Downregulation
VIP Rank m/z RT Class Name Formula Mass of Match ppm deviation Putative Role
1 231.2 3.47 C Valyl-Leucine C11H22N2O3 230.1630426 2.452935949 Incomplete AA degradation product
2 237.1 3.79 C Phenylalanyl-Alanine C12H16N2O3 236.1160924 1.615602428 Incomplete AA degradation product
3 219.1 6.64 C - - - - -
4 233.1 2.69 C Threoninyl-Leucine C10H20N2O4 232.1423071 1.380336826 Incomplete AA degradation product
5 203.1 11.4 C
2-Pentyl-3-phenyl-2-
propenal C14H18O 202.1357652 0.981341675 Aromatic cinnamaldehyde compounds
6 439.3 7.38 B - - - - -
7 120.1 3.04 B - - - - -
8 1016 6.6 C - - - - -
9 268.1 1.49 C Neuraminic acid C9H17NO8 267.0954165 0.91405767 Common sialic acid, bacterial by-product
10 550.6 28.4 B - - - - -
11 166.1 4.28 C
Multiple phenylalanine 
degradation products
- - -
By-products of phenylalanine metabolism
12 205.1 3.93 B
Multiple tryptophan 
degradation Products
- - -
By-products of tryptophan metabolism
13 682.4 8.76 B - - - - -
14 536.9 7.24 C - - - - -
15 682.9 9 B - - - - -
VIP Rank m/z RT Class Name Formula Mass of Match ppm deviation Putative Role
1 955 10.2 B - - - - -
2 1335 7.1 B - - - - -
3 294.7 2.09 C - - - - -
4 880.5 10 B - - - - -
5 1186 10 B - - - - -
6 366.3 14.6 B - - - - -
7 442.3 10.5 B - - - - -
8 197.2 15.2 B
Multiple uncatorgorised 
fatty acid esters
- - - -
9 735.4 4.57 C - - - - -
10 540.8 10.3 B - - - - -
11 367.1 3.79 B - - - - -
12 275.1 11.9 B
4,4'-dihydroxy-3,5-
dimethoxydihydrostilbene C16H18O4 274.1205 0.222658113 Cinnamylphenols, no known role
13 411.2 14.9 B - - - - -
14 482.4 15.2 B - - - - -
15 1158 7.5 B
PIM2(18:1(9Z)/16:2(9Z,12
Z)) C55H97O23P 1156.6158 4.643800943 Glycerophospholipids, no known role
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3.5 DISCUSSION 
3.5.1 Differences in Growth between BHIB and TSB 
Both BHIB and TSB successfully cultivated S. constellatus as both media are nutrient 
rich and contain components such as dextrose, which can have a substantial impact 
on bacterial growth as well as supporting high cell densities (Jaradat and Bhunia, 
2002). Despite statistically there being no significant difference between the growth 
in both media, there was an observed disparity in growth, with TSB slightly slower at 
initiating growth and a shorter stationary stage. Studies have previously shown a 
potential cause for this reported trend, with BHIB being reported to stimulate 
proteinase production leading to favourable conditions for some streptococcal 
species (Jack and Tagg, 1992). One of the reasons behind this proteinase production 
could be because of the addition of the component protease peptone within BHIB. 
Protease peptone is one of the main differences in formula between BHIB and TSB, 
with TSB containing no amount of protease peptone. Another previous study grew 
Streptococci in a variety of media and showed that growth of several strains was best 
supported in a protease peptone broth even in comparison with TSB (Ferretti and 
Ward, 1976). Protease peptone contains elements of nitrogen as well as providing an 
effective buffering range for bacteria, which is potentially a favourable environment 
for S. constellatus and could be responsible for the slight disparity in growth between 
BHIB and TSB. With a notable disparity between two relatively similar media having 
a large effect on the metabolites, this further solidifies the reasoning for the 
development and utilisation of a more representative periodontal growth medium 
(Chapter 2) for comparisons between microorganisms and collection of microbial 
products. 
3.5.2 Trends From Metabolites Identified 
The developed untargeted metabolomics pathway was successful in being able to 
translate raw LCMS results from a large number of peaks to a selection of ~100 
metabolite features for each dataset, which are putatively responsible for differences 
between control media and microbial inoculation. It is also clear from the PCA and 
PLS-DA analyses that there is a statistically significant difference between the control 
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and bacterial classes, confirming that microbial degradation of both BHIB and TSB 
took place and the classes can be separated based on the products present. 
The use of a variety of methods such as univariate analysis, multivariate analysis and 
machine learning for identification of features that significantly contribute to class 
separation between control and bacteria was successful in highlighting features of 
interest. However, the identification of these features was poor with a 7.1% success 
rate in identification for BHIB and 30% for TSB. Of these features identified, none 
were a match for the known mass values for PAs, which does not necessarily indicate 
they are not there, rather that they were not able to be detected. The majority of the 
features that were identified were nonspecific degradation products related to 
amino acid metabolism along with non-specific glycophospholipids known to be 
related to microbial metabolism (Shaw, 1975). 
Not being able to identify the large majority of the features of interest limits the 
experiment as it restricts translation of potential metabolites to look at their 
biological role. Indeed, of the metabolites successfully identified the majority were 
very non-specific such as amino acids and amino acid degradation products, which 
are not useful candidate molecules for potential biomarkers involved in disease as 
they are ubiquitous in all forms of life. 
3.5.3 The Problems Facing the Emergent Metabolomics Field 
Currently there are multiple issues facing untargeted metabolomics, which hinder 
the translation of LCMS analysis to results of biological significance. With the data 
generated for S. constellatus, even after three different methods of metabolite 
identification and four different databases utilised, only a small selection of 
metabolites were identified. This can be down to a variety of reasons, they may 
indeed be truly novel, they may be false positives or they may be fragments of known 
metabolites. 
Unambiguous metabolite identification is a bottleneck, which is limiting the success 
of metabolomics (Dunn et al., 2013), as multiple metabolites can match one mass 
peak it makes identification of that peak harder to undertake. Even with algorithms 
such as the ‘Seven Golden Rules’ (Kind and Fiehn, 2007) which utilises filtering by 
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chemical rules such as hydrogen carbon ratios, there is a substantial problem in 
untargeted metabolomics of actually deciphering what peak corresponds to which 
metabolite.  
To compound the problem of identification, there is also a limited number of 
metabolites, which have actually been characterised. Of the four major metabolite 
databases, there is approximately ~40,000 metabolites with structures and 
associated spectra and MS/MS. If this is compared to the proteomic databases such 
as UniProt, which has ~550,000 manually annotated and ~89,000,000 automatically 
annotated proteins, it is clear that there is a lack of characterised data for 
comparison, which is needed to decipher what m/z value corresponds to a 
metabolite. 
Furthermore, if you consider that each organism will have a different genome, 
proteome and transcriptome leading to wholly unique metabolites, it means that 
identification of these metabolites is at present difficult unless working with model 
organisms. The suitability for untargeted metabolomics for identification of novel 
compounds and/or mediators of disease is hindered by a combination of all these 
factors.  
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3.6 CONCLUSIONS 
The development of an untargeted metabolomics pathway for analysis was 
successful in principle, as raw LCMS data was successfully translated from thousands 
of features to a smaller selection of significant features putatively responsible for 
difference between the control and bacterial inoculation. However, the suitability of 
untargeted metabolomics for screening of multiple periodontal associated organisms 
is questionable as while some metabolite identification took place the majority of 
significant features could not be identified and of the metabolites identified the 
majority were relatively non-specific degradation products. In order to find ‘novel’ 
compounds that may be involved in disease a microbial library for each organism 
would need to be made which would be an expensive and time-consuming process 
that is not feasible for this pilot study. 
Rather than screening a wide selection of periodontitis associated organisms through 
this untargeted pathway the decision was taken that it would be more practical, 
provide less ambiguous results and be less time consuming to consider an alternative 
approach. The alternative approach was cell culture based experiments (Chapter 4), 
that would allow testing of periodontitis microbial supernatants against kidney cells 
in order to test a variety of parameters. This could serve as a provisional screening 
step to cut down the number of organisms of interest and pave the way for future 
more targeted LCMS based investigations and/or reanalysis of untargeted LCMS data 
to look for identified molecules. 
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CHAPTER 4: KIDNEY CELL BASED 
INVESTIGATIONS 
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4.1 INTRODUCTION 
In healthy humans, host-microbiome interactions are critical to maintaining 
homeostasis and play a key role in a wide selection of processes such as production 
of key metabolites, providing a barrier to pathogenic attack and priming the immune 
system (Cho and Blaser, 2012, Engevik and Versalovic, 2017). In diseases states, such 
as CP, the oral microbiota undergoes dysbiosis and a move to a more Gram negative 
dominated environment with distinct differences between healthy and diseased 
patients seen in the saliva and plaque (Shi et al., 2018a, Chen et al., 2018). This more 
pathogenic periodontal microbiota has been reported to have a wide variety of 
potentially deleterious effects such as tissue invasion, production of toxic 
compounds and evasion of the immune system (Guthmiller and Novak, 2002). The 
production of secreted toxic compounds are of particular interest when investigating 
CP and CKD as they could potentially interact with the kidneys through translocation 
from the oral cavity via the bloodstream to the kidneys (Chapter 1.2.1). Using the 
supernatants collected from the chosen periodontal pathogens (Chapter 2.3.8), cell-
based investigations can be used to investigate whether the microbial products can 
elicit a deleterious effect on kidney cells. 
4.1.1 Evidence for periodontal supernatants eliciting cellular effects 
Numerous studies have investigated the cellular effects of periodontitis-associated 
microbial extracts, but this research has predominately focused around the effect of 
sonicated bacterial extracts (SBEs) on cells of the oral cavity such as gingival 
fibroblasts. With these studies there is evidence to show that SBEs of 
Aggregatibacter actinomycetemcomitans (Stevens et al., 1983, Stevens and 
Hammond, 1988), Porphyromonas endodontalis (Yamasaki et al., 1998), 
Porphyromonas gingivalis (Yamasaki et al., 1998, Fotos et al., 1990, Stevens and 
Hammond, 1988, Morioka et al., 1993) and Fusobacterium nucleatum (Yamasaki et 
al., 1998, Stevens and Hammond, 1988) elicit cytotoxic effects on gingival fibroblasts. 
However, it is important to understand the difference between the two types of 
microbial preparations; microbial supernatants are more representative of the 
potential exposure human cells would receive compared to the SBEs (Figure 4.1). This 
is because microbial supernatants do not contain the lysis and intracellular products 
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of the microorganisms that become released upon microbial cell death may be more 
cytotoxic than secreted products in supernatants. In some cases the SBEs may be 
toxic to cells, while the microorganisms alone are not (Shah et al., 1992). 
Furthermore, SBEs can contain greater concentrations of cell wall components like 
LPS and fimbriae that are known to be cytotoxic (Nishio et al., 2013, Rossol et al., 
2011) and can be released by the sonication step as this disrupts the cell wall. 
 
Figure 4.1 The differences between sample preparation of sonicated bacterial extracts and microbial 
supernatant samples. Sample preparation aggregated from a selection of publications (Yamasaki et 
al., 1998, Stevens and Hammond, 1988, Morioka et al., 1993). 
 
However, evidence for the effects of periodontal microbial supernatants on various 
human cell types is sparse. Although, some experiments have investigated the effect 
of supernatants on gingival fibroblasts, with A. actinomycetemcomitans (Letzelter et 
al., 1998), F. nucleatum (Johansson et al., 1994) and P. gingivalis (Letzelter et al., 
1998, Johansson et al., 1996) being reported to be cytotoxic and Capnocytophaga 
ochracea and Peptostreptoccocus micros reported to produce toxins that can inhibit 
fibroblast proliferation (Letzelter et al., 1998). It has been suggested that the 
cytotoxicity of microbial products, be it supernatant or SBE, can vary depending on 
the different cell types exposed, which may be due to different target sites and 
capacity for neutralisation of toxicity (Johansson et al., 1994, Gibbons, 1989). With 
this in mind, testing the effect of a selection of CP associated microbial supernatants 
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against kidney cell lines may provide an insight into how secreted periodontal 
microbial products could potentially be interacting with the kidneys and how this 
may be different to interactions with cells of the oral cavity. 
4.1.2 Renal Fibrosis 
Fibrosis is a non-specific wound healing process in which injured organs and tissues 
are repaired by recruitment of fibroblasts and local and/or circulating immune cells 
(Wynn, 2007). Renal fibrosis, which presents as glomerular or tubulointerstitial 
fibrosis, is the excessive accumulation and deposition of excess extracellular matrix 
(ECM) within the kidney parenchyma, which over time can lead to loss of function 
(Efstratiadis et al., 2009). Renal fibrosis occurs in the vast majority of chronic kidney 
diseases and the progressive excessive accumulation of ECM can ultimately lead to 
end-stage renal failure (Liu, 2006, Hewitson, 2012). 
The process of renal fibrosis is depicted in Figure 4.2. Initially, renal fibrosis starts as 
a protective response to an insult to the epithelial or endothelial cells of the kidney. 
A number of factors can damage these cells, for example infections, metabolic factors 
(e.g. hyperglycaemia in diabetes), toxins and hypertension (Hewitson, 2012). Upon 
initial injury of the cells and/or activation of endothelial cells, tissue factor is exposed 
to the blood thereby promoting platelet activation, fibrin formation and feedback 
inhibition (Madhusudhan et al., 2016). The damage along with tissue factor 
stimulates the complement cascade and the development of a fibrin clot with the 
release of pro-fibrotic growth factors such as transforming growth factor beta (TGF-
β) (López-Hernández and López-Novoa, 2012) and platelet-derived growth factor 
(PDGF) (Floege et al., 2008) along with various chemokines. These chemokines and 
growth factors drive the recruitment of leukocytes from the circulatory system which 
in-turn initiate inflammation and tissue remodelling (Wynn, 2007). These immune 
cells secrete a selection of components which drive these processes such as matrix 
metalloproteases (MMPs) (Zhao et al., 2013), tissue inhibitors of metalloproteases 
(TIMPs) (Bieniaś and Sikora, 2018), interleukins 6 and 13 (Su et al., 2017), TGF-β and 
Epidermal growth factor (EGF) (Rayego-Mateos et al., 2018).  
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After the initial inflammation and remodelling caused by the components secreted 
by the leukocytes, the fibroblasts are activated by the pro-fibrotic fibroblast growth 
factor (FGF). These differentiated fibroblasts, known as myofibroblasts, proliferate 
heavily and are a feature of all forms of kidney disease (Meran and Steadman, 2011). 
Accumulation of this specific cell type is heavily associated with CKD disease 
progression due to the production of ECM components such as collagen that are 
integral to the scarification seen in CKD (Hewitson, 2012). In the normal process of 
inflammation, the growth factor vascular endothelial growth factor (VEGF) is key in 
the stimulation of angiogenesis, which takes place alongside the activation of 
myofibroblasts and normally would lead to wound contraction and eventual 
regeneration of tissues (Doi et al., 2010, Wynn, 2007). However in CKD this normal 
healing process is disrupted with failed angiogenesis and a more pro-fibrotic 
response characterised by persistent myofibroblast activation, inflammation, 
imbalance in MMPs and TMPS and excessive ECM deposition (Ballermann and 
Obeidat, 2014).  
The cause of the difference between healthy wound healing and the fibrotic response 
seen in CKD is hard to decipher despite it being clear that the chronic persistence of 
myofibroblasts plays a key role (Meran and Steadman, 2011). One key distinction is 
the duration of the injury, which provides a sustained pro-fibrotic signal that can lead 
to accumulation of interstitial matrix and unchecked fibrosis (Liu, 2006). 
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Figure 4.2 The fibrotic pathway in chronic kidney disease. Adapted from (Wynn, 2007)  
 
It is clear that there are myriad factors involved in the excessive fibrotic phenotype 
seen in CKD (Figure 4.2) with no singular cell type or secreted component responsible 
for this phenotype. Because of this, choosing a singular marker for use as a fast test 
for fibrosis induction in cells is a difficult conundrum. A potential marker which is 
specific enough for fibrosis and sensitive enough to react to changes in the 
environment and damage such as reactive oxidative species and stress is 
plasminogen activator inhibitor 1 (PAI-1). PAI-1 is an inhibitor of tissue plasminogen 
activator and urokinase plasminogen activator, which convert plasminogen to 
plasmin and are key in the formation of clots (Figure 4.3) (Malgorzewicz et al., 2013). 
In addition to its role in clot formation there is a large body of evidence to support 
PAI-1 as a powerful fibrosis promoting molecule which can effect cellular migration, 
recruiting fibroblasts and inflammatory cells along with inhibiting ECM degradation, 
the activation of MMPs and being directly related to TGF-β expression (Eddy and 
Fogo, 2006). Due to this, there has been some success in transfecting cells with PAI-
1 luminescence reporters in order to monitor TGF-β expression and general fibrosis 
in cell based luciferase reporter assays (Abe et al., 1994); this will be utilised in this 
chapter to provisionally investigate fibrotic potential of the selected microorganism 
supernatants. 
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4.2 AIM AND OBJECTIVES 
4.2.1 Aim 
To test the effect of microbial supernatants on cytotoxicity, migration, and induction 
of a fibrosis in human proximal tubule epithelial (HK-2) cells.  
4.2.2 Objectives 
 Evaluate whether selected microbial supernatants have cytotoxic effects on 
human kidney cells. 
 Evaluate whether the selected microbial supernatants have migratory effects on 
human kidney cells. 
 Evaluate whether the selected microbial supernatants induce fibrosis in 
transfected human kidney cells. 
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4.3 METHODS 
4.3.1 Preparation of Bacterial Supernatants for Cell Based Investigations 
The bacterial supernatants used were prepared as described earlier in Chapter 2.3.8. 
4.3.2 Cell Culture 
HK-2 cell culture and maintenance was conducted as described earlier in Chapter 
2.3.2. 
4.3.3 Cell Viability Testing 
Cell viability testing of HK-2 cell was conducted as described in Chapter 2.3.3. The 
only modification was incubation of the bacterial supernatant alongside the AGCF-P 
media collected for 1 D, 2 D, 3 D, 4 D and 5 D or 24 h and 48 h depending on the 
microorganism tested. The HK-2 cell viability tests were conducted for 24 and 48 h 
and the medium was refreshed daily. The data analysis of cell viability results was 
undertaken as described in Chapter 2.3.3.1. 
4.3.4 Scratch Test – Cell Migration Assay 
The in vitro scratch assay was adapted from (Liang et al., 2007) and used to study the 
effect of periodontal microorganism supernatants on cell migration of HK-2 cells. HK-
2 cells were seeded into 24-well plates and cultured in growth media with serum until 
cell confluence of 70-80% was reached. The growth medium was removed, the cells 
were rinsed twice with PBS and serum free medium was added. After 24 h, a scratch 
was made with a sterile p200 pipette tip straight across the monolayer of each well. 
The debris and detached cells were removed by washing twice with serum free 
media. A 1:20 dilution of prepared bacterial supernatant to serum-free medium was 
used for all tests (25 µL : 475 µL). Images were taken at 0 h, 6 h, 24 h, 48 h and 72 h, 
and the same frame of reference for each well was kept approximately by marking 
the bottom of each well with a pen. Images were captured using GXCapture-T camera 
attached to a light microscope (Gtvision, UK) and saved for further analysis. 
In order to calculate the migration of cells over time the images taken were analysed 
using the open source image processor Image J (Schneider et al., 2012). A macro, MRI 
Wound Healing Tool, was used to estimate the area of each image and this value was 
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exported to a Microsoft Excel document. The percentage wound closure over time 
was then calculated and plotted in a graph. 
4.3.5 PAI-1 Luciferase Reporting Assay 
A PAI-1 luciferase-reporting assay was developed using the pNL2.3 luciferase 
reporter vector (Promega, UK) which produces soluble luciferase and the human 
Plasminogen activator inhibitor-1 (PAI-1) 955 bp promoter region (upstream of start 
codon -853bp; downstream +82bp ) was cloned into the vector. The pNL2.3 vector 
with no insert was used as a negative control. The control and pNL2.3 PAI-1 reporter 
vector were transfected into the HK-2 kidney cell line to create HK-2 pNL and HK-2 
PAI-1 cell lines. The cloning and transfection experiments were completed in the 
Renal group of Dr Liliana Shalamanova in Manchester Metropolitan University prior 
to the start of this project. 
HK-2 cell line clones containing either the native pNL2.3 vector or the PAI-1 reporter 
vector were cultured in the same culture media as non-transfected HK-2 cells. Cells 
were seeded into 24-well tissue culture plates and cultured until a confluence of 80-
90% was reached. The cells were then washed twice with PBS and the medium was 
changed to serum free medium. After 24 h, the medium was replaced with bacterial 
supernatants 25 µL, diluted with serum free medium 475 µL (1:20).  
After 24 h, 20 µL aliquots were taken from all samples after aspirating to avoid 
concentration gradients; these were then centrifuged at 12470 x g for 5 min to 
deposit any protein fragments. These aliquots were mixed with 40 µL of distilled 
water and 50 µL of prepared NanoLuc Luciferase substrate (Promega, UK) in a 96 well 
black cell culture plate (Sigma-Aldrich, UK). The samples were left to stand for 5 min 
and then luminescence readings were taken using a Synergy HTX Multi-mode plate 
reader (Agilent, UK) thrice with 15 min in-between. The results were normalised to 
total cellular protein content. 
4.3.6 Normalisation of PAI-1 Luciferase Reporter Assay Results 
Normalisation of the PAI-1 luciferase reporter assay results was completed using a 
Bicinchoninic acid (BCA) kit (Merck, UK). The 24 well culture plates used in the PAI-1 
Reporter Assay were aspirated and washed twice with PBS after the assay was 
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completed. All liquid was then removed and the plates were stored at -20oC prior 
further analysis.  
The total cellular protein in the 24 wells was harvested in 80 μL of 0.1 NaOH, 
transferred into sterile 1.5 ml tubes and hydrolysed with 0.1M NaOH for 2 hours at 
37oC. 
The samples were then diluted at 1:5 with deionised water in preparation for BCA 
assay. A set of protein standards (0, 100, 200, 250, 400 μg/mL) was created using 
bovine serum albumin from the BCA kit. A further control consisting of 0.1 M NaOH 
diluted 1:5 into deionised water was also used. From each sample 20 μL were added 
to a 96 well plate in duplicate and 200 μL of BCA working solution, consisting of 50:1 
reagents A (Bicinchoninic acid) and B (Copper II Sulphate Pentahydrate), were added 
to each well.  
After a 30 min incubation at 37oC the absorbance was measured at 562 nm using a 
microplate reader (Thermo-Scientific Multiskan 60, UK). A standard curve of 
absorbance against standards of known BSA concentration was generated and used 
to determine the concentration of total protein in cell lysates via interpolation after 
factoring in the dilution factor of 1:5. 
The calculated total protein content of each well was converted to mg and the PAI-1 
fluorescence-reporter assay results were divided by the total protein content, with 
the finalised results plotted as Luminescence Arbitrary Unit per mg of protein. 
4.3.7 Statistical Testing 
All statistical testing was undertaken using GraphPad Prism 8.1.1 software. A two-
way ANOVA with multiple comparisons was used to determine significant differences 
between the cell viability control and the different dilutions of AGCF-P and for the 
scratch assay comparisons and fibrosis reporting comparisons between control, 
AGCF-P media and bacterial supernatants. 
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4.4 RESULTS 
4.4.1 Cell Viability Testing 
Cell viability testing was undertaken of all chosen microorganisms against HK-2 cells 
in order to assess the effect bacterial products excreted in the supernatants may 
have on the viability and proliferation of human kidney cells over 24 h and 48 h with 
the media refreshed daily. 
4.4.1.1 Keystone Pathogen 
Porphyromonas gingivalis 
Cell viability testing was undertaken following exposure of HK-2 cells for 24 h or 48 h 
to P. gingivalis bacterial supernatants collected over 5 days (Figure 4.3). 
After 24 hours (Figure 4.3a), the viability of cells treated with all P. gingivalis 
supernatants was significantly lower than the control, with the exception of the 3 D 
P. gingivalis supernatant. There was no significant differences between the viability 
of all the AGCF-P media samples in comparison to the control. 
Similar effects were observed after 48 hours (Figure 4.3b); with the viability of cells 
treated with all P. gingivalis supernatants significantly lower than the control. There 
was also no significant differences between the viability of all the AGCF-P media 
samples in comparison to the control.  
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Figure 4.3 Cell viability of HK-2 cells after A) 24 h or B) 48 h incubation with AGCF-P supernatants and 
P. gingivalis supernatants collected over 5 days. Viability is presented as percentage change from the 
control (C: HK-2 cells exposed to serum-free cell culture medium). The error bars represent SEM. * p≤ 
0.05, ** p≤ 0.01, *** p≤ 0.001; (n=3).  
 
The detrimental viability effects exhibited by the P. gingivalis supernatants (Figure 
4.3) correlate with images taken of the same wells prior to sampling (Figure 4.4). Cell 
damage manifests by cell detachment (red arrows), as visible in images from cells 
exposed to P. gingivalis supernatants (Figure 4.4c) and (Figure 4.4e) compared to 
(Figure 4.4a) serum free media control and (Figure 4.4b) and (Figure 4.4d) which are 
AGCF-P media controls. 
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Figure 4.4 Images of HK-2 cells taken during cell viability testing of AGCF-P supernatants and P. 
gingivalis supernatants collected over 5 days exposed to HK-2 cells for 24 h and 48 h. A) Control 
(Serum-free cell culture medium) B) 5 day AGCF-P after 24 h exposure of HK-2 cells C) 5 day P. 
gingivalis after 24 h exposure of HK-2 cells D) 5 day AGCF-P after 48 h exposure of HK-2 cells E) 5 day 
P. gingivalis after 48 h exposure of HK-2 cells. Scale length = 100µM. Red arrows = cell detachment 
indicated by lack of cells in areas pointed to. 
 
4.4.1.2 Accessory Organisms  
Actinomyces israelii 
Cell viability testing was undertaken following exposure of HK-2 cells for 24 h or 48 h 
to A. israelii bacterial supernatants collected over 48 hours (Figure 4.5). 
After 24 and 48 h, statistical tests showed no significant differences between the 
effects of the bacterial supernatants and AGCF-P media on cellular viability in 
comparison with the control. 
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Figure 4.5 Cell viability of HK-2 cells after A) 24 h or B) 48 h incubation with AGCF-P supernatants and 
A. israelii supernatants collected over 48h. Viability is presented as percentage change from the 
control (C: HK-2 cells exposed to serum-free cell culture medium) and error bars represent SEM; (n=3). 
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Fusobacterium nucleatum 
Cell viability testing was undertaken following exposure of HK-2 cells for 24 h or 48 h 
to F. nucleatum bacterial supernatants collected over 48 hours (Figure 4.6). 
After 24 and 48 h, statistical tests showed no significant differences between the 
effects of the bacterial supernatants and AGCF-P media on cellular viability in 
comparison with the control. 
 
 
Figure 4.6 Cell viability of HK-2 cells after A) 24 h or B) 48 h incubation with AGCF-P supernatants and 
F. nucleatum supernatants collected over 48h. Viability is presented as percentage change from the 
control (C: cells exposed to serum-free cell culture medium) and error bars represent SEM; (n=3).  
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Parvimonas micra 
Cell viability testing was undertaken following exposure of HK-2 cells for 24 h or 48 h 
to P. micra bacterial supernatants collected over 48 hours (Figure 4.7). 
After 24 and 48 h, statistical tests showed no significant differences between the 
effects of the bacterial supernatants and AGCF-P media on cellular viability in 
comparison with the control. 
 
Figure 4.7 Cell viability of HK-2 cells after A) 24 h or B) 48 h incubation with AGCF-P supernatants and 
P. micra supernatants collected over 48h. Viability is presented as percentage change from the control 
(C: cells exposed to serum-free cell culture medium) and error bars represent SEM; (n=3).  
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Streptococcus constellatus 
Cell viability testing was undertaken following exposure of HK-2 cells for 24 h or 48 h 
to S. constellatus bacterial supernatants collected over 48 hours (Figure 4.7). 
After 24 and 48 h, statistical tests showed no significant differences between the 
effects of the bacterial supernatants and AGCF-P media on cellular viability in 
comparison with the control. 
 
Figure 4.8 Cell viability of HK-2 cells after A) 24 h or B) 48 incubation with AGCF-P supernatants and S. 
constellatus supernatants collected over 48h. Viability is presented as percentage change from the 
control (C: cells exposed to serum-free cell culture medium) and error bars represent SEM; (n=3).  
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Streptococcus sanguinis 
Cell viability testing was undertaken following exposure of HK-2 cells for 24 h or 48 h 
to S. sanguinis bacterial supernatants collected over 48 hours (Figure 4.9). 
After 24 and 48 h, statistical tests showed no significant differences between the 
effects of the bacterial supernatants and AGCF-P media on cellular viability in 
comparison with the control. 
 
 
Figure 4.9 Cell viability of HK-2 cells after A) 24 h or B) 48 h incubation with AGCF-P supernatants and 
S. sanguinis supernatants collected over 48h. Viability is presented as percentage change from the 
control (C: cells exposed to serum-free cell culture medium) and error bars represent SEM; (n=3).  
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4.4.1.3 Other Organisms related to Oral disease 
Enterococcus faecalis 
Cell viability testing was undertaken following exposure of HK-2 cells for 24 h or 48 h 
to E. faecalis bacterial supernatants collected over 48 hours (Figure 4.10). 
After 24 and 48 h, statistical tests showed no significant differences between the 
effects of the bacterial supernatants and AGCF-P media on cellular viability in 
comparison with the control. 
 
Figure 4.10 Cell viability of HK-2 cells after A) 24 h or B) 48 h incubation with AGCF-P supernatants and 
E. faecalis supernatants collected over 48h. Viability is presented as percentage change from the 
control (C: cells exposed to serum-free cell culture medium) and error bars represent SEM; (n=3).  
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Streptococcus mutans 
Cell viability testing was undertaken following exposure of HK-2 cells for 24 h or 48 h 
to S. mutans bacterial supernatants collected over 48 hours (Figure 4.11). 
After 24 and 48 h, statistical tests showed no significant differences between the 
effects of the bacterial supernatants and AGCF-P media on cellular viability in 
comparison with the control. 
 
Figure 4.11 Cell viability of HK-2 cells after A) 24 h or B) 48 h incubation with AGCF-P supernatants and 
S. mutans supernatants collected over 48h. Viability is presented as percentage change from the 
control (C: cells exposed to serum-free cell culture medium) and error bars represent SEM; (n=3). 
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4.4.2 Cell Migration and Wound Healing Assay 
The scratch wound healing assay was undertaken with all chosen microorganisms 
supernatants, in order to investigate the effect of the bacterial products on the 
migration and wound closure of human kidney cells. 
4.4.2.1 Keystone Pathogen 
Porphyromonas gingivalis 
A cell migration assay was undertaken testing the effect of P. gingivalis and AGCF-P 
supernatants sampled for 5 D and the ability of these supernatants to effect cell 
migration and wound closure of HK-2 cells (Figure 4.12). Each graph represents a 
different day of bacterial supernatant and non-inoculated AGCF-P media supernatant 
sampled from 1 D to 5 D.  
Statistical analysis of all scratch assays was undertaken comparing the means of the 
control (serum-free media), the AGCF-P media and P. gingivalis percentage wound 
closure with each other at each time point using a two-way ANOVA with multiple 
comparisons. All wounds achieved closure after 72 h incubation in the respective 
media. With the exception of cells exposed to AGCF-P medium collected at 1 D, all 
AGCF-P supernatant control media had a statistically significant positive effect on 
wound closure after 24 and 48 h when compared with cells exposed to the control 
serum-free medium.  
For all 1 D results (Figure 4.12a) the only significant result was the 48 h AGCF-P Media 
vs P. gingivalis. For 2 D (Figure 4.12c) there were three significant results, 24 h Control 
vs. AGCF-P Media, 24 h Control vs. P. gingivalis and 48 h Control vs. AGCF-P Media. 
However, there was no significant difference between the 2D 24 h P. gingivalis and 
24 h AGCF-P Media. For 3 D (Figure 4.12d) there were three significant results, 24 h 
Control vs. AGCF-P Media, 24 h Control vs. P. gingivalis and 48 h Control vs. AGCF-P 
Media. However, there was no significant difference between the 3D 24 h P. 
gingivalis and 24 h AGCF-P Media. For 4D (Figure 4.12e) there were two significant 
results, 24 h Control vs. AGCF-P Media and 48 h Control vs. AGCF-P Media. For 5 D 
(Figure 4.12f) there was two significant results, 24 h Control vs. P. gingivalis and 48 h 
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Control vs. AGCF-P Media. However, there was no significant difference between the 
24 h P. gingivalis and 24 h AGCF-P Media. 
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Figure 4.12 Percentage wound closure over 48 h of HK-2 cells exposed to serum-free medium alone 
(Black),  AGCF-P media supernatants in serum-free medium (1:20) (Blue), or P. gingivalis supernatants 
in serum free medium (1:20) (Red), all concurrently collected over 5 days. A) 1 d B) 2 d C) 3 d D) 4 d E) 
5 d F) Representative images captured of assay, dashed line indicates starting wound. Wound closure 
is presented as percentage closure of individual wells and error bars represent SEM. * = p≤ 0.05, ** = 
p≤ 0.01, *** = p≤ 0.001. Scale length = 200µM (n=3). 
F) 
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The observed variance from the control that was reported as statistically significant 
was for faster wound closure and this can be attributed to the AGCF-P media. Indeed, 
in most instances where there was significance reported for P. gingivalis 
supernatants, there was no statistical significance from the matched AGCF-P non-
inoculated media for that time point. In two instances 2D 48 h and 5D 48 h the 
observed variance was statistically significant between the AGCF-P media and P. 
gingivalis, with P. gingivalis supernatant delaying the wound closure over time, as 
compared to the AGCF-P medium alone. 
4.4.2.2 Accessory Organisms  
Actinomyces israelii 
A cell migration assay demonstrated that in comparison to the control serum free 
medium, supernatants from A. israelii sampled at 24 h to 48 h significantly 
accelerated wound closure of HK-2 cells after 24h (Figure 4.13A) and 48h (Figure 
4.13B) of exposure. However, the effect of the A. israelii supernatants were not 
significantly different from the wound closure effect of the non-inoculated AGCF-P 
media. 
Statistical analysis of all scratch assay results were compared to the control (no 
addition). For the 24 h supernatants (Figure 4.13a) there were four significant results, 
24 h Control vs A. israelii, 24 h Control vs AGCF-P media, 48 h Control vs A. israelii 
and 48 h Control vs. AGCF-P Media. For the 48 h supernatants (Figure 4.13b) there 
were four significant results, 24 h Control vs F. nucleatum, 24 h Control vs AGCF-P, 
48 h Control vs A. israelii and 48 h Control vs. AGCF-P Media. 
However, in all instances where there was significance for bacterial supernatants 
there was no significant difference between the bacterial supernatant and AGCF-P 
media. 
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Figure 4.13 Percentage wound closure over 48 h of HK-2 cells incubated with serum-free medium 
(Black), treatment with diluted AGCF-P media supernatants (Blue) and treatment with diluted A. 
israelii supernatants (Purple). A) 24 h B) 48 h C) Representative images captured of assay, dashed line 
indicates starting wound. Wound closure is presented as percentage closure in individual wells and 
error bars represent SEM. * p≤ 0.05, ** p≤ 0.01, *** p≤ 0.001, **** p≤ 0.0001. Scale length = 200µM 
(n=3).  
 
C) 
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Fusobacterium nucleatum 
A cell migration assay demonstrated that in comparison to the control serum free 
medium, supernatants from F. nucleatum sampled at 24 h to 48 h significantly 
accelerated wound closure of HK-2 cells after 24h (Figure 4.14A) and 48h (Figure 
4.14B) of exposure. However, the effect of the F. nucleatum supernatants were not 
significantly different from the wound closure effect of the non-inoculated AGCF-P 
media.  
Statistical analysis of all scratch assay results were compared to the control (no 
addition). For the 24 h supernatants (Figure 4.14a) there were two significant results, 
24 h Control vs F. nucleatum and 48 h Control vs. AGCF-P Media. For the 48 h 
supernatants (Figure 4.14b) there were two significant results, 48 h Control vs F. 
nucleatum and 48 h Control vs AGCF-P Media. 
However, in all instances where there was significance for bacterial supernatants 
there was no significant difference between the bacterial supernatant and AGCF-P 
media. 
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Figure 4.14 Percentage wound closure over 48 h of HK-2 cells incubated with serum-free medium 
(Black), treatment with diluted AGCF-P media supernatants (Blue) and treatment with diluted F. 
nucleatum (Purple). A) 24 h B) 48 h C) Representative images captured of assay, dashed line indicates 
starting wound. Wound closure is presented as percentage closure in individual wells and error bars 
represent SEM. * p≤ 0.05, ** p≤ 0.01, *** p≤ 0.001. Scale length = 200µM (n=3).  
C) 
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Parvimonas micra 
A cell migration assay demonstrated that in comparison to the control serum free 
medium, supernatants from P. micra sampled at 24 h to 48 h significantly accelerated 
wound closure of HK-2 cells after 24h (Figure 4.15A) and 48h (Figure 4.15B) of 
exposure. However, the effect of the P. micra supernatants were not significantly 
different from the wound closure effect of the non-inoculated AGCF-P media.  
Statistical analysis of all scratch assay results were compared to the control (no 
addition). For the 24 h supernatants (Figure 4.15a) there was one significant result, 
48 h Control vs. AGCF-P Media. For the 48 h supernatants (Figure 4.15b) there were 
three significant results, 24 h Control vs. AGCF-P Media, 48 h Control vs. AGCF-P 
Media and Control vs. P. micra. 
However, in all instances where there was significance for bacterial supernatants 
there was no significant difference between the bacterial supernatant and AGCF-P 
media. 
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Figure 4.15 Percentage wound closure over 48 h of HK-2 cells incubated with serum-free medium 
(Black), treatment with diluted AGCF-P media supernatants (Blue) and treatment with diluted P. micra 
(Purple). A) 24 h B) 48 h C) Representative images captured of assay, dashed line indicates starting 
wound. Wound closure is presented as percentage closure in individual wells and error bars represent 
SEM. * p≤ 0.05, ** p≤ 0.01, *** p≤ 0.001. Scale length = 200µM (n=3).   
 
C) 
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Streptococcus constellatus 
A cell migration assay demonstrated that in comparison to the control serum free 
medium, supernatants from S. constellatus sampled at 24 h to 48 h significantly 
accelerated wound closure of HK-2 cells after 24h (Figure 4.16A) and 48h (Figure 
4.16B) of exposure. However, the effect of the S. constellatus supernatants were not 
significantly different from the wound closure effect of the non-inoculated AGCF-P 
media.  
Statistical analysis of all scratch assay results were compared to the control (no 
addition). For the 24 h supernatants (Figure 4.16a) there were five significant results, 
24 h Control vs. AGCF-P Media, 24 h Control vs S. sanguinis, 24 h AGCF-P Media vs. 
S. constellatus, 48 h Control vs. AGCF-P Media and 48 h Control vs S. sanguinis. For 
the 48 h supernatants (Figure 4.16b) there were four significant results 24 h Control 
vs. AGCF-P Media, 24 h Control vs S. sanguinis, 48 h Control vs. AGCF-P Media and 48 
h Control vs S. sanguinis. 
However, in all instances where there was significance for bacterial supernatants 
there was no significant difference between the bacterial supernatant and AGCF-P 
media. The only exception to this is 24 h AGCF-P Media vs. S. constellatus. 
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Figure 4.16 Percentage wound closure over 48 h of HK-2 cells incubated with serum-free medium 
(Black), treatment with diluted AGCF-P media supernatants (Blue) and treatment with diluted S. 
constellatus (Purple). A) 24 h B) 48 h C) Representative images captured of assay, dashed line indicates 
starting wound. Wound closure is presented as percentage closure in individual wells and error bars 
represent SEM. * p≤ 0.05, ** p≤ 0.01, *** p≤ 0.001, **** p≤ 0.0001. Scale length = 200µM (n=3).  
C) 
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Streptococcus sanguinis 
A cell migration assay demonstrated that in comparison to the control serum free 
medium, supernatants from S. sanguinis sampled at 24 h to 48 h significantly 
accelerated wound closure of HK-2 cells after 24h (Figure 4.17A) and 48h (Figure 
4.17B) of exposure. However, the effect of the S. sanguinis supernatants were not 
significantly different from the wound closure effect of the non-inoculated AGCF-P 
media.  
Statistical analysis of all scratch assay results were compared to the control (no 
addition). For the 24 h supernatants (Figure 4.17a) there were two significant results, 
48 h Control vs. AGCF-P Media and 48 h Control vs S. sanguinis. For the 48 h 
supernatants (Figure 4.17b) there were three significant results, 24 h Control vs. 
AGCF-P Media, 48 h Control vs. AGCF-P Media and 48 h Control vs S. sanguinis.  
However, in all instances where there was significance for bacterial supernatants 
there was no significant difference between the bacterial supernatant and AGCF-P 
media. 
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Figure 4.17 Percentage wound closure over 48 h of HK-2 cells incubated with serum-free medium 
(Black), treatment with diluted AGCF-P media supernatants (Blue) and treatment with diluted S. 
sanguinis (Purple). A) 24 h B) 48 h C) Representative images captured of assay, dashed line indicates 
starting wound. Wound closure is presented as percentage closure in individual wells and error bars 
represent SEM. * p≤ 0.05, ** p≤ 0.01. Scale length = 200µM (n=3).   
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4.4.2.3 Other Organisms related to oral disease 
Enterococcus faecalis 
A cell migration assay demonstrated that in comparison to the control serum free 
medium, supernatants from E. faecalis sampled at 24 h to 48 h significantly 
accelerated wound closure of HK-2 cells after 24h (Figure 4.18A) and 48h (Figure 
4.18B) of exposure. However, the effect of the E. faecalis supernatants were not 
significantly different from the wound closure effect of the non-inoculated AGCF-P 
media.  
Statistical analysis of all scratch assay results were compared to the control (no 
addition). For the 24 h supernatants (Figure 4.18a) there were two significant results, 
48 h Control vs. AGCF-P Media and 48 h Control vs E. faecalis. For the 48 h 
supernatants (Figure 4.18b) there were four significant results, 24 h Control vs. AGCF-
P Media, 24 h Control vs E. faecalis, 48 h Control vs. AGCF-P Media and 48 h Control 
vs E. faecalis. 
However, in all instances where there was significance for bacterial supernatants 
there was no significant difference between the bacterial supernatant and AGCF-P 
media. 
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Figure 4.18 Percentage wound closure over 48 h of HK-2 cells incubated with serum-free medium 
(Black), treatment with diluted AGCF-P media supernatants (Blue) and treatment with diluted E. 
faecalis (Purple). A) 24 h B) 48 h C) Representative images captured of assay, dashed line indicates 
starting wound. Wound closure is presented as percentage closure in individual wells and error bars 
represent SEM. * p≤ 0.05, ** p≤ 0.01, *** p≤ 0.001. Scale length = 200µM (n=3).  
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Streptococcus mutans 
A cell migration assay demonstrated that in comparison to the control serum free 
medium, supernatants from S. mutans sampled at 24 h to 48 h significantly 
accelerated wound closure of HK-2 cells after 24h (Figure 4.19A) and 48h (Figure 
4.19B) of exposure. However, the effect of the S. mutans supernatants were not 
significantly different from the wound closure effect of the non-inoculated AGCF-P 
media.  
Statistical analysis of all scratch assay results were compared to the control (no 
addition). For the 24 h supernatants (Figure 4.19a) there were four significant results, 
24 h Control vs. AGCF-P Media, 24 h Control vs S. mutans, 48 h Control vs. AGCF-P 
Media and 48 h Control vs. S. mutans. For the 48 h supernatants (Figure 4.19b) there 
were four significant results, 24 h Control vs. AGCF-P Media, 24 h Control vs S. 
mutans, 48 h Control vs. AGCF-P Media and 48 h Control vs S. mutans. 
However, in all instances where there was significance for bacterial supernatants 
there was no significant difference between the bacterial supernatant and AGCF-P 
media. 
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Figure 4.19 Percentage wound closure over 48 h of HK-2 cells incubated with serum-free medium 
(Black), treatment with diluted AGCF-P media (Blue) and treatment with diluted S. mutans 
supernatants (Purple). A) 24 h B) 48 h. Wound closure is presented as percentage closure in individual 
wells and error bars represent SEM. * p≤ 0.05, ** p≤ 0.01, *** p≤ 0.001, **** p≤ 0.0001. Scale length 
= 200µM (n=3).  
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4.4.3 PAI-1 Luciferase Reporter Assay 
A PAI-1 luciferase reporter assay was undertaken to examine the effect of bacterial 
products on the expression of the marker for fibrosis (PAI-1) in human kidney cells 
over 24 h. Diluted supernatants of P. gingivalis, F. nucleatum and S. mutans were 
incubated with HK-2 cells transfected with either the native reporter vector pNL2.3 
or with the PAI-1-pNL2.3 reporter construct. Only three microorganisms were chosen 
due to time constraints and the cost of the components used. The three 
microorganisms represent each of the three categories of microorganisms 
investigated so far in this study: keystone pathogens, accessory organisms and other 
organisms related to disease.  
4.3.3.1 Testing the Transfected Cell Lines 
To evaluate the effectiveness of the PAI-1-pNL2.3 construct in reporting on the 
transcription regulation of PAI-1, soluble luciferase activity was measured in 
supernatants of transfected HK-2 cells exposed either to serum free medium or to 
AGCF-P supernatants. The AGCF-P supernatants had been collected over 5 days and 
were incubated for 24 h with HK-2 cells transfected either with PAI-1-pNL2.3 or with 
the native pNL2.3 vector. Luminescence was quantified in the HK-2 cell supernatants 
and it was then normalised per mg of total cellular protein (Figure 4.20). The results 
demonstrate that no detectable luciferase was secreted by cells transfected with the 
native pNL2.3 (PNL) vector neither in response to serum free medium, nor AGCF-P 
supernatants. In contrast, HK-2 cells transfected with the PAI-1 reporter construct 
demonstrated significant fluorescence in response to serum free and AGCF-P media. 
Although there was no significant difference of PAI-1 transcription regulation 
between the different AGCF-P media collection dates, all AGCF-P media significantly 
upregulated the expression of PAI-1, as compared to serum-free medium treatment. 
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Figure 4.20 Effect of AGCF-P supernatants on the transcription regulation of PAI-1 expression. HK-2 
cells transfected either with the PAI-1-pNL2.3 reporter construct (PAI-1) or with native pNL2.3 vector 
(PNL) were exposed for 24 h to AGCF-P supernatants collected over 5 days. The soluble luciferase 
activity (presented as Luminescence Arbitrary Units normalised to mg of total cellular protein) was 
measured in HK-2 supernatants. Serum Free Media PAI-1 (Black), PAI-1 transfected HK-2 (Blue) and 
PNL transfected HK-2 (Grey). Error bars represent SEM; (n=3).  
 
4.3.3.2 Keystone Pathogen 
The transcription regulation of PAI-1 was measured for P. gingivalis bacterial 
supernatants and AGCF-P control supernatants collected over 5 days against HK-2 
cells transfected with the PAI-1-pNL2.3 construct (Figure 4.21). The results 
demonstrate that after 24 h, all AGCF-P media and P. gingivalis supernatants have 
statistically significant differences compared with serum free media indicating 
increased PAI-1 expression. However, there is no significant difference between all 
matched AGCF-P media and P. gingivalis supernatants indicating that the AGCF-P 
media was responsible for the increased PAI-1 expression. 
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Figure 4.21 Effect of AGCF-P and P. gingivalis supernatants on the transcription regulation of PAI-1 
expression. HK-2 cells transfected with the PAI-1-pNL2.3 reporter construct (PAI-1) were exposed for 
24 h to AGCF-P and P. gingivalis supernatants collected over 5 days. The soluble luciferase activity 
(presented as Luminescence Arbitrary Units normalised to mg of total cellular protein) was measured 
in HK-2 supernatants. Serum Free Media (Black), AGCF-P supernatants (Blue) and P. gingivalis 
supernatants (Red). |-| indicates significance between the first bar and all others. Error bars represent 
SEM ** p≤ 0.01; (n=3).  
 
4.3.3.3 Other Microorganisms  
The transcription regulation of PAI-1 was measured for F. nucleatum and S. mutans 
bacterial supernatants along with AGCF-P control supernatants collected over 48 
hours against HK-2 cells transfected with the PAI-1-pNL2.3 construct (Figure 4.22). 
The results demonstrate that after 24 h, all AGCF-P media along with for F. nucleatum 
and S. mutans supernatants have statistically significant differences compared with 
serum free media indicating increased PAI-1 expression. However, there is no 
significant difference between all matched AGCF-P media and bacterial supernatants 
indicating that the AGCF-P media was responsible for the increased PAI-1 expression. 
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Figure 4.22 Effect of AGCF-P, F. nucleatum and S. mutans supernatants on the transcription regulation 
of PAI-1 expression. HK-2 cells transfected with the PAI-1-pNL2.3 reporter construct (PAI-1) were 
exposed for 24 h to AGCF-P and P. gingivalis supernatants collected over 5 days. The soluble luciferase 
activity (presented as Luminescence Arbitrary Units normalised to mg of total cellular protein) was 
measured in HK-2 supernatants. Serum Free Media (Black), AGCF-P supernatants (Blue), F. nucleatum 
supernatants (Pink) and S. mutans supernatants (Green). |-| indicates significance between the first 
bar and all others. Error bars represent SEM. ** p≤ 0.01; (n=3).  
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4.5 DISCUSSION 
4.5.1 Cell Viability 
The results of all the cell viability assays indicated that only the P. gingivalis 
supernatants had a statistically significant effect on the viability of the kidney cells. 
This corresponds with evidence of the cytotoxicity of P. gingivalis supernatants to 
various human cell lines such as human gingival fibroblasts (Desta and Graves, 2007, 
Morioka et al., 1993), human aortic endothelial cells (Roth et al., 2007) and various 
human urothelial cells (Shah et al., 1992). One of these studies investigated various 
components of P. gingivalis on three different urothelial cell lines and identified a 
few different virulence factors that could have cytotoxic effects on cells such as LPS, 
and Gingipain preparations with heterogeneity between cell type with epithelial cells 
less effected (Shah et al., 1992, Johansson et al., 1996). There has also been reports 
of heterogeneity between P. gingivalis subtypes, with P. gingivalis 33277 (NCTC 
11834 - used in this study) being more cytotoxic than P. gingivalis 381 and P. 
gingivalis W50 which has been suggested is due to the different immunogenicity of 
the serotypes (Johansson et al., 1996, Ebersole and Steffen, 1995).  
The majority of these reported studies have identified the main cause of this P. 
gingivalis cytotoxicity to be protein based (Chen et al., 2001, Desta and Graves, 2007, 
Morioka et al., 1993), with a cytotoxic effect that could be dose-dependently 
neutralised by heat inactivation (Johansson et al., 1996) or the addition of anti-sera 
(Chen et al., 2001) . Furthermore, several studies have identified P. gingivalis specific 
Gingipains as one of the major causes of this protein mediated cytotoxicity (Desta 
and Graves, 2007, Morioka et al., 1993, Chen et al., 2001). It is reported that these 
Gingipains are secreted in outer membrane vesicles and are capable of degradation 
of the intracellular matrix (Johansson et al., 1996, Chen et al., 2001) and induction of 
apoptosis (Desta and Graves, 2007) in human cells.  
Indeed, alongside visible cell death, morphology changes were also observed in cells 
treated with P. gingivalis supernatants compared to those treated with AGCF-P 
media and serum media alone. These results are in agreement with evidence in the 
literature that P. gingivalis supernatants can induce morphological changes in 
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gingival fibroblasts to become rounded (Yamasaki et al., 1998). It is suggested that 
the cause of these effects could be related to degradation of E-cadherin and the 
intracellular matrix (Chen et al., 2001) and this may account for the increased HK-2 
cell detachment observed in this study as a result of P. gingivalis supernatant 
treatments. However, it has also been suggested that the mechanism of cellular 
morphology changes is different from that of cell death (Morioka et al., 1993) or 
bacteria induced apoptosis (Desta and Graves, 2007). 
4.5.2 Cell Migration 
The results of the wound healing assays demonstrated that the AGCF-P media alone 
increased the migration compared to serum free media. This is most likely due to the 
AGCF-P medium containing more nutrients and potential growth factors from the 
addition of blood, in comparison to serum free media, potentially inducing cellular 
proliferation and migration (Brunner et al., 2010). In contrast to the other bacterial 
supernatants that mirrored the AGCF-P media, two P. gingivalis supernatants and the 
24 h S. constellatus supernatant had a significant effect on wound closure. The 24 h 
S. constellatus supernatant at 24 h had a statistically significant positive effect on the 
migration and proliferation of HK-2 cells and this could potentially be due to the 
production of fermented sugars which could enhance growth (Vos et al., 2011). There 
were also two significant reductions in migration of cells treated with P. gingivalis 
supernatants (Figure 4.12), compared with the AGCF-P media control. These 
instances may be the result of the cytotoxic activity of the P. gingivalis supernatants 
(Section 4.4.1) counteracting the positive effect of the AGCF-P media, especially as 
the viability of cells was not known.  
4.5.3 PAI-1 Luciferase Reporter Assay 
The successful transfection of HK-2 cells with the PAI-1 reporter vector allowed for 
the establishment of a fast assay indicative for fibrosis. The test can be completed in 
a relatively short amount of time and is specifically useful for screening compounds 
for pro-fibrotic effects along with being successful in prior publications (Abe et al., 
1994). Of the three microorganisms tested, none of them appeared to be inducing 
the increased production of PAI-1 in comparison with the AGCF-P media control. 
However, this does not necessarily mean PAI-1 is not being induced as this test is an 
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indicator of gene transcription, with protein translation being regulated by miRNA 
which could be interfered with by the complexity of the microbial growth medium 
used. Indeed, as PAI-1 is one of many markers associated with fibrosis there is also a 
possibility that while PAI-1 is not induced, other pro-fibrotic markers could be 
induced by a variety of microbial secreted products so it still warrants further testing. 
 After normalisation of the data, it is clear that the AGCF-P medium is inducing the 
production of PAI-1 and this highlights that this assay may not be useful for the 
analysis of complex microbial samples. The induction of PAI-1 by the AGCF-P media 
does not necessarily mean the AGCF-P media is causing fibrosis; it may be that the 
chosen indicator of fibrosis is too non-specific and the test is too sensitive, especially 
as PAI-1 can be induced by a variety of different non-fibrosis related stimuli. This may 
be because of AGCF-P is a complex medium which most likely has a selection of non-
specific stimuli such as growth factors and metabolic factors such as glucose present 
from the addition of blood and this could be interfering with the production of PAI-1 
(Eddy and Fogo, 2006, Ghosh and Vaughan, 2012) (Figure 4.23).  
 
Figure 4.23 Summary of potential ways PAI-1 production can be induced and its interactions in the 
pathogenesis of renal fibrosis. Taken from (Eddy and Fogo, 2006). 
 
Despite some drawbacks, this luciferase reporter assay was utilised in order to 
provide an early indicator of potential fibrotic effects and while the assay appeared 
to work the consistency of AGCF-P medium may be interfering. In order to provide a 
real indicator of the induction/moderation of pro-fibrotic effects a wide selection of 
protein and genetic markers would need to be quantitatively investigated, including 
PAI-1. 
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4.6 CONCLUSIONS 
The utilisation of cell-based assays for evaluation of the viability, proliferation and 
migration effects of all chosen microbial supernatants against HK-2 cells were 
successful in screening these organisms for harmful effects. From these tests it has 
been possible to narrow down the number of organisms that had secreted products 
capable of eliciting a damaging effect to kidney cells to only P. gingivalis, with 
significant cell death observed. This leads onto investigating the causative 
agent/agents behind this injury with particular interest in Gingipains, investigated in 
the final research chapter (Chapter 5). 
However, the developed reporter assay for the fibrosis associated PAI-1 gene did not 
allow elucidation of potential fibrotic activity of the selection of microbial 
supernatants due to high background reading with the utilised microbial growth 
medium AGCF-P. This problem is most likely due to the relatively broad nature of 
how PAI-1 can be activated which has led to the AGCF-P media being responsible for 
a ‘pro-fibrotic effect’ and potentially masking any pro-fibrotic effects from the 
microbial supernatants. In order to investigate whether these microbial supernatants 
can elicit any pro-fibrotic effects it would be of interest to use a more specific test for 
a wider selection of pro-fibrotic markers such as quantitative reverse transcriptase 
polymerase chain reaction (qPCR); this forms the content of the final research 
chapter (Chapter 5). 
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5.1 INTRODUCTION 
It is clear that oral microorganisms in periodontal disease are the main aetiological 
agents of disease and that they have the potential to damage the host in CP itself and 
in a multitude of other associated diseases (Chapter 1). However, of the chosen 
microorganisms investigated in this study, P. gingivalis supernatants were the only 
ones cytotoxic to kidney cells (Chapter 4). In order to understand what component/s 
of P. gingivalis is causing damage it is important to consider all potential virulence 
factors of this microorganism and identify those that could be isolated in the 
microbial supernatants. As P. gingivalis has been identified as one of the keystone 
pathogens in CP and a key member of the ‘red complex’, many of its virulence 
mechanisms such are well reported (Hajishengallis and Lamont, 2012). Figure 5.1 
depicts the wide variety of reported virulence mechanisms that P. gingivalis 
possesses such as direct translocation, LPS, fimbriae, outer membrane vesicles and 
peptidoglycan and highlights how these may interact with the human host. The 
capacity for the involvement of P. gingivalis with CKD via these virulence factors are 
discussed in depth in this chapter. 
 
Figure 5.1 The virulence mechanisms of Porphyromonas gingivalis and how these may interact with 
the human host.  
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5.1.1 Evidence for Direct Translocation and Invasion 
Currently there is no evidence showing the direct translocation of oral 
microorganisms to the kidneys. However, there is evidence for the translocation and 
invasion of periodontitis associated microorganisms in a variety of human cell types 
not present in the oral cavity. P. gingivalis has been reported to be able to invade the 
following human cell lines: coronary artery  (Dorn et al., 1999), osteoblasts (Zhang et 
al., 2010), oral epidermoid epithelial (Dorn et al., 2000, Duncan et al., 1993), umbilical 
vein endothelial (Dorn et al., 2000) and gingival fibroblasts (Amornchat et al., 2003). 
Indeed, a causal link between CP and atherosclerosis has been suggested as the 
genomic DNA of P. gingivalis has been found in atherosclerotic plaques (Velsko et al., 
2014), along with viable bacteria of invasive Aggregatibacter  
actinomycetemcomitans and P. gingivalis (Kozarov et al., 2005). 
It is clear that oral bacteraemia is a common event in diseases such as CP (Chapter 
1.2.2) and with the mechanistic nature of the cardiovascular system; it is highly 
plausible that periodontal and oral microorganisms that enter the blood could 
encounter a part of the kidney such as the glomerulus or tubules. For example, in 
individuals who already have kidney disease the glomeruli can be damaged (López-
Novoa et al., 2011) which could allow translocated organisms to penetrate further 
into the kidney to the interstitial, tubular and vascular compartments. With P. 
gingivalis able to adhere and invade a variety of oral and non-oral human tissues, it 
is possible that this organism has the capacity to adhere and/or invade kidney 
epithelial cells, which has similarities with oral epithelial cells. There is also evidence 
that P. gingivalis can degrade the cell junctional complexes of human gingival 
epithelial cells allowing access to deeper structures (Katz et al., 2002b); these are the 
same junctional proteins that exist in kidney epithelial cells (Katz et al., 2000). 
5.1.2 Evidence of Acquired Immune Response to Periodontal Pathogens in Relation 
to CKD  
Evidence from cross-sectional studies of serum antibody titres to periodontal 
pathogens in cohorts with CP and CKD, highlights a link between CP and CKD. In one 
such study of elderly individuals in Japan (mean age of aged 79 yrs), individuals with 
elevated serum antibody levels to P. gingivalis were 2.6 times more likely to have 
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CKD and decreased kidney function when compared with other quartiles (Iwasaki et 
al., 2012). High serum IgG levels to P. gingivalis, T. denticola and A. 
actinomycetemcomitans are significantly associated with impaired kidney function 
when adjusted for confounders in a similar elderly community living population 
(Kshirsagar et al., 2007). However, a larger cross-sectional study of 4,053 American 
adults all aged 40 or older (mean age of 57.4 yrs) showed that 9% of the population 
had CKD and 9% had CP, while 24% had high A. actinomycetemcomitans titres and 
22% had high P. gingivalis titres (Fisher et al., 2008). Of these results, a low antibody 
titre of A. actinomycetemcomitans was found to be statistically significant as a risk 
factor for CKD.  
While most of these studies appeared to show alternate correlations between 
individual periodontal organisms and CKD it is important to consider their population 
demographics. They are not directly comparable especially as CP is usually observed 
in those over 40 and increases in prevalence with advancing age. Another interesting 
point to consider is it has been reported that periodontal pathogens such as P. 
gingivalis produce proteases that can degrade various immunoglobulins such as IgA1, 
IgA2 and IgG (Guthmiller and Novak, 2002, Kilian, 1981). They can even hydrolyse 
antibodies that have bound to the bacterial cell surface allowing the key pathogen to 
evade host defences (Grenier et al., 1989). 
5.1.3 Lipopolysaccharides 
LPS, commonly referred to as endotoxin, is integral to the structure of the cell wall in 
most Gram-negative bacteria such as the black pigmented keystone pathogens. LPS 
is considered one of the main proponents of the systemic inflammatory burden in 
periodontal disease and is known to enhance production of the inflammatory 
cytokines such as the interleukins IL-1, IL-6, IL-8 and Tumour Necrosis Factor α (Wang 
and Ohura, 2002). Normally LPS can bind to CD14 in cell membranes from which it 
can be transferred to toll-like receptor 4 (TLR-4) initiating cell activation and innate 
host defence mediator production (Bainbridge and Darveau, 2001). However it has 
been reported that periodontal LPS such a P. gingivalis LPS can bind to TLR-2 along 
with being an antagonist for TLR-4; this may allow inhibition of immune responses in 
the fibroblasts in human inflamed gingiva and the chronic inflammation seen 
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(Bainbridge and Darveau, 2001). Consequently, a recent study highlighted that P. 
gingivalis LPS can inhibit a secondary immune response from gingival fibroblasts, 
preventing cytokine and chemokine release, thus the LPS enables the sustained 
inflammation characteristic of periodontitis (Fitzsimmons et al., 2018). Furthermore, 
high serum LPS levels have been associated with development of kidney disease in 
those with diabetes (Nymark et al., 2009), which highlights a potential link to kidney 
damage. However, this may be predominant in those patients with comorbidities 
such as diabetes. For LPS to be implicated in kidney disease, it would need to be 
stable within the blood and cause a distal response at the site of the kidney. 
Although, there is evidence that LPS is rapidly eliminated by the liver in healthy 
patients, this may be different in those with chronic diseases (Yao et al., 2016). If the 
LPS could remain viable in the blood it could potentially be concentrated within the 
kidney and stimulate an immune response in the kidney. This is evidenced with the 
association of LPS in sepsis with acute kidney injury; 40-50% of septic patients 
develop an acute kidney injury with suggestions this is mediated by 
lipopolysaccharide binding protein (Gómez and Kellum, 2016, Stasi et al., 2017). The 
source of LPS does not necessarily need to be from Gram-negative periodontitis 
associated pathogens; there is some evidence that dysbiosis of the gut microbiota 
can lead to LPS entering the bloodstream and this is associated with inflammation in 
CKD patients (Salguero et al., 2019). 
5.1.4 Peptidoglycan 
Peptidoglycan is an exoskeleton-like mesh made up of sugars and amino acids, which 
is a structural component of Gram-negative and predominantly Gram-positive 
bacterial cell walls. Peptidoglycan is a common target for beta-lactam drugs and can 
be an endotoxin which can induce an inflammatory response, such as the production 
of numerous cytokines (Okugawa et al., 2010). Peptidoglycan is constantly degraded 
and remodelled in the bacterial cell wall through growth and can be released into the 
environment where it can be a ligand for detection by the innate immune system 
(Johnson et al., 2013). In particular, the Gram-negative periodontitis associated 
organisms such A. actinomycetemcomitans, P. gingivalis and F. nucleatum can 
activate Nucleotide-binding oligomerization domain containing 1 (NOD1) and NOD2 
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receptors on macrophages which can cause inflammation in periodontitis (Chaves de 
Souza et al., 2016). In patients with CKD, it has also been found that peptidoglycan 
recognition protein 1 (PGLYRP1) is upregulated in those with poor oral health and 
was correlated with the number of periodontal pockets (Nylund et al., 2017); 
however the putative effect of peptidoglycan on the pathogenesis of CKD outside of 
inflammation is unknown. 
5.1.5 Fimbriae  
Fimbriae are present as numerous appendages on some Gram-negative and Gram-
positive microorganisms; they form a key part in the adhesion of bacterial cells to 
surfaces, other microorganisms and nutrients (Marsh et al., 2009). It has been 
proposed that P. gingivalis fimbriae act as pathogen-associated molecular patterns 
(Enersen et al., 2013). These can activate toll-like receptors and their signalling 
pathways, resulting in the release of inflammatory cytokines and chemokines such 
as IL-1β, IL-6, and TNF-α and IL-8 in monocytes (Hajishengallis et al., 2004) along with 
separately producing IgA2 anti-fimbriae antibodies (Ogawa et al., 1991). There is also 
evidence showing that in P. gingivalis, adhesion and invasion of epithelial cells is 
promoted by the major fimbriae fimA (Umeda et al., 2006). Fimbriae would most 
likely play an important role in attachment of periodontal pathogens to kidney 
tissues if invasion and/or damage took place. 
5.1.6 Outer Membrane Vesicles 
P. gingivalis is not known to produce any exotoxins but it does produce a variety of 
enzymes and metabolites which are secreted into the local environment and have 
been reported to cause a variety of deleterious effects (Lamont and Jenkinson, 1998). 
Many Gram negative bacteria secrete spherical buds of periplasmic material called 
outer membrane vesicles (OMVs), which can be bound to the microbial surface or 
secreted directly into the environment (Schwechheimer and Kuehn, 2015). P. 
gingivalis is known to secrete OMVs of 50-250 nm in size which can act as vehicles 
for virulence factors such as LPS, adhesins and proteolytic enzymes (Xie, 2015). It has 
been reported that P. gingivalis specific proteases, Gingipains, are disproportionately 
packed into these OMVs (Veith et al., 2014, Haurat et al., 2011). Furthermore, 
treatment of human epithelial cells (Nakao et al., 2014) and human gingival 
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fibroblasts (Mantri et al., 2015) with P. gingivalis OMVs of >3 μg ml-1 has been shown 
to detach cells from confluent monolayers with the effect diminished upon heat 
activation. 
5.1.7 Proteases 
A protease is an enzyme that can break down peptides and proteins. It has been 
known for some time that proteases are produced by periodontal pathogens and are 
important virulence factors, which can cause tissue destruction and inflammation 
(Nakayama, 2003). In P. gingivalis there are a selection of proteases which are 
secreted extracellularly or predominately in OMVs, with the major group being 
cysteine proteinases called Gingipains which have been reported to account for 85% 
of the proteolytic activity and 99% of the trypsin-like activity of OMVs (Potempa et 
al., 2003). 
Three types of Gingipains are produced by P. gingivalis: Lysine-specific gingipain 
(Kgp), arginine-specific gingipain A (RgpA), and arginine-specific gingipain B (RgpB) (Li 
and Collyer, 2011). These Gingipains are known to activate Proteinase Activated 
Receptors (PAR) in the periodontium and circulating immune cells which can lead to 
an inflammatory response (Rovai and Holzhausen, 2017). As a predominant virulence 
factor, the Gingipains can have a variety of interactions with the host immune system 
leading to destructive loss of attachment and a pro-inflammatory response with 
disease sustained inflammation which facilitates invasion and tissue damage (Figure 
5.2) (Sandholm, 1986).  
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Figure 5.2 The interactions Gingipains produced by P. gingivalis has with the immune system. Lysine-
specific gingipain (Kgp), arginine-specific gingipain A (RgpA), and arginine-specific gingipain B (RgpB), 
Complement components (C3, C4bp, C5, C5a), protease activated receptors (PARs), 
polymorphonuclear lymphocytes (PML). 
P. gingivalis has been shown to be highly resistant to the bactericidal activity of 
human complement and this has been reported to be due to Rgp Gingipains binding 
to human complement inhibitor C4b-binding protein (C4BP) along with degradation 
of complement component C3 (Potempa et al., 2008, Wingrove et al., 1992). 
Moreover, the degradation of the complement component C5 to C5a can lead to the 
release of this potent chemoattractant which can recruit PMLs to the gingival lesion, 
thus promoting sustained inflammation (Wingrove et al., 1992). Gingipains have also 
been shown to degrade CD14 macrophages preventing LPS activating leukocytes, 
facilitating the continual colonisation of the gingival crevice (Imamura, 2003). 
 An interesting discovery was that secreted Gingipains could stimulate the 
accumulation of PML by the conversion of interleukin 8 (IL-8) to a more potent 
truncated version, while Gingipains present in OMV can degrade the truncated IL-8 
locally which may be a reason behind the chronic inflammation combined with 
persistence of P. gingivalis seen in periodontitis (Mikolajczyk-Pawlinska et al., 1998). 
It is also reported that these proteases stimulate the activation of dormant matrix 
metalloproteinases such as MMP-9 that degrade the extracellular matrix, which 
combined with depletion of plasminogen and the destruction of cell junctional 
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complexes can promote fibrosis and invasion (Kuula et al., 2009, Fleetwood et al., 
2015, Katz et al., 2002b, Katz et al., 2000). 
5.1.8 Metabolites 
Metabolites are low molecular weight compounds, which represent the precursors, 
intermediates and reactants of biochemical reactions which take place intracellularly 
and extracellularly (Dunn et al., 2011). It has previously been highlighted that certain 
microorganisms can generate primary and secondary metabolites and some of these 
have been shown to interact with the human body through immune regulation 
(Brestoff and Artis, 2013), protection against pathogens (Clarke et al., 2010) and 
metabolism of synthetic substances (Kuhn et al., 2014).  
Secreted metabolites in P. gingivalis are relatively unstudied, however the anaerobic 
nature of P. gingivalis growth can lead to the production of major fermentation 
products such as butyric acid and indole (Parte et al., 2011). A selection of other 
metabolic end products have also been reported such as: Acetic acid, Isobutryric, 
Isovaleric, Phenylacetic acid, Propionic and Succinic with the major fatty products 
being 13-methyltetradecanoic acid (C13:10 iso) (Parte et al., 2011). Of the 
metabolites known to be produced, little is known about their potential effects on 
the host, however their abundance can be measured using a metabolomics-based 
approach discussed in Chapter 3. 
5.1.9 Components that would be present in microbial supernatants 
As discussed in more depth in Chapter 4.1.1 and Figure 4.1, the use of microbial 
supernatants for this study narrows down the potential causes of the damage 
observed to the HK-2 cells. These bacterial supernatants do not contain any microbes 
and do not contain the lysis and intracellular products of the microorganisms. There 
would also be lower amounts of LPS, peptidoglycan and fimbriae due to the lack of 
sonication. The supernatants would contain degradation products of the growth 
medium (AGCF-P) along with outer membrane vesicles, secreted metabolites and 
small amounts of LPS and peptidoglycan. This chapter focuses on identifying the 
factors in these microbial supernatants that cause the deleterious effect observed 
Chapter 5: Elucidation of the Cause of Effect 
141 
 
against HK-2 cells along with using further tests to assess whether these supernatants 
can induce fibrosis in HK-2 cells. 
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5.2 AIM AND OBJECTIVES 
5.2.1 Aim 
To identify the cause of the cytotoxic effects seen in HK-2 cells treated with P. 
gingivalis supernatants and to further investigate the fibrotic potential of microbial 
supernatants. 
5.2.2 Objective 
 Determine whether LPS can have cytotoxic effects on human kidney cells. 
 Determine whether secreted microbial proteins can have cytotoxic effects on 
human kidney cells. 
 Utilise the metabolomics pipeline developed in Chapter 3 to investigate P. 
gingivalis for any potentially cytotoxic compounds. 
 Determine whether P. gingivalis supernatants can induce a selection of fibrosis 
markers using qPCR. 
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5.3 METHODS 
5.3.1 Endotoxin Quantification 
The Pierce LAL Chromogenic Endotoxin Quantitation Kit (ThermoFisher Scientific, UK) 
was utilised to create a standard curve of Escherichia coli lipopolysaccharide to 
compare against microbial supernatant samples. In order to quantify the amount of 
lipopolysaccharide present in the microbial supernatants, these supernatants were 
diluted at 1:10 with endotoxin free water (ThermoFisher Scientific, UK) because of 
the high innate colour of the microbial samples. The standard protocol was used and 
in order to account for the slight colour of the microbial samples, the 96 well plate 
was read before and after the addition of the chromogenic substrate at 405nm on a 
Multiskan FC Microplate Photometer (ThermoFisher Scientific, UK). All results were 
exported to Microsoft Excel, the blank endotoxin free water values were averaged 
and subtracted from all samples and a standard curve of high and low concentrations 
of LPS was produced with a linear regression. Using the linear equation, the LPS 
concentrations of the microbial samples were derived by averaging the replicates for 
each sample and inputting the results into the equation of the standard curves.  
5.3.2 LPS Testing Against Kidney and Gingival Cell Lines 
HGF-1 and HK-2 cells were maintained and viability testing was conducted as 
discussed in Chapter 2.3.3-2.3.4.  
P. gingivalis LPS (Sigma Aldrich, UK) and Escherichia coli O111:B4 LPS (Sigma Aldrich, 
UK) were reconstituted in HGF-1 and HK-2 cell medium prior to use and inoculated 
into the cell culture medium at a range of concentrations to be investigated for 
effects on cell viability. 
5.3.3 Protein Inactivation and testing of P. gingivalis and AGCF-P supernatants 
An aliquot (100 µL) of P. gingivalis supernatants (1D-5D) which elicited viability 
effects and AGCF-P supernatants (1D-5D) were heat inactivated by heating at 90oC 
for 30 minutes in a dry heat block. Another aliquot (100 µL) of the P. gingivalis and 
AGCF-P supernatants were inactivated by the addition of 10 µL of filter sterilised 
Trypsin-EDTA (Lonza, UK). Cell viability testing of these inactivated supernatants was 
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repeated as in Chapter 4.3.1.1 using the cell viability method described in Chapter 
2.3.3-2.3.4. 
5.3.4 Testing of Protease Inhibitors 
The cell viability testing of P. gingivalis and AGCF-P media was repeated as completed 
in Chapter 4.3.1.1 alongside the same bacterial and control supernatants, with the 
addition of 1 µL of cell culture safe protease inhibitor cocktail mixture (Sigma Aldrich, 
UK) using the cell viability method described in Chapter 2.3.3-2.3.4. 
5.3.5 LCMS Preparation and Analysis 
P. gingivalis supernatant samples and matched AGCF-P media controls were 
prepared to untargeted LCMS analysis as described in Chapter 3.3.2-3.3.5.  
Further additions were made to these reported LCMS methods, with preparation of 
pooled quality controls taking place after section 3.3.3 and quality control and 
assurance after section 3.3.5.3. 
5.3.5.1 Preparation of Pooled Quality Control (QC) 
Pooled quality control samples were created by taking 150 µL from every sample, 
methanol washes and blanks and mixing in a universal. The number of quality control 
samples required was then worked out and 750 µL of the pooled QC was aliquoted 
into the number of 2 mL LCMS vials required. To work out the number of quality 
controls needed per run the equation used was: 
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑄𝐶 𝑠𝑎𝑚𝑝𝑙𝑒𝑠 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑 =  3 +  (𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒𝑠 / 6 ) 
5.3.5.2 Quality Control and Quality Assurance 
In order to reduce the number of false positives and negatives, quality control and 
assurance of raw data files was undertaken in Microsoft Excel prior to further 
analysis. The quality control and assurance methods used are described below: 
Step 1 – Work out % control contribution 
 Work out average intensity of controls and average intensity of QCs =average 
 % Control contribution formula =(Average of controls/Average of QC)*100 
Step 2 – Work out Relative Standard Deviation of Quality Control and Samples 
 Work out Standard Deviation of QC and Samples =STDEV 
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 Work out mean of QC and Samples =AVERAGE 
 Work out RSD of QC and samples =SUM(SD/mean)*100 
Step 3 – Work out % count of QC and Samples 
 Work out count of QC and samples which contain more than 0 (make sure 
they are in chronological order i.e. QC1, QC 2, QC 3 etc) 
=COUNTIF(FirstSample:LastSample,”>0”) 
 Work out % count =SUM(COUNT/Total number of QC or Sample)*100 
Step 4 – Work out Relative Standard Deviation ratio of Samples / Quality Control 
 =SUM(RSDsamples/RSDQC)*100 
Step 5 – Filter data  
 Delete all rows with % QC Count of <60 
 Delete all rows with QC RSD >20% 
 Delete all rows with blanks contribution >5% 
5.3.6 Quantitative Polymerase Chain Reaction (qPCR) 
5.3.6.1 Cell Culture and Experimental Plan 
HK-2 cells were maintained as discussed in Chapter 4.2.2. Six well tissue culture 
plates were seeded with HK-2 cells (4 x 104 cells) and grown to 70% confluency in 
growth medium. The cells were exposed to 15 conditions (Serum free media, AGCF-
P media supernatants x 5, P. gingivalis supernatants x 5, S. mutans supernatants x 2 
and F. nucleatum supernatants x 2), with each one in triplicate. 
5.3.6.2 RNA Extraction 
After 24 hours of exposure to the respective treatment, the media were aspirated 
and the cells were washed three times with ice cold Phosphate Buffered Saline 
(Lonza, UK). Total RNA was extracted on ice using an RNeasy kit (Qiagen, UK) as per 
manufacturer’s protocol. A Thermo Scientific™ NanoDrop™ One Spectrophotometer 
(Fisher Scientific, UK) was used to measure the total RNA concentration and its purity, 
and the RNA samples were diluted with DNase/RNase-free water to 0.6 µg of RNA 
per sample to ensure comparability. All samples were stored at -80oC until needed. 
5.3.6.3 cDNA Synthesis 
A Bioline Tetro™ cDNA Synthesis Kit (Sigma Aldrich, UK) was utilised to convert mRNA 
to cDNA to allow quantification of gene expression by qPCR. The standard protocol 
was followed with Oligo(dT) primers rather than random hexamer primers as this 
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qPCR experiment aims to look at mature messenger RNA. Once converted all cDNA 
samples were kept at -20oC for long-term storage. 
5.3.6.4 Primers 
The primers used for the qPCR experiments and the respective sequences are shown 
in Table 5.1. All primers were diluted to stock solutions of 70 µM with PCR grade 
water to allow for 1:10 dilutions for the qPCR master mix.  
Table 5.1 All primer genes and sequences for qPCR experiments.  
Primer Sequence Fragment Size Expected 
(Base Pairs) 
β-actin 
(Housekeeping) 
Forward CACTCTTCCAGCCTTCCTTC 
90 
Reverse GGATGTCCACGTCACACTTC 
Protease Activated 
Receptor 1 (PAR1) 
Forward AGAAGTCAGGAGAGAGGGTGAA 
177 
Reverse CTTTTGATTCTGGCCTGCGG 
Protease Activated 
Receptor 2 (PAR2) 
Forward GCTCTGAGTTTCGAATCGGC 
152 
Reverse TCTACTGGTTCCTTGGATGGT 
Transforming growth 
factor beta 1 (TGF-βR1) 
Forward CCTCGAGATAGGCCGTTTGT 
121 
Reverse GCAATGGTAAACCAGTAGTTGGA 
Vascular Endothelial 
Growth Factor (VEGF) 
Forward GCCTTGCTGCTCTACCTCCAC 
75 
Reverse ATGATTCTGCCCTCCTCCTTCT 
Tissue Inhibitor of 
Metalloproteinases 1 
(TIMP1) 
Forward CGCAGCGAGGAGTTTCTCAT 
188 Reverse CTCTGCAGTTTGCAGGGGATG 
Plasminogen Activator 
Inhibitor-1 (PAI-1) 
Forward CGAGGTGAACGAGAGTGGCA 
170 
Reverse CCGAGGGTCAGGGTTCCATC 
Collagen type 1 Alpha 1 
(COL1A1) 
Forward GTCGAGGGCCAAGACGAAGA 
114 
Reverse GTTGTCGCAGACGCAGATCC 
 
5.3.7.5 qPCR  
The QuantiNova SYBR Green PCR kit (Qiagen, UK) was used for all qPCR experiments. 
The reagent mixture used (Table 5.1) was based off the standard protocol which 
came with the kit and the reaction volume was 20 µL. The ROX reference dye was 
not used as the qPCR instrument used (BioRad CFX96) did not require ROX. 
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Table 5.2 Reaction mixture for all qPCR experiments 
Component Amount (µL) Final Concentration 
2 x SYBR Green QPCR master mix 10 1x 
FW Primer  2 0.7 µM  
RV Primer  2 0.7 µM 
Template DNA 1 <100 ng/reaction 
Nuclease free PCR grade water 5  
(Adjust to make 20 µL final) 
 
Total 20 20 µL 
 
The PCR cycling program (Table 5.3) was based upon the standard protocol from the 
kit. 
Table 5.3 PCR cycling program for all qPCR experiments  
Cycles Duration of Cycle Temperature (oC) Ramp Rate 
PCR initial heat 
activation 
2 min 95 Maximal/fast 
Denaturing 5 seconds 95 Maximal/fast 
Combined 
annealing/extension 
10 seconds 60 Maximal/fast 
Number of cycles = 39 
Use melting curve analysis 
 
5.3.7.6 Agarose Gel Electrophoresis  
In order to ensure the correct fragment size and a lack of multiple products present 
in the qPCR reactions, qPCR products were separated by 2% agarose gel 
electrophoresis. To make this gel, 1.5 g of molecular grade agarose powder (Bioline, 
UK) was added to 50 mL of 1 x Tris base, boric acid and EDTA (TBE) buffer and heated 
until dissolved. Next, 2 µL of midori green dye (Bioline, UK) was mixed into the 
agarose solution and the gel was poured and allowed to set. Subsequently, 450 mL 
of 1 x TBE buffer was use to fill an electrophoresis tank and 4 µL of all samples was 
mixed with 1 µL of 5 x loading buffer (Bioline, UK). These mixed samples were then 
added to the wells along with 5 µL of a 1kb hyperladder (Bioline, UK) loaded on each 
gel to facilitate the determination of the size of the PCR products. The gel 
electrophoresis was carried out for 45 minutes at 80 mV and the PCR products were 
then visualised with UV light.  
5.3.7.7 Data Analysis 
All qPCR data was checked prior to exporting cycle threshold (Ct) values to Microsoft 
Excel. The baseline setting was set to baseline subtracted curve fit for all plates and 
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the threshold value was manually set as the average of plate 1 and plate 2 for each 
gene to ensure consistency. Fold gene expression was calculated in Microsoft Excel 
using the 2-∆∆Ct method (Livak and Schmittgen, 2001), with β-actin used as the 
housekeeping gene. The 2-∆∆Ct values were used to depict fold change and statistical 
analysis was completed on Log2 of the 2-∆∆Ct values to reduce error.  
5.3.7.8 Graph Plotting and Statistical Analysis 
Prism 8.1.1 was used for all graph plotting and statistical analysis of qPCR data. A two 
way ANOVA with multiple comparisons (Tukey) was used to compare all Log2 fold 
changes between all samples at each time point. 
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5.3 RESULTS 
5.3.1 Investigating the Role of LPS in Perceived Cell Damage 
Quantification of LPS amounts in microbial and control supernatant samples was 
undertaken to evaluate whether P. gingivalis LPS could be responsible for the 
cytotoxic effects observed in Chapter 4 caused by P. gingivalis supernatants. 
5.3.1.1 Quantification of LPS in Cell Damaging Samples 
The Limulus Amebocyte Lysate (LAL) assay was used to quantify LPS in all P. gingivalis 
samples and 1 D and 5 D AGCF-P media supernatant samples (Figure 5.3). Not all 
AGCF-P media samples were investigated due to the prohibitive cost of the kit and 
the lack of microbial inoculation. 
All P. gingivalis samples averaged around 0.3 EU/mL which equates to 0.3 ng/mL 
while AGCF-P media supernatants averaged around 0.1 EU/mL which equates to 0.1 
ng/mL. There was no significant difference between LPS concentration of 1D P. 
gingivalis supernatants compared with 1D AGCF-P supernatants along with 5D P. 
gingivalis supernatants compared with 5D  AGCF-P supernatants. 
 
Figure 5.3 Endotoxin amount in 1-5 Day (D) Porphyromonas gingivalis (PG) and 1 and 5D AGCF-P (C) 
supernatant samples. Error bars represent SEM (n=3).  
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5.3.1.2 Creating a Standard Curve of Cell Damage with E. coli and P. gingivalis LPS 
In order to determine whether the EU/mL concentration present in the supernatant 
samples could elicit a cytotoxic effect on kidney cells, titration experiments were 
carried out using of P. gingivalis LPS (Figure 5.4) and E. coli O111:B4 LPS (Figure 5.5). 
Only up to 10 µg/mL of P. gingivalis LPS could be tested due to the starting 
concentration of P. gingivalis LPS not being sufficiently high enough for appropriate 
dilution into cell culture media. 
 
Figure 5.4 Cell viability of HK-2 cells incubated with serum free media (Control), 1:20 dilution of 
endotoxin free water and a dilution series of P. gingivalis and E. coli LPS for A) 24 h and B) 48 h. Error 
bars represent SEM (n=3).  
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After 24 and 48 hours incubations of LPS with HK-2 cells, neither E. coli nor P. 
gingivalis LPS had a statistically significant effect on the cellular viability (Figure 5.4). 
The same effect was also observed after 24 and 48 hours exposure of HGF-1 cells to 
E. coli or P. gingivalis (Figure 5.5). 
 
Figure 5.5 Cell viability of HGF-1 cells incubated with serum free media (Control), 1:20 dilution of 
endotoxin free water and a dilution series of P. gingivalis and E. coli LPS for A) 24 h and B) 48 h. Error 
bars represent SEM (n=3).  
 
5.3.2 Investigating the Role of Secreted Proteins in Perceived Cell Damage 
In order to determine whether the bacterial proteins secreted in the supernatant 
samples could elicit a cytotoxic effect on kidney cells, denaturing and inhibition of 
potential target proteins (Gingipains) was undertaken.  
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5.3.2.1 Inactivation of Proteins Present in P. gingivalis and AGCF-P samples 
Heat inactivation of an aliquot of all P. gingivalis samples and all AGCF-P media 
supernatant samples was undertaken and the cell viability experiment of P. gingivalis 
supernatants incubated with HK-2 cells (Chapter 4.3.1.1) was repeated with or 
without inactivated supernatants. However, the viscosity caused by protein 
inactivation interfered colorimetrically with the viability assay dye, providing 
inaccurate results (Data not shown). The same issue was found when trypsin was 
used to inactivate the P. gingivalis and AGCF-P supernatants and the cell viability 
experiments repeated (Data not shown). 
5.3.2.2 Incubation with Protease Inhibitors 
In order to determine whether P. gingivalis specific proteases, Gingipains, may be 
responsible for the cytotoxic effects observed in Chapter 4.3.1.1 a protease inhibitor 
cocktail mix was used to repeat the cell viability experiments with and without the 
addition to the bacterial supernatants (Figure 5.6). 
 
Figure 5.6 Cell viability of HK-2 cells after 24 h incubation with AGCF-P supernatants and P. gingivalis 
supernatants collected over 5 days with and without protease inhibitors. Viability is presented as 
percentage change from the control (Control: cells exposed to serum-free cell culture medium). 
Protease inhibitors (White) is serum free media with the addition of protease inhibitors alone. Error 
bars represent SEM. * = p-value ≤ 0.05, ** = p-value ≤ 0.01, *** = p-value ≤ 0.0001 (n=3).  
 
After 24 hours, with the exception of the 3 D P. gingivalis supernatant, a significant 
decrease in cell viability was observed in response to all P. gingivalis supernatants, 
as compared to the control. In contrast, there was no significant difference in viability 
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of cells exposed to AGCF-P media and the control (serum free) medium. The protease 
inhibitor cocktail added to serum free media had no significant effect on cellular 
viability compared to the control. However, the addition of the protease inhibitor 
cocktail preventing the loss of viability of cells exposed to P. gingivalis supernatants. 
5.3.2.3 qPCR of Protease Activated Receptors 
It has been demonstrated the protease activated receptors 1 and 2 (PAR1 and PAR2) 
are activated by Gingipains (Chapter 5.1.7). In order to establish their involvement in 
the cytotoxic effects of Gingipains, the mRNA levels of PAR1 and PAR2 were 
evaluated in HK-2 cells exposed to serum free media (control), P. gingivalis 
supernatants and AGCF-P supernatants using qPCR (Figure 5.7a) and (Fig 5.7b) 
respectively.  
 
 
Figure 5.7 Relative gene expression in comparison to β actin of A) PAR1 and B) PAR2 mRNA in HK-2 
cells after exposure to P. gingivalis and AGCF-P supernatants for 24 hours. C = serum free medium. 
Error bars represent SEM. * = p-value ≤ 0.05; (n=3). 
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After 24 hours of treatment with P. gingivalis and AGCF-P supernatants, no significant 
differences were observed between the PAR1 mRNA levels in cells exposed to P. 
gingivalis supernatants and AGCF-P supernatants in comparison with the serum free 
media control. There was also no significant difference between PAR1 mRNA levels 
of P. gingivalis supernatants in comparison with the matched AGCF-P supernatants 
for each day. 
For the PAR2 receptor, there was no significant difference between PAR2 receptor 
mRNA in cells exposed to P. gingivalis supernatants and AGCF-P supernatants in 
comparison with the serum free media control. However, a significant reduction of 
PAR2 receptor mRNA was observed between 1 and 2 D AGCF-P supernatants and the 
respective 1 and 2 D P. gingivalis supernatants.  
5.3.3 LCMS of P. gingivalis Supernatants  
The P. gingivalis and AGCF-P supernatants collected over 5 days in triplicate (Chapter 
2.4.2.1) were prepared for untargeted metabolomics with the AGCF-P media used to 
account for abiotic degradation and quality control samples. After LCMS analysis and 
deconvolution using XCMS online, quality assurance of the raw data files reduced the 
number of total features from all samples from 5576 to 4047 by blank contribution 
and 4047 to 2273 by quality assurance with QC samples. Peak alignment, missing 
value imputation and data normalisation was then conducted through 
MetaboAnalyst, (Figure 5.8) showing the normalisation step which allows for better 
comparison of features. 
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Figure 5.8 Box plots and kernel density plots before and after normalization of LCMS data of P. 
gingivalis cultured in AGCF-P (PG), control AGCF-P samples (C) at 0, 1, 2, 3, 4 and 5 D and quality 
control samples (QC). Quantile normalization and Pareto scaling were used. (n=3). 
5.3.3.1 Univariate Analysis 
Univariate analysis was conducted on all features to ascertain which features were 
significantly upregulated or downregulated (p=<0.05 and fold change of 2≥ or -2≤) 
from the AGCF-P control to P. gingivalis cultured in AGCF-P. From the 2273 features 
initially identified, 406 were identified to be significantly changed with 117 
upregulated and 289 downregulated (Figure 5.9). 
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Figure 5.9 Important features identified from P. gingivalis supernatants in comparison to AGCF-P 
control supernatants, selected by a univariate volcano plot with a fold change threshold (x) 2 and t-
tests threshold (y) 0.05. The red circles represent features above the threshold, the further the 
position away from the (0, 0) the more significant the feature. All values are log transformed.  
 
5.3.3.2 Principle Component Analysis 
PCA is an unsupervised method that attempts to find directions that can explain the 
variance in data irrespective of class. The scores plot of all QC, P. gingivalis and AGCF-
P control samples (Figure 5.10) shows that the quality control samples (QC) are 
tightly clustered, indicating good experimental design. Furthermore, the AGCF-P 
media (AGCF-P) samples are more tightly clustered than the P. gingivalis (P.G) 
samples highlighting microbial degradation of the growth media is taking place. 
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Figure 5.10 A 2D scores plot of a PCA between all QC, P. gingivalis and AGCF-P control classes. The 
explained variances are shown in brackets.  
 
5.3.3.3 Partial Least Squares – Discriminant Analysis 
PLS-DA is a supervised method of multivariate regression that is similar to PCA, 
however it takes into account the classes of samples and attempts to work out which 
variables have the class separating information. The 2D scores plot of all QC, P. 
gingivalis and  AGCF-P control samples (Figure 5.11) shows that the AGCF-P control 
is much more tightly clustered (Red) than AGCF-P inoculated with P. gingivalis 
(Green) along with a tight QC cluster, this correlates with the PCA (Figure 5.10). PLS-
DA usually has sharper separation between classes than PCA, which is shown with 
the difference between Figure 5.10 and Figure 5.11.  
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Figure 5.11 A 2D scores plot of a PLS-DA between all AGCF-P bacterial and control classes. The 
explained variances are shown in brackets. B after a class denotes Bacterial and T denotes controls 
with the number denoting a biological replicate. 
 
A VIP score graph was plotted with the QC class removed (Figure 5.12), which 
calculates weighted sum of squares of the PLS loadings taking into account the 
amount of explained Y-variation in each dimension for each component. A higher VIP 
indicates that the feature in question has a larger contribution to class discrimination 
in the PLS-DA model. The top 15 VIP features identified were selected for metabolite 
identification. 
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Figure 5.12 Important features identified by a PLS-DA of P. gingivalis and AGCF-P bacterial control 
samples. The coloured boxes on the right indicate the relative concentrations of the corresponding 
metabolite in each group under study. The x-axis denotes VIP scores and y-axis the feature m/z value. 
 
5.3.3.4 Significant Feature Selection Using Random Forest Algorithm 
RF is a supervised algorithm for data analysis, which uses random feature selection 
and classification trees to predict class based on majority vote. It is useful for feature 
selection as it can identify important features by measuring the increased error in 
class identification when a feature is omitted. The P. gingivalis and AGCF-P control 
samples were analysed using RF (Figure 5.13) in order to identify features that are 
important for class segregation. The top 15 significant features identified were 
selected for metabolite identification.  
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Figure 5.13 Significant features from AGCF-P (control) and P. gingivalis inoculated into AGCF-P 
identified by Random Forest. The features are ranked by the mean decrease in classification accuracy 
when they are permuted. The x axis denotes mean decrease in accuracy and y axis the feature m/z 
and retention time separated by /. 
 
5.3.3.5 Metabolite Identification 
All significantly upregulated and downregulated features identified by volcano plots, 
Variable Importance in Projection features identified by PLS-DA and important 
features in classification identified by RF were extracted into an Microsoft Excel 
spreadsheet for identification of metabolites. The program MetaboSearch was used 
to compare the m/z and retention times of the metabolites of interest with a 
selection of mass spectral databases for putative identification and the results 
extracted. For all significant features, there was a 6.6% success rate in identification. 
There were no clear metabolite identification trends associated with the classes due 
to the low metabolite identification rate. The only exception being amino acids and 
their various degradation products being increased in the P. gingivalis samples. 
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Table 5.4 Metabolite identification of significantly up and downregulated metabolites identified by 
volcano plots of AGCF-P bacterial and control samples. 
 
m/z Retention Time Fold Change p value Name Formula Mass of Match PPM Deviation Putative Role
197.102 0.79 7.97 0.00000 - - - - -
292.201 0.83 7.43 0.00001 - - - - -
268.074 1.24 6.05 0.00000 - - - - -
287.073 0.78 5.53 0.00000 - - - - -
355.061 0.77 4.75 0.00000 - - - - -
245.187 5.62 4.47 0.00000 Isoleucyl-Leucine/Leucyl-Isoleucine C12H24N2O3 244.179 2.562 Amino acid degradation product
269.077 1.23 4.19 0.00000 Portulacaxanthin II C11H12N2O6 268.070 1.594 Amino acid related compounds
245.186 5.15 4.18 0.00000 Isoleucyl-Leucine/Leucyl-Isoleucine C12H24N2O3 244.179 0.062
246.189 5.15 4.17 0.00000 - - - - -
265.155 5.47 3.76 0.00000 Phenylalanyl-Valine C14H20N2O3 264.147 1.733 Amino acid degradation product
371.035 0.78 3.47 0.00001 - - - - -
336.168 7.02 3.34 0.00000 - - - - -
247.192 5.63 3.32 0.00000 - - - - -
440.315 12.98 3.29 0.00000 LysoPE(16:0/0:0) C21H46NO6P 439.306 2.292 Phospholipid degredation product
423.048 0.77 3.29 0.00000 - - - - -
356.255 7.82 3.15 0.00000 - - - - -
259.166 7.05 3.14 0.00000 - - - - -
304.167 5.85 3.12 0.00000 Tryptophyl-Valine C16H21N3O3 303.158 3.221 Amino acid degradation product
233.123 1.21 3.06 0.00000 - - - - -
266.159 5.47 3.03 0.00000 - - - - -
466.330 13.30 3.02 0.00000 PE(P-18:0/0:0) C23H48NO6P 465.322 2.558 Phospholipid degredation product
295.166 5.40 2.92 0.00000 Tyrosyl-Leucine C15H22N2O4 294.158 2.905 Amino acid degradation product
491.036 0.77 2.87 0.00000 - - - - -
260.167 1.19 2.87 0.00000 - - - - -
260.131 1.19 2.77 0.00000 - - - - -
318.183 6.35 2.70 0.00000 - - - - -
288.170 1.19 2.69 0.00000 - - - - -
491.233 6.95 2.66 0.00005 - - - - -
370.235 8.14 2.62 0.00000 - - - - -
290.053 1.24 2.60 0.00000 - - - - -
482.362 13.08 2.59 0.00000 PC(O-16:0/0:0) C24H52NO6P 481.353 2.536 Phospholipid degredation product
993.637 6.29 2.58 0.00004 - - - - -
404.134 5.74 2.57 0.00003 - - - - -
492.236 6.95 2.57 0.00002 - - - - -
377.227 6.84 2.57 0.00000 - - - - -
362.196 6.11 2.56 0.00000 - - - - -
791.418 7.52 2.55 0.00000 - - - - -
468.346 14.38 2.54 0.00000 PE(O-18:0/0:0) C23H50NO6P 467.338 3.069 Phospholipid degredation product
395.712 7.50 2.53 0.00000 - - - - -
219.109 1.19 2.52 0.00004 - - - - -
790.416 7.52 2.51 0.00000 - - - - -
396.213 7.52 2.50 0.00000 - - - - -
360.196 6.10 2.48 0.00000 - - - - -
376.224 6.84 2.48 0.00003 - - - - -
1049.009 7.07 2.46 0.00002 - - - - -
905.478 6.12 2.44 0.00000 - - - - -
405.137 5.74 2.44 0.00001 - - - - -
270.079 1.24 2.44 0.00000 - - - - -
1165.667 7.19 2.44 0.00003 - - - - -
522.357 13.06 2.43 0.00025 PC(P-16:0/2:0) C26H52NO7P 521.348 2.459 Phospholipid degredation product
792.421 7.52 2.42 0.00000 - - - - -
361.199 6.10 2.42 0.00000 Tryptophyl-Arginine C17H24N6O3 360.191 2.627 Amino acid degradation product
523.360 13.06 2.42 0.00014 - - - - -
1164.665 7.19 2.41 0.00011 - - - - -
363.198 6.11 2.40 0.00000 - - - - -
994.640 6.29 2.35 0.00012 - - - - -
289.173 1.19 2.32 0.00000 - - - - -
281.152 2.26 2.31 0.00027 - - - - -
289.196 5.55 2.31 0.00058 - - - - -
582.837 7.19 2.30 0.00004 - - - - -
546.293 6.10 2.30 0.00002 - - - - -
343.243 6.27 2.24 0.00001 - - - - -
497.344 12.75 2.24 0.00047 - - - - -
342.240 6.27 2.23 0.00001 - - - - -
186.161 0.76 2.22 0.00000 - - - - -
683.472 6.27 2.22 0.00052 - - - - -
496.341 12.75 2.21 0.00056 PE(19:0/0:0) C24H50NO7P 495.333 2.772 Phospholipid degredation product
380.713 7.15 2.21 0.00001 - - - - -
670.341 6.95 2.20 0.00000 - - - - -
306.145 5.24 2.20 0.00018 Threoninyl-Tryptophan C15H19N3O4 305.138 1.300 Amino acid degradation product
700.010 7.04 2.19 0.00000 - - - - -
213.160 6.29 2.19 0.00008 - - - - -
524.345 6.75 2.18 0.00042 - - - - -
680.400 7.64 2.17 0.00050 - - - - -
491.287 6.53 2.17 0.00014 - - - - -
1166.670 7.19 2.16 0.00007 - - - - -
344.246 6.27 2.16 0.00000 - - - - -
759.413 7.15 2.15 0.00009 - - - - -
493.235 6.95 2.15 0.00008 - - - - -
527.287 8.75 2.14 0.00069 - - - - -
525.377 14.10 2.13 0.00099 PC(O-18:1(9Z)/0:0) C26H54NO6P 507.369 1.925 Phospholipid degredation product
508.377 13.38 2.13 0.00000 - - - - -
327.209 6.29 2.13 0.00073 - - - - -
681.402 7.64 2.12 0.00025 - - - - -
786.405 8.26 2.12 0.00010 - - - - -
447.312 13.73 2.12 0.00000 - - - - -
583.338 7.19 2.12 0.00002 - - - - -
327.710 6.29 2.11 0.00020 - - - - -
290.198 5.55 2.11 0.00017 - - - - -
525.348 6.75 2.11 0.00022 - - - - -
330.677 6.51 2.11 0.00002 - - - - -
428.296 6.40 2.09 0.00056 - - - - -
313.156 6.62 2.08 0.00065 - - - - -
330.176 6.50 2.08 0.00003 - - - - -
380.211 7.15 2.08 0.00014 - - - - -
724.034 7.02 2.07 0.00000 - - - - -
887.468 7.60 2.07 0.00002 PIP(16:1(9Z)/16:1(9Z)) C41H76O16P2 886.461 0.000 Phospholipid degredation product
379.710 7.15 2.07 0.00021 - - - - -
340.704 7.64 2.07 0.00018 - - - - -
288.193 5.55 2.07 0.00327 - - - - -
604.347 7.24 2.06 0.00024 - - - - -
241.088 1.19 2.06 0.00016 - - - - -
653.408 6.29 2.06 0.00159 - - - - -
760.416 7.15 2.05 0.00018 - - - - -
660.344 6.50 2.04 0.00009 - - - - -
498.347 12.76 2.04 0.00028 - - - - -
766.922 7.84 2.04 0.00006 - - - - -
691.679 6.71 2.04 0.00001 - - - - -
724.701 7.04 2.03 0.00000 - - - - -
326.707 6.29 2.03 0.00193 - - - - -
316.188 7.05 2.03 0.00001 - - - - -
888.471 7.60 2.03 0.00003 - - - - -
605.350 7.24 2.03 0.00013 - - - - -
282.111 1.19 2.03 0.00000 - - - - -
492.291 6.53 2.02 0.00025 - - - - -
524.373 14.09 2.01 0.00496 PC(O-16:0/2:0) C26H54NO7P 523.364 4.082 Phospholipid degredation product
1049.510 7.05 2.00 0.00000 PIP2(18:0/20:3(5Z,8Z,11Z)) C47H87O19P3 1048.505 2.561 Phospholipid degredation product
Upregulation
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m/z Retention Time Fold Change p value Name Formula Mass of Match PPM Deviation Putative Role
197.102 0.79 7.97 0.00000 - - - - -
292.201 0.83 7.43 0.00001 - - - - -
268.074 1.24 6.05 0.00000 - - - - -
287.073 0.78 5.53 0.00000 - - - - -
355.061 0.77 4.75 0.00000 - - - - -
245.187 5.62 4.47 0.00000 Isoleucyl-Leucine/Leucyl-Isoleucine C12H24N2O3 244.179 2.562 Amino acid degradation product
269.077 1.23 4.19 0.00000 Portulacaxanthin II C11H12N2O6 268.070 1.594 Amino acid related compounds
245.186 5.15 4.18 0.00000 Isoleucyl-Leucine/Leucyl-Isoleucine C12H24N2O3 244.179 0.062
246.189 5.15 4.17 0.00000 - - - - -
265.155 5.47 3.76 0.00000 Phenylalanyl-Valine C14H20N2O3 264.147 1.733 Amino acid degradation product
371.035 0.78 3.47 0.00001 - - - - -
336.168 7.02 3.34 0.00000 - - - - -
247.192 5.63 3.32 0.00000 - - - - -
440.315 12.98 3.29 0.00000 LysoPE(16:0/0:0) C21H46NO6P 439.306 2.292 Phospholipid degredation product
423.048 0.77 3.29 0.00000 - - - - -
356.255 7.82 3.15 0.00000 - - - - -
259.166 7.05 3.14 0.00000 - - - - -
304.167 5.85 3.12 0.00000 Tryptophyl-Valine C16H21N3O3 303.158 3.221 Amino acid degradation product
233.123 1.21 3.06 0.00000 - - - - -
266.159 5.47 3.03 0.00000 - - - - -
466.330 13.30 3.02 0.00000 PE(P-18:0/0:0) C23H48NO6P 465.322 2.558 Phospholipid degredation product
295.166 5.40 2.92 0.00000 Tyrosyl-Leucine C15H22N2O4 294.158 2.905 Amino acid degradation product
491.036 0.77 2.87 0.00000 - - - - -
260.167 1.19 2.87 0.00000 - - - - -
260.131 1.19 2.77 0.00000 - - - - -
318.183 6.35 2.70 0.00000 - - - - -
288.170 1.19 2.69 0.00000 - - - - -
491.233 6.95 2.66 0.00005 - - - - -
370.235 8.14 2.62 0.00000 - - - - -
290.053 1.24 2.60 0.00000 - - - - -
482.362 13.08 2.59 0.00000 PC(O-16:0/0:0) C24H52NO6P 481.353 2.536 Phospholipid degredation product
993.637 6.29 2.58 0.00004 - - - - -
404.134 5.74 2.57 0.00003 - - - - -
492.236 6.95 2.57 0.00002 - - - - -
377.227 6.84 2.57 0.00000 - - - - -
362.196 6.11 2.56 0.00000 - - - - -
791.418 7.52 2.55 0.00000 - - - - -
468.346 14.38 2.54 0.00000 PE(O-18:0/0:0) C23H50NO6P 467.338 3.069 Phospholipid degredation product
395.712 7.50 2.53 0.00000 - - - - -
219.109 1.19 2.52 0.00004 - - - - -
790.416 7.52 2.51 0.00000 - - - - -
396.213 7.52 2.50 0.00000 - - - - -
360.196 6.10 2.48 0.00000 - - - - -
376.224 6.84 2.48 0.00003 - - - - -
1049.009 7.07 2.46 0.00002 - - - - -
905.478 6.12 2.44 0.00000 - - - - -
405.137 5.74 2.44 0.00001 - - - - -
270.079 1.24 2.44 0.00000 - - - - -
1165.667 7.19 2.44 0.00003 - - - - -
522.357 13.06 2.43 0.00025 PC(P-16:0/2:0) C26H52NO7P 521.348 2.459 Phospholipid degredation product
792.421 7.52 2.42 0.00000 - - - - -
361.199 6.10 2.42 0.00000 Tryptophyl-Arginine C17H24N6O3 360.191 2.627 Amino acid degradation product
523.360 13.06 2.42 0.00014 - - - - -
1164.665 7.19 2.41 0.00011 - - - - -
363.198 6.11 2.40 0.00000 - - - - -
994.640 6.29 2.35 0.00012 - - - - -
289.173 1.19 2.32 0.00000 - - - - -
281.152 2.26 2.31 0.00027 - - - - -
289.196 5.55 2.31 0.00058 - - - - -
582.837 7.19 2.30 0.00004 - - - - -
546.293 6.10 2.30 0.00002 - - - - -
343.243 6.27 2.24 0.00001 - - - - -
497.344 12.75 2.24 0.00047 - - - - -
342.240 6.27 2.23 0.00001 - - - - -
186.161 0.76 2.22 0.00000 - - - - -
683.472 6.27 2.22 0.00052 - - - - -
496.341 12.75 2.21 0.00056 PE(19:0/0:0) C24H50NO7P 495.333 2.772 Phospholipid degredation product
380.713 7.15 2.21 0.00001 - - - - -
670.341 6.95 2.20 0.00000 - - - - -
306.145 5.24 2.20 0.00018 Threoninyl-Tryptophan C15H19N3O4 305.138 1.300 Amino acid degradation product
700.010 7.04 2.19 0.00000 - - - - -
213.160 6.29 2.19 0.00008 - - - - -
524.345 6.75 2.18 0.00042 - - - - -
680.400 7.64 2.17 0.00050 - - - - -
491.287 6.53 2.17 0.00014 - - - - -
1166.670 7.19 2.16 0.00007 - - - - -
344.246 6.27 2.16 0.00000 - - - - -
759.413 7.15 2.15 0.00009 - - - - -
493.235 6.95 2.15 0.00008 - - - - -
527.287 8.75 2.14 0.00069 - - - - -
525.377 14.10 2.13 0.00099 PC(O-18:1(9Z)/0:0) C26H54NO6P 507.369 1.925 Phospholipid degredation product
508.377 13.38 2.13 0.00000 - - - - -
327.209 6.29 2.13 0.00073 - - - - -
681.402 7.64 2.12 0.00025 - - - - -
786.405 8.26 2.12 0.00010 - - - - -
447.312 13.73 2.12 0.00000 - - - - -
583.338 7.19 2.12 0.00002 - - - - -
327.710 6.29 2.11 0.00020 - - - - -
290.198 5.55 2.11 0.00017 - - - - -
525.348 6.75 2.11 0.00022 - - - - -
330.677 6.51 2.11 0.00002 - - - - -
428.296 6.40 2.09 0.00056 - - - - -
313.156 6.62 2.08 0.00065 - - - - -
330.176 6.50 2.08 0.00003 - - - - -
380.211 7.15 2.08 0.00014 - - - - -
724.034 7.02 2.07 0.00000 - - - - -
887.468 7.60 2.07 0.00002 PIP(16:1(9Z)/16:1(9Z)) C41H76O16P2 886.461 0.000 Phospholipid degredation product
379.710 7.15 2.07 0.00021 - - - - -
340.704 7.64 2.07 0.00018 - - - - -
288.193 5.55 2.07 0.00327 - - - - -
604.347 7.24 2.06 0.00024 - - - - -
241.088 1.19 2.06 0.00016 - - - - -
653.408 6.29 2.06 0.00159 - - - - -
760.416 7.15 2.05 0.00018 - - - - -
660.344 6.50 2.04 0.00009 - - - - -
498.347 12.76 2.04 0.00028 - - - - -
766.922 7.84 2.04 0.00006 - - - - -
691.679 6.71 2.04 0.00001 - - - - -
724.701 7.04 2.03 0.00000 - - - - -
326.707 6.29 2.03 0.00193 - - - - -
316.188 7.05 2.03 0.00001 - - - - -
888.471 7.60 2.03 0.00003 - - - - -
605.350 7.24 2.03 0.00013 - - - - -
282.111 1.19 2.03 0.00000 - - - - -
492.291 6.53 2.02 0.00025 - - - - -
524.373 14.09 2.01 0.00496 PC(O-16:0/2:0) C26H54NO7P 523.364 4.082 Phospholipid degredation product
1049.510 7.05 2.00 0.00000 PIP2(18:0/20:3(5Z,8Z,11Z)) C47H87O19P3 1048.505 2.561 Phospholipid degredation product
Upregulation
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m/z Retention Time Fold Change p value Name Formula Mass of Match PPM Deviation Putative Role
774.883 5.76 0.50 0.00011 - - - - -
268.660 5.95 0.50 0.00177 - - - - -
506.704 5.86 0.50 0.00878 - - - - -
1011.582 7.02 0.50 0.00681 - - - - -
277.674 5.95 0.50 0.00173 - - - - -
561.296 5.65 0.50 0.00212 - - - - -
398.534 5.15 0.50 0.00015 - - - - -
278.176 5.95 0.50 0.00227 - - - - -
402.728 5.28 0.50 0.03961 - - - - -
590.355 6.55 0.50 0.00004 - - - - -
718.300 6.42 0.49 0.00073 - - - - -
417.215 6.34 0.49 0.00362 - - - - -
714.366 7.52 0.49 0.00068 - - - - -
1206.020 6.39 0.49 0.00012 - - - - -
411.016 0.78 0.49 0.00042 - - - - -
768.416 6.56 0.49 0.00001 - - - - -
662.163 6.45 0.49 0.00037 - - - - -
1247.361 10.78 0.49 0.03234 - - - - -
190.914 0.79 0.49 0.00000 - - - - -
630.480 13.87 0.49 0.00015 - - - - -
427.220 5.77 0.49 0.00133 - - - - -
863.432 7.59 0.49 0.00038 - - - - -
666.319 5.69 0.49 0.00052 - - - - -
1250.361 10.78 0.49 0.02783 - - - - -
402.228 5.28 0.49 0.06934 - - - - -
989.356 6.25 0.49 0.00278 - - - - -
763.782 6.40 0.49 0.00351 - - - - -
477.238 5.24 0.48 0.00004 - - - - -
960.382 5.97 0.48 0.00200 - - - - -
665.316 5.69 0.48 0.01320 - - - - -
642.379 5.23 0.48 0.00000 - - - - -
275.041 0.78 0.48 0.00004 - - - - -
433.549 5.31 0.48 0.00009 - - - - -
489.869 1.23 0.48 0.00024 - - - - -
515.782 7.02 0.48 0.00512 - - - - -
124.923 0.80 0.48 0.00000 - - - - -
1000.526 6.05 0.48 0.00685 - - - - -
584.330 8.05 0.48 0.03291 - - - - -
709.408 7.15 0.47 0.00221 - - - - -
709.909 7.15 0.47 0.00318 - - - - -
498.402 14.03 0.47 0.00003 - - - - -
1418.810 7.17 0.47 0.00141 - - - - -
313.140 1.23 0.47 0.00160 - - - - -
586.454 13.92 0.47 0.00005 - - - - -
266.657 7.24 0.47 0.00014 - - - - -
534.712 6.09 0.47 0.00098 - - - - -
931.406 5.75 0.47 0.00245 - - - - -
864.435 7.59 0.47 0.00021 - - - - -
331.198 6.79 0.47 0.00097 - - - - -
940.376 5.61 0.47 0.00442 - - - - -
456.317 5.08 0.47 0.01593 - - - - -
493.170 5.74 0.47 0.00047 - - - - -
445.315 13.30 0.47 0.00003 - - - - -
296.260 15.23 0.47 0.00001 - - - - -
636.343 6.64 0.46 0.00651 - - - - -
542.428 13.97 0.46 0.00004 - - - - -
542.286 5.95 0.46 0.00228 - - - - -
451.221 5.54 0.46 0.00002 - - - - -
1096.552 6.18 0.46 0.00002 - - - - -
909.392 6.05 0.46 0.00083 - - - - -
649.818 5.31 0.46 0.00000 - - - - -
905.479 7.72 0.45 0.00998 - - - - -
217.098 5.44 0.45 0.00001 - - - - -
990.359 6.25 0.45 0.00274 - - - - -
345.699 5.37 0.45 0.00070 - - - - -
746.356 5.99 0.45 0.00000 - - - - -
369.194 14.16 0.45 0.00013 - - - - -
650.821 5.31 0.45 0.00000 - - - - -
759.376 5.65 0.45 0.00699 - - - - -
196.880 0.83 0.45 0.00002 - - - - -
439.255 7.27 0.45 0.00254 - - - - -
802.444 5.28 0.45 0.09672 - - - - -
451.720 5.54 0.45 0.00000 - - - - -
307.161 5.74 0.45 0.00077 - - - - -
340.188 6.45 0.44 0.00873 - - - - -
593.330 7.91 0.44 0.00000 - - - - -
1846.520 10.78 0.44 0.02030 - - - - -
998.511 6.37 0.44 0.01017 - - - - -
447.962 1.31 0.44 0.00007 - - - - -
616.301 7.98 0.44 0.01241 - - - - -
617.468 13.13 0.44 0.00010 - - - - -
636.272 6.35 0.44 0.00000 - - - - -
390.834 0.83 0.44 0.00003 - - - - -
1252.362 10.78 0.44 0.01306 - - - - -
629.366 7.50 0.44 0.00132 PI(20:0/0:0) C29H57O12P 628.359 0.486 Monoacylglycerophosphoinositol
359.683 5.32 0.43 0.00601 - - - - -
308.223 8.02 0.43 0.00022 - - - - -
803.447 5.28 0.43 0.05996 - - - - -
710.911 7.17 0.43 0.00070 - - - - -
507.213 5.83 0.43 0.00053 - - - - -
797.433 7.59 0.43 0.01391 - - - - -
775.258 5.55 0.43 0.01453 - - - - -
1847.520 10.78 0.43 0.01871 - - - - -
338.173 2.19 0.42 0.00034 - - - - -
521.722 6.33 0.42 0.00082 - - - - -
635.341 6.65 0.42 0.00495 - - - - -
529.415 13.21 0.42 0.00006 - - - - -
652.330 6.64 0.42 0.00000 - - - - -
612.802 5.79 0.42 0.00671 - - - - -
628.374 5.80 0.42 0.00081 - - - - -
343.846 5.09 0.42 0.00000 - - - - -
469.233 6.25 0.42 0.00333 - - - - -
440.411 12.13 0.41 0.00002 Pentacosanoylglycine C27H53NO3 439.403 2.292 Indicator of fatty acid oxidation
627.372 5.80 0.41 0.00060 - - - - -
489.340 13.26 0.41 0.00004 - - - - -
514.289 5.90 0.41 0.00432 - - - - -
1062.478 6.66 0.41 0.00296 - - - - -
567.907 1.31 0.41 0.00013 - - - - -
337.186 0.78 0.41 0.00130 - - - - -
495.183 6.25 0.41 0.00116 - - - - -
1024.493 7.17 0.41 0.00482 - - - - -
1248.365 10.78 0.41 0.01119 - - - - -
587.457 13.92 0.41 0.00005 - - - - -
499.278 5.38 0.41 0.00047 - - - - -
1031.557 7.02 0.41 0.00277 - - - - -
560.333 6.99 0.41 0.00048 - - - - -
1097.557 6.19 0.41 0.00001 - - - - -
795.426 7.59 0.40 0.00866 - - - - -
991.359 6.25 0.40 0.00175 - - - - -
629.375 5.80 0.40 0.00070 - - - - -
515.291 5.89 0.40 0.00334 - - - - -
562.280 6.15 0.40 0.00065 - - - - -
455.379 14.08 0.40 0.00002 - - - - -
220.012 1.23 0.40 0.00014 - - - - -
796.429 7.59 0.40 0.00970 - - - - -
1273.617 7.52 0.39 0.00076 - - - - -
764.857 5.35 0.39 0.00006 - - - - -
1848.524 10.78 0.39 0.01258 - - - - -
398.218 7.59 0.39 0.00835 - - - - -
630.369 7.50 0.39 0.00223 - - - - -
915.412 5.32 0.39 0.00609 - - - - -
511.277 8.37 0.39 0.00005 - - - - -
170.079 5.84 0.38 0.00024 - - - - -
1272.613 7.52 0.38 0.00068 - - - - -
627.971 6.59 0.38 0.00000 - - - - -
450.211 5.19 0.38 0.00901 - - - - -
449.207 5.19 0.38 0.04292 - - - - -
780.499 5.90 0.38 0.06795 - - - - -
843.443 6.19 0.38 0.00532 - - - - -
339.204 6.44 0.38 0.00839 - - - - -
526.323 6.35 0.38 0.00221 - - - - -
666.419 7.17 0.37 0.00034 - - - - -
817.409 7.59 0.37 0.00664 - - - - -
302.118 6.75 0.37 0.00001 - - - - -
559.742 6.05 0.37 0.00014 - - - - -
238.108 7.20 0.37 0.00022 - - - - -
637.313 7.52 0.37 0.00054 - - - - -
314.189 5.80 0.37 0.00026 - - - - -
637.814 7.52 0.37 0.00101 - - - - -
495.683 6.25 0.37 0.00148 - - - - -
427.391 13.65 0.37 0.00016 - - - - -
383.230 5.87 0.37 0.00123 - - - - -
624.274 5.75 0.36 0.00031 - - - - -
914.409 5.32 0.36 0.00386 - - - - -
636.811 7.52 0.36 0.00074 - - - - -
553.336 6.45 0.36 0.00963 - - - - -
1274.619 7.52 0.36 0.00057 - - - - -
268.167 6.45 0.36 0.01384 - - - - -
640.366 5.85 0.36 0.00035 - - - - -
533.367 13.21 0.36 0.00000 - - - - -
218.101 5.44 0.36 0.00002 - - - - -
744.404 6.11 0.36 0.00470 - - - - -
776.262 5.55 0.36 0.01155 - - - - -
383.189 5.34 0.36 0.00000 - - - - -
623.270 5.74 0.36 0.00083 - - - - -
384.233 5.87 0.36 0.00247 - - - - -
652.663 6.64 0.35 0.00000 - - - - -
740.459 7.34 0.35 0.00174 - - - - -
654.382 6.07 0.35 0.00028 - - - - -
382.687 5.35 0.35 0.00000 - - - - -
614.357 6.35 0.35 0.00319 - - - - -
758.374 5.65 0.35 0.00511 - - - - -
999.517 5.99 0.35 0.00590 - - - - -
387.273 12.53 0.35 0.00001 Glycerol trihexanoate C21H38O6 386.267 3.950 Triacylglycerol - Fatty Acid
764.363 5.35 0.35 0.00000 - - - - -
578.287 5.49 0.35 0.00658 - - - - -
498.274 5.37 0.34 0.00056 - - - - -
325.716 5.87 0.34 0.00778 - - - - -
485.316 6.30 0.34 0.00726 - - - - -
383.689 5.34 0.34 0.00000 - - - - -
612.302 5.79 0.34 0.00264 - - - - -
443.184 7.52 0.34 0.00068 - - - - -
525.303 5.86 0.34 0.00011 - - - - -
561.276 6.15 0.34 0.00033 - - - - -
515.399 12.47 0.34 0.00000 - - - - -
909.504 6.75 0.34 0.00186 - - - - -
456.219 6.19 0.34 0.00097 - - - - -
769.444 6.40 0.33 0.00936 - - - - -
554.339 6.45 0.33 0.01169 - - - - -
708.430 6.40 0.33 0.00320 - - - - -
502.291 8.02 0.33 0.00011 PE(20:4(5Z,8Z,11Z,14Z)/0:0);LysoPE(20:4(5Z,8Z,11Z,14Z)/0:0)C25H44NO7P 501.286 4.018 Glycerophospholipid - In blood
998.515 5.99 0.33 0.00666 - - - - -
468.442 12.95 0.33 0.00002 - - - - -
997.512 5.99 0.32 0.00597 - - - - -
560.273 6.15 0.32 0.00019 - - - - -
455.215 6.19 0.32 0.00069 - - - - -
475.284 7.12 0.32 0.00100 - - - - -
516.791 7.37 0.32 0.00299 - - - - -
743.402 6.11 0.32 0.00436 - - - - -
280.641 6.15 0.32 0.00044 - - - - -
371.705 6.10 0.32 0.00422 - - - - -
316.168 5.74 0.31 0.01854 - - - - -
391.255 5.90 0.31 0.03590 - - - - -
855.498 7.57 0.31 0.00368 PI(16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)) C45H75O13P 854.495 4.357 Glycerophosphoinositol
499.261 5.99 0.31 0.01117 - - - - -
497.272 5.37 0.31 0.00023 - - - - -
329.151 5.91 0.31 0.01691 Phenylalanyl-Tyrosine C18H20N2O4 328.142 3.348 Amino acid degradation product
781.502 5.90 0.31 0.02047 PG(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) C43H73O10P 780.494 1.017 Glycerophosphoglycerol
1023.488 7.15 0.31 0.00544 - - - - -
519.255 5.37 0.31 0.00072 - - - - -
317.169 5.74 0.31 0.01200 - - - - -
613.357 6.35 0.31 0.00402 - - - - -
829.431 6.00 0.30 0.00580 - - - - -
379.194 5.64 0.30 0.00652 - - - - -
757.373 5.65 0.30 0.00326 - - - - -
1159.592 7.37 0.29 0.00783 - - - - -
471.373 12.50 0.29 0.00000 - - - - -
316.669 5.74 0.29 0.02009 - - - - -
594.327 7.47 0.29 0.00049 - - - - -
499.763 5.99 0.29 0.00805 - - - - -
492.221 5.12 0.29 0.00000 - - - - -
742.400 6.10 0.29 0.00408 - - - - -
637.285 6.15 0.29 0.00051 - - - - -
1158.591 7.37 0.29 0.00827 - - - - -
254.169 6.45 0.28 0.00983 - - - - -
308.104 6.35 0.28 0.00002 - - - - -
647.801 7.51 0.28 0.00064 - - - - -
281.142 6.15 0.28 0.00028 - - - - -
1157.588 7.35 0.28 0.00609 - - - - -
563.225 6.10 0.28 0.00024 - - - - -
316.798 0.89 0.27 0.00000 - - - - -
638.289 6.15 0.27 0.00050 - - - - -
945.946 6.19 0.27 0.00045 - - - - -
491.217 5.12 0.27 0.00000 - - - - -
856.500 7.57 0.27 0.00298 - - - - -
568.298 7.17 0.27 0.00444 - - - - -
579.799 7.37 0.26 0.00800 - - - - -
560.293 5.65 0.26 0.01113 - - - - -
359.003 0.78 0.25 0.00002 - - - - -
406.809 0.81 0.25 0.00000 - - - - -
440.249 5.34 0.25 0.01330 - - - - -
540.339 6.47 0.25 0.00496 - - - - -
579.297 7.37 0.24 0.00622 - - - - -
231.114 5.71 0.24 0.00011 - - - - -
893.537 7.15 0.24 0.00273 - - - - -
408.537 5.79 0.23 0.00461 - - - - -
569.299 7.15 0.23 0.00222 - - - - -
474.280 7.10 0.23 0.00335 - - - - -
473.277 7.10 0.22 0.00335 - - - - -
572.346 7.49 0.22 0.00016 - - - - -
566.331 7.12 0.22 0.00185 - - - - -
511.746 7.14 0.22 0.00327 - - - - -
563.295 6.47 0.22 0.02675 PKOOA-PA C27H47O10P 562.291 4.776 Oxidized glycerophosphoglycerol
1022.483 7.14 0.21 0.00588 - - - - -
575.353 7.49 0.21 0.00007 - - - - -
1105.663 5.95 0.20 0.00066 - - - - -
287.179 7.49 0.20 0.00031 - - - - -
574.351 7.49 0.20 0.00028 - - - - -
573.349 7.49 0.20 0.00022 - - - - -
286.677 7.47 0.20 0.00025 - - - - -
1106.398 5.57 0.19 0.00000 - - - - -
562.292 6.47 0.18 0.02824 - - - - -
137.030 1.19 0.18 0.00032 - - - - -
433.753 6.59 0.17 0.00516 - - - - -
866.497 6.59 0.17 0.00758 - - - - -
177.062 0.78 0.16 0.00000 - - - - -
595.325 5.79 0.16 0.01228 OOB-PG C28H51O11P 594.317 2.054 Oxidized glycerophosphate
504.922 6.24 0.15 0.00001 - - - - -
421.211 5.85 0.15 0.00264 - - - - -
892.534 7.15 0.13 0.00186 - - - - -
326.207 5.31 0.13 0.00484 - - - - -
446.269 7.14 0.13 0.00177 - - - - -
594.323 5.79 0.13 0.00852 - - - - -
691.859 6.12 0.13 0.00060 - - - - -
133.098 0.78 0.13 0.00000 - - - - -
891.531 7.15 0.13 0.00194 - - - - -
155.081 0.79 0.12 0.00000 - - - - -
461.576 6.14 0.12 0.00069 - - - - -
446.771 7.14 0.11 0.00187 - - - - -
685.396 6.53 0.10 0.01802 - - - - -
517.286 6.21 0.10 0.00230 - - - - -
342.702 6.53 0.10 0.01585 - - - - -
867.535 8.24 0.09 0.00003 PI(P-16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) C47H79O12P 866.531 4.015 Fatty acid
516.283 6.21 0.09 0.00244 - - - - -
684.394 6.53 0.09 0.01991 - - - - -
480.281 6.19 0.08 0.01644 - - - - -
669.402 6.37 0.08 0.00774 - - - - -
334.703 6.37 0.07 0.00755 - - - - -
668.398 6.37 0.05 0.00804 - - - - -
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m/z Retention Time Fold Change p value Name Formula Mass of Match PPM Deviation Putative Role
774.883 5.76 0.50 0.00011 - - - - -
268.660 5.95 0.50 0.00177 - - - - -
506.704 5.86 0.50 0.00878 - - - - -
1011.582 7.02 0.50 0.00681 - - - - -
277.674 5.95 0.50 0.00173 - - - - -
561.296 5.65 0.50 0.00212 - - - - -
398.534 5.15 0.50 0.00015 - - - - -
278.176 5.95 0.50 0.00227 - - - - -
402.728 5.28 0.50 0.03961 - - - - -
590.355 6.55 0.50 0.00004 - - - - -
718.300 6.42 0.49 0.00073 - - - - -
417.215 6.34 0.49 0.00362 - - - - -
714.366 7.52 0.49 0.00068 - - - - -
1206.020 6.39 0.49 0.00012 - - - - -
411.016 0.78 0.49 0.00042 - - - - -
768.416 6.56 0.49 0.00001 - - - - -
662.163 6.45 0.49 0.00037 - - - - -
1247.361 10.78 0.49 0.03234 - - - - -
190.914 0.79 0.49 0.00000 - - - - -
630.480 13.87 0.49 0.00015 - - - - -
427.220 5.77 0.49 0.00133 - - - - -
863.432 7.59 0.49 0.00038 - - - - -
666.319 5.69 0.49 0.00052 - - - - -
1250.361 10.78 0.49 0.02783 - - - - -
402.228 5.28 0.49 0.06934 - - - - -
989.356 6.25 0.49 0.00278 - - - - -
763.782 6.40 0.49 0.00351 - - - - -
477.238 5.24 0.48 0.00004 - - - - -
960.382 5.97 0.48 0.00200 - - - - -
665.316 5.69 0.48 0.01320 - - - - -
642.379 5.23 0.48 0.00000 - - - - -
275.041 0.78 0.48 0.00004 - - - - -
433.549 5.31 0.48 0.00009 - - - - -
489.869 1.23 0.48 0.00024 - - - - -
515.782 7.02 0.48 0.00512 - - - - -
124.923 0.80 0.48 0.00000 - - - - -
1000.526 6.05 0.48 0.00685 - - - - -
584.330 8.05 0.48 0.03291 - - - - -
709.408 7.15 0.47 0.00221 - - - - -
709.909 7.15 0.47 0.00318 - - - - -
498.402 14.03 0.47 0.00003 - - - - -
1418.810 7.17 0.47 0.00141 - - - - -
313.140 1.23 0.47 0.00160 - - - - -
586.454 13.92 0.47 0.00005 - - - - -
266.657 7.24 0.47 0.00014 - - - - -
534.712 6.09 0.47 0.00098 - - - - -
931.406 5.75 0.47 0.00245 - - - - -
864.435 7.59 0.47 0.00021 - - - - -
331.198 6.79 0.47 0.00097 - - - - -
940.376 5.61 0.47 0.00442 - - - - -
456.317 5.08 0.47 0.01593 - - - - -
493.170 5.74 0.47 0.00047 - - - - -
445.315 13.30 0.47 0.00003 - - - - -
296.260 15.23 0.47 0.00001 - - - - -
636.343 6.64 0.46 0.00651 - - - - -
542.428 13.97 0.46 0.00004 - - - - -
542.286 5.95 0.46 0.00228 - - - - -
451.221 5.54 0.46 0.00002 - - - - -
1096.552 6.18 0.46 0.00002 - - - - -
909.392 6.05 0.46 0.00083 - - - - -
649.818 5.31 0.46 0.00000 - - - - -
905.479 7.72 0.45 0.00998 - - - - -
217.098 5.44 0.45 0.00001 - - - - -
990.359 6.25 0.45 0.00274 - - - - -
345.699 5.37 0.45 0.00070 - - - - -
746.356 5.99 0.45 0.00000 - - - - -
369.194 14.16 0.45 0.00013 - - - - -
650.821 5.31 0.45 0.00000 - - - - -
759.376 5.65 0.45 0.00699 - - - - -
196.880 0.83 0.45 0.00002 - - - - -
439.255 7.27 0.45 0.00254 - - - - -
802.444 5.28 0.45 0.09672 - - - - -
451.720 5.54 0.45 0.00000 - - - - -
307.161 5.74 0.45 0.00077 - - - - -
340.188 6.45 0.44 0.00873 - - - - -
593.330 7.91 0.44 0.00000 - - - - -
1846.520 10.78 0.44 0.02030 - - - - -
998.511 6.37 0.44 0.01017 - - - - -
447.962 1.31 0.44 0.00007 - - - - -
616.301 7.98 0.44 0.01241 - - - - -
617.468 13.13 0.44 0.00010 - - - - -
636.272 6.35 0.44 0.00000 - - - - -
390.834 0.83 0.44 0.00003 - - - - -
1252.362 10.78 0.44 0.01306 - - - - -
629.366 7.50 0.44 0.00132 PI(20:0/0:0) C29H57O12P 628.359 0.486 Monoacylglycerophosphoinositol
359.683 5.32 0.43 0.00601 - - - - -
308.223 8.02 0.43 0.00022 - - - - -
803.447 5.28 0.43 0.05996 - - - - -
710.911 7.17 0.43 0.00070 - - - - -
507.213 5.83 0.43 0.00053 - - - - -
797.433 7.59 0.43 0.01391 - - - - -
775.258 5.55 0.43 0.01453 - - - - -
1847.520 10.78 0.43 0.01871 - - - - -
338.173 2.19 0.42 0.00034 - - - - -
521.722 6.33 0.42 0.00082 - - - - -
635.341 6.65 0.42 0.00495 - - - - -
529.415 13.21 0.42 0.00006 - - - - -
652.330 6.64 0.42 0.00000 - - - - -
612.802 5.79 0.42 0.00671 - - - - -
628.374 5.80 0.42 0.00081 - - - - -
343.846 5.09 0.42 0.00000 - - - - -
469.233 6.25 0.42 0.00333 - - - - -
440.411 12.13 0.41 0.00002 Pentacosanoylglycine C27H53NO3 439.403 2.292 Indicator of fatty acid oxidation
627.372 5.80 0.41 0.00060 - - - - -
489.340 13.26 0.41 0.00004 - - - - -
514.289 5.90 0.41 0.00432 - - - - -
1062.478 6.66 0.41 0.00296 - - - - -
567.907 1.31 0.41 0.00013 - - - - -
337.186 0.78 0.41 0.00130 - - - - -
495.183 6.25 0.41 0.00116 - - - - -
1024.493 7.17 0.41 0.00482 - - - - -
1248.365 10.78 0.41 0.01119 - - - - -
587.457 13.92 0.41 0.00005 - - - - -
499.278 5.38 0.41 0.00047 - - - - -
1031.557 7.02 0.41 0.00277 - - - - -
560.333 6.99 0.41 0.00048 - - - - -
1097.557 6.19 0.41 0.00001 - - - - -
795.426 7.59 0.40 0.00866 - - - - -
991.359 6.25 0.40 0.00175 - - - - -
629.375 5.80 0.40 0.00070 - - - - -
515.291 5.89 0.40 0.00334 - - - - -
562.280 6.15 0.40 0.00065 - - - - -
455.379 14.08 0.40 0.00002 - - - - -
220.012 1.23 0.40 0.00014 - - - - -
796.429 7.59 0.40 0.00970 - - - - -
1273.617 7.52 0.39 0.00076 - - - - -
764.857 5.35 0.39 0.00006 - - - - -
1848.524 10.78 0.39 0.01258 - - - - -
398.218 7.59 0.39 0.00835 - - - - -
630.369 7.50 0.39 0.00223 - - - - -
915.412 5.32 0.39 0.00609 - - - - -
511.277 8.37 0.39 0.00005 - - - - -
170.079 5.84 0.38 0.00024 - - - - -
1272.613 7.52 0.38 0.00068 - - - - -
627.971 6.59 0.38 0.00000 - - - - -
450.211 5.19 0.38 0.00901 - - - - -
449.207 5.19 0.38 0.04292 - - - - -
780.499 5.90 0.38 0.06795 - - - - -
843.443 6.19 0.38 0.00532 - - - - -
339.204 6.44 0.38 0.00839 - - - - -
526.323 6.35 0.38 0.00221 - - - - -
666.419 7.17 0.37 0.00034 - - - - -
817.409 7.59 0.37 0.00664 - - - - -
302.118 6.75 0.37 0.00001 - - - - -
559.742 6.05 0.37 0.00014 - - - - -
238.108 7.20 0.37 0.00022 - - - - -
637.313 7.52 0.37 0.00054 - - - - -
314.189 5.80 0.37 0.00026 - - - - -
637.814 7.52 0.37 0.00101 - - - - -
495.683 6.25 0.37 0.00148 - - - - -
427.391 13.65 0.37 0.00016 - - - - -
383.230 5.87 0.37 0.00123 - - - - -
624.274 5.75 0.36 0.00031 - - - - -
914.409 5.32 0.36 0.00386 - - - - -
636.811 7.52 0.36 0.00074 - - - - -
553.336 6.45 0.36 0.00963 - - - - -
1274.619 7.52 0.36 0.00057 - - - - -
268.167 6.45 0.36 0.01384 - - - - -
640.366 5.85 0.36 0.00035 - - - - -
533.367 13.21 0.36 0.00000 - - - - -
218.101 5.44 0.36 0.00002 - - - - -
744.404 6.11 0.36 0.00470 - - - - -
776.262 5.55 0.36 0.01155 - - - - -
383.189 5.34 0.36 0.00000 - - - - -
623.270 5.74 0.36 0.00083 - - - - -
384.233 5.87 0.36 0.00247 - - - - -
652.663 6.64 0.35 0.00000 - - - - -
740.459 7.34 0.35 0.00174 - - - - -
654.382 6.07 0.35 0.00028 - - - - -
382.687 5.35 0.35 0.00000 - - - - -
614.357 6.35 0.35 0.00319 - - - - -
758.374 5.65 0.35 0.00511 - - - - -
999.517 5.99 0.35 0.00590 - - - - -
387.273 12.53 0.35 0.00001 Glycerol trihexanoate C21H38O6 386.267 3.950 Triacylglycerol - Fatty Acid
764.363 5.35 0.35 0.00000 - - - - -
578.287 5.49 0.35 0.00658 - - - - -
498.274 5.37 0.34 0.00056 - - - - -
325.716 5.87 0.34 0.00778 - - - - -
485.316 6.30 0.34 0.00726 - - - - -
383.689 5.34 0.34 0.00000 - - - - -
612.302 5.79 0.34 0.00264 - - - - -
443.184 7.52 0.34 0.00068 - - - - -
525.303 5.86 0.34 0.00011 - - - - -
561.276 6.15 0.34 0.00033 - - - - -
515.399 12.47 0.34 0.00000 - - - - -
909.504 6.75 0.34 0.00186 - - - - -
456.219 6.19 0.34 0.00097 - - - - -
769.444 6.40 0.33 0.00936 - - - - -
554.339 6.45 0.33 0.01169 - - - - -
708.430 6.40 0.33 0.00320 - - - - -
502.291 8.02 0.33 0.00011 PE(20:4(5Z,8Z,11Z,14Z)/0:0);LysoPE(20:4(5Z,8Z,11Z,14Z)/0:0)C25H44NO7P 501.286 4.018 Glycerophospholipid - In blood
998.515 5.99 0.33 0.00666 - - - - -
468.442 12.95 0.33 0.00002 - - - - -
997.512 5.99 0.32 0.00597 - - - - -
560.273 6.15 0.32 0.00019 - - - - -
455.215 6.19 0.32 0.00069 - - - - -
475.284 7.12 0.32 0.00100 - - - - -
516.791 7.37 0.32 0.00299 - - - - -
743.402 6.11 0.32 0.00436 - - - - -
280.641 6.15 0.32 0.00044 - - - - -
371.705 6.10 0.32 0.00422 - - - - -
316.168 5.74 0.31 0.01854 - - - - -
391.255 5.90 0.31 0.03590 - - - - -
855.498 7.57 0.31 0.00368 PI(16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)) C45H75O13P 854.495 4.357 Glycerophosphoinositol
499.261 5.99 0.31 0.01117 - - - - -
497.272 5.37 0.31 0.00023 - - - - -
329.151 5.91 0.31 0.01691 Phenylalanyl-Tyrosine C18H20N2O4 328.142 3.348 Amino acid degradation product
781.502 5.90 0.31 0.02047 PG(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) C43H73O10P 780.494 1.017 Glycerophosphoglycerol
1023.488 7.15 0.31 0.00544 - - - - -
519.255 5.37 0.31 0.00072 - - - - -
317.169 5.74 0.31 0.01200 - - - - -
613.357 6.35 0.31 0.00402 - - - - -
829.431 6.00 0.30 0.00580 - - - - -
379.194 5.64 0.30 0.00652 - - - - -
757.373 5.65 0.30 0.00326 - - - - -
1159.592 7.37 0.29 0.00783 - - - - -
471.373 12.50 0.29 0.00000 - - - - -
316.669 5.74 0.29 0.02009 - - - - -
594.327 7.47 0.29 0.00049 - - - - -
499.763 5.99 0.29 0.00805 - - - - -
492.221 5.12 0.29 0.00000 - - - - -
742.400 6.10 0.29 0.00408 - - - - -
637.285 6.15 0.29 0.00051 - - - - -
1158.591 7.37 0.29 0.00827 - - - - -
254.169 6.45 0.28 0.00983 - - - - -
308.104 6.35 0.28 0.00002 - - - - -
647.801 7.51 0.28 0.00064 - - - - -
281.142 6.15 0.28 0.00028 - - - - -
1157.588 7.35 0.28 0.00609 - - - - -
563.225 6.10 0.28 0.00024 - - - - -
316.798 0.89 0.27 0.00000 - - - - -
638.289 6.15 0.27 0.00050 - - - - -
945.946 6.19 0.27 0.00045 - - - - -
491.217 5.12 0.27 0.00000 - - - - -
856.500 7.57 0.27 0.00298 - - - - -
568.298 7.17 0.27 0.00444 - - - - -
579.799 7.37 0.26 0.00800 - - - - -
560.293 5.65 0.26 0.01113 - - - - -
359.003 0.78 0.25 0.00002 - - - - -
406.809 0.81 0.25 0.00000 - - - - -
440.249 5.34 0.25 0.01330 - - - - -
540.339 6.47 0.25 0.00496 - - - - -
579.297 7.37 0.24 0.00622 - - - - -
231.114 5.71 0.24 0.00011 - - - - -
893.537 7.15 0.24 0.00273 - - - - -
408.537 5.79 0.23 0.00461 - - - - -
569.299 7.15 0.23 0.00222 - - - - -
474.280 7.10 0.23 0.00335 - - - - -
473.277 7.10 0.22 0.00335 - - - - -
572.346 7.49 0.22 0.00016 - - - - -
566.331 7.12 0.22 0.00185 - - - - -
511.746 7.14 0.22 0.00327 - - - - -
563.295 6.47 0.22 0.02675 PKOOA-PA C27H47O10P 562.291 4.776 Oxidized glycerophosphoglycerol
1022.483 7.14 0.21 0.00588 - - - - -
575.353 7.49 0.21 0.00007 - - - - -
1105.663 5.95 0.20 0.00066 - - - - -
287.179 7.49 0.20 0.00031 - - - - -
574.351 7.49 0.20 0.00028 - - - - -
573.349 7.49 0.20 0.00022 - - - - -
286.677 7.47 0.20 0.00025 - - - - -
1106.398 5.57 0.19 0.00000 - - - - -
562.292 6.47 0.18 0.02824 - - - - -
137.030 1.19 0.18 0.00032 - - - - -
433.753 6.59 0.17 0.00516 - - - - -
866.497 6.59 0.17 0.00758 - - - - -
177.062 0.78 0.16 0.00000 - - - - -
595.325 5.79 0.16 0.01228 OOB-PG C28H51O11P 594.317 2.054 Oxidized glycerophosphate
504.922 6.24 0.15 0.00001 - - - - -
421.211 5.85 0.15 0.00264 - - - - -
892.534 7.15 0.13 0.00186 - - - - -
326.207 5.31 0.13 0.00484 - - - - -
446.269 7.14 0.13 0.00177 - - - - -
594.323 5.79 0.13 0.00852 - - - - -
691.859 6.12 0.13 0.00060 - - - - -
133.098 0.78 0.13 0.00000 - - - - -
891.531 7.15 0.13 0.00194 - - - - -
155.081 0.79 0.12 0.00000 - - - - -
461.576 6.14 0.12 0.00069 - - - - -
446.771 7.14 0.11 0.00187 - - - - -
685.396 6.53 0.10 0.01802 - - - - -
517.286 6.21 0.10 0.00230 - - - - -
342.702 6.53 0.10 0.01585 - - - - -
867.535 8.24 0.09 0.00003 PI(P-16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) C47H79O12P 866.531 4.015 Fatty acid
516.283 6.21 0.09 0.00244 - - - - -
684.394 6.53 0.09 0.01991 - - - - -
480.281 6.19 0.08 0.01644 - - - - -
669.402 6.37 0.08 0.00774 - - - - -
334.703 6.37 0.07 0.00755 - - - - -
668.398 6.37 0.05 0.00804 - - - - -
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m/z Retention Time Fold Change p value Name Formula Mass of Match PPM Deviation Putative Role
774.883 5.76 0.50 0.00011 - - - - -
268.660 5.95 0.50 0.00177 - - - - -
506.704 5.86 0.50 0.00878 - - - - -
1011.582 7.02 0.50 0.00681 - - - - -
277.674 5.95 0.50 0.00173 - - - - -
561.296 5.65 0.50 0.00212 - - - - -
398.534 5.15 0.50 0.00015 - - - - -
278.176 5.95 0.50 0.00227 - - - - -
402.728 5.28 0.50 0.03961 - - - - -
590.355 6.55 0.50 0.00004 - - - - -
718.300 6.42 0.49 0.00073 - - - - -
417.215 6.34 0.49 0.00362 - - - - -
714.366 7.52 0.49 0.00068 - - - - -
1206.020 6.39 0.49 0.00012 - - - - -
411.016 0.78 0.49 0.00042 - - - - -
768.416 6.56 0.49 0.00001 - - - - -
662.163 6.45 0.49 0.00037 - - - - -
1247.361 10.78 0.49 0.03234 - - - - -
190.914 0.79 0.49 0.00000 - - - - -
630.480 13.87 0.49 0.00015 - - - - -
427.220 5.77 0.49 0.00133 - - - - -
863.432 7.59 0.49 0.00038 - - - - -
666.319 5.69 0.49 0.00052 - - - - -
1250.361 10.78 0.49 0.02783 - - - - -
402.228 5.28 0.49 0.06934 - - - - -
989.356 6.25 0.49 0.00278 - - - - -
763.782 6.40 0.49 0.00351 - - - - -
477.238 5.24 0.48 0.00004 - - - - -
960.382 5.97 0.48 0.00200 - - - - -
665.316 5.69 0.48 0.01320 - - - - -
642.379 5.23 0.48 0.00000 - - - - -
275.041 0.78 0.48 0.00004 - - - - -
433.549 5.31 0.48 0.00009 - - - - -
489.869 1.23 0.48 0.00024 - - - - -
515.782 7.02 0.48 0.00512 - - - - -
124.923 0.80 0.48 0.00000 - - - - -
1000.526 6.05 0.48 0.00685 - - - - -
584.330 8.05 0.48 0.03291 - - - - -
709.408 7.15 0.47 0.00221 - - - - -
709.909 7.15 0.47 0.00318 - - - - -
498.402 14.03 0.47 0.00003 - - - - -
1418.810 7.17 0.47 0.00141 - - - - -
313.140 1.23 0.47 0.00160 - - - - -
586.454 13.92 0.47 0.00005 - - - - -
266.657 7.24 0.47 0.00014 - - - - -
534.712 6.09 0.47 0.00098 - - - - -
931.406 5.75 0.47 0.00245 - - - - -
864.435 7.59 0.47 0.00021 - - - - -
331.198 6.79 0.47 0.00097 - - - - -
940.376 5.61 0.47 0.00442 - - - - -
456.317 5.08 0.47 0.01593 - - - - -
493.170 5.74 0.47 0.00047 - - - - -
445.315 13.30 0.47 0.00003 - - - - -
296.260 15.23 0.47 0.00001 - - - - -
636.343 6.64 0.46 0.00651 - - - - -
542.428 13.97 0.46 0.00004 - - - - -
542.286 5.95 0.46 0.00228 - - - - -
451.221 5.54 0.46 0.00002 - - - - -
1096.552 6.18 0.46 0.00002 - - - - -
909.392 6.05 0.46 0.00083 - - - - -
649.818 5.31 0.46 0.00000 - - - - -
905.479 7.72 0.45 0.00998 - - - - -
217.098 5.44 0.45 0.00001 - - - - -
990.359 6.25 0.45 0.00274 - - - - -
345.699 5.37 0.45 0.00070 - - - - -
746.356 5.99 0.45 0.00000 - - - - -
369.194 14.16 0.45 0.00013 - - - - -
650.821 5.31 0.45 0.00000 - - - - -
759.376 5.65 0.45 0.00699 - - - - -
196.880 0.83 0.45 0.00002 - - - - -
439.255 7.27 0.45 0.00254 - - - - -
802.444 5.28 0.45 0.09672 - - - - -
451.720 5.54 0.45 0.00000 - - - - -
307.161 5.74 0.45 0.00077 - - - - -
340.188 6.45 0.44 0.00873 - - - - -
593.330 7.91 0.44 0.00000 - - - - -
1846.520 10.78 0.44 0.02030 - - - - -
998.511 6.37 0.44 0.01017 - - - - -
447.962 1.31 0.44 0.00007 - - - - -
616.301 7.98 0.44 0.01241 - - - - -
617.468 13.13 0.44 0.00010 - - - - -
636.272 6.35 0.44 0.00000 - - - - -
390.834 0.83 0.44 0.00003 - - - - -
1252.362 10.78 0.44 0.01306 - - - - -
629.366 7.50 0.44 0.00132 PI(20:0/0:0) C29H57O12P 628.359 0.486 Monoacylglycerophosphoinositol
359.683 5.32 0.43 0.00601 - - - - -
308.223 8.02 0.43 0.00022 - - - - -
803.447 5.28 0.43 0.05996 - - - - -
710.911 7.17 0.43 0.00070 - - - - -
507.213 5.83 0.43 0.00053 - - - - -
797.433 7.59 0.43 0.01391 - - - - -
775.258 5.55 0.43 0.01453 - - - - -
1847.520 10.78 0.43 0.01871 - - - - -
338.173 2.19 0.42 0.00034 - - - - -
521.722 6.33 0.42 0.00082 - - - - -
635.341 6.65 0.42 0.00495 - - - - -
529.415 13.21 0.42 0.00006 - - - - -
652.330 6.64 0.42 0.00000 - - - - -
612.802 5.79 0.42 0.00671 - - - - -
628.374 5.80 0.42 0.00081 - - - - -
343.846 5.09 0.42 0.00000 - - - - -
469.233 6.25 0.42 0.00333 - - - - -
440.411 12.13 0.41 0.00002 Pentacosanoylglycine C27H53NO3 439.403 2.292 Indicator of fatty acid oxidation
627.372 5.80 0.41 0.00060 - - - - -
489.340 13.26 0.41 0.00004 - - - - -
514.289 5.90 0.41 0.00432 - - - - -
1062.478 6.66 0.41 0.00296 - - - - -
567.907 1.31 0.41 0.00013 - - - - -
337.186 0.78 0.41 0.00130 - - - - -
495.183 6.25 0.41 0.00116 - - - - -
1024.493 7.17 0.41 0.00482 - - - - -
1248.365 10.78 0.41 0.01119 - - - - -
587.457 13.92 0.41 0.00005 - - - - -
499.278 5.38 0.41 0.00047 - - - - -
1031.557 7.02 0.41 0.00277 - - - - -
560.333 6.99 0.41 0.00048 - - - - -
1097.557 6.19 0.41 0.00001 - - - - -
795.426 7.59 0.40 0.00866 - - - - -
991.359 6.25 0.40 0.00175 - - - - -
629.375 5.80 0.40 0.00070 - - - - -
515.291 5.89 0.40 0.00334 - - - - -
562.280 6.15 0.40 0.00065 - - - - -
455.379 14.08 0.40 0.00002 - - - - -
220.012 1.23 0.40 0.00014 - - - - -
796.429 7.59 0.40 0.00970 - - - - -
1273.617 7.52 0.39 0.00076 - - - - -
764.857 5.35 0.39 0.00006 - - - - -
1848.524 10.78 0.39 0.01258 - - - - -
398.218 7.59 0.39 0.00835 - - - - -
630.369 7.50 0.39 0.00223 - - - - -
915.412 5.32 0.39 0.00609 - - - - -
511.277 8.37 0.39 0.00005 - - - - -
170.079 5.84 0.38 0.00024 - - - - -
1272.613 7.52 0.38 0.00068 - - - - -
627.971 6.59 0.38 0.00000 - - - - -
450.211 5.19 0.38 0.00901 - - - - -
449.207 5.19 0.38 0.04292 - - - - -
780.499 5.90 0.38 0.06795 - - - - -
843.443 6.19 0.38 0.00532 - - - - -
339.204 6.44 0.38 0.00839 - - - - -
526.323 6.35 0.38 0.00221 - - - - -
666.419 7.17 0.37 0.00034 - - - - -
817.409 7.59 0.37 0.00664 - - - - -
302.118 6.75 0.37 0.00001 - - - - -
559.742 6.05 0.37 0.00014 - - - - -
238.108 7.20 0.37 0.00022 - - - - -
637.313 7.52 0.37 0.00054 - - - - -
314.189 5.80 0.37 0.00026 - - - - -
637.814 7.52 0.37 0.00101 - - - - -
495.683 6.25 0.37 0.00148 - - - - -
427.391 13.65 0.37 0.00016 - - - - -
383.230 5.87 0.37 0.00123 - - - - -
624.274 5.75 0.36 0.00031 - - - - -
914.409 5.32 0.36 0.00386 - - - - -
636.811 7.52 0.36 0.00074 - - - - -
553.336 6.45 0.36 0.00963 - - - - -
1274.619 7.52 0.36 0.00057 - - - - -
268.167 6.45 0.36 0.01384 - - - - -
640.366 5.85 0.36 0.00035 - - - - -
533.367 13.21 0.36 0.00000 - - - - -
218.101 5.44 0.36 0.00002 - - - - -
744.404 6.11 0.36 0.00470 - - - - -
776.262 5.55 0.36 0.01155 - - - - -
383.189 5.34 0.36 0.00000 - - - - -
623.270 5.74 0.36 0.00083 - - - - -
384.233 5.87 0.36 0.00247 - - - - -
652.663 6.64 0.35 0.00000 - - - - -
740.459 7.34 0.35 0.00174 - - - - -
654.382 6.07 0.35 0.00028 - - - - -
382.687 5.35 0.35 0.00000 - - - - -
614.357 6.35 0.35 0.00319 - - - - -
758.374 5.65 0.35 0.00511 - - - - -
999.517 5.99 0.35 0.00590 - - - - -
387.273 12.53 0.35 0.00001 Glycerol trihexanoate C21H38O6 386.267 3.950 Triacylglycerol - Fatty Acid
764.363 5.35 0.35 0.00000 - - - - -
578.287 5.49 0.35 0.00658 - - - - -
498.274 5.37 0.34 0.00056 - - - - -
325.716 5.87 0.34 0.00778 - - - - -
485.316 6.30 0.34 0.00726 - - - - -
383.689 5.34 0.34 0.00000 - - - - -
612.302 5.79 0.34 0.00264 - - - - -
443.184 7.52 0.34 0.00068 - - - - -
525.303 5.86 0.34 0.00011 - - - - -
561.276 6.15 0.34 0.00033 - - - - -
515.399 12.47 0.34 0.00000 - - - - -
909.504 6.75 0.34 0.00186 - - - - -
456.219 6.19 0.34 0.00097 - - - - -
769.444 6.40 0.33 0.00936 - - - - -
554.339 6.45 0.33 0.01169 - - - - -
708.430 6.40 0.33 0.00320 - - - - -
502.291 8.02 0.33 0.00011 PE(20:4(5Z,8Z,11Z,14Z)/0:0);LysoPE(20:4(5Z,8Z,11Z,14Z)/0:0)C25H44NO7P 501.286 4.018 Glycerophospholipid - In blood
998.515 5.99 0.33 0.00666 - - - - -
468.442 12.95 0.33 0.00002 - - - - -
997.512 5.99 0.32 0.00597 - - - - -
560.273 6.15 0.32 0.00019 - - - - -
455.215 6.19 0.32 0.00069 - - - - -
475.284 7.12 0.32 0.00100 - - - - -
516.791 7.37 0.32 0.00299 - - - - -
743.402 6.11 0.32 0.00436 - - - - -
280.641 6.15 0.32 0.00044 - - - - -
371.705 6.10 0.32 0.00422 - - - - -
316.168 5.74 0.31 0.01854 - - - - -
391.255 5.90 0.31 0.03590 - - - - -
855.498 7.57 0.31 0.00368 PI(16:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)) C45H75O13P 854.495 4.357 Glycerophosphoinositol
499.261 5.99 0.31 0.01117 - - - - -
497.272 5.37 0.31 0.00023 - - - - -
329.151 5.91 0.31 0.01691 Phenylalanyl-Tyrosine C18H20N2O4 328.142 3.348 Amino acid degradation product
781.502 5.90 0.31 0.02047 PG(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) C43H73O10P 780.494 1.017 Glycerophosphoglycerol
1023.488 7.15 0.31 0.00544 - - - - -
519.255 5.37 0.31 0.00072 - - - - -
317.169 5.74 0.31 0.01200 - - - - -
613.357 6.35 0.31 0.00402 - - - - -
829.431 6.00 0.30 0.00580 - - - - -
379.194 5.64 0.30 0.00652 - - - - -
757.373 5.65 0.30 0.00326 - - - - -
1159.592 7.37 0.29 0.00783 - - - - -
471.373 12.50 0.29 0.00000 - - - - -
316.669 5.74 0.29 0.02009 - - - - -
594.327 7.47 0.29 0.00049 - - - - -
499.763 5.99 0.29 0.00805 - - - - -
492.221 5.12 0.29 0.00000 - - - - -
742.400 6.10 0.29 0.00408 - - - - -
637.285 6.15 0.29 0.00051 - - - - -
1158.591 7.37 0.29 0.00827 - - - - -
254.169 6.45 0.28 0.00983 - - - - -
308.104 6.35 0.28 0.00002 - - - - -
647.801 7.51 0.28 0.00064 - - - - -
281.142 6.15 0.28 0.00028 - - - - -
1157.588 7.35 0.28 0.00609 - - - - -
563.225 6.10 0.28 0.00024 - - - - -
316.798 0.89 0.27 0.00000 - - - - -
638.289 6.15 0.27 0.00050 - - - - -
945.946 6.19 0.27 0.00045 - - - - -
491.217 5.12 0.27 0.00000 - - - - -
856.500 7.57 0.27 0.00298 - - - - -
568.298 7.17 0.27 0.00444 - - - - -
579.799 7.37 0.26 0.00800 - - - - -
560.293 5.65 0.26 0.01113 - - - - -
359.003 0.78 0.25 0.00002 - - - - -
406.809 0.81 0.25 0.00000 - - - - -
440.249 5.34 0.25 0.01330 - - - - -
540.339 6.47 0.25 0.00496 - - - - -
579.297 7.37 0.24 0.00622 - - - - -
231.114 5.71 0.24 0.00011 - - - - -
893.537 7.15 0.24 0.00273 - - - - -
408.537 5.79 0.23 0.00461 - - - - -
569.299 7.15 0.23 0.00222 - - - - -
474.280 7.10 0.23 0.00335 - - - - -
473.277 7.10 0.22 0.00335 - - - - -
572.346 7.49 0.22 0.00016 - - - - -
566.331 7.12 0.22 0.00185 - - - - -
511.746 7.14 0.22 0.00327 - - - - -
563.295 6.47 0.22 0.02675 PKOOA-PA C27H47O10P 562.291 4.776 Oxidized glycerophosphoglycerol
1022.483 7.14 0.21 0.00588 - - - - -
575.353 7.49 0.21 0.00007 - - - - -
1105.663 5.95 0.20 0.00066 - - - - -
287.179 7.49 0.20 0.00031 - - - - -
574.351 7.49 0.20 0.00028 - - - - -
573.349 7.49 0.20 0.00022 - - - - -
286.677 7.47 0.20 0.00025 - - - - -
1106.398 5.57 0.19 0.00000 - - - - -
562.292 6.47 0.18 0.02824 - - - - -
137.030 1.19 0.18 0.00032 - - - - -
433.753 6.59 0.17 0.00516 - - - - -
866.497 6.59 0.17 0.00758 - - - - -
177.062 0.78 0.16 0.00000 - - - - -
595.325 5.79 0.16 0.01228 OOB-PG C28H51O11P 594.317 2.054 Oxidized glycerophosphate
504.922 6.24 0.15 0.00001 - - - - -
421.211 5.85 0.15 0.00264 - - - - -
892.534 7.15 0.13 0.00186 - - - - -
326.207 5.31 0.13 0.00484 - - - - -
446.269 7.14 0.13 0.00177 - - - - -
594.323 5.79 0.13 0.00852 - - - - -
691.859 6.12 0.13 0.00060 - - - - -
133.098 0.78 0.13 0.00000 - - - - -
891.531 7.15 0.13 0.00194 - - - - -
155.081 0.79 0.12 0.00000 - - - - -
461.576 6.14 0.12 0.00069 - - - - -
446.771 7.14 0.11 0.00187 - - - - -
685.396 6.53 0.10 0.01802 - - - - -
517.286 6.21 0.10 0.00230 - - - - -
342.702 6.53 0.10 0.01585 - - - - -
867.535 8.24 0.09 0.00003 PI(P-16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) C47H79O12P 866.531 4.015 Fatty acid
516.283 6.21 0.09 0.00244 - - - - -
684.394 6.53 0.09 0.01991 - - - - -
480.281 6.19 0.08 0.01644 - - - - -
669.402 6.37 0.08 0.00774 - - - - -
334.703 6.37 0.07 0.00755 - - - - -
668.398 6.37 0.05 0.00804 - - - - -
Downregulation
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Table 5.5 Putative metabolite identification of Variable Importance in Projection features identified 
by PLS-DA of AGCF-P bacterial and control samples. Grey = AGCF-P Control, Blue = P. gingivalis. 
 
Table 5.6 Putative metabolite identification of important features in classification identified by RF 
analysis of AGCF-P bacterial and control samples. Grey = AGCF-P Control, Blue = P. gingivalis. 
 
 
5.3.4 qPCR of Fibrosis Associated Genes 
In order to further investigate the potential fibrosis inducing properties of bacterial 
supernatants on kidneys, a more sensitive assay was utilised. Multiple qPCR 
experiments were conducted on mRNA extracted from kidney cells treated with P. 
gingivalis, F. nucleatum, S. mutans supernatants or with AGCF-P media controls. A 
selection of markers that are indicative of fibrosis were used as discussed in Chapter 
4.1.2: Collagen Type 1 Alpha 1 (ColA1), Plasminogen Activator Inhibitor 1 (PAI-1), 
Tissue Inhibitor of Metalloproteases 1 (TIMP1), Transforming growth factor beta 1 
(TGF-β) and Vascular Endothelial Growth Factor (VEGF). 
  
VIP Rank m/z RT Class Name Formula Mass of Match PPM Deviation Putative Role
1 360.196 6.10 C - - - - -
2 572.346 7.49 PG - - - - -
3 268.074 1.24 C - - - - -
4 652.405 6.29 C - - - - -
5 758.411 7.15 C - - - - -
6 553.336 5.95 PG - - - - -
7 342.240 6.27 C - - - - -
8 385.246 5.92 C - - - - -
9 288.193 5.55 C - - - - -
10 560.273 6.15 PG - - - - -
11 245.187 5.62 C Leucyl-leucine C12H24N2O3 244.179 2.562 Amino acid degradation product
12 497.272 5.37 PG - - - - -
13 361.199 6.10 C Arginyl-Tryptophan C17H24N6O3 360.191 2.627 Amino acid degradation product
14 245.186 5.15 C Leucyl-Isoleucine C12H24N2O3 244.179 0.062 Amino acid degradation product
15 573.349 7.49 PG - - - - -
VIP Rank m/z RT Class Name Formula Mass of Match PPM Deviation Putative Role
1 383.189 5.34 PG - - - - -
2 466.330 13.30 C PC(P-15:0/0:0) C23H48NO6P 465.3219 2.557768178 Breakdown of phosphatidylcholine
3 746.356 5.99 PG - - - - -
4 582.768 6.64 C - - - - -
5 259.166 7.05 C - - - - -
6 268.074 1.24 C - - - - -
7 304.167 5.85 C Tryptophyl-Valine C16H21N3O3 303.1582916 3.221295664 Amino Acid degradation product
8 1106.398 5.57 PG - - - - -
9 724.034 7.02 C - - - - -
10 764.363 5.35 PG - - - - -
11 342.702 6.53 PG - - - - -
12 696.009 6.69 PG - - - - -
13 316.798 0.89 PG - - - - -
14 294.681 6.55 PG - - - - -
15 217.098 5.44 PG - - - - -
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5.3.4.1 Collagen Type 1 Alpha 1 mRNA Expression 
After 24 hours of treatment with serum free media along with P. gingivalis and AGCF-
P supernatants collected over 5 days, mRNA levels of the ColA1 were measured by 
qPCR (Figure 5.14). ColA1 mRNA levels were significantly reduced in HK-2 cells 
exposed to P. gingivalis or AGCF-P supernatants in comparison to cells exposed to 
serum free medium. Although a time-dependent decrease of ColA1 mRNA levels was 
observed in HK-2 cells exposed to P. gingivalis supernatants, the ColA1 mRNA levels 
were significantly higher for 1, 2 and 4 D supernatants, as compared to AGCF-P 
media. In contrast, at 5 D ColA1 mRNA was significantly higher in cells exposed to 
AGCF-P media, as compared to P. gingivalis supernatants.  
 
Figure 5.14 Relative gene expression in comparison to β actin of Collagen Type 1 Alpha 1 mRNA in HK-
2 cells after exposure to exposure to serum free media along with P. gingivalis or AGCF-P supernatants 
for 24 hours. |-| indicates significance between the first bar and all others. Error bars represent SEM. 
* = p-value ≤ 0.05, **= p-value ≤ 0.01 (n=3).  
 
Similar results were obtained when HK-2 cells were exposed to F. nucleatum and S. 
mutans supernatants (Fig 5.15). The ColA1 mRNA levels were significantly reduced 
HK-2 cells exposed to 1 D F. nucleatum, S. mutans or AGCF-P supernatants and 2 D 
AGCF-P supernatants in comparison to cells exposed to serum free medium. There 
were also significant differences between both respective 2 D bacterial supernatants 
in comparison to the 2 D AGCF-P media control.  
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Figure 5.15 Relative gene expression in comparison to β actin of Collagen Type 1 Alpha 1 mRNA in HK-
2 cells after exposure to serum free media along with Fusobacterium nucleatum, Streptococcus 
mutans or AGCF-P supernatants for 24 hours. Error bars represent SEM. * = p-value ≤ 0.05, ** = p-
value ≤ 0.01, *** = p-value ≤ 0.001 (n=3). 
5.3.4.2 Plasminogen Activator Inhibitor 1 mRNA Expression 
After 24 hours of treatment with serum free media along with P. gingivalis and AGCF-
P supernatants collected over 5 days, mRNA levels of the PAI-1 gene were 
significantly downregulated by P. gingivalis or AGCF-P supernatants in comparison to 
the serum free media control (Fig 5.16). There was also a significant increase 
between 3 D P. gingivalis supernatants and 3 D AGCF-P media.  
 
Figure 5.16 Relative gene expression in comparison to β actin of Plasminogen Activator Inhibitor 1 
mRNA in HK-2 cells after exposure to serum free media along with P. gingivalis or AGCF-P supernatants 
for 24 hours. |-| indicates significance between the first bar and all others. Error bars represent SEM. 
* = p-value ≤ 0.05 (n=3). 
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In agreement with the experiment above, the PAI-1 mRNA levels were significantly 
downregulated in HK-2 cells exposed to 1 and 2D AGCF-P media as compared to the 
serum free media control (Fig 5.17). However, 1 and 2 D F. nucleatum and S. mutans 
supernatants, had no significant difference in comparison to the serum free media 
control. There was also a significant increase between both respective 2 D bacterial 
supernatants in comparison to the 2 D AGCF-P media control. 
 
Figure 5.17 Relative gene expression in comparison to β actin of Plasminogen Activator Inhibitor 1 
mRNA in HK-2 cells after exposure to serum free media along with Fusobacterium nucleatum, 
Streptococcus mutans or AGCF-P supernatants for 24 hours. Error bars represent SEM. * = p-value ≤ 
0.05, ** = p-value ≤ 0.01, *** = p-value ≤ 0.001, **** = p-value ≤ 0.0001 (n=3). 
 
5.3.4.3 Transforming Growth Factor Beta 1 mRNA Expression 
After 24 hours of treatment with serum free media along with P. gingivalis and AGCF-
P supernatants collected over 5 days, mRNA concentrations of the TGF-β gene were 
measured (Figure 5.18). In comparison to the serum free medium control, 1 and 2 D 
P. gingivalis supernatants were significantly upregulated whereas 3 D AGCF-P 
supernatants were significantly downregulated. There rest of the microbial and 
AGCF-P supernatants had no significant difference in comparison to the control. 
There was also a significant increase in mRNA concentrations of the TGF-β gene 
between 1, 2 and 4 D P. gingivalis supernatants in comparison to 1, 2 and 4 D AGCF-
P media.  
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Figure 5.18 Relative gene expression in comparison to β actin of Transforming Growth Factor beta 1 
mRNA in HK-2 cells after exposure to serum free media along with P. gingivalis and AGCF-P 
supernatants for 24 hours. Error bars represent SEM. * = p-value ≤ 0.05, ** = p-value ≤ 0.01, *** = p-
value ≤ 0.001, **** = p-value ≤ 0.0001 (n=3). 
For the F. nucleatum and S. mutans supernatants (Figure 5.19), statistical tests 
showed that both 1 D F. nucleatum and 2D AGCF-P supernatants were significantly 
downregulated in comparison to the serum free media control. There was also a 
significant increase between both respective 2 D bacterial supernatants in 
comparison to the 2 D AGCF-P media control. 
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Figure 5.19 Relative gene expression in comparison to β actin of Transforming Growth Factor beta 1 
mRNA in HK-2 cells after exposure to serum free media along with Fusobacterium nucleatum, 
Streptococcus mutans or AGCF-P supernatants for 24 hours. Error bars represent SEM. * = p-value ≤ 
0.05, ** = p-value ≤ 0.01 (n=3). 
 
5.3.4.4 Tissue Inhibitor of Metalloproteases 1 mRNA Expression 
After 24 hours of treatment with serum free media along with P. gingivalis and AGCF-
P supernatants collected over 5 days, mRNA levels of the TIMP1 were measured by 
qPCR (Figure 5.20). There was no significant change between all P. gingivalis and 
AGCF-P supernatants in comparison to cells exposed to serum free medium control. 
However, there was a significant increase between 1 and 4 D P. gingivalis 
supernatants and 1 and 4 D AGCF-P media.  
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Figure 5.20 Relative gene expression in comparison to β actin of Tissue Inhibitor of Metalloproteases 
1 mRNA in HK-2 cells after exposure to serum free media along with P. gingivalis or AGCF-P 
supernatants for 24 hours. Error bars represent SEM. * = p-value ≤ 0.05 (n=3).  
 
Similar results were obtained when HK-2 cells were exposed to F. nucleatum or S. 
mutans supernatants (Fig 5.21). There was no significant change between all P. 
gingivalis and AGCF-P supernatants in comparison to cells exposed to serum free 
medium control. There was also no significant differences between the bacterial 
supernatants in comparison to the AGCF-P media control. 
 
 
Figure 5.21 Relative gene expression in comparison to β actin of Tissue Inhibitor of Metalloproteases 
1 mRNA in HK-2 cells after exposure to serum free media along with Fusobacterium nucleatum, 
Streptococcus mutans and AGCF-P supernatants for 24 hours. Error bars represent SEM (n=3). 
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5.3.4.5 Vascular Endothelial Growth Factor mRNA Expression 
After 24 hours of treatment with serum free media along with P. gingivalis or AGCF-
P supernatants collected over 5 days, mRNA levels of the VEGF were measured by 
qPCR (Figure 5.22). There was no significant change between all P. gingivalis and 
AGCF-P supernatants in comparison to cells exposed to serum free medium control. 
In addition, there were no significant differences between all P. gingivalis and AGCF-
P media supernatants at each respective time point.  
 
Figure 5.22 Relative gene expression in comparison to β actin of Vascular Endothelial Growth Factor 
mRNA in HK-2 cells after exposure to serum free media along with P. gingivalis or AGCF-P supernatants 
for 24 hours. Error bars represent SEM (n=3). 
 
Similar results were obtained when HK-2 cells were exposed to F. nucleatum or S. 
mutans supernatants (Fig 5.23). There was no significant change between all P. 
gingivalis and AGCF-P supernatants in comparison to cells exposed to serum free 
medium control. There was also no significant differences between the bacterial 
supernatants in comparison to the respective AGCF-P media control. 
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Figure 5.23 Relative gene expression in comparison to β actin of Vascular Endothelial Growth Factor 
mRNA in HK-2 cells after exposure to serum free media along with Fusobacterium nucleatum, 
Streptococcus mutans or AGCF-P supernatants for 24 hours. Error bars represent SEM (n=3). 
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5.4 DISCUSSION 
5.4.1 LPS Quantification and Testing 
The results of the LPS testing of supernatant samples shows that there is a very low 
intrinsic amount of LPS within the P. gingivalis (~0.3 EU/mL) and AGCF-P (~0.1 EU/mL) 
samples that is relatively constant. The low amount of LPS in the P. gingivalis samples 
is mostly likely due to the lack of an LPS extraction protocol utilised during the 
preparation of microbial supernatants, without this the LPS would stay relatively 
intact and attached to the cell wall even after death. In order for LPS to be extracted, 
more aggressive methods need to be employed to break the bacterial cell wall, for 
example the phenol water method used to purify P. gingivalis LPS (Asai et al., 2005), 
this was not used as this study did plan on studying the effect of LPS on cells 
specifically. The presence of more LPS within the P. gingivalis compared to the AGCF-
P control is most likely an indicator of release of small amounts of LPS over the 
growth cycle of P. gingivalis. The presence of small amounts of LPS within the non-
inoculated media is most likely due to the long-term storage vessels of these 
supernatants being autoclaved glass bijoux, with it being well reported that 
endotoxin can survive filtering and autoclaving (Wang and Doyle, 1998, Holland et 
al., 2000). However, it is important to note that the EU/mL levels reported are 
comparatively low and within the Federal Drug Administration guidelines for sterile 
water (0.25-0.5 EU/mL) depending on intended use (2014).  
There are suggestions that P. gingivalis LPS elicits a weaker immune response 
compared to pathogenic E. coli, with a heterogeneous population of lipid A molecules 
allowing for a weak agonistic and antagonistic response in order to disrupt oral 
homeostasis and ensure the chronic nature of CP (Jain and Darveau, 2010). However, 
the results of this study have demonstrated that pathological levels of these specific 
strains of E. coli or P. gingivalis derived LPS have no effect on the  viability of HK-2 
and HGF-1 cells in vitro. The lack of effect by both LPS preparations is most likely due 
to this model using a singular cell line and may be different in other cell types; there 
are also known strain variations between different clinical subtypes and this could 
have a different effect. The pathogenic effects of LPS are known to be related to the 
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induction of an inflammatory response by activation of toll like receptors and 
immune cell recruitment (Underhill and Ozinsky, 2002, Biswas and Lopez-Collazo, 
2009). In this case, it is clear that the P. gingivalis LPS released and present in the 
supernatant samples are not responsible for the cytotoxic cell viability effects 
reported in Chapter 4. 
5.4.2 Secreted Protein Testing 
The heat and trypsin inactivation of protein complexes in the microbial and control 
supernatants was unsuccessful due to interference with the colorimetric cell viability 
assays. However, by restoring the viability of HK-2 cells, the more targeted protease 
inhibitor cocktail mix was successful in providing evidence for the putative cause of 
the cytotoxic effect of the P. gingivalis supernatants. This is consistent with evidence 
in the literature of the proteinase-dependent cytotoxicity towards various cell lines 
(Johansson and Kalfas, 1998, Sheets et al., 2005, Sheets et al., 2008, Frisch and 
Francis, 1994) which has been suggested to be caused by a special type of apoptosis 
called ‘anoikis’ caused by the disruption of cell-matrix interactions (Frisch and 
Francis, 1994). There is also evidence that Gingipains have been specifically 
implicated in Alzheimer’s disease, with evidence of the presence in the cerebral 
spinal fluid and brains of patients and correlations with the levels of tau and ubiquitin 
pathology (Dominy et al., 2019). Gingipains are also reported to stimulate the 
secretion of pro-inflammatory cytokines through protease-activated receptors and is 
suggested to be one of the ways P. gingivalis can induce inflammation in CP (Uehara 
et al., 2008). 
In this research chapter, qPCR was used to look at mRNA levels of two coupled G-
protein receptors, PAR1 and PAR2, known to be associated with serine proteases 
such as Gingipains (Olczak et al., 2001). The PAR1 receptor is reported to be activated 
by serine proteases such as thrombin, while the PAR2 receptor is activated by serine 
proteases like trypsin and both are thought to be a detector system for tissue injury 
and play a role in initiating inflammation (Coughlin and Camerer, 2003). In the 
literature there is some evidence to suggest PAR2 receptors play a role in 
periodontitis associated inflammation (Vergnolle, 2004), with P. gingivalis Gingipains 
being implicated in activating PAR2 receptors and stimulating the release of 
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interleukin-6 (Holzhausen et al., 2006, Lourbakos et al., 2001). Currently there is 
evidence from enzyme based assays that P. gingivalis derived proteases can activate 
PAR2 receptors in neutrophils (Lourbakos et al., 1998) and oral epithelial cells 
(Lourbakos et al., 2001) but there are no studies that have investigated the effect on 
PAR2 activation in kidney epithelial cells or utilising qPCR, highlighting the novelty of 
the work completed. The qPCR evidence (Figure 5.7) shows no significant change 
with mRNA levels of the PAR1 receptor (Figure 5.7a) with the addition of P. gingivalis 
and AGCF-P supernatants in comparison with the serum free media control, which is 
consistent with the literature (Dommisch et al., 2007). The qPCR determining mRNA 
levels of the PAR2 receptor showed only a significant difference between 1 and 2 D 
P. gingivalis and AGCF-P supernatant samples but no difference in comparison with 
the serum free media, however activation of a receptor does not necessarily affect 
receptor mRNA levels. Evidence in the literature suggests a high affinity of Gingipains 
for activation of PAR2 receptors, which can recruit inflammatory cells, and as a major 
virulence factor of CP (Holzhausen et al., 2006, Lourbakos et al., 2001, Lourbakos et 
al., 1998). The lack of a statically significant mRNA upregulation in comparison to 
serum free media could be due to a variety of reasons such as: mRNA levels of the 
receptors not being significantly increased on activation of the PAR receptors or even 
the presence of siRNA in the AGCF-P medium preventing the increased expression 
(Dommisch et al., 2007). With this in mind, it would be of interest in the future to 
measure the calcium signalling response of the receptors from activation and 
cleavage rather than mRNA levels of the genes encoding PARs, as this has been 
successfully used to quantify PAR activation in various other studies (Holzhausen et 
al., 2006, Lourbakos et al., 2001).  
5.4.3 LCMS Testing of P. gingivalis and AGCF-P Supernatants 
As similarly discussed in Chapter 3 (Section 3.4-3.5) the untargeted metabolomics 
pathway was successful in being able to translate raw LCMS results to a selection of 
significant metabolite features associated with microbial degradation of AGCF-P 
media. This is confirmed from the PCA and PLS-DA analyses that there is a statistically 
significant difference between the QC, AGCF-P control and bacterial classes, 
confirming that microbial degradation of AGCF-P took place and the classes can be 
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separated based on the products present. The modifications to the methods from 
Chapter 3 (Section 3.3.5) such as extra quality assurance steps with the addition of 
the QC samples allows the data to be much more robust and can allow for re-analysis 
in the future. 
However, as also discussed in depth in Chapter 3 (Section 3.4-3.5), metabolite 
identification of features reported to be ‘significant’ was poor with a 6.6% success 
rate in identification. Of the metabolites that were identified the majority were 
relatively non-specific being amino acid degradation products upregulated and 
nutrient sources downgraded which are not specific enough biomarkers. Not being 
able to identify the large majority of the features of interest limits the experiment as 
it restricts translation of potential metabolites to look at their biological role. While 
currently many of these significant features cannot be identified, there is a high 
chance that they will be elucidated in the future. Currently there are only a few 
microorganisms who have had their metabolome studied thoroughly such as E. coli 
(Guo et al., 2012) and Pseudomonas aeruginosa (Huang et al., 2017) after following 
on from the examples of the curated yeast metabolome database (Jewison et al., 
2011) and the human metabolome database (Wishart et al., 2017). With more 
experiments being undertaken on the role of the collective metabolome of the oral 
cavity in periodontitis (Gawron et al., 2019, Velsko et al., 2017) and  growth in the 
use of metabolomics in studies (Kell and Oliver, 2016), a project to create a CP 
metabolome database looking at key microorganisms could be achievable in the near 
future and will allow the data generated here to be re-analysed. 
5.4.4 mRNA levels of markers of fibrosis in response to bacterial supernatants 
5.4.4.1 ColA1 mRNA Levels 
The ColA1 mRNA was a significantly downregulated by all P. gingivalis supernatants, 
1 D F. nucleatum and S. mutans supernatants and AGCF-P media in comparison with 
the serum free medium. However, there were no significant differences between 2 
D F. nucleatum and S. mutans supernatants compared with serum free medium and 
they were significantly upregulated from the matched 2 D AGCF-P media.  
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The reason behind the significant downregulation could be due to the pro-
proliferative and pro-migratory nature of the AGCF-P medium (Section 4.3.2 and 
4.4.2). As the collagen family of proteins play an important part of the ECM, they are 
more likely to be upregulated if there is more space between cells and need for ECM 
production (Brunner et al., 2010). With the AGCF-P medium inducing proliferation 
and migration of HK-2 cells, there will be less space between the cells compared to 
the serum free medium, so the expression of collagen mRNA may be decreased. The 
significant upregulation of collagen mRNA by 1, 2 and 4 D P. gingivalis, 2 D F. 
nucleatum and S. mutans supernatants compared to the matched AGCF-P control 
medium suggests that these bacteria release pro-fibrotic factors in their 
supernatants. This may be due to a feedback loop of regulation due to the collagen 
proteolytic activity of P. gingivalis secreted Gingipains (Tokuda et al., 1998). The 
upregulation of 2 D F. nucleatum and S. mutans supernatants compared to the 
matched 2 D AGCF-P control could potentially be related to the reported abilities of 
both organisms to bind to collagen type 1 (Xie et al., 1991, Chow et al., 2019). The 
downregulation of collagen mRNA expression by 5 D P. gingivalis supernatants may 
be related to the growth cycle of the microorganisms being in stationary/death 
phase, with less pro-fibrotic mediators being secreted. 
5.4.4.2 PAI-1 mRNA Levels 
The PAI-1 mRNA levels were significantly downregulated by all P. gingivalis and 
AGCF-P supernatants in comparison with the serum free medium, whereas there was 
no significant differences with F. nucleatum and S. mutans supernatants. Indeed, only 
3 D P. gingivalis supernatants significantly upregulated PAI-1 mRNA expression 
compared to matched 3 D AGCF-P medium, while 2 D F. nucleatum and S. mutans 
supernatants were significantly upregulated compared to the matched 2 D AGCF-P 
medium.  
There is some evidence to suggest that P. gingivalis Gingipains can degrade PAI-1 
with Gingipain defective strains having a negligible effect on degradation (Klarström 
Engström et al., 2015). However, this degradation would not have an impact on the 
mRNA levels of PAI-1 so would not be apparent via PCR. Conversely, there is also 
some evidence P. gingivalis can increase PAI-1 and suppress t-PA in aortic cells 
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(HAEC), which induces a pro-coagulant response (Roth et al., 2006). Currently there 
is nothing in the literature to describe potential interactions with both F. nucleatum 
and S. mutans and PAI-1. 
5.4.4.3 TGF-β mRNA Levels 
The TGF-β mRNA levels were significantly upregulated by only 1 and 2 D P. gingivalis 
supernatants while and 3 D AGCF-P supernatants were downregulated in comparison 
with the serum free medium, whereas there was no significant differences with F. 
nucleatum and S. mutans supernatants. In addition 1 and 2 D P. gingivalis 
supernatants had significantly upregulated TGF-β mRNA expression compared to 
matched 1 and 2 D AGCF-P medium, while 2 D F. nucleatum and S. mutans 
supernatants were significantly upregulated compared to the matched 2 D AGCF-P 
medium.  
There is evidence in the literature that treatment of human fibroblasts (Palm et al., 
2015), human aortic smooth muscles (Zhang et al., 2013) and human monocytes 
(Gemmell and Seymour, 1993) with P. gingivalis induced expression of TGF-β. This 
effect is attenuated in a Gingipain deficient strain (Palm et al., 2015) and appears to  
be mediated by the notch signalling pathway (Zhang et al., 2013). However, despite 
the upregulation reported in these results, there is evidence that TGF-β may have 
tissue specific activation, suggesting comparisons of expression with other cell lines 
may not be useful (Annes et al., 2003). There is some evidence for upregulation of 
TGF-β by F. nucleatum (Zhang et al., 2013) but none for S. mutans. 
5.4.4.4 TIMP1 mRNA Levels 
The TIMP1 mRNA levels did not significantly change for all microbial and AGCF-P 
media supernatants in comparison to the mRNA levels of the serum free media 
control. However, there was significant upregulation between TIMP1 mRNA levels of 
1 and 4 D P. gingivalis supernatants in comparison to matched 1 and 4 D AGCF-P 
medium supernatants.  
This outcome could potentially be due to TIMP1 gene expression activation by P. 
gingivalis LPS, as demonstrated in gingival fibroblasts (Herath et al., 2013). 
Conversely, there is also evidence that P. gingivalis strains with Gingipains (Type 
strain) and deficient in Gingipains (KDP128) do not significantly affect mRNA levels of 
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TIMP1 but affect the expression of TIMP2 in an engineered oral mucosa model of 
fibroblasts and epithelial cells (Andrian et al., 2007). Therefore, the regulation of 
TIMP-1 gene expression may vary between tissue types and it remains to be 
examined in HK-2 cells.  
5.4.4.5 VEGF mRNA Levels 
The TIMP1 mRNA levels did not significantly change for all microbial and AGCF-P 
medium supernatants in comparison to the mRNA levels of the serum free media 
control. There was also no significance between any microbial supernatant and 
matched AGCF-P medium supernatant sample, indicating a lack of effect for all 
preparations on the mRNA regulation of VEGF. This does appear to be contrary to 
evidence of VEGF gene expression being upregulated in gingival fibroblasts by P. 
gingivalis (Domon et al., 2014). However, this was after incubation with a more 
virulent P. gingivalis strain (W83) which may mean this upregulation is due to a 
multiple of other virulence factors or due to the fact this was direct live incubation 
rather than supernatant samples such as like we were testing. 
5.4.4.6 Overall trend 
There does not appear to be any significant trend associated with the five different 
fibrosis associated mRNA markers. However, there does seem to be a trend related 
to downregulation of the mRNA of both ColA1 and PAI-1 after treatment with the 
AGCF-P medium and all microbial samples compared to serum free medium, 
indicating that it may be due to the AGCF-P medium. As seen in the cellular migration 
studies (Section 4.3.2 and 4.4.2) the AGCF-P media appears to significantly increase 
the migration and proliferation of HK-2 cells and this is most likely due to the 
increased nutrients and potential growth factors from the addition of horse blood 
compared to the serum free media control. As serum free media is known to be less 
proliferative and lacking in soluble factors to stimulate growth (Brunner et al., 2010), 
it may be that the increased ColA1 and PAI-1 levels in the serum free medium could 
be due to a compensatory mechanisms to ensure integrity of the cell monolayer of 
the proximal tubule. Therefore, the decreased proliferation of cells cultured in serum 
free media could lead to compensatory changes leading to the upregulation of ColA1 
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and PAI-1 among other mRNA products, which induce the production of extracellular 
matrix and ensure the tubules maintain integrity in the monolayer. 
Only P. gingivalis supernatants collected on day 1 and 2 had a significant upregulation 
compared to serum free media and the AGCF-P media control for TGF-β mRNA and 
this appears to be consistent with the literature for P. gingivalis upregulating TGF-β. 
For F. nucleatum and S. mutans there were no instances of significance when 
comparing to both serum free medium and AGCF-P medium. 
If the results of the mRNA amounts in HK-2 cells after treatment with all bacterial 
supernatants are compared to the matched AGCF-P medium alone, it does appear 
that there is a potential pro-fibrotic effect with three different markers (TGF-β, ColA1 
and TIMP1). There are much higher TGF-β mRNA levels when treated with 1 and 2 D 
P. gingivalis supernatants, increased ColA1 levels when treated with 1, 2 and 4 D P. 
gingivalis supernatants and increased TIMP1 mRNA levels when treated with 2 and 
4 D P. gingivalis supernatants. In addition, if the PAI-1 results are compared with the 
PAI-1 Luciferase Reporter Assay (Chapter 4.5.3) and the qPCR tests in this chapter, 
there does appear to be a corroboration between levels for P. gingivalis and AGCF-P 
supernatants, with the exception of 3 D P. gingivalis supernatants that have 
increased levels in the qPCR. 
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5.5 Conclusions 
This chapter has identified potential factors behind the cellular damage elicited by P. 
gingivalis supernatants. This work has demonstrated that in contrast to secreted 
proteases such as Gingipains, LPS does not play a role in HK-2 cytotoxicity and the 
role of secreted proteins such as Gingipains appearing as the lead candidate in both 
these experiments and in the literature. Indeed, further experiments need to be 
conducted in order to confirm this association. 
The investigations into the fibrotic potential of periodontitis associated pathogens 
still remains unclear, with no distinct up-regulatory trends across the five markers. 
The only mRNA marker with significant upregulation compared to serum free and the 
AGCF-P growth medium control was TGF-β for 1 and 2 D P. gingivalis supernatants. 
However, if fold change in comparison to the AGCF-P medium is only considered 
there does appear to be a potential pro-fibrotic effect with increased expression of 
three different markers: TGF-β, ColA1 and TIMP1. Further studies investigating this 
upregulation are also warranted in order to confirm this.  
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6.1 DISCUSSION 
CKD and CP are both common diseases, which are frequently comorbid with each 
other and have an overlap in risk factors (Jones, 2010, Schellevis et al., 1993, Stringer 
et al., 2013). They are also both risk factors for each other and there is evidence that 
the concurrent presence of both diseases has a detrimental effect on the progression 
of each respective disease (Sharma et al., 2016, Zhang et al., 2017). CKD is reported 
to have a variety of effects on the body such as systemic inflammation and retention 
of uremic toxins, along with localised effects at the site of the oral cavity such as 
changes in the increased pH of oral fluids and inflammation of oral tissue (Akar et al., 
2011, Oyetola et al., 2015). In addition, CP is also reported to have a variety of effects 
on the body with evidence of systemic inflammation along with bacteraemia of 
microbes and their products into the bloodstream (Moutsopoulos and Madianos, 
2006, Fisher et al., 2010). These effects have led to reports of its involvement in a 
variety of other diseases such as Alzheimer’s and cardiovascular disease (Dominy et 
al., 2019, Dietrich et al., 2008). With the known association between CKD and CP, 
understanding how they may influence each over is paramount as the identification 
of novel interventions/modifiable risk factors to slow disease progression is an area 
of urgency particularly in CKD (James et al., 2010). Previous studies have investigated 
the directionality of the relationship between these two diseases (Zhao et al., 2018, 
Fisher et al., 2011, Wahid et al., 2013); however there is a lack of literature that has 
examined how these diseases may be interacting at systemic and microbial level to 
cause this association.  
This research has delivered an in depth review of the potential interactions between 
CKD and CP (Chapter 1) and developed a more representative growth medium for 
cultivation of a selection of periodontitis associated pathogens which better enabled 
the studying of their prospective effects (Chapter 2). Furthermore, a novel 
metabolomics based method using LCMS was developed in order to trial the use of 
metabolomics as a way of rapidly screening microbes for their ability to produce 
uremic toxins (Chapter 3). Additionally, the ability of bacterial products from selected 
microorganisms to elicit a detrimental effect on kidney cells was investigated 
(Chapter 4), with a specific focus on investigation of the potential to initiate fibrosis 
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(Chapters 4 and 5). Only one chosen microorganism elicited a detrimental effect on 
kidney cells, Porphyromonas gingivalis, and the causative component behind this 
effect was also explored (Chapter 5). 
One of the objectives of this study was to identify a selection of microorganisms 
implicated in CP, along with developing a growth medium representative of the 
diseased environment. The selection of periodontitis organisms to study is complex 
due to a large number of associated organisms reported as being involved in 
periodontal disease (Table 1.1) (Wade, 2013) and it was not feasible to investigate all 
of them individually along with the various permutations of multispecies biofilms. 
With that being the case, the organisms chosen to be investigated (Chapter 2.1.4) 
represent a small subsection of periodontitis associated pathogens that have been 
implicated either in association with CP and CKD or just CP and systemic disease, 
along with two non-associated microorganisms to act as controls. The development 
of a new growth medium (Hickey et al., 2019) whilst not an original intention of the 
research, became apparent from the literature the difficulties of culturing 
periodontal pathogens and the lack of one commercially available growth medium 
that would support the growth of the selected organisms. One reasoning behind the 
development of this new growth medium was that cultivation of particularly 
fastidious organisms is reported to be achievable by mimicking components of the 
physiological environment where certain microbes are found (Kaeberlein et al., 2002, 
Vartoukian et al., 2010). Furthermore, there is evidence that different nutrient 
sources could potentially induce regulatory changes in gene expression and 
downstream products (Shimizu, 2014, Balleza et al., 2009), which may induce the 
chosen microorganisms to produce potential uremic compounds. The initial 
metabolomic proof of concept tests between two growth media BHIB and TSB 
partially confirmed the variance based on nutrient source, with a wide variety of 
potential metabolites produced by the same microorganism grown in two different 
media (Chapter 3). Overall, the use of a singular medium for all microorganisms 
allowed for better comparisons between the potential effects or lack of between the 
chosen microorganisms and a common control and facilitated further in vitro 
investigations in later chapters. However, these in vitro investigations did highlight a 
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disadvantage, with the complex formulation of this medium appearing to have some 
effects when in contact with human kidney cells which caused issues when 
investigating specific fibrosis markers. 
The next objective was to develop an untargeted LCMS based metabolomics pipeline 
as a screening tool of microbial samples for potential toxic products. This was 
successfully completed with a microbial metabolomics pipeline developed detailing 
the purification of microbial supernatants from microbial culture, preparation for 
LCMS, analysis using LCMS and data processing and interpretation (Chapter 3.3 and 
optimised in Chapter 5.3.5). This developed pathway was primarily tested using S. 
constellatus cultivated in BHIB and TSB and was successful in translating thousands 
of different mass peaks to a selection of ~100 metabolite features, which are 
putatively responsible for differences between control media and microbial 
inoculation (Chapter 3). However, there was poor success in identification of these 
statistically significant metabolic features with a 7.1% success rate in identification 
for BHIB and 30 % for TSB. Of the features identified, the majority were very non-
specific products such as amino acids and amino acid degradation products, which 
are not useful candidate molecules for potential biomarkers. This partial metabolite 
identification is a well-known bottleneck of metabolomics (Dunn et al., 2013) and is 
compounded by the lack of microorganism specific metabolite libraries to enable 
successful metabolite identification by cross reference. Due to the large amount of 
time needed for the employment of metabolomics and the ambiguous metabolite 
identification, its use for fast screening of microbial supernatants was deemed 
limited for this project.  
Consequently, the collected microbial supernatants were tested against a kidney cell 
line to investigate their cytotoxic and pro-fibrotic effects (Chapter 4 and 5). The aim 
of this research was to identify pathogenic supernatants to conduct metabolomics 
experiments on them. With P. gingivalis supernatants inducing a cytotoxic effect on 
kidney cells (Chapter 5), an optimised version of the untargeted metabolomics 
pipeline was completed. However, the same inherent issues highlighted with S. 
constellatus supernatants arose with the P. gingivalis supernatants. While thousands 
of features were narrowed down to ~100 significant features, only 6.6% were 
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identified and those identified were non-specific products. While untargeted 
metabolomics was not successful for this project, the meticulous nature of the 
pipeline with multiple QA and QC steps should allow reanalysis in the future when 
mass spectral databases are more developed for microorganisms. Additionally, the 
developed metabolomics pipeline was successfully employed for a targeted study, 
with pyocyanin being quantified and used to determine the highest producing 
Pseudomonas aeruginosa strains for use in optimising microbial fuel cells (Slate, 
2019). This highlights this pipeline has the potential to be applied to various other 
projects outside of this body of work. 
The third objective was to determine whether the microbial products produced by 
the chosen microorganisms can induce cytotoxic and migratory effects in human 
kidney cells. This was completed by testing all the microbial supernatants against 
human kidney cells and measuring their effect on cellular viability (via assessment of 
biochemical activity) after 24 and 48 hours, along with separately testing the 
migratory effects by testing wound closure over time (Chapter 4). Of the 
supernatants tested, only one organism (P. gingivalis) significantly reduced cellular 
viability and migration. This research presents novel data that shows P. gingivalis 
derived microbial products elicit cytotoxic effects against the human kidney cells 
along with a weak anti-migratory effect. The results support the findings of P. 
gingivalis mediated cytotoxicity in other cell lines with direct incubation cytotoxicity 
in human gingival fibroblasts (Desta and Graves, 2007, Morioka et al., 1993), human 
aortic endothelial cells (Roth et al., 2007) and various human urothelial cells (Shah et 
al., 1992). However, there is evidence of variable cytotoxicity against different human 
cell types treated with the same periodontal microorganisms supernatants 
(Johansson et al., 1994), which may be the reason behind associations of CP with 
cardiovascular disease, endocarditis and kidney disease. There is also reported 
heterogeneity between different subtypes of P. gingivalis and cytotoxicity, which is 
suggested to be related to the different immunogenicity of the serotypes (Johansson 
et al., 1996, Ebersole and Steffen, 1995). Furthermore, the results support evidence 
that growth medium supernatants of P. gingivalis are cytotoxic to human gingival 
fibroblasts (Johansson et al., 1996) and human oral epithelial cells (Chen et al., 2001). 
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The mild anti-migratory effect we report of P. gingivalis supernatants after 24 h may 
just be due to the cytotoxic effects slowing cell migration, although there have  been 
reports of anti-migratory activity due to the degradation of adhesion molecules such 
paxillin and focal adhesion kinase, resulting in cellular impairment (Furuta et al., 
2009). This is also corroborated by evidence of hydrolysis of kidney epithelial 
junctional proteins such as E-cadherin by Gingipains, which may also have an anti-
migratory effect as well as potentially promoting invasion of kidney tissue to 
underlying connective tissues in CKD (Katz et al., 2002a). 
The fourth objective was to determine whether the microbial products secreted by 
the selected microorganisms could induce fibrotic effects in human kidney cells. This 
was completed initially by the use of transfected luminescent HK-2 cells with a 
fibrosis associated reporter gene (PAI-1) (Chapter 4). However, this was not 
successful due to the complexity of the AGCF-P medium control masking any 
potential effect. This was  probably due to non-specific stimuli such as growth factors 
and metabolic factors (e.g. glucose) most likely present in the AGCF-P growth media 
from the addition of blood which could be interfering with the production of PAI-1 
(Eddy and Fogo, 2006, Ghosh and Vaughan, 2012). Consequently, a more sensitive 
qPCR based approach was used to quantify the change in the mRNA of a selection of 
fibrosis associated genes (ColA1, PAI-1, TGF-β, TIMP1 and VEGF) in kidney cells 
treated with F. nucleatum, P. gingivalis and S. mutans microbial products. There was 
a lack of overall trends observed with these results. However, there was 
downregulation of the mRNA of both ColA1 and PAI-1 after treatment with the AGCF-
P media and all microbial samples, indicating that it may be due to the AGCF-P media 
or due to the serum free media causing the cells to be more stressed due to a lack of 
growth factors present in the blood added to AGCF-P media. There was a significant 
upregulation of TGF-β after treatment with P. gingivalis supernatants in comparison 
to both the serum free medium and AGCF-P supernatants, but only for day 1 and 2 
of the growth. This supports evidence in the literature that Gingipains (specifically 
lysine Gingipains) can induce the production of TGF-β alongside the suppression of 
CXCL8 and IL-6 (Bengtsson et al., 2015, Khalaf et al., 2014b). This effect was also 
shown to be attenuated in a Gingipain deficient strain indicating a potential role of 
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Gingipains (Palm et al., 2015) and there are also suggestions this induction by P. 
gingivalis may be mediated by the notch signalling pathway (Zhang et al., 2013). 
While notch signalling is not normally detectable in mature human kidneys (Hu and 
Phan, 2016), there is evidence that notch pathway proteins correlate with 
albuminuria, glomerulosclerosis, and renal function (Murea et al., 2010) and 
epithelial notch signalling can regulate interstitial fibrosis development (Bielesz et al., 
2010). This suggests a possible mechanism of P. gingivalis microbial product 
interaction with CKD, mediated by Gingipains. However, if the 
upregulation/downregulation of the mRNA of the selection of fibrosis-associated 
genes is only considered in regards to differences between the microbial 
supernatants and matched AGCF-P control medium supernatants, there does appear 
to be a potential trend. For the P. gingivalis supernatants, there is upregulation of 
three different pro-fibrotic markers TGF-β, ColA1 and TIMP1 at various days of 
supernatant sampling with the upregulation of TGF-β being the largest fold change. 
This data does appear promising and highlights a potential future avenue to further 
unravel the putative role of CP associated microorganisms in CKD. 
The final objective was to identify any microbial products capable of producing a 
cytotoxic, migratory or fibrotic effect on human kidney cells. As P. gingivalis 
supernatants were the only microbial supernatant to elicit a cytotoxic and anti-
migratory effect. It was therefore the only supernatant fully investigated. Firstly, a 
summary of the different mechanisms by which P. gingivalis could conceivably cause 
cellular damage and the different components and virulence factors that would be 
present in microbial supernatants was discussed (Chapter 5.1). Next, LPS was 
investigated, and evidence was presented showing that LPS concentrations found in 
the microbial and control supernatant samples were insufficient to cause the 
reported cytotoxic effects and that even at high concentrations (100 µg/mL) of P. 
gingivalis and E. coli LPS, no statistically significant cytotoxicity was reported against 
human kidney and human fibroblast cell lines. The low quantity of LPS was most likely 
due to the preparation of the microbial supernatants as there was no sonication step. 
Despite P. gingivalis and E. coli LPS not initiating cytotoxic cell effects in these two 
cells lines, there is known variation in clinical and lab strains of microbial LPS along 
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with LPS having different effects on different cell lines. The pathogenic effects of LPS 
are known to be mediated by the induction of an inflammatory response by 
activation of toll like receptors and immune cell recruitment (Underhill and Ozinsky, 
2002, Biswas and Lopez-Collazo, 2009). This research also presents evidence that the 
addition of a cell culture specific protease inhibitor cocktail mix attenuated the 
cytotoxicity of P. gingivalis supernatants against human kidney cells. This supports 
the literature regarding P. gingivalis specific proteases (Gingipains) as the cause of 
the observed cytotoxic effects against various cell lines (Johansson and Kalfas, 1998, 
Sheets et al., 2005, Sheets et al., 2008, Frisch and Francis, 1994) and the attenuation 
of this effect reported with heat treatment or proteinase inhibitors (Johansson and 
Kalfas, 1998) along with the addition of anti-sera (Chen et al., 2001). However, the 
literature lacks  agreement regarding how  Gingipains cause cytotoxicity, with some 
studies suggesting this occurs through the caspase dependent apoptosis (Sheets et 
al., 2005, Wang et al., 1999, Roth et al., 2007) whilst others have suggested cell death 
was caspase independent (Desta and Graves, 2007). More recent studies have 
proposed caspase independent apoptosis mediated by an apoptosis-inducing factor 
and involving the disruption of epithelial-cell adhesion by integrin β1 degradation (Li 
et al., 2019, Qiu et al., 2018). Indeed, this is consistent with a special type of apoptosis 
called ‘anoikis’ which is induced by the disruption of cell-matrix interactions (Frisch 
and Francis, 1994). To further investigate whether this effect was caused by 
Gingipains, multiple qPCR tests were conducted on RNA extracted from HK-2 cells, 
treated with and without P. gingivalis supernatants. The expression of protease-
activated receptors 1 and 2 was investigated but there was no significant difference 
between the control and P. gingivalis over 48 h. In the literature there is evidence for 
the activation of PAR2 receptors by Gingipains in neutrophils (Lourbakos et al., 1998) 
and oral epithelial cells (Lourbakos et al., 2001), with activation of PAR2 stimulating 
release of interleukin-6 (Holzhausen et al., 2006, Lourbakos et al., 2001). The 
reasoning behind this lack of effect may be due to previous literature utilising calcium 
signalling to investigate PAR2 activation whereas this study utilised qPCR to 
investigate mRNA upregulation of the receptors, which may not take place upon 
activation (Holzhausen et al., 2006, Lourbakos et al., 2001, Lourbakos et al., 1998). 
More recent research has shown the activation and cleavage of PAR2 receptors can 
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stimulate a calcium signalling response and trigger platelet activation (Klarström 
Engström et al., 2015). 
 Overall, the main finding of this study is that microbial product/s derived from 
key CP pathogen, P. gingivalis, can elicit a cytotoxic and slight anti-migratory effect 
on human kidney cells. A secondary finding is that a microbial product/s derived from 
key CP pathogen P. gingivalis can induce the production of TGF-β mRNA in 
comparison to the AGCF-P medium and serum free medium controls. In both cases, 
it seems probable that this microbial product is P. gingivalis derived proteases, 
Gingipains, with evidence of Gingipains inducing cytotoxicity and the production of 
TGF- β (Khalaf et al., 2014a), although further work is warranted to confirm this. 
Another secondary finding is that in comparison to the ACGF-P control medium 
supernatant, microbial product/s derived from P. gingivalis supernatants can induce 
upregulation of three different pro-fibrotic markers TGF-β, ColA1 and TIMP1 over the 
5 D sampling of P. gingivalis growth. These findings suggest evidence for a potential 
role of the keystone CP pathogen P. gingivalis in the mediation of inflammation and 
fibrosis, which is associated with CKD, and highlight potential avenues for future 
work. It is clear that chronic bacteraemia and translocation of periodontitis 
associated pathogens and their microbial products in CP takes place over the lifespan 
of the disease, which is evidenced by the multiple associations and isolations with 
systemic disease (Otomo-Corgel et al., 2012, Segura‐Egea et al., 2015). This combined 
with the evidence of cellular damage to kidney cells, the reported hydrolysis of 
kidney epithelial junctions to allow invasion, along with the capability to trigger 
platelet activation through PAR2 receptors and pro-fibrotic effects through TGF-β 
and the notch-signalling pathway suggest a potential role for this key periodontal 
pathogen in mediating CKD. 
6.2 Limitations and Future work 
 As this study was conducted on singular, predominantly planktonic 
microorganisms (Chapter 2) this represents a limitation as it is well established 
that periodontitis consists of oral biofilms that are formed of polymicrobial 
communities that undertake a microbial shift with the progression of the disease 
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(Berezow and Darveau, 2011, Hajishengallis, 2015). These oral biofilms can have 
structural and functional heterogeneity along with a microcosm of environmental 
conditions and interactions between multiple oral microorganisms through 
quorum sensing which can modulate the environment (Kolenbrander et al., 2002, 
Dalwai et al., 2006). With the stark differences between singular planktonic and 
polymicrobial biofilms, the secreted microbial products could differ especially as 
there was limited biofilm characterisation, so confirmation of the effects seen in 
this study would be useful. Repeating some of these experiments using fractions 
collected from reproducible subgingival biofilm models such as described by 
Fernandez y Mostajo et al. (2017) along with a dental plaque biofilm models 
described by Davrandi et al. (2017) would be beneficial as batch culture is 
artificial and continuous culture or steady-state biofilms are more representative 
of the disease. This will enable confirmation of an effect on kidney cells and 
further warrant investigations into the potential interactions between CKD and 
CP.  
 
 In this study, experiments (Chapter 2) were only conducted on one keystone 
pathogen of the red complex (P. gingivalis, not T. forsythia or T. denticola) 
(Hajishengallis and Lamont, 2012), predominately due to difficulties in cultivation 
(Wardle, 1997). In order to build a better picture of whether CP associated 
microorganisms can secrete products that have a potential effect on kidney cells 
it would be particularly useful to investigate these remaining two keystone 
pathogens. Progress has been made in cultivating previously uncultivatable 
members of the Tannerella sp. (Vartoukian et al., 2016) and it is known that T. 
forsythia requires supplementation of a exogenous source of N-acetyl muramic 
acid (Sharma, 2010). T. denticola, being a spirochete, is known to be particularly 
hard to grow but this is possible with modifications to the media to ensure a low 
redox potential along with sodium bicarbonate (Fenno, 2006). Future 
modifications to the developed growth medium AGCF-P (Hickey et al., 2019) 
would be warranted to allow investigations into these microbes of interest.  
 In Chapter 3 and Chapter 5 a limitation highlighted of metabolomics and LCMS 
for mass screening of microbial supernatants is the lack of an appropriate mass 
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spectroscopy database for confirmation and identification of microbial products. 
Future work to look at the creation of a periodontitis metabolome database 
would rectify this issue and facilitate further investigations into the complex 
interactions of CP. In order to go about doing this it would be prudent to follow 
the example of the Pseudomonas aeruginosa metabolome database (PAMDB) 
(Huang et al., 2017).  
 
 In this study, the only cell line used to investigate the cytotoxic and migratory 
effects of the microbial products was HK-2 cells (Chapter 4). This is a potential 
limitation because it has been reported that cytotoxicity can vary depending on 
the cell type due to cell specific toxins produced by the different periodontal 
pathogens (Johansson et al., 1994). While human gingival fibroblast cells (HGF-1) 
were used for testing the AGCF-P media in Chapter 2, they were found not to be 
appropriate for cytotoxicity testing due to difficulties regarding prolonged 
cultivation, as they are primary cells. Repeating the cytotoxicity and migratory 
tests in a wider variety of cell lines, more representative of the tissues the 
microbial products would come in contact with would be beneficial to further 
elucidate potential effects. Some cell lines that would be useful to investigate 
would be: human endothelial cells which are indicative of the contact with the 
circulatory systems, human oral epithelial cells and human gingival fibroblast cells 
which are indicative of the oral cavity and human macrophages which are 
indicative of the immune cells. Another avenue to consider would be co-culture 
of the kidney proximal tubules with other immune cells such as macrophages, 
which are present in the local tubule environment.  
 
 Another limitation of the cytotoxicity investigations in this study (Chapter 4) is 
the microorganisms used; type strains were used to make it more repeatable 
however they may not be as representative of the clinical disease as clinical 
strains. This is shown by certain strains of P. gingivalis, specifically the type strain 
(NCTC 11834) used in this study, being more cytotoxic to oral cell lines than 
clinical 381 and W 50 strains which has been suggested to be due to different 
immunogenicity of the serotypes (Ebersole and Steffen, 1995). Repeating the 
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cytotoxicity, migration and fibrosis tests with different clinical serotypes of P. 
gingivalis would be of use to investigate whether the cytotoxicity and induction 
of fibrosis markers reported against kidney cells is reproducible in clinical based 
samples. 
 
 The use of the colorimetric tetrazolium based CCK-8 dye for cell viability assays is 
a limitation due to the potential of the purified supernatants to potentially 
interact with the readings. Tetrazolium-based methods for assessing cellular 
viability looks at biochemical activity; the ability of cells to reduce the tetrazolium 
to formazan in the presence of electron carriers (Riss et al., 2016). This method 
gives an indirect measure of cellular viability directly proportional to absorbance 
at two wavelengths (450/600nm). There is the potential of chemical interference 
from components of the supernatants with this reaction along with the issue of 
damaged cells still being viable and thus a false positive. In order to provide a 
more specific measure of cell death, assays utilising flow cytometry such as 
Annexin V/Propidium Iodide could be utilised which can provide an direct 
indication of necrosis and apoptosis (Rieger et al., 2011). 
 
 The investigations into the pathogenic involvement of proteases such as 
Gingipains in Chapter 5 used degradation of the P. gingivalis supernatants by 
trypsin and heat inactivation along with the use of protease inhibitors. However, 
a limitation of these tests is that the cytotoxic effects were not completely proven 
to be due to the activity of Gingipains. Future work to definitively confirm this 
could be to utilise a Gingipains deficient strain of P. gingivalis such as (KDP128) 
(Brochu et al., 2001) and repeat the cytotoxicity and migration assays. An 
alternative option could be to purify Gingipains from the outer membrane 
vesicles using acetone precipitation followed by gel filtration (Potempa and 
Nguyen, 2007) or by the generation of a poly histidine tagged recombinant 
Gingipain that can be recovered by affinity chromatography (Veillard et al., 2015). 
 
 The investigations into Gingipains in Chapter 5 utilised qPCR to assess 
upregulation of mRNA of the PAR1 and PAR2 receptors, in order to determine if 
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Gingipains are activating the receptors and stimulating upregulation. In the 
literature there was evidence for activation of PAR2 receptors in neutrophils and 
oral epithelial cells (Lourbakos et al., 1998, Lourbakos et al., 2001) and this 
activation stimulating the release of interleukin-6 (Holzhausen et al., 2006, 
Lourbakos et al., 2001), however there was no evidence of upregulation mRNA 
levels. The reasoning behind the non-significant results may be due to the 
activation of the PAR2 receptor not upregulating the amount of receptor 
produced and/or that mRNA levels do not correlate to activation; this highlights 
the assay chosen as a potential limitation. In order to better investigate activation 
of PAR2 receptors it would beneficial to study the calcium signalling response to 
activation of PAR2 receptors, as has been completed in other studies 
investigating Gingipain based activation (Holzhausen et al., 2006, Lourbakos et 
al., 2001, Lourbakos et al., 1998). Another avenue to consider would be 
investigating the secretion of interleukin-6 using an enzyme-linked 
immunosorbent assay (ELISA) or cytometric bead array to see if secretion is 
comparable from kidney cells to neutrophils and oral epithelial cells.  
 
 A limitation of the qPCR conducted in Chapter 5 was that it was conducted on 
cDNA created from RNA extracted from HK-2 cells after a 24 h incubation with 
the microbial or control supernatants; this incubation may not be long enough to 
induce measurable changes in gene expression over time. In order to overcome 
this limitation it would be prudent to repeat the qPCR results on cDNA created 
from RNA extracted from HK-2 cells after a 48 h incubation with the microbial or 
control supernatants and compare these results to the 24 h results. This cDNA 
was generated alongside the 24 h cDNA but was not tested because of time 
constraints.  
 
 The qPCR experiments in Chapter 5 investigating a selection of fibrosis related 
markers highlighted upregulation of only TGF-β by P. gingivalis supernatants 
compared to both the control media and serum free media. Future work to 
elucidate this would be warranted as there is already evidence of P. gingivalis 
upregulation in a variety of other cell lines such as fibroblasts and monocytes 
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(Palm et al., 2015, Gemmell and Seymour, 1993) along with suggestions this may 
be mediated by the notch signalling pathway (Zhang et al., 2013). Investigating 
the notch signalling pathway could be useful to provide further understanding 
about how this may affect cell fate as there is reported crosstalk between TGF-B 
and notch signalling (Kluppel and Wrana, 2005). Two possible ways of studying 
notch signalling in cell culture is qPCR for the specific gene products or developing 
a luciferase reporter cell line as developed in Chapter 4 for the PAI-1 gene  
(Zacharioudaki and Bray, 2014). 
 
 As this study was an in vitro investigation, the results are hard to translate to the 
complexities of chronic disease interactions. Designing a cohort study looking at 
the subgingival microbiome of CKD patients in relation to their disease status and 
periodontal health, as has been ran for rheumatoid arthritis (Beyer et al., 2018), 
would be particularly useful. This would enable further identification of 
community specific populations within CKD using multiplex qPCR (Ciric et al., 
2010) along with being able to study the effects of the different staging of CKD 
on CP in parallel with concurrent diseases, which is impossible to do in in vitro 
investigations and particularly hard in non-specific cohorts.   
 
 Another avenue to investigate for future work is the generation of a vaccine 
based on outer membrane vesicles (OMVs) against P. gingivalis. As Gingipains 
have been identified as one of the primary virulence factors for P. gingivalis and 
suggested as the key causative agent behind its interactions with chronic disease, 
such as Alzheimer’s (Dominy et al., 2019), targeting Gingipains could be highly 
effective at attenuating toxic effects. Furthermore, there is evidence that OMVs 
from P. gingivalis can cause platelet aggregation, which could link to fibrosis 
along with evidence that vesicles can travel to distal sites and play a role in the 
secondary pathogenesis related to links with systemic disease (Sharma et al., 
2000). The development of an OMV vaccine is a possibility in the future as a 
vaccine against OMVs has already been successfully employed against Neisseria 
meningitides (van der Ley and van den Dobbelsteen, 2011). OMVs make excellent 
choices to target vaccines against, as they are heat stable, non-replicative and act 
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as storage contains for a variety of enzymes implicated in disease for various 
microorganisms (Cai et al., 2018). 
 
 In money was no barrier, it would be of great benefit to this new area of research 
to conduct a longitudinal matched cohort study of CKD patients. In this study, a 
large cohort of patients with various stages of chronic kidney disease and a 
matched control population would be tracked over a 5-10 year period. During 
this timeframe blood samples, subgingival plaque samples and urine samples 
would collected and stored alongside clinical data on various co-morbidities and 
other known risk factors for CKD progression. Within this study, a dentist would 
record dental status and periodontitis status in all patients and controls, to 
enable effective comparisons. With this large dataset and the availability of 
clinical samples, a large number of area specific parameters could be 
investigated. Metagenomics could be employed to look at the difference 
between the subgingival microbial community between patients and controls 
along with between different stages of CKD in relation to periodontal disease, 
both at a cross-sectional level and temporally over the 5-10 year timeframe. The 
blood and urine samples could be investigated to see if bacteraemia of 
periodontal microorganisms can be cultured and/or sequenced and if there is any 
correlations between any culture/sequence and severity of CKD and CP. 
Furthermore, LC-MS could be utilised to look at the blood, serum and urine 
metabolites between control and CKD patients to look for dysregulated 
metabolites or toxins of interest. An extension to this study could be an 
interventional study in which CKD patients with CP are treated for periodontitis 
and followed up with matched non-treated patients, over a 5-10 year timeframe. 
This would provide direct evidence on whether CP is a modifiable risk factor in 
CKD progression. All these experiments would provide further evidence on the 
interactions between CKD and CP and may provide vital insights between CP and 
other systemic diseases. 
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6.3 Conclusion 
In conclusion, this thesis describes in detail how two common chronic diseases, CKD 
and CP, can potentially interact with each other to the detriment of patients, 
addressing a gap in the knowledge. It also delivers a body of experimental evidence 
demonstrating that a key periodontitis associated pathogen has the ability to secrete 
products that can cause deleterious effects to kidney cells and induce the production 
of a selection of key pro-fibrotic factors: TGF-β, ColA1 and TIMP1. This evidence 
suggests that secreted microbial products could potentially be part of the mechanism 
of how these chronic diseases putatively interact. Furthermore, a novel microbial 
metabolomics pipeline was developed from scratch and optimised to successfully 
translate thousands of results to a select number of significant features responsible 
for differences between samples. While it was not able to be applied successfully to 
this project, it was successfully employed in a separate microbial study and has 
numerous potential uses in future studies. 
Based on content in this thesis, further investigations into the ways CKD and CP may 
interact are warranted especially as there is growing evidence both diseases can have 
a detrimental effect on the progression of each other. With the evidence presented 
in this thesis a short term proposal would be investigations into the fibrotic potential 
of periodontitis associated microorganisms along with utilising patient samples to 
look for evidence of periodontal pathogen infiltration into the blood and potentially 
urine of CKD patients. A long-term proposal would be utilising vigilance and 
treatment of CP within the CKD patient population as a novel treatment for slowing 
progression of the disease. 
  
References 
200 
 
REFERENCES 
  
References 
201 
 
2014. Bacterial Endotoxins/Pyrogens. In: DEPARTMENT OF HEALTH, E., AND WELFARE PUBLIC HEALTH 
SERVICE (ed.) 40 ed. 
ABE, M., HARPEL, J., METZ, C., NUNES, I., LOSKUTOFF, D. & RIFKIN, D. 1994. An assay for transforming 
growth factor-β using cells transfected with a plasminogen activator inhibitor-1 promoter-
luciferase construct. Anal. Biochem., 216, 276-284. 
ADDY, M. & HUNTER, M. L. 2003. Can tooth brushing damage your health? Effects on oral and dental 
tissues. Int. Dent. J., 53 Suppl 3, 177-86. 
ADEREM, A. & ULEVITCH, R. J. 2000. Toll-like receptors in the induction of the innate immune 
response. Nature, 406, 782. 
AHN, S. Y. & INGULLI, E. 2008. Acute poststreptococcal glomerulonephritis: an update. Curr. Opin. 
Pediatr., 20, 157-62. 
AIMETTI, M., CACCIATORE, S., GRAZIANO, A. & TENORI, L. 2012. Metabonomic analysis of saliva 
reveals generalized chronic periodontitis signature. Metabolomics, 8, 465-474. 
AITKEN, G. 2014. Analysis of estimates of CKD prevalence across England. In: ENGLAND, P. H. (ed.). 
AKAR, H., AKAR, G. C., CARRERO, J. J., STENVINKEL, P. & LINDHOLM, B. 2011. Systemic consequences 
of poor oral health in chronic kidney disease patients. Clin. J. Am. Soc. Nephrol., 6, 218-26. 
AKPAN, A. & MORGAN, R. 2002. Oral candidiasis. Postgrad. Med. J., 78, 455-459. 
AL-HEBSHI, N. N., SHUGA-ALDIN, H. M., AL-SHARABI, A. K. & GHANDOUR, I. 2014. Subgingival 
periodontal pathogens associated with chronic periodontitis in Yemenis. BMC Oral Health, 
14, 13-13. 
ALBANDAR, J. M. & KINGMAN, A. 1999. Gingival recession, gingival bleeding, and dental calculus in 
adults 30 years of age and older in the United States, 1988‐1994. J. Periodontol., 70, 30-43. 
ALKJAERSIG, N. K., FLETCHER, A. P., LEWIS, M. L., COLE, B. R., INGELFINGER, J. R. & ROBSON, A. M. 
1976. Pathophysiological response of the blood coagulation system in acute 
glomerulonephritis. Kidney Int., 10, 319-328. 
ALLWOOD, J. W., ELLIS, D. I. & GOODACRE, R. 2008. Metabolomic technologies and their application 
to the study of plants and plant–host interactions. Physiol. Plant., 132, 117-135. 
ALMROTH, G., LINDELL, Å., ÅSELIUS, H., SÖRÉN, L., SVENSSON, L., HULTMAN, P., ERIBE, E. R. K. & 
OLSEN, I. 2005. Acute Glomerulonephritis Associated with Streptococcus Pyogenes with 
Concomitant Spread of Streptococcus Constellatus in Four Rural Families. Ups. J. Med. Sci., 
110, 217-231. 
AMBROSIONI, J., HERNANDEZ-MENESES, M., TELLEZ, A., PERICAS, J., FALCES, C., TOLOSANA, J. M., 
VIDAL, B., ALMELA, M., QUINTANA, E. & LLOPIS, J. 2017. The changing epidemiology of 
infective endocarditis in the twenty-first century. Curr. Infect. Dis. Rep., 19, 21. 
AMORNCHAT, C., RASSAMEEMASMAUNG, S., SRIPAIROJTHIKOON, W. & SWASDISON, S. 2003. 
Invasion of Porphyromonas gingivalis into human gingival fibroblasts in vitro. J. Int. Acad. 
Periodontol., 5, 98-105. 
ANAND, N., S C, C. & ALAM, M. N. 2013. The malnutrition inflammation complex syndrome-the micsing 
factor in the perio-chronic kidney disease interlink. J. Clin. Diagn. Res., 7, 763-767. 
ANDRIAN, E., MOSTEFAOUI, Y., ROUABHIA, M. & GRENIER, D. 2007. Regulation of matrix 
metalloproteinases and tissue inhibitors of matrix metalloproteinases by Porphyromonas 
gingivalis in an engineered human oral mucosa model. J. Cell. Physiol., 211, 56-62. 
ANNES, J. P., MUNGER, J. S. & RIFKIN, D. B. 2003. Making sense of latent TGFβ activation. J. Cell Sci., 
116, 217-224. 
ARAÚJO, M. V. F., HONG, B.-Y., FAVA, P. L., KHAN, S., BURLESON, J. A., FARES, G., SAMSON, W., 
STRAUSBAUGH, L. D., DIAZ, P. I. & IOANNIDOU, E. 2015. End stage renal disease as a modifier 
of the periodontal microbiome. BMC Nephrol., 16, 80. 
ARIYAMUTHU, V. K., NOLPH, K. D. & RINGDAHL, B. E. 2013. Periodontal Disease in Chronic Kidney 
Disease and End-Stage Renal Disease Patients: A Review. Cardiorenal Med., 3, 71-78. 
ARORA, N., MISHRA, A. & CHUGH, S. 2014. Microbial role in periodontitis: Have we reached the top? 
Some unsung bacteria other than red complex. J. Indian Soc. Periodontol., 18, 9-13. 
ASAI, Y., HASHIMOTO, M., FLETCHER, H. M., MIYAKE, K., AKIRA, S. & OGAWA, T. 2005. 
Lipopolysaccharide preparation extracted from Porphyromonas gingivalis lipoprotein-
deficient mutant shows a marked decrease in toll-like receptor 2-mediated signaling. Infect. 
Immun., 73, 2157-2163. 
References 
202 
 
AVLUND, K., SCHULTZ-LARSEN, K., KRUSTRUP, U., CHRISTIANSEN, N. & HOLM-PEDERSEN, P. 2009. 
Effect of inflammation in the periodontium in early old age on mortality at 21-year follow-
up. J. Am. Geriatr. Soc., 57, 1206-12. 
BADDOUR, L. M., WILSON, W. R., BAYER, A. S., FOWLER, V. G., TLEYJEH, I. M., RYBAK, M. J., BARSIC, B., 
LOCKHART, P. B., GEWITZ, M. H. & LEVISON, M. E. 2015. Infective endocarditis in adults: 
diagnosis, antimicrobial therapy, and management of complications. Circulation, 132, 1435-
1486. 
BAINBRIDGE, B. W. & DARVEAU, R. P. 2001. Porphyromonas gingivalis lipopolysaccharide: an unusual 
pattern recognition receptor ligand for the innate host defense system. Acta Odontol. Scand., 
59, 131-138. 
BAKER, S. P., NULTON, T. J. & KITTEN, T. 2019. Genomic, phenotypic, and virulence analysis of 
Streptococcus sanguinis oral and infective-endocarditis isolates. Infect. Immun., 87, e00703-
18. 
BALLERMANN, B. J. & OBEIDAT, M. 2014. Tipping the balance from angiogenesis to fibrosis in CKD. 
Kidney Int. Suppl., 4, 45-52. 
BALLEZA, E., LÓPEZ-BOJORQUEZ, L. N., MARTÍNEZ-ANTONIO, A., RESENDIS-ANTONIO, O., LOZADA-
CHÁVEZ, I., BALDERAS-MARTÍNEZ, Y. I., ENCARNACIÓN, S. & COLLADO-VIDES, J. 2009. 
Regulation by transcription factors in bacteria: beyond description. FEMS Microbiol. Rev., 33, 
133-151. 
BARROS, S. P., WILLIAMS, R., OFFENBACHER, S. & MORELLI, T. 2016. Gingival crevicular fluid as a 
source of biomarkers for periodontitis. Periodontol. 2000, 70, 53-64. 
BASTOS, J. A., DINIZ, C. G., BASTOS, M. G., VILELA, E. M., SILVA, V. L., CHAOUBAH, A., SOUZA-COSTA, 
D. C. & ANDRADE, L. C. F. 2011. Identification of periodontal pathogens and severity of 
periodontitis in patients with and without chronic kidney disease. Arch. Oral Biol., 56, 804-
811. 
BAYER, A. S. & THEOFILOPOULOS, A. N. 1990. Immunopathogenetic aspects of infective endocarditis. 
Chest, 97, 204-12. 
BECK, J. D., MOSS, K. L., MORELLI, T. & OFFENBACHER, S. 2018. Periodontal profile class is associated 
with prevalent diabetes, coronary heart disease, stroke, and systemic markers of C-reactive 
protein and interleukin-6. J. Periodontol., 89, 157-165. 
BENGTSSON, T., KHALAF, A. & KHALAF, H. 2015. Secreted gingipains from Porphyromonas gingivalis 
colonies exert potent immunomodulatory effects on human gingival fibroblasts. Microbiol. 
Res., 178, 18-26. 
BEREZOW, A. B. & DARVEAU, R. P. 2011. Microbial shift and periodontitis. Periodontol. 2000, 55, 36-
47. 
BEYER, K., ZAURA, E., BRANDT, B. W., BUIJS, M. J., BRUN, J. G., CRIELAARD, W. & BOLSTAD, A. I. 2018. 
Subgingival microbiome of rheumatoid arthritis patients in relation to their disease status 
and periodontal health. PLoS One, 13, e0202278. 
BHARTI, V. & BANSAL, C. 2013. Drug-induced gingival overgrowth: The nemesis of gingiva unravelled. 
J. Indian Soc. Periodontol., 17, 182-7. 
BIELESZ, B., SIRIN, Y., SI, H., NIRANJAN, T., GRUENWALD, A., AHN, S., KATO, H., PULLMAN, J., GESSLER, 
M., HAASE, V. H. & SUSZTAK, K. 2010. Epithelial Notch signaling regulates interstitial fibrosis 
development in the kidneys of mice and humans. J. Clin. Invest., 120, 4040-54. 
BIENIAŚ, B. & SIKORA, P. 2018. Urinary metalloproteinases and tissue inhibitors of metalloproteinases 
as potential early biomarkers for renal fibrosis in children with nephrotic syndrome. 
Medicine, 97. 
BILLINGS, F. 1916. Focal infection, D. Appleton. 
BISWAS, S. K. & LOPEZ-COLLAZO, E. 2009. Endotoxin tolerance: new mechanisms, molecules and 
clinical significance. Trends Immunol., 30, 475-487. 
BOILS, C. L., NASR, S. H., WALKER, P. D., COUSER, W. G. & LARSEN, C. P. 2015. Update on endocarditis-
associated glomerulonephritis. Kidney Int., 87, 1241-1249. 
BOLSTAD, A. I., JENSEN, H. B. & BAKKEN, V. 1996. Taxonomy, biology, and periodontal aspects of 
Fusobacterium nucleatum. Clin. Microbiol. Rev., 9, 55. 
BORAWSKI, J., WILCZYŃSKA-BORAWSKA, M., STOKOWSKA, W. & MYŚLIWIEC, M. 2006. The 
periodontal status of pre-dialysis chronic kidney disease and maintenance dialysis patients. 
Nephrol. Dial. Transplant., 22, 457-464. 
References 
203 
 
BOSSHARDT, D. D. 2017. The periodontal pocket: pathogenesis, histopathology and consequences. 
Periodontol. 2000. 
BOTS, C. P., POORTERMAN, J. H., BRAND, H. S., KALSBEEK, H., VAN AMERONGEN, B. M., VEERMAN, E. 
C. & NIEUW AMERONGEN, A. V. 2006. The oral health status of dentate patients with chronic 
renal failure undergoing dialysis therapy. Oral Dis., 12, 176-80. 
BRADLEY, P. H., BRAUER, M. J., RABINOWITZ, J. D. & TROYANSKAYA, O. G. 2009. Coordinated 
Concentration Changes of Transcripts and Metabolites in Saccharomyces cerevisiae. PLoS 
Comput. Biol., 5, e1000270. 
BRESTOFF, J. R. & ARTIS, D. 2013. Commensal bacteria at the interface of host metabolism and the 
immune system. Nat. Immunol., 14, 676-684. 
BROCHU, V., GRENIER, D., NAKAYAMA, K. & MAYRAND, D. 2001. Acquisition of iron from human 
transferrin by Porphyromonas gingivalis: a role for Arg- and Lys-gingipain activities. Oral 
Microbiol. Immunol., 16, 79-87. 
BRODSKY, S. V. & NADASDY, T. 2017. Acute Poststreptococcal Glomerulonephritis. In: SATOSKAR, A. 
A. & NADASDY, T. (eds.) Bacterial Infections and the Kidney. Cham: Springer International 
Publishing. 
BROWN, R. S. & ARANY, P. R. 2015. Mechanism of drug-induced gingival overgrowth revisited: a 
unifying hypothesis. Oral Dis., 21, e51-61. 
BRUNNER, D., FRANK, J., APPL, H., SCHÖFFL, H., PFALLER, W. & GSTRAUNTHALER, G. 2010. The serum-
free media interactive online database. ALTEX, 27, 53-62. 
BYRNE, S. J., DASHPER, S. G., DARBY, I. B., ADAMS, G. G., HOFFMANN, B. & REYNOLDS, E. C. 2009. 
Progression of chronic periodontitis can be predicted by the levels of Porphyromonas 
gingivalis and Treponema denticola in subgingival plaque. Oral Microbiol. Immunol., 24, 469-
77. 
CABELL, C. H., ABRUTYN, E. & KARCHMER, A. W. 2003. Bacterial endocarditis. Circulation, 107, e185-
e187. 
CAI, W., KESAVAN, D. K., WAN, J., ABDELAZIZ, M. H., SU, Z. & XU, H. 2018. Bacterial outer membrane 
vesicles, a potential vaccine candidate in interactions with host cells based. Diagn. Pathol., 
13, 95-95. 
CARAPETIS, J. R., STEER, A. C., MULHOLLAND, E. K. & WEBER, M. 2005. The global burden of group A 
streptococcal diseases. Lancet Infect. Dis., 5, 685-694. 
CARMONA, I. T., DIOS, P. D. & SCULLY, C. 2002. An update on the controversies in bacterial 
endocarditis of oral origin. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod., 93, 660-670. 
CASPI, R., ALTMAN, T., BILLINGTON, R., DREHER, K., FOERSTER, H., FULCHER, C. A., HOLLAND, T. A., 
KESELER, I. M., KOTHARI, A. & KUBO, A. 2013. The MetaCyc database of metabolic pathways 
and enzymes and the BioCyc collection of Pathway/Genome Databases. Nucleic Acids Res., 
42, D459-D471. 
CASTILLO, A., MESA, F., LIEBANA, J., GARCIA-MARTINEZ, O., RUIZ, S., GARCIA-VALDECASAS, J. & 
O'VALLE, F. 2007. Periodontal and oral microbiological status of an adult population 
undergoing haemodialysis: a cross-sectional study. Oral Dis., 13, 198-205. 
CHAMBERS, M. C., MACLEAN, B., BURKE, R., AMODEI, D., RUDERMAN, D. L., NEUMANN, S., GATTO, L., 
FISCHER, B., PRATT, B., EGERTSON, J., HOFF, K., KESSNER, D., TASMAN, N., SHULMAN, N., 
FREWEN, B., BAKER, T. A., BRUSNIAK, M.-Y., PAULSE, C., CREASY, D., FLASHNER, L., KANI, K., 
MOULDING, C., SEYMOUR, S. L., NUWAYSIR, L. M., LEFEBVRE, B., KUHLMANN, F., ROARK, J., 
RAINER, P., DETLEV, S., HEMENWAY, T., HUHMER, A., LANGRIDGE, J., CONNOLLY, B., 
CHADICK, T., HOLLY, K., ECKELS, J., DEUTSCH, E. W., MORITZ, R. L., KATZ, J. E., AGUS, D. B., 
MACCOSS, M., TABB, D. L. & MALLICK, P. 2012. A cross-platform toolkit for mass 
spectrometry and proteomics. Nat. Biotechnol., 30, 918. 
CHAMBRONE, L., FOZ, A. M., GUGLIELMETTI, M. R., PANNUTI, C. M., ARTESE, H. P. C., FERES, M. & 
ROMITO, G. A. 2013. Periodontitis and chronic kidney disease: a systematic review of the 
association of diseases and the effect of periodontal treatment on estimated glomerular 
filtration rate. J. Clin. Periodontol., 40, 443-456. 
CHAVES DE SOUZA, J. A., FRASNELLI, S. C., CURYLOFO-ZOTTI, F. A., AVILA-CAMPOS, M. J., SPOLIDORIO, 
L. C., ZAMBONI, D. S., GRAVES, D. T. & ROSSA, C., JR. 2016. NOD1 in the modulation of host-
microbe interactions and inflammatory bone resorption in the periodontal disease model. 
Immunology, 149, 374-385. 
References 
204 
 
CHEN, C., HEMME, C., BELENO, J., SHI, Z. J., NING, D., QIN, Y., TU, Q., JORGENSEN, M., HE, Z. & WU, L. 
2018. Oral microbiota of periodontal health and disease and their changes after nonsurgical 
periodontal therapy. ISME J., 12, 1210. 
CHEN, L.-P., CHIANG, C.-K., CHAN, C.-P., HUNG, K.-Y. & HUANG, C.-S. 2006. Does periodontitis reflect 
inflammation and malnutrition status in hemodialysis patients? Am. J. Kidney Dis., 47, 815-
822. 
CHEN, L. P., CHIANG, C. K., PENG, Y. S., HSU, S. P., LIN, C. Y., LAI, C. F. & HUNG, K. Y. 2011. Relationship 
between periodontal disease and mortality in patients treated with maintenance 
hemodialysis. Am. J. Kidney Dis., 57, 276-82. 
CHEN, Z., CASIANO, C. A. & FLETCHER, H. M. 2001. Protease‐active extracellular protein preparations 
from Porphyromonas gingivalis W83 induce N‐cadherin proteolysis, loss of cell adhesion, and 
apoptosis in human epithelial cells. J. Periodontol., 72, 641-650. 
CHO, I. & BLASER, M. J. 2012. The human microbiome: at the interface of health and disease. Nat. Rev. 
Genet., 13, 260. 
CHOW, A., QUAH, S., BERGENHOLTZ, G., LIM, K., YU, V. & TAN, K. 2019. Bacterial species associated 
with persistent apical periodontitis exert differential effects on osteogenic differentiation. 
Int. Endod. J., 52, 201-210. 
CIRIC, L., PRATTEN, J., WILSON, M. & SPRATT, D. 2010. Development of a novel multi‐triplex qPCR 
method for the assessment of bacterial community structure in oral populations. Environ. 
Microbiol. Rep., 2, 770-774. 
CLARKE, T. B., DAVIS, K. M., LYSENKO, E. S., ZHOU, A. Y., YU, Y. & WEISER, J. N. 2010. Recognition of 
peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. Nat. Med., 
16, 228-231. 
COHEN, G. & HÖRL, W. H. 2012. Immune dysfunction in uremia—an update. Toxins (Basel), 4, 962-
990. 
COLOMBO, A., HAFFAJEE, A., DEWHIRST, F., PASTER, B., SMITH, C., CUGINI, M. & SOCRANSKY, S. 1998. 
Clinical and microbiological features of refractory periodontitis subjects. J. Clin. Periodontol., 
25, 169-180. 
CORESH, J. 2017. Update on the Burden of CKD. J. Am. Soc. Nephrol., 28, 1020-1022. 
COUGHLIN, S. R. & CAMERER, E. 2003. PARticipation in inflammation. Clin. Investig. (Lond.), 111, 25-
27. 
COUSER, W. G., REMUZZI, G., MENDIS, S. & TONELLI, M. 2011. The contribution of chronic kidney 
disease to the global burden of major noncommunicable diseases. Kidney Int., 80, 1258-1270. 
COYKENDALL, A. L. 1989. Classification and identification of the viridans streptococci. Clin. Microbiol. 
Rev., 2, 315-328. 
CRAIG, R. G. 2008. Interactions between chronic renal disease and periodontal disease. Oral Dis., 14, 
1-7. 
CRONIN, W., DEOL, H., AZADEGAN, A. & LANGE, K. 1989. Endostreptosin: isolation of the probable 
immunogen of acute post-streptococcal glomerulonephritis (PSGN). Clin. Exp. Immunol., 76, 
198-203. 
CUI, Q., LEWIS, I. A., HEGEMAN, A. D., ANDERSON, M. E., LI, J., SCHULTE, C. F., WESTLER, W. M., 
EGHBALNIA, H. R., SUSSMAN, M. R. & MARKLEY, J. L. 2008. Metabolite identification via the 
madison metabolomics consortium database. Nat. Biotechnol., 26, 162. 
DA SILVA, R. M., CAUGANT, D. A., JOSEFSEN, R., TRONSTAD, L. & OLSEN, I. 2004. Characterization of 
Streptococcus constellatus strains recovered from a brain abscess and periodontal pockets in 
an immunocompromised patient. J. Periodontol., 75, 1720-1723. 
DALWAI, F., SPRATT, D. & PRATTEN, J. 2006. Modeling shifts in microbial populations associated with 
health or disease. Appl. Environ. Microbiol., 72, 3678-3684. 
DARVEAU, R. P. 2010. Periodontitis: a polymicrobial disruption of host homeostasis. Nat. Rev. 
Microbiol., 8, 481-90. 
DASHPER, S. G., SEERS, C. A., TAN, K. H. & REYNOLDS, E. C. 2011. Virulence factors of the oral 
spirochete Treponema denticola. J. Dent. Res., 90, 691-703. 
DAVRANDI, M., PATTEM, J., BOZEC, L., ALLAN, E. & SPRATT, D. 2017. Development of a Reproducible 
Model for Dental Plaque. IADR 2017. San Francisco, Calif., US. 
DE LA ROSA GARCIA, E., MONDRAGON PADILLA, A., ARANDA ROMO, S. & BUSTAMANTE RAMIREZ, M. 
A. 2006. Oral mucosa symptoms, signs and lesions, in end stage renal disease and non-end 
stage renal disease diabetic patients. Med. Oral Patol. Oral Cir. Bucal., 11, E467-73. 
References 
205 
 
DE ROSSI, S. S. & GLICK, M. 1996. Dental considerations for the patient with renal disease receiving 
hemodialysis. J. Am. Dent. Assoc., 127, 211-9. 
DESHPANDE, R. G., KHAN, M. B. & GENCO, C. A. 1998. Invasion of aortic and heart endothelial cells by 
Porphyromonas gingivalis. Infect. Immun., 66, 5337-43. 
DESTA, T. & GRAVES, D. T. 2007. Fibroblast apoptosis induced by Porphyromonas gingivalis is 
stimulated by a gingipain and caspase‐independent pathway that involves apoptosis‐
inducing factor. Cell. Microbiol., 9, 2667-2675. 
DEWHIRST, F. E., CHEN, T., IZARD, J., PASTER, B. J., TANNER, A. C. R., YU, W.-H., LAKSHMANAN, A. & 
WADE, W. G. 2010. The human oral microbiome. J. Bacteriol., 192, 5002-5017. 
DHONDUP, T. & QIAN, Q. 2017. Electrolyte and Acid-Base Disorders in Chronic Kidney Disease and 
End-Stage Kidney Failure. Blood Purif., 43, 179-188. 
DIETRICH, T., JIMENEZ, M., KRALL KAYE, E. A., VOKONAS, P. S. & GARCIA, R. I. 2008. Age-Dependent 
Associations Between Chronic Periodontitis/Edentulism and Risk of Coronary Heart Disease. 
Circulation, 117, 1668. 
DOI, K., NOIRI, E. & FUJITA, T. 2010. Role of vascular endothelial growth factor in kidney disease. Curr. 
Vasc. Pharmacol., 8, 122-8. 
DOMINY, S. S., LYNCH, C., ERMINI, F., BENEDYK, M., MARCZYK, A., KONRADI, A., NGUYEN, M., 
HADITSCH, U., RAHA, D. & GRIFFIN, C. 2019. Porphyromonas gingivalis in Alzheimer’s disease 
brains: Evidence for disease causation and treatment with small-molecule inhibitors. Science 
advances, 5, eaau3333. 
DOMMISCH, H., CHUNG, W. O., ROHANI, M. G., WILLIAMS, D., RANGARAJAN, M., CURTIS, M. A. & 
DALE, B. A. 2007. Protease-activated receptor 2 mediates human beta-defensin 2 and CC 
chemokine ligand 20 mRNA expression in response to proteases secreted by Porphyromonas 
gingivalis. Infect. Immun., 75, 4326-4333. 
DOMON, H., TABETA, K., NAKAJIMA, T. & YAMAZAKI, K. 2014. Age-related alterations in gene 
expression of gingival fibroblasts stimulated with Porphyromonas gingivalis. J. Periodontal 
Res., 49, 536-43. 
DORN, B. R., BURKS, J. N., SEIFERT, K. N. & PROGULSKE-FOX, A. 2000. Invasion of endothelial and 
epithelial cells by strains of Porphyromonas gingivalis. FEMS Microbiol. Lett., 187, 139-44. 
DORN, B. R., DUNN, W. A. & PROGULSKE-FOX, A. 1999. Invasion of human coronary artery cells by 
periodontal pathogens. Infect. Immun., 67, 5792-5798. 
DUNCAN, M., NAKAO, S., SKOBE, Z. & XIE, H. 1993. Interactions of Porphyromonas gingivalis with 
epithelial cells. Infect. Immun., 61, 2260-2265. 
DUNN, W. B., BROADHURST, D. I., ATHERTON, H. J., GOODACRE, R. & GRIFFIN, J. L. 2011. Systems level 
studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic 
resonance spectroscopy. Chem. Soc. Rev., 40, 387-426. 
DUNN, W. B., ERBAN, A., WEBER, R. J. M., CREEK, D. J., BROWN, M., BREITLING, R., HANKEMEIER, T., 
GOODACRE, R., NEUMANN, S., KOPKA, J. & VIANT, M. R. 2013. Mass appeal: metabolite 
identification in mass spectrometry-focused untargeted metabolomics. Metabolomics, 9, 44-
66. 
DYCK, R. F., HAYWARD, M. N. & HARRIS, S. B. 2012. Prevalence, determinants and co-morbidities of 
chronic kidney disease among First Nations adults with diabetes: results from the CIRCLE 
study. BMC Nephrol., 13, 57. 
DYE, B. A., CHOUDHARY, K., SHEA, S. & PAPAPANOU, P. N. 2005. Serum antibodies to periodontal 
pathogens and markers of systemic inflammation. J. Clin. Periodontol., 32, 1189-99. 
EARLE, D. P. 1985. Poststreptococcal acute glomerulonephritis. Hosp. Pract., 20, 84E-84BB. 
EBERSOLE, J. & STEFFEN, M. 1995. Human antibody responses to outer envelope antigens of 
Porphyromonas gingivalis serotypes. J. Periodontal Res., 30, 1-14. 
EDDY, A. A. & FOGO, A. B. 2006. Plasminogen activator inhibitor-1 in chronic kidney disease: evidence 
and mechanisms of action. J. Am. Soc. Nephrol., 17, 2999-3012. 
EDGAR, W. M., O'MULLANE, D. M. & DAWES, C. 2004. Saliva and oral health, British Dental Association 
London. 
EFSTRATIADIS, G., DIVANI, M., KATSIOULIS, E. & VERGOULAS, G. 2009. Renal fibrosis. Hippokratia, 13, 
224. 
ENERSEN, M., NAKANO, K. & AMANO, A. 2013. Porphyromonas gingivalis fimbriae. J. Oral Microbiol., 
5, 20265. 
References 
206 
 
ENGEBRETSON, S. P., HYMAN, L. G., MICHALOWICZ, B. S. & ET AL. 2013. The effect of nonsurgical 
periodontal therapy on hemoglobin a1c levels in persons with type 2 diabetes and chronic 
periodontitis: A randomized clinical trial. JAMA, 310, 2523-2532. 
ENGEVIK, M. A. & VERSALOVIC, J. 2017. Biochemical features of beneficial microbes: foundations for 
therapeutic microbiology. Microbiol. Spectr., 5. 
EPSTEIN, S. R., MANDEL, I. & SCOPP, I. W. 1980. Salivary composition and calculus formation in 
patients undergoing hemodialysis. J. Periodontol., 51, 336-8. 
EVERETT, E. D. & HIRSCHMANN, J. V. 1977. Transient bacteremia and endocarditis prophylaxis. A 
review. Medicine, 56, 61-77. 
FAHY, E., SUBRAMANIAM, S., MURPHY, R. C., NISHIJIMA, M., RAETZ, C. R. H., SHIMIZU, T., SPENER, F., 
VAN MEER, G., WAKELAM, M. J. O. & DENNIS, E. A. 2009. Update of the LIPID MAPS 
comprehensive classification system for lipids. J. Lipid Res., 50, S9-S14. 
FENNO, J. C. 2006. Laboratory maintenance of Treponema denticola. Curr. Protoc. Microbiol., 12B. 1.1-
12B. 1.21. 
FERGUSON, D. B. 2006. Oral Bioscience, Authors Online Limited. 
FERNANDEZ Y MOSTAJO, M., EXTERKATE, R., BUIJS, M., BEERTSEN, W., VAN DER WEIJDEN, G., ZAURA, 
E. & CRIELAARD, W. 2017. A reproducible microcosm biofilm model of subgingival microbial 
communities. J. Periodontal Res., 52, 1021-1031. 
FERRETTI, J. J. & WARD, M. 1976. Susceptibility of Streptococcus mutans to antimicrobial agents. 
Antimicrob. Agents Chemother., 10, 274-276. 
FINN, W. F. 1977. Renal response to environmental toxics. Environ. Health Perspect., 20, 15. 
FISHER, M. A., BORGNAKKE, W. S. & TAYLOR, G. W. 2010. Periodontal disease as a risk marker in 
coronary heart disease and chronic kidney disease. Curr. Opin. Nephrol. Hypertens., 19, 519-
526. 
FISHER, M. A., TAYLOR, G. W., PAPAPANOU, P. N., RAHMAN, M. & DEBANNE, S. M. 2008. Clinical and 
serologic markers of periodontal infection and chronic kidney disease. J. Periodontol., 79, 
1670-8. 
FISHER, M. A., TAYLOR, G. W., WEST, B. T. & MCCARTHY, E. T. 2011. Bidirectional relationship between 
chronic kidney and periodontal disease: a study using structural equation modeling. Kidney 
Int., 79, 347-55. 
FITZSIMMONS, T. R., GE, S. & BARTOLD, P. M. 2018. Compromised inflammatory cytokine response to 
Porphyromonas gingivalis LPS by fibroblasts from inflamed human gingiva. Clin. Oral 
Investig., 22, 919-927. 
FLEETWOOD, A. J., O'BRIEN-SIMPSON, N. M., VEITH, P. D., LAM, R. S., ACHUTHAN, A., COOK, A. D., 
SINGLETON, W., LUND, I. K., REYNOLDS, E. C. & HAMILTON, J. A. 2015. Porphyromonas 
gingivalis-derived RgpA-Kgp Complex Activates the Macrophage Urokinase Plasminogen 
Activator System. J. Biol. Chem., 290, 16031-16042. 
FLEMMIG, T. F. 1999. Periodontitis. Ann. Periodontol., 4, 32-8. 
FLOEGE, J., EITNER, F. & ALPERS, C. E. 2008. A new look at platelet-derived growth factor in renal 
disease. J. Am. Soc. Nephrol., 19, 12-23. 
FOTOS, P. G., LEWIS, D. M., GERENCSER, V. F. & GERENCSER, M. A. 1990. Cytotoxic and 
immunostimulatory effects of Bacteroides cell products. J. Oral Pathol. Med., 19, 360-366. 
FRENCKEN, J. E., SHARMA, P., STENHOUSE, L., GREEN, D., LAVERTY, D. & DIETRICH, T. 2017. Global 
epidemiology of dental caries and severe periodontitis–a comprehensive review. Journal of 
clinical periodontology, 44, S94-S105. 
FRISCH, S. M. & FRANCIS, H. 1994. Disruption of epithelial cell-matrix interactions induces apoptosis. 
Int. J. Cell Biol., 124, 619-626. 
FUKUI, K., KATO, N., KATO, H., WATANABE, K. & TATEMATSU, N. 1999. Incidence of Prevotella 
intermedia and Prevotella nigrescens Carriage among Family Members with Subclinical 
Periodontal Disease. J. Clin. Microbiol., 37, 3141-3145. 
FURUTA, N., TAKEUCHI, H. & AMANO, A. 2009. Entry of Porphyromonas gingivalis outer membrane 
vesicles into epithelial cells causes cellular functional impairment. Infect. Immun., 77, 4761-
4770. 
GAWRON, K., WOJTOWICZ, W., ŁAZARZ-BARTYZEL, K., ŁAMASZ, A., QASEM, B., MYDEL, P., 
CHOMYSZYN-GAJEWSKA, M., POTEMPA, J. & MLYNARZ, P. 2019. Metabolomic Status of The 
Oral Cavity in Chronic Periodontitis. In Vivo, 33, 1165-1174. 
References 
207 
 
GEMMELL, E. & SEYMOUR, G. 1993. Interleukin 1, interleukin 6 and transforming growth factor‐β 
production by human gingival mononuclear cells following stimulation with Porphyromonas 
gingivalis and Fusobacterium nucleatum. J. Periodontal Res., 28, 122-129. 
GENDRON, R., GRENIER, D. & MAHEU-ROBERT, L.-F. 2000. The oral cavity as a reservoir of bacterial 
pathogens for focal infections. Microb. Infect., 2, 897-906. 
GERMAN, R. Z. & PALMER, J. B. 2006. Anatomy and development of oral cavity and pharynx. GI Mot. 
On. 
GEVREKCI, A. O. 2017. The roles of polyamines in microorganisms. World J. Microbiol. Biotechnol., 33, 
204. 
GHOSH, A. K. & VAUGHAN, D. E. 2012. PAI‐1 in tissue fibrosis. J. Cell. Physiol., 227, 493-507. 
GIBBONS, R. J. 1989. Bacterial adhesion to oral tissues: a model for infectious diseases. J. Dent. Res., 
68, 750-760. 
GOEK, O. N., PREHN, C., SEKULA, P., ROMISCH-MARGL, W., DORING, A., GIEGER, C., HEIER, M., KOENIG, 
W., WANG-SATTLER, R., ILLIG, T., SUHRE, K., ADAMSKI, J., KOTTGEN, A. & MEISINGER, C. 2013. 
Metabolites associate with kidney function decline and incident chronic kidney disease in the 
general population. Nephrol. Dial. Transplant., 28, 2131-8. 
GOLDENBERG, D. & KOCH, W. M. 2009. Surgical Treatment of Early Oral Cavity and Oropharyngeal 
Cancers. Early Diagnosis and Treatment of Cancer Series: Head and Neck Cancers. Elsevier 
Inc. 
GOLUB, L. M., BORDEN, S. M. & KLEINBERG, I. 1971. Urea content of gingival crevicular fluid and its 
relation to periodonal disease in humans. J. Periodontal Res., 6, 243-251. 
GÓMEZ, H. & KELLUM, J. A. 2016. Sepsis-induced acute kidney injury. Curr. Opin. Crit. Care, 22, 546-
553. 
GOWDA, H., IVANISEVIC, J., JOHNSON, C. H., KURCZY, M. E., BENTON, H. P., RINEHART, D., NGUYEN, 
T., RAY, J., KUEHL, J., AREVALO, B., WESTENSKOW, P. D., WANG, J., ARKIN, A. P., 
DEUTSCHBAUER, A. M., PATTI, G. J. & SIUZDAK, G. 2014. Interactive XCMS Online: Simplifying 
Advanced Metabolomic Data Processing and Subsequent Statistical Analyses. Anal. Chem., 
86, 6931-6939. 
GRENIER, D., MAYRAND, D. & MCBRIDE, B. C. 1989. Further studies on the degradation of 
immunoglobulins by black‐pigmented Bacteroides. Oral Microbiol. Immunol., 4, 12-18. 
GRUBBS, V., PLANTINGA, L. C., TUOT, D. S. & POWE, N. R. 2012. Chronic kidney disease and use of 
dental services in a United States public healthcare system: a retrospective cohort study. 
BMC Nephrol., 13, 16. 
GUALTERO, D. F., LAFAURIE, G. I. & FONTANILLA, M. R. 2018. Two-dimensional and three-dimensional 
models for studying atherosclerosis pathogenesis induced by periodontopathogenic 
microorganisms. Mol. Oral Microbiol., 33, 29-37. 
GUAN, S. M., SHU, L., FU, S. M., LIU, B., XU, X. L. & WU, J. Z. 2008. Prevotella intermedia induces matrix 
metalloproteinase-9 expression in human periodontal ligament cells. FEMS Microbiol. Lett., 
283, 47-53. 
GUO, A. C., JEWISON, T., WILSON, M., LIU, Y., KNOX, C., DJOUMBOU, Y., LO, P., MANDAL, R., 
KRISHNAMURTHY, R. & WISHART, D. S. 2012. ECMDB: the E. coli Metabolome Database. 
Nucleic Acids Res., 41, D625-D630. 
GUTHMILLER, J. M. & NOVAK, K. F. 2002. Periodontal diseases. Polymicrobial diseases. American 
Society of Microbiology. 
HAAG-WEBER, M. & HORL, W. H. 1996. Dysfunction of polymorphonuclear leukocytes in uremia. 
Semin. Nephrol., 16, 192-201. 
HAFFAJEE, A. D., TELES, R. P. & SOCRANSKY, S. S. 2006. Association of Eubacterium nodatum and 
Treponema denticola with human periodontitis lesions. Oral Microbiol. Immunol., 21, 269-
282. 
HAJISHENGALLIS, G. 2009. Porphyromonas gingivalis-host interactions: open war or intelligent guerilla 
tactics? Microbes Infect, 11, 637-45. 
HAJISHENGALLIS, G. 2015. Periodontitis: from microbial immune subversion to systemic 
inflammation. Nat. Rev. Immunol., 15, 30-44. 
HAJISHENGALLIS, G. & LAMONT, R. J. 2012. Beyond the red complex and into more complexity: the 
polymicrobial synergy and dysbiosis (PSD) model of periodontal disease etiology. Mol. Oral 
Microbiol., 27, 409-19. 
References 
208 
 
HAJISHENGALLIS, G., SOJAR, H., GENCO, R. J. & DENARDIN, E. 2004. Intracellular signaling and cytokine 
induction upon interactions of Porphyromonas gingivalis fimbriae with pattern-recognition 
receptors. Immunol. Invest., 33, 157-72. 
HAMER, R. A. & EL NAHAS, A. M. 2006. The burden of chronic kidney disease: is rising rapidly 
worldwide. BMJ, 332, 563. 
HAN, Y. W., REDLINE, R. W., LI, M., YIN, L., HILL, G. B. & MCCORMICK, T. S. 2004. Fusobacterium 
nucleatum induces premature and term stillbirths in pregnant mice: implication of oral 
bacteria in preterm birth. Infect. Immun., 72, 2272-2279. 
HASEGAWA, S., JAO, T.-M. & INAGI, R. 2017. Dietary Metabolites and Chronic Kidney Disease. 
Nutrients, 9, 358. 
HAURAT, M. F., ADUSE-OPOKU, J., RANGARAJAN, M., DOROBANTU, L., GRAY, M. R., CURTIS, M. A. & 
FELDMAN, M. F. 2011. Selective sorting of cargo proteins into bacterial membrane vesicles. 
J. Biol. Chem., 286, 1269-1276. 
HEIDARI, E., BANERJEE, A. & NEWTON, J. T. 2015. Oral health status of non-phobic and dentally phobic 
individuals; a secondary analysis of the 2009 Adult Dental Health Survey. Br. Dent. J., 219, E9. 
HEMMELGARN, B. R., MANNS, B. J., LLOYD, A., JAMES, M. T., KLARENBACH, S., QUINN, R. R., WIEBE, 
N., TONELLI, M. & ALBERTA KIDNEY DISEASE, N. 2010. Relation between kidney function, 
proteinuria, and adverse outcomes. JAMA, 303, 423-429. 
HENDERSON, B., WARD, J. M. & READY, D. 2010. Aggregatibacter (Actinobacillus) 
actinomycetemcomitans: a triple A* periodontopathogen? Periodontol. 2000, 54, 78-105. 
HENDRICKSON, E. L., BECK, D. A. C., MILLER, D. P., WANG, Q., WHITELEY, M., LAMONT, R. J. & HACKETT, 
M. 2017. Insights into Dynamic Polymicrobial Synergy Revealed by Time-Coursed RNA-Seq. 
Front. Microbiol., 8, 261. 
HERATH, T. D., WANG, Y., SENEVIRATNE, C. J., DARVEAU, R. P., WANG, C.-Y. & JIN, L. 2013. The 
expression and regulation of matrix metalloproteinase-3 is critically modulated by 
Porphyromonas gingivalis lipopolysaccharide with heterogeneous lipid A structures in human 
gingival fibroblasts. BMC Microbiol., 13, 73. 
HEWITSON, T. D. Fibrosis in the kidney: is a problem shared a problem halved?  Fibrogenesis & tissue 
repair, 2012. BioMed Central, S14. 
HICKEY, N. A., WHITEHEAD, K. A., SHALAMANOVA, L., BUTLER, J. A. & TAYLOR, R. L. 2019. A novel 
microbiological medium for the growth of periodontitis associated pathogens. J. Microbiol. 
Methods, 105647. 
HOLLAND, S. P., MATHIAS, R. G., MORCK, D. W., CHIU, J. & SLADE, S. G. 2000. Diffuse lamellar keratitis 
related to endotoxins released from sterilizer reservoir biofilms. J. Ophthalmol., 107, 1227-
1233. 
HOLZHAUSEN, M., SPOLIDORIO, L. C., ELLEN, R. P., JOBIN, M.-C., STEINHOFF, M., ANDRADE-GORDON, 
P. & VERGNOLLE, N. 2006. Protease-activated receptor-2 activation: a major role in the 
pathogenesis of Porphyromonas gingivalis infection. Am. J. Pathol., 168, 1189-1199. 
HONARMAND, M., FARHAD-MOLLASHAHI, L., NAKHAEE, A. & SARGOLZAIE, F. 2017. Oral manifestation 
and salivary changes in renal patients undergoing hemodialysis. J Clin Exp Dent, 9, e207-e210. 
HOY, W. E., HUGHSON, M. D., BERTRAM, J. F., DOUGLAS-DENTON, R. & AMANN, K. 2005. Nephron 
number, hypertension, renal disease, and renal failure. J. Am. Soc. Nephrol., 16, 2557-2564. 
HRUSKA, K. A., MATHEW, S., LUND, R., QIU, P. & PRATT, R. 2008. Hyperphosphatemia of chronic kidney 
disease. Kidney Int., 74, 148-157. 
HU, B. & PHAN, S. H. 2016. Notch in fibrosis and as a target of anti-fibrotic therapy. Pharmacol. Res., 
108, 57-64. 
HUANG, W., BREWER, L. K., JONES, J. W., NGUYEN, A. T., MARCU, A., WISHART, D. S., OGLESBY-
SHERROUSE, A. G., KANE, M. A. & WILKS, A. 2017. PAMDB: a comprehensive Pseudomonas 
aeruginosa metabolome database. Nucleic Acids Res., 46, D575-D580. 
IGARASHI, K., UEDA, S., YOSHIDA, K. & KASHIWAGI, K. 2006. Polyamines in renal failure. Amino Acids, 
31, 477-483. 
IMAMURA, T. 2003. The role of gingipains in the pathogenesis of periodontal disease. J. Periodontol., 
74, 111-118. 
INKER, L. A., ASTOR, B. C., FOX, C. H., ISAKOVA, T., LASH, J. P., PERALTA, C. A., KURELLA TAMURA, M. 
& FELDMAN, H. I. KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for 
the Evaluation and Management of CKD. AJKD, 63, 713-735. 
References 
209 
 
INKER, L. A. & LEVEY, A. S. 2014. 53 - Staging and Management of Chronic Kidney Disease. In: GILBERT, 
S. J. & WEINER, D. E. (eds.) National Kidney Foundation Primer on Kidney Diseases (Sixth 
Edition). Philadelphia: W.B. Saunders. 
ISHIKAWA, M., YOSHIDA, K., OKAMURA, H., OCHIAI, K., TAKAMURA, H., FUJIWARA, N. & OZAKI, K. 
2013. Oral Porphyromonas gingivalis translocates to the liver and regulates hepatic glycogen 
synthesis through the Akt/GSK-3β signaling pathway. Biochim. Biophys. Acta, 1832, 2035-
2043. 
ISMAIL, F. B., ISMAIL, G., DUMITRIU, A. S., BASTON, C., BERBECAR, V., JURUBITA, R., ANDRONESI, A., 
DUMITRIU, H. T. & SINESCU, I. 2015. Identification of subgingival periodontal pathogens and 
association with the severity of periodontitis in patients with chronic kidney diseases: a cross-
sectional study. Biomed Res. Int., 2015, 370314. 
IWASAKI, M., TAYLOR, G. W., MANZ, M. C., KANEKO, N., IMAI, S., YOSHIHARA, A. & MIYAZAKI, H. 2012. 
Serum antibody to Porphyromonas gingivalis in chronic kidney disease. J. Dent. Res., 91, 828-
33. 
JACK, R. W. & TAGG, J. R. 1992. Factors affecting production of the group A streptococcus bacteriocin 
SA-FF22. J. Med. Microbiol., 36, 132-138. 
JAIN, S. & DARVEAU, R. P. 2010. Contribution of Porphyromonas gingivalis lipopolysaccharide to 
periodontitis. Periodontol. 2000, 54, 53-70. 
JAMES, M. T., HEMMELGARN, B. R. & TONELLI, M. 2010. Early recognition and prevention of chronic 
kidney disease. The Lancet, 375, 1296-1309. 
JAMESON, J. L. & LOSCALZO, J. 2016. Harrison's Nephrology and Acid-Base Disorders, 3e, McGraw-Hill 
Education. 
JARADAT, Z. W. & BHUNIA, A. K. 2002. Glucose and nutrient concentrations affect the expression of a 
104-kilodalton Listeria adhesion protein in Listeria monocytogenes. Appl. Environ. Microbiol., 
68, 4876-4883. 
JAWETZ, M. 2007. Adelberg’s Medical microbiology. Antibacterial and Antifungal chemotherapy 
(Prentice-Hall International Inc). 
JEWISON, T., KNOX, C., NEVEU, V., DJOUMBOU, Y., GUO, A. C., LEE, J., LIU, P., MANDAL, R., 
KRISHNAMURTHY, R. & SINELNIKOV, I. 2011. YMDB: the yeast metabolome database. Nucleic 
Acids Res., 40, D815-D820. 
JHA, V., GARCIA-GARCIA, G., ISEKI, K., LI, Z., NAICKER, S., PLATTNER, B., SARAN, R., WANG, A. Y.-M. & 
YANG, C.-W. 2013. Chronic kidney disease: global dimension and perspectives. The Lancet, 
382, 260-272. 
JOHANSSON, A., BERGENHOLTZ, A. & HOLM, S. 1994. Cytotoxicity in bacterial cultures: interaction and 
cell‐specificity, possible factors in periodontal disease. J. Periodontal Res., 29, 318-323. 
JOHANSSON, A., BERGENHOLTZ, A. & HOLM, S. E. 1996. Strong cytotoxicity to human gingival 
fibroblasts by Porphyromonas gingivalis ATCC 33277. J. Periodontal Res., 31, 477-482. 
JOHANSSON, A. & KALFAS, S. 1998. Characterization of the proteinase-dependent cytotoxicity of 
Porphyromonas gingivalis. Eur. J. Oral Sci., 106, 863-871. 
JOHNSON, J. W., FISHER, J. F. & MOBASHERY, S. 2013. Bacterial cell-wall recycling. Ann. N.Y. Acad. Sci., 
1277, 54-75. 
JONES, R. 2010. Chronic disease and comorbidity. Br. J. Gen. Pract., 60, 394-394. 
JUDD, E. & CALHOUN, D. A. 2015. Management of hypertension in CKD: beyond the guidelines. Adv. 
Chronic Kidney Dis., 22, 116-22. 
KAEBERLEIN, T., LEWIS, K. & EPSTEIN, S. S. 2002. Isolating "Uncultivable" Microorganisms in Pure 
Culture in a Simulated Natural Environment. Science, 296, 1127. 
KALANTAR-ZADEH, K., SHAH, A., DUONG, U., HECHTER, R. C., DUKKIPATI, R. & KOVESDY, C. P. 2010. 
Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, 
alkaline phosphatase, and minerals. Kidney Int., 78, S10-S21. 
KASSEBAUM, N. J., BERNABE, E., DAHIYA, M., BHANDARI, B., MURRAY, C. J. & MARCENES, W. 2014. 
Global Burden of Severe Tooth Loss: A Systematic Review and Meta-analysis. J. Dent. Res., 
93, 20s-28s. 
KATZ, J., CHEGINI, N., SHIVERICK, K. T. & LAMONT, R. J. 2009. Localization of Porphyromonas gingivalis 
in preterm delivery placenta. J. Dent. Res., 88, 575-8. 
KATZ, J., SAMBANDAM, V., WU, J. H., MICHALEK, S. M. & BALKOVETZ, D. F. 2000. Characterization of 
Porphyromonas gingivalis-induced degradation of epithelial cell junctional complexes. Infect. 
Immun., 68, 1441-1449. 
References 
210 
 
KATZ, J., YANG, Q.-B., ZHANG, P., POTEMPA, J., TRAVIS, J., MICHALEK, S. M. & BALKOVETZ, D. F. 2002a. 
Hydrolysis of epithelial junctional proteins by Porphyromonas gingivalis gingipains. Infect. 
Immun., 70, 2512-2518. 
KATZ, J., YANG, Q.-B., ZHANG, P., POTEMPA, J., TRAVIS, J., MICHALEK, S. M. & BALKOVETZ, D. F. 2002b. 
Hydrolysis of epithelial junctional proteins by Porphyromonas gingivalis gingipains. Infection 
and immunity, 70, 2512-2518. 
KAZANCIOGLU, R. 2013. Risk factors for chronic kidney disease: an update. Kidney Int Suppl (2011), 3, 
368-371. 
KELL, D. B. & OLIVER, S. G. 2016. The metabolome 18 years on: a concept comes of age. Metabolomics, 
12, 148. 
KENNY, D. J., NICHOLSON, J. K., WILSON, I. D. & KASS, I. J. 2010. A novel LC–MS approach for the 
detection of metabolites in DMPK studies. Bioanalysis, 2, 1767-1778. 
KESAVALU, L., SATHISHKUMAR, S., BAKTHAVATCHALU, V., MATTHEWS, C., DAWSON, D., STEFFEN, M. 
& EBERSOLE, J. L. 2007. Rat model of polymicrobial infection, immunity, and alveolar bone 
resorption in periodontal disease. Infect. Immun., 75, 1704-12. 
KHALAF, H., LONN, J. & BENGTSSON, T. 2014a. Cytokines and chemokines are differentially expressed 
in patients with periodontitis: possible role for TGF-beta1 as a marker for disease 
progression. Cytokine, 67, 29-35. 
KHALAF, H., LÖNN, J. & BENGTSSON, T. 2014b. Cytokines and chemokines are differentially expressed 
in patients with periodontitis: possible role for TGF-β1 as a marker for disease progression. 
Cytokine, 67, 29-35. 
KHO, H.-S., LEE, S.-W., CHUNG, S.-C. & KIM, Y.-K. 1999. Oral manifestations and salivary flow rate, pH, 
and buffer capacity in patients with end-stage renal disease undergoing hemodialysis. Oral 
Surg. Oral Med. Oral Pathol. Oral Radiol., 88, 316-319. 
KILIAN, M. 1981. Degradation of immunoglobulins A2, A2, and G by suspected principal periodontal 
pathogens. Infect. Immun., 34, 757-765. 
KIND, T. & FIEHN, O. 2007. Seven Golden Rules for heuristic filtering of molecular formulas obtained 
by accurate mass spectrometry. BMC Bioinformatics, 8, 105. 
KLARSTRÖM ENGSTRÖM, K., KHALAF, H., KÄLVEGREN, H. & BENGTSSON, T. 2015. The role of 
Porphyromonas gingivalis gingipains in platelet activation and innate immune modulation. 
Mol. Oral Microbiol., 30, 62-73. 
KLUPPEL, M. & WRANA, J. L. 2005. Turning it up a Notch: cross-talk between TGF beta and Notch 
signaling. Bioessays, 27, 115-8. 
KOLENBRANDER, P. E., ANDERSEN, R. N., BLEHERT, D. S., EGLAND, P. G., FOSTER, J. S. & PALMER, R. J., 
JR. 2002. Communication among oral bacteria. Microbiol. Mol. Biol. Rev., 66, 486-505, table 
of contents. 
KÖNÖNEN, E. & WADE, W. G. 2015. Actinomyces and Related Organisms in Human Infections. Clin. 
Microbiol. Rev., 28, 419-442. 
KOZAROV, E. V., DORN, B. R., SHELBURNE, C. E., DUNN JR, W. A. & PROGULSKE-FOX, A. 2005. Human 
atherosclerotic plaque contains viable invasive Actinobacillus actinomycetemcomitans and 
Porphyromonas gingivalis. Arterioscler. Thromb. Vasc. Biol., 25, e17-e18. 
KSHIRSAGAR, A. V., OFFENBACHER, S., MOSS, K. L., BARROS, S. P. & BECK, J. D. 2007. Antibodies to 
periodontal organisms are associated with decreased kidney function. The Dental 
Atherosclerosis Risk In Communities study. Blood Purif., 25, 125-32. 
KUBONIWA, M., SAKANAKA, A., HASHINO, E., BAMBA, T., FUKUSAKI, E. & AMANO, A. 2016. Prediction 
of Periodontal Inflammation via Metabolic Profiling of Saliva. J. Dent. Res., 95, 1381-1386. 
KUHN, K. M., MAURICE, P. A., NEUBAUER, E., HOFMANN, T. & VON DER KAMMER, F. 2014. 
Accessibility of Humic-Associated Fe to a Microbial Siderophore: Implications for 
Bioavailability. Environ. Sci. Technol., 48, 1015-1022. 
KUKSA, V., BUCHAN, R. & LIN, P. K. T. 2000. Synthesis of polyamines, their derivatives, analogues and 
conjugates. Synthesis, 2000, 1189-1207. 
KUMAR, M., UMASHANKAR, D. N., VISWANATH, D. & GIRISH, G. 2013. Role of the Oral Microflora in 
Health and Disease. JIAOMR, 25, 184-187. 
KUULA, H., SALO, T., PIRILA, E., TUOMAINEN, A. M., JAUHIAINEN, M., UITTO, V. J., TJADERHANE, L., 
PUSSINEN, P. J. & SORSA, T. 2009. Local and systemic responses in matrix metalloproteinase 
8-deficient mice during Porphyromonas gingivalis-induced periodontitis. Infect. Immun., 77, 
850-9. 
References 
211 
 
LAMONT, R. J. & JENKINSON, H. F. 1998. Life below the gum line: pathogenic mechanisms of 
Porphyromonas gingivalis. Microbiol. Mol. Biol. Rev., 62, 1244-1263. 
LETZELTER, C., CROUTE, F., PIANEZZI, B., ROQUES, C. & SOLEILHAVOUP, J. P. 1998. Supernatant 
cytotoxicity and proteolytic activity of selected oral bacteria against human gingival 
fibroblasts in vitro. Arch. Oral Biol., 43, 15-23. 
LEVEY, A. S., CORESH, J., BALK, E. & ET AL. 2003. National kidney foundation practice guidelines for 
chronic kidney disease: Evaluation, classification, and stratification. Ann. Intern. Med., 139, 
137-147. 
LI, N. & COLLYER, C. A. 2011. Gingipains from Porphyromonas gingivalis—complex domain structures 
confer diverse functions. Eur. J. Microbiol. Immunol., 1, 41-58. 
LI, Q., ZHOU, J., LIN, L., ZHAO, H., MIAO, L. & PAN, Y. 2019. Porphyromonas gingivalis degrades integrin 
β1 and induces AIF-mediated apoptosis of epithelial cells. Infect. Dis., 51, 793-801. 
LI, X., KOLLTVEIT, K. M., TRONSTAD, L. & OLSEN, I. 2000. Systemic diseases caused by oral infection. 
Clin. Microbiol. Rev., 13, 547-558. 
LI, Y., SEKULA, P., WUTTKE, M., WAHRHEIT, J., HAUSKNECHT, B., SCHULTHEISS, U. T., GRONWALD, W., 
SCHLOSSER, P., TUCCI, S., EKICI, A. B., SPIEKERKOETTER, U., KRONENBERG, F., ECKARDT, K. 
U., OEFNER, P. J. & KOTTGEN, A. 2018. Genome-Wide Association Studies of Metabolites in 
Patients with CKD Identify Multiple Loci and Illuminate Tubular Transport Mechanisms. J. Am. 
Soc. Nephrol., 29, 1513-1524. 
LIANG, C.-C., PARK, A. Y. & GUAN, J.-L. 2007. In vitro scratch assay: a convenient and inexpensive 
method for analysis of cell migration in vitro. Nat. Protoc., 2, 329. 
LINDEN, G. J., LINDEN, K., YARNELL, J., EVANS, A., KEE, F. & PATTERSON, C. C. 2012. All-cause mortality 
and periodontitis in 60-70-year-old men: a prospective cohort study. J. Clin. Periodontol., 39, 
940-6. 
LISTGARTEN, M. A. 1986. Pathogenesis of periodontitis. J. Clin. Periodontol., 13. 
LIU, Y. 2006. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int., 69, 213-
217. 
LIVAK, K. J. & SCHMITTGEN, T. D. 2001. Analysis of relative gene expression data using real-time 
quantitative PCR and the 2− ΔΔCT method. Methods, 25, 402-408. 
LOESCHE, W. J. 1986. Role of Streptococcus mutans in human dental decay. Microbiol. Rev., 50, 353. 
LOOS, B. G. 2005. Systemic markers of inflammation in periodontitis. J. Periodontol., 76, 2106-2115. 
LOOS, B. G. 2006. Systemic effects of periodontitis. Int. J. Dent. Hyg., 4, 34-38. 
LÓPEZ-HERNÁNDEZ, F. J. & LÓPEZ-NOVOA, J. M. 2012. Role of TGF-β in chronic kidney disease: an 
integration of tubular, glomerular and vascular effects. Cell Tissue Res., 347, 141-154. 
LÓPEZ-NOVOA, J. M., RODRÍGUEZ-PEÑA, A. B., ORTIZ, A., MARTÍNEZ-SALGADO, C. & LÓPEZ 
HERNÁNDEZ, F. J. 2011. Etiopathology of chronic tubular, glomerular and renovascular 
nephropathies: Clinical implications. J. Transl. Med., 9, 13-13. 
LOURBAKOS, A., CHINNI, C., THOMPSON, P., POTEMPA, J., TRAVIS, J., MACKIE, E. J. & PIKE, R. N. 1998. 
Cleavage and activation of proteinase‐activated receptor‐2 on human neutrophils by 
gingipain‐R from Porphyromonas gingivalis. FEBS Lett., 435, 45-48. 
LOURBAKOS, A., POTEMPA, J., TRAVIS, J., D'ANDREA, M. R., ANDRADE-GORDON, P., SANTULLI, R., 
MACKIE, E. J. & PIKE, R. N. 2001. Arginine-Specific Protease from Porphyromonas gingivalis 
Activates Protease-Activated Receptors on Human Oral Epithelial Cells and Induces 
Interleukin-6 Secretion. Infect. Immun., 69, 5121-5130. 
LUSCO, M. A., FOGO, A. B., NAJAFIAN, B. & ALPERS, C. E. 2016. AJKD Atlas of Renal Pathology: Subacute 
Bacterial Endocarditis–Associated Glomerulonephritis. Am. J. Kidney Dis., 68, e11-e12. 
LUYCKX, V. A., TUTTLE, K. R., GARCIA-GARCIA, G., GHARBI, M. B., HEERSPINK, H. J. L., JOHNSON, D. W., 
LIU, Z.-H., MASSY, Z. A., MOE, O., NELSON, R. G., SOLA, L., WHEELER, D. C. & WHITE, S. L. 
2017. Reducing major risk factors for chronic kidney disease. Kidney Int. Suppl., 7, 71-87. 
MACUCH, P. J. & TANNER, A. C. 2000. Campylobacter species in health, gingivitis, and periodontitis. J. 
Dent. Res., 79, 785-92. 
MADHUSUDHAN, T., KERLIN, B. A. & ISERMANN, B. 2016. The emerging role of coagulation proteases 
in kidney disease. Nat. Rev. Nephrol., 12, 94. 
MAGNES, C., FAULAND, A., GANDER, E., NARATH, S., RATZER, M., EISENBERG, T., MADEO, F., PIEBER, 
T. & SINNER, F. 2014. Polyamines in biological samples: rapid and robust quantification by 
solid-phase extraction online-coupled to liquid chromatography-tandem mass spectrometry. 
J. Chromatogr. A, 1331, 44-51. 
References 
212 
 
MAJUMDAR, A., CHOWDHARY, S., FERREIRA, M. A., HAMMOND, L. A., HOWIE, A. J., LIPKIN, G. W. & 
LITTLER, W. A. 2000. Renal pathological findings in infective endocarditis. Nephrol. Dial. 
Transplant., 15, 1782-1787. 
MALGORZEWICZ, S., SKRZYPCZAK-JANKUN, E. & JANKUN, J. 2013. Plasminogen activator inhibitor-1 in 
kidney pathology (Review). Int. J. Mol. Med., 31, 503-10. 
MANTRI, C. K., CHEN, C. H., DONG, X., GOODWIN, J. S., PRATAP, S., PAROMOV, V. & XIE, H. 2015. 
Fimbriae‐mediated outer membrane vesicle production and invasion of Porphyromonas 
gingivalis. Microbiologyopen, 4, 53-65. 
MARSH, P. D. 2000. Role of the oral microflora in health. Microb. Ecol. Health Dis., 12, 130-137. 
MARSH, P. D., MARTIN, M. V., LEWIS, M. A. O. & WILLIAMS, D. 2009. Oral Microbiology E-Book, Elsevier 
health sciences. 
MERAN, S. & STEADMAN, R. 2011. Fibroblasts and myofibroblasts in renal fibrosis. Int. J. Exp. Pathol., 
92, 158-167. 
MEYER, T. W. & HOSTETTER, T. H. 2007. Uremia. N. Engl. J. Med., 357, 1316-1325. 
MIKKONEN, J. J., SINGH, S. P., HERRALA, M., LAPPALAINEN, R., MYLLYMAA, S. & KULLAA, A. M. 2016. 
Salivary metabolomics in the diagnosis of oral cancer and periodontal diseases. J. Periodontal 
Res., 51, 431-7. 
MIKOLAJCZYK-PAWLINSKA, J., TRAVIS, J. & POTEMPA, J. 1998. Modulation of interleukin‐8 activity by 
gingipains from Porphyromonas gingivalis: implications for pathogenicity of periodontal 
disease. FEBS Lett., 440, 282-286. 
MILES, A. A., MISRA, S. S. & IRWIN, J. O. 1938. The estimation of the bactericidal power of the blood. 
Epidemiol. Infect., 38, 732-749. 
MILLER-FLEMING, L., OLIN-SANDOVAL, V., CAMPBELL, K. & RALSER, M. 2015. Remaining Mysteries of 
Molecular Biology: The Role of Polyamines in the Cell. J. Mol. Biol., 427, 3389-406. 
MILLER, W. D. 1891. The human mouth as a focus of infection. The Lancet, 138, 340-342. 
MIRRAKHIMOV, A. E. 2012. Obstructive sleep apnea and kidney disease: is there any direct link? Sleep 
Breath, 16, 1009-16. 
MITCH, W. E. & MARONI, B. J. 1999. Factors causing malnutrition in patients with chronic uremia. Am. 
J. Kidney Dis., 33, 176-9. 
MORIOKA, M., HINODE, D., NAGATA, A., HAYASHI, H., ICHIMIYA, S., UEDA, M., KIDO, R. & NAKAMURA, 
R. 1993. Cytotoxicity of Porphyromonas gingivalis toward cultured human gingival 
fibroblasts. Oral Microbiol. Immunol., 8, 203-207. 
MOUTSOPOULOS, N. M. & MADIANOS, P. N. 2006. Low-grade inflammation in chronic infectious 
diseases: paradigm of periodontal infections. Ann. N. Y. Acad. Sci., 1088, 251-64. 
MUREA, M., PARK, J.-K., SHARMA, S., KATO, H., GRUENWALD, A., NIRANJAN, T., SI, H., THOMAS, D. B., 
PULLMAN, J. M. & MELAMED, M. L. 2010. Expression of Notch pathway proteins correlates 
with albuminuria, glomerulosclerosis, and renal function. Kidney Int., 78, 514-522. 
NAKAO, R., TAKASHIBA, S., KOSONO, S., YOSHIDA, M., WATANABE, H., OHNISHI, M. & SENPUKU, H. 
2014. Effect of Porphyromonas gingivalis outer membrane vesicles on gingipain-mediated 
detachment of cultured oral epithelial cells and immune responses. Microb. Infect., 16, 6-16. 
NAKAYAMA, K. 2003. Molecular genetics of Porphyromonas gingivalis: gingipains and other virulence 
factors. Curr. Protein Pept. Sci., 4, 389-95. 
NASR, S. H., FIDLER, M. E., VALERI, A. M., CORNELL, L. D., SETHI, S., ZOLLER, A., STOKES, M. B., 
MARKOWITZ, G. S. & D'AGATI, V. D. 2011. Postinfectious glomerulonephritis in the elderly. J. 
Am. Soc. Nephrol., 22, 187-195. 
NASR, S. H., MARKOWITZ, G. S., STOKES, M. B., SAID, S. M., VALERI, A. M. & D'AGATI, V. D. 2008. Acute 
postinfectious glomerulonephritis in the modern era: experience with 86 adults and review 
of the literature. Medicine, 87, 21-32. 
NICOLAS, G. G. & LAVOIE, M. C. 2011. Streptococcus mutans and oral streptococci in dental plaque. 
Can. J. Microbiol., 57, 1-20. 
NIEDERMAN, R., BRUNKHORST, B., SMITH, S., WEINREB, R. N. & RYDER, M. I. 1990. Ammonia as a 
potential mediator of adult human periodontal infection: inhibition of neutrophil function. 
Arch. Oral Biol., 35 Suppl, 205s-209s. 
NISHIO, K., HORIE, M., AKAZAWA, Y., SHICHIRI, M., IWAHASHI, H., HAGIHARA, Y., YOSHIDA, Y. & NIKI, 
E. 2013. Attenuation of lipopolysaccharide (LPS)-induced cytotoxicity by tocopherols and 
tocotrienols. Redox Biology, 1, 97-103. 
References 
213 
 
NOGUEIRA, A., PIRES, M. J. & OLIVEIRA, P. A. 2017. Pathophysiological mechanisms of renal fibrosis: a 
review of animal models and therapeutic strategies. In Vivo, 31, 1-22. 
NYLUND, K. M., RUOKONEN, H., SORSA, T., HEIKKINEN, A. M., MEURMAN, J. H., ORTIZ, F., 
TERVAHARTIALA, T., FURUHOLM, J. & BOSTANCI, N. 2017. Association of the Salivary 
Triggering Receptor Expressed on Myeloid Cells/ its Ligand Peptidoglycan Recognition Protein 
1 Axis With Oral Inflammation in Kidney Disease. J. Periodontol., 1-17. 
NYMARK, M., PUSSINEN, P. J., TUOMAINEN, A. M., FORSBLOM, C., GROOP, P. H. & LEHTO, M. 2009. 
Serum lipopolysaccharide activity is associated with the progression of kidney disease in 
finnish patients with type 1 diabetes. Diabetes Care, 32, 1689-93. 
OBERG, B. P., MCMENAMIN, E., LUCAS, F., MCMONAGLE, E., MORROW, J., IKIZLER, T. & HIMMELFARB, 
J. 2004. Increased prevalence of oxidant stress and inflammation in patients with moderate 
to severe chronic kidney disease. Kidney Int., 65, 1009-1016. 
OGAWA, T., KONO, Y., MCGHEE, M. L., MCGHEE, J. R., ROBERTS, J. E., HAMADA, S. & KIYONO, H. 1991. 
Porphyromonas gingivalis-specific serum IgG and IgA antibodies originate from 
immunoglobulin-secreting cells in inflamed gingiva. Clin. Exp. Immunol., 83, 237-44. 
OHKUNI, H., FRIEDMAN, J., VAN DE RIJN, I., FISCHETTI, V. A., POON-KING, T. & ZABRISKIE, J. B. 1983. 
Immunological studies of post-streptococcal sequelae: serological studies with an 
extracellular protein associated with nephritogenic streptococci. Clin. Exp. Immunol., 54, 185. 
OKUGAWA, T., KANEKO, T., YOSHIMURA, A., SILVERMAN, N. & HARA, Y. 2010. NOD1 and NOD2 
Mediate Sensing of Periodontal Pathogens. J. Dent. Res., 89, 186-191. 
OLCZAK, T., DIXON, D. W. & GENCO, C. A. 2001. Binding specificity of the Porphyromonas gingivalis 
heme and hemoglobin receptor HmuR, gingipain K, and gingipain R1 for heme, porphyrins, 
and metalloporphyrins. J. Bacteriol., 183, 5599-5608. 
OLSEN, I. & YAMAZAKI, K. 2019. Can oral bacteria affect the microbiome of the gut? J. Oral Microbiol., 
11, 1586422. 
OTOMO-CORGEL, J., PUCHER, J. J., RETHMAN, M. P. & REYNOLDS, M. A. 2012. State of the science: 
chronic periodontitis and systemic health. J. Evid-Based Dent. Pr., 12, 20-28. 
OYETOLA, E. O., OWOTADE, F. J., AGBELUSI, G. A., FATUSI, O. A. & SANUSI, A. A. 2015. Oral findings in 
chronic kidney disease: implications for management in developing countries. BMC Oral 
Health, 15, 24. 
PADILLA, C., LOBOS, O., HUBERT, E., GONZALEZ, C., MATUS, S., PEREIRA, M., HASBUN, S. & 
DESCOUVIERES, C. 2006. Periodontal pathogens in atheromatous plaques isolated from 
patients with chronic periodontitis. J. Periodontal Res., 41, 350-3. 
PALM, E., KHALAF, H. & BENGTSSON, T. 2015. Suppression of inflammatory responses of human 
gingival fibroblasts by gingipains from Porphyromonas gingivalis. Mol. Oral Microbiol., 30, 74-
85. 
PARASKEVAS, S., HUIZINGA, J. D. & LOOS, B. G. 2008. A systematic review and meta-analyses on C-
reactive protein in relation to periodontitis. J. Clin. Periodontol., 35, 277-290. 
PARK, M. H. & IGARASHI, K. 2013. Polyamines and their metabolites as diagnostic markers of human 
diseases. Biomol. Ther. (Seoul), 21, 1. 
PARTE, A., KRIEG, N. R., LUDWIG, W., WHITMAN, W. B., HEDLUND, B. P., PASTER, B. J., STALEY, J. T., 
WARD, N. & BROWN, D. 2011. Bergey's Manual of Systematic Bacteriology: Volume 4: The 
Bacteroidetes, Spirochaetes, Tenericutes (Mollicutes), Acidobacteria, Fibrobacteres, 
Fusobacteria, Dictyoglomi, Gemmatimonadetes, Lentisphaerae, Verrucomicrobia, 
Chlamydiae, and Planctomycetes, Springer New York. 
PATTI, G. J., YANES, O. & SIUZDAK, G. 2012. Metabolomics: the apogee of the omic triology. Nature 
reviews. Molecular cell biology, 13, 263-269. 
PAYNE, M., HASHIM, A., ALSAM, A., JOSEPH, S., ADUSE-OPOKU, J., WADE, W. & CURTIS, M. 2019. 
Horizontal and Vertical Transfer of Oral Microbial Dysbiosis and Periodontal Disease. J. Dent. 
Res., 0022034519877150. 
PEGG, A. E. 2009. Mammalian polyamine metabolism and function. IUBMB life, 61, 880-894. 
PEGG, A. E. 2013. Toxicity of polyamines and their metabolic products. Chem. Res. Toxicol., 26, 1782-
1800. 
PETERSON, S., WOODHEAD, J. & CRALL, J. 1985. Caries resistance in children with chronic renal failure: 
plaque pH, salivary pH, and salivary composition. Pediatr. Res., 19, 796. 
PIHLSTROM, B. L., MICHALOWICZ, B. S. & JOHNSON, N. W. 2005. Periodontal diseases. The Lancet, 
366, 1809-1820. 
References 
214 
 
PIRHAJI, L., MILANI, P., LEIDL, M., CURRAN, T., AVILA-PACHECO, J., CLISH, C. B., WHITE, F. M., 
SAGHATELIAN, A. & FRAENKEL, E. 2016. Revealing disease-associated pathways by network 
integration of untargeted metabolomics. Nat. Meth., 13, 770-776. 
PIZZO, G., GUIGLIA, R., RUSSO, L. L. & CAMPISI, G. 2010. Dentistry and internal medicine: from the 
focal infection theory to the periodontal medicine concept. Eur. J. Intern. Med., 21, 496-502. 
PORTER, S. R., SCULLY, C. & HEGARTY, A. M. 2004. An update of the etiology and management of 
xerostomia. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod., 97, 28-46. 
POTEMPA, J. & NGUYEN, K. A. 2007. Purification and characterization of gingipains. Curr. Protoc. 
Protein Sci., Chapter 21, Unit 21.20. 
POTEMPA, J., SROKA, A., IMAMURA, T. & TRAVIS, J. 2003. Gingipains, the major cysteine proteinases 
and virulence factors of Porphyromonas gingivalis: structure, function and assembly of 
multidomain protein complexes. Curr. Protein Pept. Sci., 4, 397-407. 
POTEMPA, M., POTEMPA, J., OKROJ, M., POPADIAK, K., EICK, S., NGUYEN, K.-A., RIESBECK, K. & BLOM, 
A. M. 2008. Binding of complement inhibitor C4b-binding protein contributes to serum 
resistance of Porphyromonas gingivalis. J. Immunol. Res., 181, 5537-5544. 
POVEDA-RODA, R., JIMENEZ, Y., CARBONELL, E., GAVALDA, C., MARGAIX-MUNOZ, M. M. & SARRIÓN-
PÉREZ, G. 2008. Bacteremia originating in the oral cavity. A review. Med. Oral Patol. Oral Cir. 
Bucal., 13, E355-62. 
PRESHAW, P., ALBA, A., HERRERA, D., JEPSEN, S., KONSTANTINIDIS, A., MAKRILAKIS, K. & TAYLOR, R. 
2012. Periodontitis and diabetes: a two-way relationship. Diabetologia, 55, 21-31. 
QIU, Q., ZHANG, F., WU, J., XU, N. & LIANG, M. 2018. Gingipains disrupt F‐actin and cause osteoblast 
apoptosis via integrin β1. J. Periodontal Res., 53, 762-776. 
RAMANATHAN, G., ABEYARATNE, A., SUNDARAM, M., FERNANDES, D. K., PAWAR, B., PERRY, G. J., 
SAJIV, C. & MAJONI, S. W. 2017. Analysis of clinical presentation, pathological spectra, 
treatment and outcomes of biopsy‐proven acute postinfectious glomerulonephritis in adult 
indigenous people of the Northern Territory of Australia. Nephrology, 22, 403-411. 
RAMS, T. E., FEIK, D., MORTENSEN, J. E., DEGENER, J. E. & WINKELHOFF, A. J. 2014. Antibiotic 
susceptibility of periodontal Streptococcus constellatus and Streptococcus intermedius 
clinical isolates. J. Periodontol., 85, 1792-1798. 
RASIAH, I. A., WONG, L., ANDERSON, S. A. & SISSONS, C. H. 2005. Variation in bacterial DGGE patterns 
from human saliva: over time, between individuals and in corresponding dental plaque 
microcosms. Arch. Oral Biol., 50, 779-787. 
RAYEGO-MATEOS, S., RODRIGUES-DIEZ, R., MORGADO-PASCUAL, J. L., VALENTIJN, F., VALDIVIELSO, J. 
M., GOLDSCHMEDING, R. & RUIZ-ORTEGA, M. 2018. Role of Epidermal Growth Factor 
Receptor (EGFR) and Its Ligands in Kidney Inflammation and Damage. Mediators Inflamm., 
2018. 
REALI, L., ZULIANI, E., GABUTTI, L., SCHÖNHOLZER, C. & MARONE, C. 2009. Poor oral hygiene enhances 
gingival overgrowth caused by calcineurin inhibitors. J. Clin. Pharm. Ther., 34, 255-260. 
RIEGER, A. M., NELSON, K. L., KONOWALCHUK, J. D. & BARREDA, D. R. 2011. Modified annexin 
V/propidium iodide apoptosis assay for accurate assessment of cell death. JOVE-J. VIS. EXP., 
2597. 
RIJKSCHROEFF, P., JANSEN, I. D. C., VAN DER WEIJDEN, F. A., KEIJSER, B. J. F., LOOS, B. G. & NICU, E. A. 
2016. Oral polymorphonuclear neutrophil characteristics in relation to oral health: a cross-
sectional, observational clinical study. Int. J. Oral Sci., 8, 191-198. 
RISS, T. L., MORAVEC, R. A., NILES, A. L., DUELLMAN, S., BENINK, H. A., WORZELLA, T. J. & MINOR, L. 
2016. Cell viability assays. Assay Guidance Manual [Internet]. Eli Lilly & Company and the 
National Center for Advancing Translational Sciences. 
ROBERTS, G., JAFFRAY, E., SPRATT, D., PETRIE, A., GREVILLE, C., WILSON, M. & LUCAS, V. 2006. 
Duration, prevalence and intensity of bacteraemia after dental extractions in children. Heart, 
92, 1274-1277. 
ROSSOL, M., HEINE, H., MEUSCH, U., QUANDT, D., KLEIN, C., SWEET, M. J. & HAUSCHILDT, S. 2011. 
LPS-induced cytokine production in human monocytes and macrophages. Crit. Rev. 
Immunol., 31. 
ROTH, G., MOSER, B., HUANG, S., BRANDT, J., HUANG, Y., PAPAPANOU, P., SCHMIDT, A. & LALLA, E. 
2006. Infection with a periodontal pathogen induces procoagulant effects in human aortic 
endothelial cells. J. Thromb. Haemost., 4, 2256-2261. 
References 
215 
 
ROTH, G. A., ANKERSMIT, H. J., BROWN, V. B., PAPAPANOU, P. N., SCHMIDT, A. M. & LALLA, E. 2007. 
Porphyromonas gingivalis infection and cell death in human aortic endothelial cells. FEMS 
Microbiol. Lett., 272, 106-113. 
ROVAI, E. & HOLZHAUSEN, M. 2017. The role of proteinase-activated receptors 1 and 2 in the 
regulation of periodontal tissue metabolism and disease. J. Immunol. Res., 2017. 
RURENGA, P., RAANGS, E., SINGADJI, Z., WEKEMA-MULDER, G., VELOO, A. C. M. & WINKELHOFF, A. J. 
2012. Evaluation of three selective media for isolation of Aggregatibacter 
actinomycetemcomitans. J. Periodontal Res., 48, 549-552. 
SAKANAKA, A., KUBONIWA, M., HASHINO, E., BAMBA, T., FUKUSAKI, E. & AMANO, A. 2017. Distinct 
signatures of dental plaque metabolic byproducts dictated by periodontal inflammatory 
status. Sci. Rep., 7, 42818. 
SALGADO-PABON, W., BRESHEARS, L., SPAULDING, A. R., MERRIMAN, J. A., STACH, C. S., HORSWILL, 
A. R., PETERSON, M. L. & SCHLIEVERT, P. M. 2013. Superantigens are critical for 
Staphylococcus aureus Infective endocarditis, sepsis, and acute kidney injury. MBio, 4. 
SALGUERO, M. V., AL‑OBAIDE, M. A., SINGH, R., SIEPMANN, T. & VASYLYEVA, T. L. 2019. Dysbiosis of 
Gram‑negative gut microbiota and the associated serum lipopolysaccharide exacerbates 
inflammation in type 2 diabetic patients with chronic kidney disease. Exp. Ther. Med., 18, 
3461-3469. 
SANDHOLM, L. 1986. Proteases and their inhibitors in chronic inflammatory periodontal disease. J. 
Clin. Periodontol., 13, 19-26. 
SANDILANDS, E. A., DHAUN, N., DEAR, J. W. & WEBB, D. J. 2013. Measurement of renal function in 
patients with chronic kidney disease. Br. J. Clin. Pharmacol., 76, 504-515. 
SCANNAPIECO, F. A. 1998. Position paper of The American Academy of Periodontology: periodontal 
disease as a potential risk factor for systemic diseases. J. Periodontol., 69, 841-850. 
SCHATZLE, M., LOE, H., LANG, N. P., BURGIN, W., ANERUD, A. & BOYSEN, H. 2004. The clinical course 
of chronic periodontitis. J. Clin. Periodontol., 31, 1122-7. 
SCHELD, W. M., VALONE, J. A. & SANDE, M. A. 1978. Bacterial adherence in the pathogenesis of 
endocarditis. Interaction of bacterial dextran, platelets, and fibrin. J. Clin. Invest., 61, 1394-
1404. 
SCHELLEVIS, F. G., VAN DER VELDEN, J., VAN DE LISDONK, E., VAN EIJK, J. T. M. & VAN WEEL, C. 1993. 
Comorbidity of chronic diseases in general practice. J. Clin. Epidemiol., 46, 469-473. 
SCHNEIDER, C. A., RASBAND, W. S. & ELICEIRI, K. W. 2012. NIH Image to ImageJ: 25 years of image 
analysis. Nat. Methods, 9, 671. 
SCHWECHHEIMER, C. & KUEHN, M. J. 2015. Outer-membrane vesicles from Gram-negative bacteria: 
biogenesis and functions. Nat. Rev. Microbiol., 13, 605. 
SEGURA‐EGEA, J., MARTÍN‐GONZÁLEZ, J. & CASTELLANOS‐COSANO, L. 2015. Endodontic medicine: 
connections between apical periodontitis and systemic diseases. Int. Endod. J., 48, 933-951. 
SEN, S., GIAMBERARDINO, L. D., MOSS, K., MORELLI, T., ROSAMOND, W. D., GOTTESMAN, R. F., BECK, 
J. & OFFENBACHER, S. 2018. Periodontal Disease, Regular Dental Care Use, and Incident 
Ischemic Stroke. Stroke, 49, 355-362. 
SERRA E SILVA FILHO, W., CASARIN, R. C., NICOLELA, E. L., JR., PASSOS, H. M., SALLUM, A. W. & 
GONCALVES, R. B. 2014. Microbial diversity similarities in periodontal pockets and 
atheromatous plaques of cardiovascular disease patients. PLoS One, 9, e109761. 
SETTEM, R. P., EL-HASSAN, A. T., HONMA, K., STAFFORD, G. P. & SHARMA, A. 2012. Fusobacterium 
nucleatum and Tannerella forsythia Induce Synergistic Alveolar Bone Loss in a Mouse 
Periodontitis Model. Infect. Immun., 80, 2436-2443. 
SEYMOUR, G. J., FORD, P. J., CULLINAN, M. P., LEISHMAN, S. & YAMAZAKI, K. 2007. Relationship 
between periodontal infections and systemic disease. Clin. Microbiol. Infect., 13, 3-10. 
SHAH, H., GHARBIA, S. & O'TOOLE, C. 1992. Assessment of the relative cytotoxicity of Porphyromonas 
gingivalis cells, products, and components on human epithelial cell lines. J. Periodontol., 63, 
44-51. 
SHAH, P. & SWIATLO, E. 2008. A multifaceted role for polyamines in bacterial pathogens. Mol. 
Microbiol., 68, 4-16. 
SHAIKH, H. F. M., PATIL, S. H., PANGAM, T. S. & RATHOD, K. V. 2018. Polymicrobial synergy and 
dysbiosis: An overview. J. Indian Soc. Periodontol., 22, 101-106. 
SHARMA, A. 2010. Virulence mechanisms of Tannerella forsythia. Periodontol. 2000, 54, 106-116. 
References 
216 
 
SHARMA, A., NOVAK, E., SOJAR, H., SWANK, R., KURAMITSU, H. & GENCO, R. 2000. Porphyromonas 
gingivalis platelet aggregation activity: outer membrane vesicles are potent activators of 
murine platelets. Oral Microbiol. and Immun., 15, 393-396. 
SHARMA, P., DIETRICH, T., FERRO, C. J., COCKWELL, P. & CHAPPLE, I. L. C. 2016. Association between 
periodontitis and mortality in stages 3–5 chronic kidney disease: NHANES III and linked 
mortality study. J. Clin. Periodontol., 43, 104-113. 
SHAW, N. 1975. Bacterial glycolipids and glycophospholipids. Adv. Microb. Physiol.: Elsevier. 
SHEETS, S. M., POTEMPA, J., TRAVIS, J., CASIANO, C. A. & FLETCHER, H. M. 2005. Gingipains from 
Porphyromonas gingivalis W83 induce cell adhesion molecule cleavage and apoptosis in 
endothelial cells. Infect. Immun., 73, 1543-52. 
SHEETS, S. M., ROBLES-PRICE, A. G., MCKENZIE, R. M., CASIANO, C. A. & FLETCHER, H. M. 2008. 
Gingipain-dependent interactions with the host are important for survival of Porphyromonas 
gingivalis. Front. Biosci., 13, 3215. 
SHI, M., WEI, Y., HU, W., NIE, Y., WU, X. & LU, R. 2018a. The subgingival microbiome of periodontal 
pockets with different probing depths in chronic and aggressive periodontitis: a pilot study. 
Front. Cell. Infect. Microbiol., 8, 124. 
SHI, Y., LIU, Z., SHEN, Y. & ZHU, H. 2018b. A Novel Perspective Linkage Between Kidney Function and 
Alzheimer's Disease. Front. Cell. Neurosci., 12, 384-384. 
SHIMIZU, K. 2014. Regulation Systems of Bacteria such as Escherichia coli in Response to Nutrient 
Limitation and Environmental Stresses. Metabolites, 4, 1-35. 
SIGNAT, B., ROQUES, C., POULET, P. & DUFFAUT, D. 2011. Role of Fusobacterium nucleatum in 
periodontal health and disease. Curr. Issues Mol. Biol., 13, 25-36. 
SIMENHOFF, M. L., BURKE, J. F., SAUKKONEN, J. J., ORDINARIO, A. T., DOTY, R. & DUNN, S. 1977. 
Biochemical profile of uremic breath. N. Engl. J. Med., 297, 132-135. 
SLADE, G. D., GHEZZI, E. M., HEISS, G., BECK, J. D., RICHE, E. & OFFENBACHER, S. 2003. Relationship 
between periodontal disease and C-reactive protein among adults in the Atherosclerosis Risk 
in Communities study. Arch. Intern. Med., 163, 1172-1179. 
SLATE, A. J. 2019. Optomisation of a Pseudomonas aeruginosa microbial fuel cell coupled with 
additivce manufacturiong of graphene electrodes to enhance power outputs. Doctor of 
Philosophy, Manchester Metropolitan University. 
SMITH, C. A., O'MAILLE, G., WANT, E. J., QIN, C., TRAUGER, S. A., BRANDON, T. R., CUSTODIO, D. E., 
ABAGYAN, R. & SIUZDAK, G. 2005. METLIN: a metabolite mass spectral database. Ther. Drug 
Monit., 27, 747-751. 
SOMACARRERA, M. L., HERNANDEZ, G., ACERO, J. & MOSKOW, B. S. 1994. Factors related to the 
incidence and severity of cyclosporin-induced gingival overgrowth in transplant patients. A 
longitudinal study. J. Periodontol., 65, 671-5. 
STASI, A., INTINI, A., DIVELLA, C., FRANZIN, R., MONTEMURNO, E., GRANDALIANO, G., RONCO, C., 
FIACCADORI, E., PERTOSA, G. B., GESUALDO, L. & CASTELLANO, G. 2017. Emerging role of 
Lipopolysaccharide binding protein in sepsis-induced acute kidney injury. Nephrol. Dial. 
Transplant., 32, 24-31. 
STEVENS, R., GATEWOOD, C. & HAMMOND, B. 1983. Cytotoxicity of the bacterium Actinobacillus 
actinomycetemcomitans extracts in human gingival fibroblasts. Arch. Oral Biol., 28, 981-987. 
STEVENS, R. & HAMMOND, B. 1988. The comparative cytotoxicity of periodontal bacteria. J. 
Periodontol., 59, 741-749. 
STINGU, C. S., SCHAUMANN, R., JENTSCH, H., ESCHRICH, K., BROSTEANU, O. & RODLOFF, A. C. 2013. 
Association of periodontitis with increased colonization by Prevotella nigrescens. J. Investig. 
Clin. Dent., 4, 20-5. 
STRINGER, S., SHARMA, P., DUTTON, M., JESKY, M., NG, K., KAUR, O., CHAPPLE, I., DIETRICH, T., FERRO, 
C. & COCKWELL, P. 2013. The natural history of, and risk factors for, progressive chronic 
kidney disease (CKD): the Renal Impairment in Secondary care (RIISC) study; rationale and 
protocol. BMC Nephrol., 14, 95. 
SU, H., LEI, C.-T. & ZHANG, C. 2017. Interleukin-6 Signaling Pathway and Its Role in Kidney Disease: An 
Update. Front. Immunol., 8, 405-405. 
TABOR, C. W. & ROSENTHAL, S. M. 1956. Pharmacology of spermine and spermidine; some effects on 
animals and bacteria. J. Pharmacol. Exp. Ther., 116, 139-55. 
TADA, A. & HANADA, N. 2010. Opportunistic respiratory pathogens in the oral cavity of the elderly. 
FEMS Immunol. Med. Microbiol., 60, 1-17. 
References 
217 
 
TAKEUCHI, Y., ISHIKAWA, H., INADA, M., SHINOZUKA, O., UMEDA, M., YAMAZAKI, T., YOSHIKAWA, M. 
& SASAKI, S. 2007. Study of the oral microbial flora in patients with renal disease. Nephrology 
(Carlton), 12, 182-90. 
TANAKA, S., YOSHIDA, M., MURAKAMI, Y., OGIWARA, T., SHOJI, M., KOBAYASHI, S., WATANABE, S., 
MACHINO, M. & FUJISAWA, S. 2008. The relationship of Prevotella intermedia, Prevotella 
nigrescens and Prevotella melaninogenica in the supragingival plaque of children, caries and 
oral malodor. J. Clin. Pediatr. Dent., 32, 195-200. 
TAYLOR, J. J. & PRESHAW, P. M. 2016. Gingival crevicular fluid and saliva. Periodontol. 2000, 70, 7-10. 
THODEN VAN VELZEN, S. K., ABRAHAM-INPIJN, L. & MOORER, W. R. 1984. Plaque and systemic 
disease: a reappraisal of the focal infection concept. J. Clin. Periodontol., 11, 209-20. 
THUDICHUM, J. L. W. 1857. On the Analysis of Urea in Urine for Clinical Purposes. Br. Med. J., 1, 788-
790. 
TOKUDA, M., KARUNAKARAN, T., DUNCAN, M., HAMADA, N. & KURAMITSU, H. 1998. Role of Arg-
gingipain A in virulence of Porphyromonas gingivalis. Infect. Immun., 66, 1159-1166. 
TOMINAGA, H., ISHIYAMA, M., OHSETO, F., SASAMOTO, K., HAMAMOTO, T., SUZUKI, K. & WATANABE, 
M. 1999. A water-soluble tetrazolium salt useful for colorimetric cell viability assay. Anal. 
Commun., 36, 47-50. 
TONELLI, M., WIEBE, N., GUTHRIE, B., JAMES, M. T., QUAN, H., FORTIN, M., KLARENBACH, S. W., 
SARGIOUS, P., STRAUS, S., LEWANCZUK, R., RONKSLEY, P. E., MANNS, B. J. & HEMMELGARN, 
B. R. 2015. Comorbidity as a driver of adverse outcomes in people with chronic kidney 
disease. Kidney Int., 88, 859-866. 
TONETTI, M. S., D'AIUTO, F., NIBALI, L., DONALD, A., STORRY, C., PARKAR, M., SUVAN, J., HINGORANI, 
A. D., VALLANCE, P. & DEANFIELD, J. 2007. Treatment of periodontitis and endothelial 
function. N. Engl. J. Med., 356, 911-920. 
TORRES, S. A., ROSA, O. P., HAYACIBARA, M. F., GUIMARAES MDO, C., HAYACIBARA, R. M. & BRETZ, 
W. A. 2010. Periodontal parameters and BANA test in patients with chronic renal failure 
undergoing hemodialysis. J. Appl. Oral Sci., 18, 297-302. 
TRIVEDI, M., PASARI, A., CHOWDHURY, A., KURIEN, A. & PANDEY, R. 2017. The epidemiology, clinical 
features, and outcome of infection-related glomerulonephritis from East India: A single 
center experience. Indian J. Nephrol., 27, 307. 
TSUZUKIBASHI, O., TAKADA, K., SAITO, M., KIMURA, C., YOSHIKAWA, T., MAKIMURA, M. & HIRASAWA, 
M. 2008. A novel selective medium for isolation of Aggregatibacter (Actinobacillus) 
actinomycetemcomitans. J. Periodontal Res., 43, 544-548. 
UEHARA, A., IMAMURA, T., POTEMPA, J., TRAVIS, J. & TAKADA, H. 2008. Gingipains from 
Porphyromonas gingivalis synergistically induce the production of proinflammatory 
cytokines through protease‐activated receptors with Toll‐like receptor and NOD1/2 ligands 
in human monocytic cells. Cell. Microbiol., 10, 1181-1189. 
UMEDA, J. E., MISSAILIDIS, C., LONGO, P. L., ANZAI, D., WIKSTROM, M. & MAYER, M. P. 2006. Adhesion 
and invasion to epithelial cells by fimA genotypes of Porphyromonas gingivalis. Oral 
Microbiol. Immunol., 21, 415-9. 
UNDERHILL, D. M. & OZINSKY, A. 2002. Toll-like receptors: key mediators of microbe detection. Curr. 
Opin. Immunol., 14, 103-110. 
USHER, A. K. H. & STOCKLEY, R. A. 2013. The link between chronic periodontitis and COPD: a common 
role for the neutrophil? BMC Med., 11, 241. 
VAN DER LEY, P. & VAN DEN DOBBELSTEEN, G. 2011. Next-generation outer membrane vesicle 
vaccines against Neisseria meningitidis based on nontoxic LPS mutants. Hum. Vaccin., 7, 886-
90. 
VAN DYKE, T. E. & DAVE, S. 2005. Risk Factors for Periodontitis. J. Int. Acad. Periodontol., 7, 3-7. 
VANHOLDER, R., DE SMET, R., GLORIEUX, G., ARGILES, A., BAURMEISTER, U., BRUNET, P., CLARK, W., 
COHEN, G., DE DEYN, P. P., DEPPISCH, R., DESCAMPS-LATSCHA, B., HENLE, T., JORRES, A., 
LEMKE, H. D., MASSY, Z. A., PASSLICK-DEETJEN, J., RODRIGUEZ, M., STEGMAYR, B., 
STENVINKEL, P., TETTA, C., WANNER, C. & ZIDEK, W. 2003. Review on uremic toxins: 
classification, concentration, and interindividual variability. Kidney Int., 63, 1934-43. 
VARTOUKIAN, S. R., MOAZZEZ, R. V., PASTER, B. J., DEWHIRST, F. E. & WADE, W. G. 2016. First 
cultivation of health-associated Tannerella sp. HOT-286 (BU063). J. Dent. Res., 95, 1308-1313. 
VARTOUKIAN, S. R., PALMER, R. M. & WADE, W. G. 2010. Strategies for culture of ‘unculturable’ 
bacteria. FEMS Microbiol. Lett., 309, 1-7. 
References 
218 
 
VAZIRI, N. D., PAHL, M. V., CRUM, A. & NORRIS, K. 2012. Effect of uremia on structure and function of 
immune system. J. Ren. Nutr., 22, 149-56. 
VEILLARD, F., POTEMPA, B., GUO, Y., KSIAZEK, M., SZTUKOWSKA, M. N., HOUSTON, J. A., KONERU, L., 
NGUYEN, K. A. & POTEMPA, J. 2015. Purification and characterisation of recombinant His-
tagged RgpB gingipain from Porphymonas gingivalis. Biol. Chem., 396, 377-84. 
VEITH, P. D., CHEN, Y.-Y., GORASIA, D. G., CHEN, D., GLEW, M. D., O’BRIEN-SIMPSON, N. M., CECIL, J. 
D., HOLDEN, J. A. & REYNOLDS, E. C. 2014. Porphyromonas gingivalis outer membrane 
vesicles exclusively contain outer membrane and periplasmic proteins and carry a cargo 
enriched with virulence factors. J. Proteome Res., 13, 2420-2432. 
VELSKO, I. M., CHUKKAPALLI, S. S., RIVERA, M. F., LEE, J.-Y., CHEN, H., ZHENG, D., BHATTACHARYYA, I., 
GANGULA, P. R., LUCAS, A. R. & KESAVALU, L. 2014. Active Invasion of Oral and Aortic Tissues 
by Porphyromonas gingivalis in Mice Causally Links Periodontitis and Atherosclerosis. PLoS 
One, 9, e97811. 
VELSKO, I. M., OVERMYER, K. A., SPELLER, C., KLAUS, L., COLLINS, M. J., LOE, L., FRANTZ, L. A., 
SANKARANARAYANAN, K., LEWIS, C. M. & MARTINEZ, J. B. R. 2017. The dental calculus 
metabolome in modern and historic samples. Metabolomics, 13, 134. 
VERGNOLLE, N. 2004. Modulation of visceral pain and inflammation by protease‐activated receptors. 
Br. J. Pharmacol., 141, 1264-1274. 
VERRAN, J. 1991. Dental plaque - associated infections and antibacterial oral hygiene products. Int. J. 
Cosmet. Sci., 13, 29-42. 
VIDANA, R., SULLIVAN, Å., BILLSTRÖM, H., AHLQUIST, M. & LUND, B. 2011. Enterococcus faecalis 
infection in root canals–host‐derived or exogenous source? Lett. Appl. Microbiol., 52, 109-
115. 
VIELKIND, P., JENTSCH, H., ESCHRICH, K., RODLOFF, A. C. & STINGU, C.-S. 2015. Prevalence of 
Actinomyces spp. in patients with chronic periodontitis. Int. J. Med. Microbiol., 305, 682-688. 
VOS, P., GARRITY, G., JONES, D., KRIEG, N. R., LUDWIG, W., RAINEY, F. A., SCHLEIFER, K.-H. & 
WHITMAN, W. B. 2011. Bergey's manual of systematic bacteriology: Volume 3: The 
Firmicutes, Springer Science & Business Media. 
VOSTI, K. L., JOHNSON, R. H. & DILLON, M. F. 1971. Further characterization of purified fractions of M 
protein from a strain of group A, type 12 Streptococcus. J. Immunol. Res., 107, 104-114. 
WADE, W. G. 2013. The oral microbiome in health and disease. Pharmacol. Res., 69, 137-43. 
WAHID, A., CHAUDHRY, S., EHSAN, A., BUTT, S. & ALI KHAN, A. 2013. Bidirectional Relationship 
between Chronic Kidney Disease & Periodontal Disease. Pak. J. Med. Sci., 29, 211-215. 
WANG, G. & DOYLE, M. P. 1998. Survival of enterohemorrhagic Escherichia coli O157: H7 in water. J. 
Food Prot., 61, 662-667. 
WANG, P. L. & OHURA, K. 2002. Porphyromonas gingivalis lipopolysaccharide signaling in gingival 
fibroblasts-CD14 and Toll-like receptors. Crit. Rev. Oral Biol. Med., 13, 132-42. 
WANG, P. L., SHIRASU, S., SHINOHARA, M., DAITO, M., OIDO, M., KOWASHI, Y. & OHURA, K. 1999. 
Induction of apoptosis in human gingival fibroblasts by a Porphyromonas gingivalis protease 
preparation. Arch. Oral Biol., 44, 337-42. 
WARDLE, H. M. 1997. The challenge of growing oral spirochaetes. J. Med. Microbiol., 46, 104-116. 
WHITMORE, S. E. & LAMONT, R. J. 2011. The pathogenic persona of community associated oral 
streptococci. Mol. Microbiol., 81, 305-314. 
WIEBE, C. B. & PUTNINS, E. E. 2000. The periodontal disease classification system of the American 
Academy of Periodontology--an update. J. Can. Dent. Assoc., 66, 594-7. 
WINGROVE, J. A., DISCIPIO, R. G., CHEN, Z., POTEMPA, J., TRAVIS, J. & HUGLI, T. E. 1992. Activation of 
complement components C3 and C5 by a cysteine proteinase (gingipain-1) from 
Porphyromonas (Bacteroides) gingivalis. J. Biol. Chem., 267, 18902-7. 
WINNING, L., PATTERSON, C. C., CULLEN, K. M., STEVENSON, K. A., LUNDY, F. T., KEE, F. & LINDEN, G. 
J. 2015. The association between subgingival periodontal pathogens and systemic 
inflammation. J Clin Periodontol, 42, 799-806. 
WISHART, D. S., FEUNANG, Y. D., MARCU, A., GUO, A. C., LIANG, K., VÁZQUEZ-FRESNO, R., SAJED, T., 
JOHNSON, D., LI, C. & KARU, N. 2017. HMDB 4.0: the human metabolome database for 2018. 
Nucleic Acids Res., 46, D608-D617. 
WISHART, D. S., JEWISON, T., GUO, A. C., WILSON, M., KNOX, C., LIU, Y., DJOUMBOU, Y., MANDAL, R., 
AZIAT, F. & DONG, E. 2012. HMDB 3.0—the human metabolome database in 2013. Nucleic 
Acids Res., 41, D801-D807. 
References 
219 
 
WONG, L. & SISSIONS, C. H. 2001. A comparison of human dental plaque microcosm biofilms grown 
in an undefined medium and a chemically defined artificial saliva. Arch. Oral Biol., 46, 477-
486. 
WYNN, T. A. 2007. Common and unique mechanisms regulate fibrosis in various fibroproliferative 
diseases. J. Clin. Invest., 117, 524-529. 
XIA, J. & WISHART, D. S. 2016. Using MetaboAnalyst 3.0 for comprehensive metabolomics data 
analysis. Curr. Protoc. Bioinformatics, 55, 14-10. 
XIE, H. 2015. Biogenesis and function of Porphyromonas gingivalis outer membrane vesicles. Future 
Microbiol., 10, 1517-1527. 
XIE, H., GIBBONS, R. & HAY, D. 1991. Adhesive properties of strains of Fusobacterium nucleatum of 
the subspecies nucleatum, vincentii and polymorphum. Oral Microbiol. Immunol., 6, 257-263. 
YAMANAKA, T., FURUKAWA, T., MATSUMOTO-MASHIMO, C., YAMANE, K., SUGIMORI, C., NAMBU, T., 
MORI, N., NISHIKAWA, H., WALKER, C. B., LEUNG, K. P. & FUKUSHIMA, H. 2009. Gene 
expression profile and pathogenicity of biofilm-forming Prevotella intermedia strain 17. BMC 
Microbiol., 9, 11. 
YAMASAKI, M., NAKATA, K., IMAIZUMI, I., IWAMA, A., NAKANE, A. & NAKAMURA, H. 1998. Cytotoxic 
effect of endodontic bacteria on periapical fibroblasts. J. Endod., 24, 534-539. 
YAO, Z., MATES, J. M., CHEPLOWITZ, A. M., HAMMER, L. P., MAISEYEU, A., PHILLIPS, G. S., WEWERS, 
M. D., RAJARAM, M. V. S., ROBINSON, J. M., ANDERSON, C. L. & GANESAN, L. P. 2016. Blood-
Borne Lipopolysaccharide Is Rapidly Eliminated by Liver Sinusoidal Endothelial Cells via High-
Density Lipoprotein. J. Immunol., 197, 2390-2399. 
YOSHIZAWA, N., OSHIMA, S., TAKEUCHI, A., KONDO, S., ODA, T., SHIMIZU, J., NISHIYAMA, J., ISHIDA, 
A., NAKABAYASHI, I. & TAZAWA, K. 1997. Experimental acute glomerulonephritis induced in 
the rabbit with a specific streptococcal antigen. Clin. Exp. Immunol., 107, 61-67. 
ZABRISKIE, J. B., LEWSHENIA, R., MÖLLER, G., WEHLE, B. & FALK, R. E. 1970. Lymphocytic responses to 
streptococcal antigens in glomerulonephritic patients. Science, 168, 1105-1108. 
ZACHARIOUDAKI, E. & BRAY, S. J. 2014. Tools and methods for studying Notch signaling in Drosophila 
melanogaster. Methods, 68, 173-182. 
ZEHNDER, M. & GUGGENHEIM, B. 2009. The mysterious appearance of enterococci in filled root 
canals. Int. Endod. J., 42, 277-287. 
ZHANG, B., ELMABSOUT, A. A., KHALAF, H., BASIC, V. T., JAYAPRAKASH, K., KRUSE, R., BENGTSSON, T. 
& SIRSJÖ, A. 2013. The periodontal pathogen Porphyromonas gingivalis changes the gene 
expression in vascular smooth muscle cells involving the TGFbeta/Notch signalling pathway 
and increased cell proliferation. BMC Genomics, 14, 770. 
ZHANG, J., JIANG, H., SUN, M. & CHEN, J. 2017. Association between periodontal disease and mortality 
in people with CKD: a meta-analysis of cohort studies. BMC Nephrol., 18, 269. 
ZHANG, W., SWEARINGEN, E. B., JU, J., RIGNEY, T. & TRIBBLE, G. D. 2010. Porphyromonas gingivalis 
invades osteoblasts and inhibits bone formation. Microb. Infect., 12, 838-845. 
ZHAO, D., KHAWAJA, A. T., JIN, L., LI, K. Y., TONETTI, M. & PELEKOS, G. 2018. The directional and non-
directional associations of periodontitis with chronic kidney disease: A systematic review and 
meta-analysis of observational studies. J. Periodontal Res., 53, 682-704. 
ZHAO, H., DONG, Y., TIAN, X., TAN, T. K., LIU, Z., ZHAO, Y., ZHANG, Y., HARRIS, D. C. & ZHENG, G. 2013. 
Matrix metalloproteinases contribute to kidney fibrosis in chronic kidney diseases. World J. 
Nephrol., 2, 84-89. 
ZHOU, B., WANG, J. & RESSOM, H. W. 2012. MetaboSearch: tool for mass-based metabolite 
identification using multiple databases. PLoS One, 7, e40096. 
ZHU, B., MACLEOD, L. C., KITTEN, T. & XU, P. 2018. Streptococcus sanguinis biofilm formation & 
interaction with oral pathogens. Future Microbiol., 13, 915-932. 
ZIJNGE, V., VAN LEEUWEN, M. B. M., DEGENER, J. E., ABBAS, F., THURNHEER, T., GMÜR, R. & M. 
HARMSEN, H. J. 2010. Oral Biofilm Architecture on Natural Teeth. PLoS One, 5, e9321. 
ZOELLNER, H., CHAPPLE, C. C. & HUNTER, N. 2002. Microvasculature in gingivitis and chronic 
periodontitis: disruption of vascular networks with protracted inflammation. Microsc. Res. 
Tech., 56, 15-31. 
 
